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Abstract 
 
Orthobunyaviruses are the largest genus within the Bunyaviridae family, with over 170 
named viruses classified into 18 serogroups (Elliott and Blakqori, 2001; Plyusnin et al., 
2012). Orthobunyaviruses are transmitted by arthropods and have a tripartite negative 
sense RNA genome, which encodes 4 structural proteins and 2 non-structural proteins. 
The non-structural protein NSs is the primary virulence factor of orthobunyaviruses 
and potent antagonist of the type I interferon (IFN) response. However, sequencing 
studies have identified pathogenic viruses that lack the NSs protein (Mohamed et al., 
2009; Gauci et al., 2010).  
 
The work presented in this thesis describes the molecular and biological 
characterisation of divergent orthobunyaviruses. Data on plaque morphology, growth 
kinetics, protein profiles, sensitivity to IFN and activation of the type I IFN system are 
presented for viruses in the Anopheles A, Anopheles B, Capim, Gamboa, Guama, 
Minatitlan, Nyando, Tete and Turlock serogroups. These are complemented with 
complete genome sequencing and phylogenetic analysis. Low activation of IFN by Tete 
serogroup viruses, which naturally lack an NSs protein, was also further investigated by 
the development of a reverse genetics system for Batama virus (BMAV). Recombinant 
viruses with mutations in the virus nucleocapsid protein amino terminus showed higher 
activation of type I IFN in vitro and data suggests that low levels of IFN are due to 
lower activation rather than active antagonism. The anti-orthobunyavirus activity of 
IFN-stimulated genes IFI44, IFITMs and human and ovine BST2 were also studied, 
revealing that activity varies not only within the orthobunyavirus genus and virus 
serogroups but also within virus species. Furthermore, there was evidence of active 
antagonism of the type I IFN response and ISGs by non-NSs viruses. 
 
In summary, the results show that pathogenicity in man and antagonism of the type I 
IFN response in vitro cannot be predicted by the presence, or absence, of an NSs ORF. 
They also highlight problems in orthobunyavirus classification with discordance 
between classical antigen based data and phylogenetic analysis.  
 
	 II	
Table of Contents 
 
ABSTRACT ................................................................................................................... I	
TABLE OF CONTENTS .................................................................................................. II	
LIST OF TABLES ....................................................................................................... VIII	
LIST OF FIGURES ........................................................................................................ IX	
ACKNOWLEDGEMENTS .............................................................................................. XII	
DECLARATION .......................................................................................................... XIII	
LIST OF ABBREVIATIONS ........................................................................................... XIV	
CHAPTER 1: GENERAL INTRODUCTION ................................................................... 1	
1.1 BUNYAVIRUSES ..................................................................................................... 2	
1.1.1 Classification ................................................................................................. 2	
1.1.2 Bunyavirus Genera ....................................................................................... 2	
1.1.2.2 Hantavirus ............................................................................................................. 6	
1.1.2.3 Phlebovirus ........................................................................................................... 7	
1.1.2.4 Nairovirus ............................................................................................................. 8	
1.1.2.5 Tospovirus............................................................................................................. 8	
1.1.2.6 Unclassified Bunyaviruses .................................................................................... 9	
1.1.3 Virion Structure ........................................................................................... 10	
1.1.4 Genome Organisation and Coding Strategy ............................................... 12	
1.1.5 Bunyavirus Gene Products ......................................................................... 15	
1.1.5.1 Nucleocapsid Protein .......................................................................................... 15	
1.1.5.2 Glycoproteins ...................................................................................................... 17	
1.1.5.3 Polymerase .......................................................................................................... 18	
1.1.5.4 S Segment Non-structural Protein ...................................................................... 19	
1.1.5.4 M segment Non-structural Proteins .................................................................... 20	
1.1.6 Replication in Mammalian Cells .................................................................. 20	
1.1.6.1 Cell Attachment and Cell Entry .......................................................................... 22	
1.1.6.2 Primary Transcription and Translation ............................................................... 23	
1.1.6.3 Genome Replication ............................................................................................ 25	
1.1.6.4 Virion Assembly, Maturation and Release ......................................................... 25	
1.1.7 Bunyavirus Interaction With The Host Cell .................................................. 27	
1.1.7.1 Activation of the Innate Immune Response ........................................................ 27	
1.1.7.2 Evasion and Antagonism of the Type I IFN Response ....................................... 30	
1.1.7.3 Host Cell Shut Off .............................................................................................. 32	
1.1.7.4. Host Cell Apoptosis and Persistent Infections ................................................... 33	
	 III	
1.2 ORTHOBUNYAVIRUSES ......................................................................................... 34	
1.2.1 Orthobunyavirus Classification  ................................................................... 34	
1.2.2 Orthobunyavirus Evolution .......................................................................... 38	
1.2.3 Orthobunyavirus Ecology ............................................................................ 40	
1.2.3.1 Anopheles A Serogroup ...................................................................................... 42	
1.2.3.2 Anopheles B Serogroup ...................................................................................... 44	
1.2.3.3 Bakau Serogroup ................................................................................................. 44	
1.2.3.4 Bunyamwera Serogroup ...................................................................................... 45	
1.2.3.5 Bwamba Serogroup ............................................................................................. 46	
1.2.3.6 California Serogroup ........................................................................................... 46	
1.2.3.7 Capim Serogroup ................................................................................................ 47	
1.2.3.8 Gamboa Serogroup ............................................................................................. 47	
1.2.3.9 Group C Serogroup ............................................................................................. 48	
1.2.3.10 Guama Serogroup ............................................................................................. 48	
1.2.3.11 Koongol Serogroup ........................................................................................... 49	
1.2.3.12 Minatitlan Serogroup ........................................................................................ 49	
1.2.3.13 Nyando Serogroup ............................................................................................ 50	
1.2.3.14 Olifantsvlei Serogroup ...................................................................................... 50	
1.2.3.15 Patois Serogroup ............................................................................................... 51	
1.2.3.16 Simbu Serogroup .............................................................................................. 51	
1.2.3.17 Tete Serogroup .................................................................................................. 52	
1.2.3.18 Turlock Serogroup ............................................................................................ 52	
1.2.3.19 New Serogroups: Wyeomyia, Mapputta and Sedlec ........................................ 53	
1.2.4 Orthobunyavirus Reverse Genetics ............................................................ 54	
CHAPTER 2: MATERIALS ..................................................................................... 56	
2.1 CELL LINES ......................................................................................................... 57	
2.2 VIRUS STRAINS ................................................................................................... 58	
2.3 BACTERIAL STRAINS AND CULTURE ...................................................................... 58	
2.4 PLASMIDS ........................................................................................................... 60	
2.5 OLIGONUCLEOTIDES ............................................................................................ 60	
2.6 ANTIBODIES ........................................................................................................ 63	
2.8 CHEMICALS AND BUFFERS ................................................................................... 63	
2.8.1 Multipurpose Chemicals .............................................................................. 63	
2.8.2 Mammalian Cell Culture .............................................................................. 64	
2.8.3 Transfection of Cultured Cells ..................................................................... 65	
2.8.4 Immunofluorescence ................................................................................... 65	
	 IV	
2.8.5 Protein Analysis .......................................................................................... 65	
2.8.6 Nucleic Acid Isolation and Analysis ............................................................. 66	
CHAPTER 3: METHODS ........................................................................................ 68	
3.1 CELL CULTURE .................................................................................................... 69	
3.1.1 Cell Maintenance ........................................................................................ 69	
3.1.2 Liquid Nitrogen – Cell Storage and Resuscitation ....................................... 69	
3.1.3 Determination of Selective Antibiotic Concentration ................................... 70	
3.2 VIRUS PROPAGATION .......................................................................................... 70	
3.2.1 Preparation of Lentivirus Pseudoparticles ................................................... 70	
3.2.2 Lentivirus Transduction ............................................................................... 71	
3.2.3 Virus Rescue ............................................................................................... 71	
3.2.4 Preparation of Virus Stocks ......................................................................... 72	
3.2.5 Blind Passage of Virus Isolates ................................................................... 72	
3.2.6 Virus Titration by Plaque Assay .................................................................. 72	
3.2.7 Virus Yield Assays ...................................................................................... 73	
3.3 INTERFERON EXPERIMENTS ................................................................................. 73	
3.3.1 Induction of Interferon-Stimulated Genes ................................................... 73	
3.3.2 Resistance to Interferon .............................................................................. 74	
3.3.3 Interferon-β Promoter Reporter Assays ...................................................... 74	
3.3.5 Biological Interferon Assay .......................................................................... 75	
3.4 NUCLEIC ACID MANIPULATION AND CLONING ....................................................... 76	
3.4.1 Extraction of Total Cellular and Virion RNA ................................................ 76	
3.4.2 RNA Extraction for High-throughput Sequencing ........................................ 76	
3.4.3 DNase Treatment ........................................................................................ 76	
3.4.4 RNA Ligation ............................................................................................... 76	
3.4.5 Standard Reverse-transcription .................................................................. 77	
3.4.6 Rapid Amplification of cDNA Ends .............................................................. 77	
3.4.6 Standard PCR ............................................................................................. 78	
3.4.7 QuickChange® PCR ................................................................................... 78	
3.4.8 Agarose Gel Electrophoresis ...................................................................... 79	
3.4.9 High-throughput Sequencing ...................................................................... 79	
3.4.10 Sanger Sequencing ................................................................................... 79	
3.4.11 Transformation of Bacterial Cells .............................................................. 80	
3.4.12 Plasmid Propagation ................................................................................. 80	
3.4.13 Restriction-Free Cloning ........................................................................... 80	
3.4.14 pGEM-T Easy ............................................................................................ 81	
	 V	
3.4.15 Colony PCR .............................................................................................. 81	
3.5 PROTEIN ANALYSIS ............................................................................................. 82	
3.5.1 Western Blotting .......................................................................................... 82	
3.5.2 Metabolic Labelling ..................................................................................... 82	
3.6 SOFTWARE PACKAGES ........................................................................................ 83	
3.6.1 Bioinformatics .............................................................................................. 83	
3.6.2 Graph Generation and Statistical Analysis .................................................. 83	
3.6.3 Imaging Programmes .................................................................................. 84	
CHAPTER 4: ORTHOBUNYAVIRUS GROWTH CHARACTERISTICS AND PROTEIN 
PROFILES ........................................................................................................... 85	
4.1 INTRODUCTION .................................................................................................... 86	
4.2 AIMS ................................................................................................................... 87	
4.3 RESULTS ............................................................................................................. 87	
4.3.1 Virus Propagation and Plaque Morphology ................................................. 87	
4.3.2 Virus Growth Kinetics .................................................................................. 95	
4.3.3 Metabolic Labelling ................................................................................... 101	
4.4 DISCUSSION ...................................................................................................... 108	
4.4.1 Virus Propagation and Plaque Morphology ............................................... 108	
4.4.2 Virus Growth Kinetics ................................................................................ 111	
4.4.3 Protein Labelling ....................................................................................... 112	
4.4.4 Concluding Remarks ................................................................................. 113	
CHAPTER 5: ORTHOBUNYAVIRUS GENOME SEQUENCING .................................... 115	
5.1 INTRODUCTION .................................................................................................. 116	
5.2 AIMS ................................................................................................................. 117	
5.3 RESULTS ........................................................................................................... 117	
5.3.1 N and NSs Coding Sequences ................................................................. 119	
5.3.2 M Coding Sequences ................................................................................ 122	
5.3.3 L Coding Sequences ................................................................................. 125	
5.3.4 Untranslated Sequences ........................................................................... 128	
5.3.5 Sequence Identity and Phylogeny ............................................................. 130	
5.4 DISCUSSION ...................................................................................................... 136	
5.4.1 Protein Conservation ................................................................................. 136	
5.4.2 Impact on Orthobunyavirus Classification ................................................. 141	
5.4.3 Concluding Remarks ................................................................................. 144	
	 VI	
CHAPTER 6: ORTHOBUNYAVIRUSES AND THE  TYPE I INTERFERON RESPONSE ..... 145	
6.1 INTRODUCTION .................................................................................................. 146	
6.2 AIMS ................................................................................................................. 147	
6.3 RESULTS ........................................................................................................... 147	
6.3.1 Activation and Antagonism of the Type I IFN System by Viruses with an NSs 
ORF .................................................................................................................... 147	
6.3.2 Sensitivity of Viruses with an NSs ORF to Pre-treatment with IFN ........... 154	
6.3.3 Activation and Antagonism of the Type I IFN System by Viruses Lacking an 
NSs ORF ............................................................................................................ 157	
6.3.4 Sensitivity of non-NSs viruses to Pre-treatment with IFN ......................... 162	
6.4 DISCUSSION ...................................................................................................... 165	
6.4.1 Viruses with an NSs ORF and Interferon .................................................. 165	
6.4.2 Viruses without an NSs ORF and Interferon ............................................. 168	
6.4.4 Concluding Remarks ................................................................................. 170	
CHAPTER 7: BATAMA VIRUS REVERSE GENETICS AND INTERFERON INDUCTION ... 174	
7.1: INTRODUCTION ................................................................................................. 175	
7.2 AIMS ................................................................................................................. 175	
7.3 RESULTS ........................................................................................................... 176	
7.3.1 Interferon Antagonism by Batama Virus Proteins ..................................... 176	
7.3.2 Batama Virus N Protein Structural Model ................................................. 178	
7.3.3 Batama Virus Reverse Genetics ............................................................... 180	
7.3.5 Growth Kinetics of Recombinant Batama Viruses .................................... 188	
7.3.6 Interferon Induction by Recombinant Batama Viruses .............................. 194	
7.4 DISCUSSION ...................................................................................................... 197	
7.4.1 Structural Modelling of Batama Virus N Protein ........................................ 197	
7.4.2 Batama Virus Reverse Genetics and Recombinant Virus Rescue ........... 198	
7.4.3 Recombinant Viruses Growth Kinetics and Plaque Morphology ............... 199	
7.4.4 Recombinant Viruses and the Type I IFN System .................................... 201	
7.4.5 Concluding Remarks ................................................................................. 201	
CHAPTER 8: ANTAGONISM BY INTERFERON STIMULATED GENES ......................... 202	
8.1 INTRODUCTION .................................................................................................. 203	
8.2 AIMS ................................................................................................................. 205	
8.3 RESULTS ........................................................................................................... 205	
8.3.1 Inducible Expression of IFI44 .................................................................... 205	
8.3.2 IFI44 Expression and Virus Replication .................................................... 210	
	 VII	
8.3.4 Anti-Orthobunyavirus Activity of Membrane Bound ISGs ......................... 219	
8.4 DISCUSSION ...................................................................................................... 234	
8.4.1 IFI44 and Bunyamwera virus Antagonism ................................................ 234	
8.4.2 Anti-Orthobunyavirus Activity of the IFITM Proteins ................................. 238	
8.4.3 Anti-Orthobunyavirus Activity of BST2 Proteins ........................................ 241	
8.4.4 Concluding Remarks ................................................................................. 243	
CHAPTER 9: FINAL REFLECTIONS ...................................................................... 244	
9.1 FULFILMENT OF AIMS ......................................................................................... 245	
9.2 THE BIGGER PICTURE ........................................................................................ 247	
APPENDICES .................................................................................................... 251	
APPENDIX 1: PRIMER SEQUENCES ........................................................................... 252	
APPENDIX 2: VIRUS DATABASE EXCERPT ................................................................ 261	
APPENDIX 3: TRANSMEMBRANE TOPOLOGY PREDICTIONS ....................................... 265	
APPENDIX 4: NON-COMPRESSED MAXIMUM-LIKELIHOOD PHYLOGENETIC TREES ...... 266	
APPENDIX 5: RBMAV CRNA SEQUENCES ............................................................... 269	
BIBLIOGRAPHY ................................................................................................. 272	
  
	 VIII	
List of Tables 
 
Table 1-1: Examples of Clinically and Economically Significant Bunyaviruses ............. 3	
Table 1-2: Unclassified Bunyaviruses ........................................................................... 5	
Table 1-3: Molecular Characteristics of the Bunyaviridae ........................................... 13 
Table 1-4: Orthobunyavirus Species List .................................................................... 35	
 
Table 2-1: Cell Lines ................................................................................................... 57	
Table 2-2: Virus Isolates .............................................................................................. 59	
Table 2-3: Expression Plasmids .................................................................................. 61	
Table 2-4: Transcription Plasmids ............................................................................... 62	
Table 2-5: Primary Antibodies ..................................................................................... 63	
Table 2-6: Secondary Antibodies ................................................................................ 63	
 
Table 4-1: Virus Propagation in Vero E6 Cells ............................................................ 89	
Table 4-2: Orthobunyavirus Ecology ......................................................................... 110 
 
Table 5-1: Virus Isolates for Genome Sequencing .................................................... 118	
Table 5-2: Virus Genome Size .................................................................................. 120	
Table 5-3: Variation in Conserved UTR Terminal Sequences .................................. 129 
Table 5-4: Amino Acid Identity within Serogroups ..................................................... 135	
 
Table 6-1: In vitro Interferon Phenotype of Viruses with an NSs ORF ...................... 156	
Table 6-2: In vitro Interferon Phenotype of Viruses lacking an NSs ORF ................. 164	
 
Table 7-1: Recombinant Batama Virus Titres ........................................................... 183	
Table 7-2: Biological Characteristics of Recombinant Batama Viruses .................... 196	
  
	 IX	
List of Figures 
 
Figure 1-1: Phylogenetic Relationships of Bunya-like Viruses ...................................... 4	
Figure 1-2: Bunyavirus Particle Structure .................................................................... 11	
Figure 1-3: Coding Strategy of Type Species ............................................................. 14	
Figure 1-4: Bunyavirus RNP and N Protein Formation ............................................... 16	
Figure 1-5: Bunyavirus Replication Cycle ................................................................... 21	
Figure 1-6: Bunyavirus Transcription and Translation ................................................. 24	
Figure 1-7: Translation and Replication ...................................................................... 26	
Figure 1-8: Interactions with Type I Interferon Response ........................................... 29	
Figure 1-9: Antigenic Relationships between Orthobunyaviruses ............................... 37	
Figure 1-10: Genetic Drift and Shift ............................................................................. 39	
Figure 1-11: Epizoonotic Life Cycle of Orthobunyaviruses ......................................... 41	
Figure 1-12: Spread of Schmallenberg virus in Europe .............................................. 43	
 
Figure 4-1: Plaque Morphology of Viruses in the Anopheles A, Anopheles B and 
Capim Serogroups ...................................................................................................... 92	
Figure 4-2: Plaque Morphology of Gamboa, Guama, Minatitlan, Nyando, Tete and 
Turlock Serogroup Viruses .......................................................................................... 93	
Figure 4-3: Weldona Virus Cytopathic Effect in Vero E6 Cells .................................... 94	
Figure 4-4: Growth Kinetics of Wild Type and Recombinant Bunyamwera Virus ....... 95	
Figure 4-5: Growth Kinetics of Viruses in the Anopheles A Serogroup ....................... 96	
Figure 4-6: Growth Kinetics of Viruses in the Anopheles B, Bwamba and Capim 
Serogroups .................................................................................................................. 98	
Figure 4-7: Growth Kinetics of Viruses in the Gamboa, Guama, Minatitlan and Nyando 
Serogroups. ................................................................................................................. 99	
Figure 4-8: Growth Kinetics of Viruses in the Tete and Turlock Serogroups ............ 100	
Figure 4-9: Metabolic Labelling of BUNV and rBUNdelNSs2 Viruses ....................... 101	
Figure 4-10: Metabolic Labelling of Viruses in the Anopheles A Serogroup ............. 103	
Figure 4-11: Metabolic Labelling of Viruses in the Anopheles B and Capim Serogroups
................................................................................................................................... 104	
Figure 4-12: Metabolic Labelling of Viruses in the Gamboa, Guama, Minatitlan and 
Nyando Serogroups .................................................................................................. 106	
Figure 4-13: Metabolic Labelling of Viruses in the Tete and Turlock Serogroups ..... 107	
 
 
 
	 X	
Figure 5-1: N Protein Conservation ........................................................................... 121	
Figure 5-2: NSs Protein Conservation ....................................................................... 123	
Figure 5-3: M Polyprotein Conservation .................................................................... 124	
Figure 5-4: Predicted M Polyprotein N-glycosylation ................................................ 126	
Figure 5-5: L Protein Conservation  .......................................................................... 127	
Figure 5-6: N ORF Phylogeny ................................................................................... 131	
Figure 5-7: M ORF Phylogeny ................................................................................... 132	
Figure 5-8: L ORF Phylogeny .................................................................................... 133	
Figure 5-9: N, M and L ORF Neighbour-Joining Phylogeny ...................................... 135	
 
Figure 6-1: Biological Induction of Interferon by NSs Encoding Viruses ................... 148	
Figure 6-2: Activation of the Interferon -β Promoter in Virus Infection ...................... 150	
Figure 6-3: Antagonism of the Type I Interferon Response in Virus Infection ........... 151	
Figure 6-4: Antagonism of the Interferon-β Promoter by Virus NSs Proteins ............ 153	
Figure 6-5: Virus Growth in Interferon Treated Cells ................................................. 155	
Figure 6-6: Biological Induction of Interferon by Non-NSs Viruses ........................... 158	
Figure 6-7: Activation of the Interferon-β Promoter in Non-NSs Virus Infection ........ 159	
Figure 6-8: Antagonism of the Type I Interferon Response in Virus Infection ........... 161	
Figure 6-9: Virus Growth in Interferon Treated Cells ................................................. 163	
Figure 6-10: NSs Conservation ................................................................................. 166	
 
Figure 7-1: Interferon-β Promoter Antagonism by Batama Virus Proteins ................ 177 
Figure 7-2: Structural Modelling of Batama Virus N Protein ...................................... 179	
Figure 7-3: Batama Virus Rescue System ................................................................ 181	
Figure 7-4: Batama Virus N Protein Constructs for Virus Rescue ............................. 182	
Figure 7-5: rBMAVn13∆ Plaque Morphology ............................................................ 184	
Figure 7-6: Plaque Morphology of Recombinant Viruses with Alanine Substitutions 186	
Figure 7-7: Plaque Morphology of Recombinant Viruses with Point Deletions ......... 187	
Figure 7-8: Growth Kinetics of Wild Type Batama Viruses ....................................... 188	
Figure 7-9: Growth Kinetics of Recombinant Viruses with Single Point Mutations ... 189	
Figure 7-10: Growth Kinetics of Recombinant Viruses with Double Alanine 
Substitutions .............................................................................................................. 191	
Figure 7-11: Growth Kinetics of Recombinant Viruses with Triple and Quadruple 
Alanine Substitutions ................................................................................................. 192	
Figure 7-12: Growth Kinetics of Recombinant Viruses with Multiple Point Deletions 193	
Figure 7-13: Interferon Induction by Recombinant Batama Viruses .......................... 195		
	 XI	
Figure 8-1: Tetracycline Induction of IFI44 ................................................................ 207	
Figure 8-2: Cellular Localisation of FLAG-tagged IFI44 ............................................ 208	
Figure 8-3: Investigation of IFN Inducible Expression of IFI44 .................................. 209	
Figure 8-4: Low MOI with BUNV in Cells Over-Expressing IFI44 ............................. 211	
Figure 8-5: Low MOI with rBUNdelNSs2 in Cells Over-Expressing IFI44 ................. 212	
Figure 8-6: BUNV and rBUNdelNSS2 Low MOI in T-Rex CAT Control Cells ........... 213	
Figure 8-7: BUNV MOI Screen in T-REx IFI44 Cells, Virus Release Assay ............. 214	
Figure 8-8: BUNV MOI Screen in T-REx IFI44, Cells Protein Expression ................ 215	
Figure 8-9: Expression of IFI44 and Virus N Protein in High MOI ............................. 217	
Figure 8-10: Inhibition of the Proteasome in T-Rex IFI44 Cells ................................ 218	
Figure 8-11: A549 Cells Constitutively Expressing IFITM Proteins ........................... 220	
Figure 8-12: BUNGc-eGFP rBUNdelNSs-GcGFP ..................................................... 221	
Figure 8-13: Fluorescent Microscopy of rBUNGc-eGFP in Cells Over-Expressing 
IFITM Proteins ........................................................................................................... 223	
Figure 8-14: BUNV Replication in A549-IFITM Cells ................................................ 224	
Figure 8-15: rBUNdelNSs2 in A549-IFITM Cells ....................................................... 225	
Figure 8-16: Replication of Anopheles A, Anopheles B and Tete Serogroup Viruses in 
A549-IFITM Cell Lines ............................................................................................... 227	
Figure 8-17: Expression of IFITM2 and IFITM3 in high MOI Virus Infection ............. 229	
Figure 8-18: BUNV Replication in Cells Over-Expressing BST2 ............................... 231	
Figure 8-19: rBUNdelNSs2 Replication in Cells Over-Expressing BST2 .................. 232	
Figure 8-20: Replication of Anopheles A, Anopheles B and Tete Serogroup Viruses in 
Cells Over-Expressing BST2 ..................................................................................... 233	
Figure 8-21: Structural Model of IFI44 ....................................................................... 237	
 
	 XII	
Acknowledgements 
 
To my lab family and the boss, Professor Richard M. Elliott, thank you for making me 
a graduate of the Elliott lab, it has been an honour and a privilege, hopefully I will do 
you proud. 
 
Ingeborg van Knippenberg and Ruth Jarrett, there were times when I wasn’t sure this 
would happen, thank you for looking out for me and getting me past the final hurdle. 
 
I would like to thank my assessors and secondary supervisors Rupert Russell and David 
Jackson, University of St Andrews, and Robert Gifford, Sam Wilson, and Margaret 
Hosie, University of Glasgow, for helpful discussions of my work. I am also indebted 
to Thomas Briese, Centre for Infection and Immunity, New York, for supporting the 
sequencing collaboration and for his continued guidance and encouragement. I would 
also like to thank previous colleagues in NHS Scotland, with special thanks to Dave 
Yirrell and the microbiology department at Ninewells Hospital, Dundee, you taught me 
how science is done and to have confidence in my abilities.  
 
To my family, it has been a long road filled with many, many flat moves and you have 
been there for everyone. Your support, encouragement and delivery of home cooked 
meals through locked metal gates has helped me do things I never thought I would. A 
special thank you must also go to the mini-Macs; Hannah, Ruaridh and Lucy, it’s hard 
to worry about work when chasing the naughty tup around the Pinky Ponk, thank you 
for letting me escape with you. 
 
Lastly, to C. David Owen, it has been an inconceivable journey from St Andrews to 
Glasgow, New York, Australia and Sierra Leone, but it is done and a new adventure 
begins. 
 
  
	 XIII	
Declaration 
 
I, Gillian Sinclair Slack, declare that, except where explicit reference is made to the 
contribution of others, that this thesis is the result of my own work and has not been 
submitted for any other degree at the University of Glasgow or any other institution. 
 
 
 
Signature: 
 
 
Printed name:     G SLACK 
 
  
	 XIV	
List of Abbreviations 
 
General Abbreviations 
aa amino acid 
AHVLA Animal Health and Veterinary Laboratories Agency 
ArboCAT International Catalog of Arboviruses 
bp base pairs 
BSA bovine serum albumin 
BST2 bone marrow stromal cell antigen 2 (tetherin) 
CAT chloramphenicol acetyl transferase 
cDNA complementary deoxyribonucleic acid 
cRNA complementary ribonucleic acid (antigenome) 
CDS coding sequence 
CFR case fatality ratio 
CFT complement fixation test 
CT cytoplasmic tail 
CII Center for Infection and Immunity 
CO2 carbon dioxide 
CPE cytopathic effect 
d p.i.  days post infection 
DEFRA Department for Environment, Food and Rural Affairs 
DMEM Dulbecco’s modified Eagle medium 
DNA deoxyribonucleic acid 
dNTP deoxynucleotide 
ds double stranded 
DTT dithiothreitol 
EDTA ethylenediaminetetraacetic acid 
EIA enzyme linked immune assays 
ER endoplasmic reticulum 
ERK extracellular signal regulated kinase 
FCS fetal calf serum 
GFP green fluorescent protein 
GIMAP2 GTPase of immunity associated proteins 2 
GMEM Glasgow minimum essential medium 
Gn/Gc glycoproteins Gn and Gc 
GTP guanosine triphosphate 
h hours 
h p.i. hours post infection 
hBST2 human bone marrow stromal cell antigen 2 
HF haemorrhagic fever 
HFRS haemorrhagic fever with renal syndrome 
	 XV	
HI haemagglutination inhibition 
Ho homologous 
HPS hantavirus pulmonary syndrome 
HRP horseradish peroxidase 
Ht heterologous 
HTS high-throughput sequencing 
ICTV International Committee on Taxonomy of Viruses 
IFI44 interferon induced protein 44 (also known as MTAP44) 
IFITM interferon stimulated transmembrane protein 
IFN interferon 
IRSE internal ribosome entry site 
ISG interferon stimulated gene 
ISRE interferon-stimulated regulatory elements 
ITAM immunoreceptor tyrosine-based activation motif 
L L protein (viral polymerase) or large genomic segment 
M medium genomic segment 
min minutes 
M-MLV Moloney murine leukemia virus  
MOI multiplicity of infection 
mRNA messenger ribonucleic acid 
MTAP44 Microtubule-associated protein 44 (also known as IFI44) 
N nucleoprotein 
NC negative control 
NEAA non-essential amino acids 
NSm non-structural protein encoded on M segment 
NSs non-structural protein encoded on S segment 
nt nucleotide 
NT neutralisation test 
oBST2 ovine bone marrow stromal cell antigen 2 
OAS oligoadenylate synthetases 
ORF open reading frame 
OSBP oxysterol-binding protein 
OTU ovarian tumour domain 
p virus passage number 
PC positive control 
p.f.u plaque forming units 
PABP poly-A binding protein 
PAMP pathogen associated molecular pattern 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PDB protein disruption buffer 
PEG polyethylene glycol 
	 XVI	
PKR protein kinase R 
PRNT plaque reduction neutralisation test 
PRR pathogen recognition receptor 
PVDF polyvinylidene fluoride 
r recombinant 
RACE rapid amplification of cDNA ends 
RdRp RNA-dependent RNA-polymerase 
RER rough endoplasmic reticulum 
RFP red fluorescent protein 
rIFN relative interferon 
RIG-I retinoic acid inducible gene I 
RLU relative light units 
RNA ribonucleic acid 
RNAPII RNA polymerase II 
RNP ribonucleocapsid protein 
RT reverse transcriptase 
sp. species 
ss single-stranded 
S small genomic segment 
SAP30 Sin3A associated protein 30 
SDS sodium dodecyl sulfate 
SLE systemic lupus erythematosus 
T7RNAP T7 RNA polymerase 
TLR toll-like receptor 
Tm melting temperature 
TPB tryptose phosphate broth 
UK United Kingdom 
USA United States of America 
UTMB University of Texas Medical Branch 
UTR untranslated region 
VAPA vesicle-membrane-protein-associated protein A 
vRNA viral ribonucleic acid 
wt wild type 
 
 
Virus Abbreviations in Main Text 
57389 Anopheles A virus ColAn 57389 
AKAV Akabane virus 
ANDV Andes virus 
ANAV Anopheles A virus, original 1940 isolate 
ANBV Anopheles B virus  
	 XVII	
ANDV Andes virus 
BAHV Bahig virus 
BAKV Bakau virus 
BCCV Black Creek Canal virus 
BMAV Batama virus 
BORV Boraceia virus 
BUCV Buffalo Creek virus 
BUNV Bunyamwera virus 
BWAV Bwamba virus 
CAPV Capim virus 
CCHFV Crimean-Congo haemorrhagic fever virus 
CPEV Caraipe virus 
CMV cytomegalovirus 
DGUV Dugbe virus 
EMCV encephalomycocarditis virus  
EREV Eretmapodites virus  
GAMV Gamboa virus  
GJAV Guajara virus 
GMAV Guama virus 
HCoV human coronavirus 
HCV hepatitis C virus 
HIV human immunodeficiency virus 
HTNV Hantaan virus 
IAV influenza A virus 
INKV Inkoo virus 
JCV Jamestown Canyon virus 
JDV Juan Diaz virus 
LACV La Crosse virus 
LEAV Leanyer virus 
LEDV Lednice virus 
JACV Jamestown Canyon virus 
KETV Ketapang virus 
KOOV Koongol virus 
KSHV Kaposi’s sarcoma-associated herpesvirus 
LUKV Lukuni virus 
LMV Las Maloyas virus 
MERS-CoV Middle East respiratory syndrome coronavirus 
MHV Mahogany Hammock virus 
MNTV Minatitlan virus 
MORV Moriche virus  
MPKV Maprik virus 
MPOV M’Poko virus 
	 XVIII	
MTRV Matruh virus 
NDV Nyando virus 
NOLAV Nola virus 
NSDV Nairobi sheep disease virus 
OLIV Olifantsvlei virus 
OROV Oropouche virus 
PGAV Pongola virus 
PLSV Palestina virus 
PTV Punta Toro virus 
RVFV Rift Valley fever virus 
SARS severe acute respiratory syndrome 
SBV Schmallenberg virus 
SEDV Sedlec virus 
SEOV Seoul virus 
SNV Sin Nombre virus 
SFSTV severe fever with thrombocytopenia syndrome virus 
SJV San Juan virus  
SNV Sindbis virus 
SSHV Snowshoe hare virus 
TAHV Tahyna virus 
TCMV Tacaiuma virus 
TETEV Tete virus 
TFV Telok Forest virus 
TRMV Trombetas virus 
TRV Tanjong Rabok virus 
TSUV Tsuruse-like virus 
TSWV tomato spotted wilt virus 
TUCV Tucurui virus 
TULV Tula virus 
TURV Turlock virus 
UMBV  Umbre virus 
UUKV Uukuniemi virus  
VSV vesicular stomatitis virus 
WELV Weldona virus 
WONV Wongal virus 
WYOV Wyeomyia virus 
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1.1 Bunyaviruses 
 
1.1.1 Classification 
 
The Bunyaviridae family was first recognised by the International Committee on 
Taxonomy of Viruses (ICTV) in 1975 (Porterfield et al., 1975; Fenner, 1976). It is 
named after the prototype virus species, Bunyamwera virus (BUNV), which was first 
described in 1946 (Smithburn et al., 1946; Fenner, 1976). The Bunyaviridae family 
now contains over 350 named virus isolates which are classified into 5 genera 
(Orthobunyavirus, Hantavirus, Phlebovirus, Nairovirus, and Tospovirus) based on 
serological cross-reactivity, conserved terminal sequences, morphological and 
biochemical characteristics (Plyusnin et al., 2012). Bunyaviruses are enveloped viruses 
80 nm - 120 nm in diameter with tripartite single-stranded negative, or ambisense, 
RNA genomes, with virus replication occurring exclusively in the cell cytoplasm 
(Holmes, 1971; Porterfield et al., 1975; Plyusnin et al., 2012). Bunyaviruses have a 
global distribution and, with the exception of hantaviruses, are arthropod-borne viruses. 
A number of bunyaviruses are of clinical and economic significance causing disease in 
humans, livestock and commercial crops (Table 1-1). It is important to note that the 
classification of bunyaviruses is currently under review as genome sequencing 
continues to identify novel virus species with little homology to currently recognised 
species or genera (Figure 1-1, Table 1-2) (Galkina et al., 2005; Lanciotti et al., 2013; 
Marklewitz et al., 2013; Li et al., 2015a).  
 
 
1.1.2 Bunyavirus Genera  
 
1.1.2.1 Orthobunyavirus 
 
The Orthobunyavirus genus is the largest genus within the Bunyaviridae family, with 
48 ICTV-recognised virus species and over 170 named virus isolates that are classified 
into 18 serogroups (Elliott and Blakqori, 2011; Plyusnin et al., 2012). 
Orthobunyaviruses have a global distribution and are transmitted by a wide range of 
arthropods including ticks, midges, mosquitoes, biting flies and bedbugs. 
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Table 1-1: Examples of Clinically and Economically Significant Bunyaviruses 
 
This table is by no means exhaustive and only serves to demonstrate the wide geographical 
distribution and possible severity of bunyavirus infection. Geographical location and vector 
information as listed in The International Catalog of Arboviruses (ArboCAT) (Berge, 1975). 
SFTSV, Severe fever with thrombocytopenia syndrome virus; CCHFV, Crimean Congo 
Haemorrhagic fever virus; NSDV, Nairobi sheep disease virus; HF, haemorrhagic fever. 
  
Virus Geographic location 
Primary 
Vector Host: Disease 
Orthobunyavirus    
La Crosse virus North America Mosquito Human: fever, headache, encephalitis 
Oropouche virus South America Midge Human: fever, myalgia, arthralgia, 
encephalitis 
Schmallenberg virus Europe Midge Ruminant: abortion, foetal malformation, 
decreased milk production 
Tahyna virus Asia, Europe Mosquito Human: fever, pneumonia, encephalitis 
Hantavirus    
Hantaan virus Asia, Europe Field mouse Human: HF with renal syndrome 
Puumala virus Europe Bank vole Human: nephropathia epidemica 
Seoul virus Americas, Asia, 
Europe 
Brown rat Human: HF with renal syndrome 
Sin Nombre virus North America Deer mouse Human: hantavirus pulmonary syndrome 
Phlebovirus    
Rift Valley fever virus Africa, Arabia Mosquito Human: encephalitis, HF, retinitis 
Ruminant: abortion, haemorrhage 
SFTSV Asia Tick Human: fever, thrombocytopenia, 
leukocytopenia 
Toscana virus Europe Sandfly Human: conjunctivitis, fever, myalgia  
Nairovirus    
CCHFV Africa, Asia, 
Europe 
Tick Human: HF 
NSDV Africa  Sheep and goats: Haemorrhagic 
gastroenteritis, abortion 
Tospovirus    
Tomato-spotted wilt 
virus 
Global Thrips Plants: necrotic spotting, wilting, death 
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Figure 1-1: Phylogenetic Relationships of Bunya-like Viruses 
Figure adapted from Li et al., 2015a showing phylogeny of bunya-like viruses by RNA-
dependent RNA polymerase alignments (412 aa) with statistical support. Bunyavirus genera are 
compressed and coloured in blue, with genus names in bold. Non-bunyavirus genera are 
compressed and coloured in grey. Novel viruses sequenced by Li et al. (2015a) that do not fall 
within current recognised genera are shown in red.  
 
  
Phlebovirus
Hantavirus
Tospovirus
Nairovirus
Orthobunyavirus
Tenuivirus
Arenavirus
Phasmavirus
Emaravirus
New Genus 1
New Genus 2
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Table 1-2: Unclassified Bunyaviruses 
Virus Geographic location 
Primary 
Vector 
Human 
Disease Virus Identification 
New Genus 1 
Herbert virus Africa Mosquitoes N, insect only Marklewitz et al., (2013) 
Kibale virus Africa Mosquitoes N, insect only Marklewitz et al., (2013) 
Taï virus Africa Mosquitoes N, insect only Marklewitz et al., (2013) 
New Genus 2 
Cumuto virus Americas Mosquitoes NR Auguste et al., (2014) 
Gouléako virus  Africa Mosquitoes N, insect only Marklewitz et al., (2011) 
KF298274 virus Europe Mosquitoes NR Cook et al., (2013) 
Unclassified Group 1 
Antequera virus South America Mosquitoes NS Calisher et al., (1985) 
Barranqueras virus South America Mosquitoes NS Calisher et al., (1985) 
Resistencia virus South America Mosquitoes NS Calisher et al., (1985) 
Unclassified Group 2 
Okola virus  Africa Mosquitoes  Brottes et al., (1966) 
Tanga virus  Africa Mosquitoes Nt Ab Woodall and Williams (1967) 
Unclassified No Group 
Bangui virus  Africa Unknown* Y, fever/rash Digoutte et al., (1973) 
Belem virus  South America Unknown† Nt Ab Berge (1975) 
Belmont virus Australia Mosquitoes NR McPhee and Westaway (1981) 
Bobaya virus Africa Unknown† NR Mekki et al., (1979) 
Caddo Canyon virus  North America Ticks NR ICTV unclassified list 
Hissar virus¥ Asia Ticks NR Gordeeva et al., (1990) 
Pacora virus  North America Mosquitoes NR Berge (1975) 
Para virus  South America Mosquitoes NR Berge (1975) 
Santarem virus South America Mosquitoes NR Berge (1975) 
Sunday Canyon virus North America Ticks NR Yunker et al., (1977) 
Tataguine virus Africa Mosquitoes Y, febrile illness Salaun et al., (1968) 
Wanowrie virus Asia Ticks NR Dandawate et al., (1970) 
Witwatersrand virus  Africa Mosquitoes Nt Ab Monath et al., (1972) 
Yacaaba virus Australia Mosquitoes NR Marshall et al., (1980) 
 
List of unclassified bunyaviruses and possible new genus classifications (Personal 
communication, Prof Richard M. Elliott). Unless stated vector, geographic location and human 
disease are as listed in The International Catalog of Arboviruses (ArboCAT) (Berge, 1975). * 
isolated from man only, † isolated from birds only. ¥ also referred to as Gissar virus. Human 
disease is classified as (NR) not reported, if limited samples have been tested, (NS) not studied, 
if no human samples tested, (Nt Ab) if neutralising antibodies have been detected, and (Y) yes, 
if samples positive for virus isolation and clinical symptoms reported.  
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Orthobunyaviruses with clinical and economic significance include La Crosse virus 
(LACV), Oropouche virus (OROV), Schmallenberg virus (SBV), and Akabane virus 
(AKAV) (Table 1-1). LACV is the second most common, domestically-acquired 
arbovirus in the United States of America (USA), and a leading cause of viral 
encephalitis in children < 16 years of age (McJunkin et al., 2001; Lindsey et al., 2014). 
OROV is widespread in South America, with > 30 documented outbreaks in Brazil, 
Peru, Panama and Trinidad and Tobago in 1960 – 2009, during which over 500 000 
people are estimated to have been infected (Pinheiro et al., 1981; Mourãão et al., 
2009). OROV causes a self-limiting febrile illness frequently associated with headache, 
myalgia, arthralgia and rash and it is increasingly recognised as a major public health 
issue (Azevedo et al., 2007; Mourãão et al., 2009). In contrast to OROV and LACV, 
which cause clinical disease in man, SBV and AKAV are associated with foetal 
malformation, still birth, and abortion in ruminants (Coverdale et al., 1978; van den 
Brom et al., 2012). The prototype species of the orthobunyavirus genus, and 
Bunyaviridae family, BUNV, is a cause of disease in both ruminants, equines and 
humans (Kokernot et al., 1958; Spence and Downs, 1968; Edwards et al., 1989; Tauro 
et al., 2012; Tauro et al., 2015). 
 
 
1.1.2.2 Hantavirus 
 
There are currently 23 ICTV-recognised hantavirus species and a further 30 named 
virus isolates that are probable, but unclassified, members of the genus (Plyusnin et al., 
2012). Hantaviruses are unique amongst the Bunyaviridae family as their life cycle 
does not contain an arthropod vector, instead they are maintained in nature through 
rodent, bat and insectivore species (Jonsson et al., 2010; Gu et al., 2014; Sabino-Santos 
et al., 2015). In rodents hantaviruses cause persistent asymptomatic infections, during 
which they are shed into the environment in rodent excreta. As the excreta dry they can 
become aerosolised, spreading to new hosts via inhalation, or occasionally via a bite. In 
humans hantaviruses cause acute infections, with human to human transmission only 
documented for Andes virus (ANDV) during outbreaks in Argentina and Chilli (Wells 
et al., 1997; Padula et al., 1998; Martinez-Valdebenito et al., 2014). Human hantavirus 
infections are associated with 2 classical clinical presentations: haemorrhagic fever 
with renal syndrome (HFRS) and hantavirus pulmonary syndrome (HPS) (Avšič-
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Županc et al., 2013). HFRS is traditionally associated with Old World hantaviruses 
such as Hantaan virus (HNTV), Dobrava-Belgrade virus, Puumala virus and Seoul 
virus (SEOV) (Chumakov et al., 1981; Tkachenko et al., 1982; Lee et al., 1982a; Lee 
et al., 1982b; Avšič-Županc et al., 2013). HPS, which normally presents as a non-
specific prodromal febrile illness that rapidly progresses to acute pulmonary oedema 
with cardiogenic shock, is associated with the New World hantaviruses which include 
Andes virus (ANDV), Black Creek Canal virus (BCCV), Bayou virus and Sin Nombre 
virus (SNV) (Nichol et al., 1993; Duchin et al., 1994; Zaki et al., 1995; MacNeil et al., 
2011; Núñez et al., 2014).  
 
 
1.1.2.3 Phlebovirus 
 
The Phlebovirus genus currently contains 9 ICTV-recognised virus species, or 
antigenic complexes, and a further 35 tentative virus species pending classification 
(Bouloy, 2011; Plyusnin et al., 2012). The genus is divided into 2 main subgroups, the 
sandfly fever group contains viruses transmitted by mosquitoes, phlebotomines and 
ceratopogonids, whilst the Uukuniemi group contains viruses transmitted by ticks 
(Bouloy, 2011; Plyusnin et al., 2012). The type species of the genus, Rift Valley fever 
virus (RVFV), a member of the sandfly fever group, causes severe disease in livestock 
and humans. Major epidemics usually follow periods of excessive rain, as flooding 
creates fresh water reservoirs and mosquito populations boom (Andriamandimby et al., 
2010; Bouloy, 2011). In ruminants RVFV causes fever, hepatitis and/or abortion, 
regardless of the stage of pregnancy, with ‘abortion storms’ a hallmark of RVFV 
outbreaks. In humans RVFV infections are frequently asymptomatic or restricted to a 
self-limiting febrile illness; however, severe and potentially fatal disease can occur with 
encephalitis, retinitis, and hepatitis associated with haemorrhagic fever (Imam et al., 
1979; McIntosh et al., 1980; Alrajhi et al., 2004; Bouloy, 2011). Other viruses in the 
sandfly fever group, such as Toscana virus (TOSV), are also associated with human 
infection, although disease is limited to a self-limiting febrile illness with occasional 
meningeal involvement, with no recorded fatalities (Charrel et al., 2005; Nougairede et 
al., 2013). Tick-borne phleboviruses were, until recently, associated only with sub-
clinical infections. However, in 2007 a novel tick-borne phlebovirus, severe fever with 
thrombocytopenia syndrome virus (SFTSV), emerged in South East Asia (Bao et al., 
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2011; Yu et al., 2011). SFTSV infection was characterised by gastrointestinal 
symptoms, arthralgia, myalgia, thrombocytopaenia and haemorrhage with a case 
fatality rate (CFR) of 2% - 15% (Guo et al., 2015a; Li, 2015b). This was quickly 
followed by the isolation of Heartland virus from patients in the USA suffering from 
fever, gastrointestinal symptoms and thrombocytopenia (Xing et al., 2013; Nasci et al., 
2014). Recent molecular studies have also identified viruses within the unclassified 
Bhanja virus antigenic complex as tick-borne phleboviruses associated with human 
disease (Matsuno et al., 2013; Palacios et al., 2013). 
 
 
1.1.2.4 Nairovirus 
 
Nairoviruses are primarily transmitted by ticks, although occasional transmission by 
mosquitoes has been reported (Sudeep et al., 2009; Frias-Staheli et al., 2011). 
Transovarial transmission in ticks ensures maintenance in the environment, whilst 
nairovirus infection of vertebrate hosts plays an important amplifying role in the virus 
life cycle. The Nairovirus genus currently contains 36 named virus isolates classified 
into 7 virus species, or antigenic complexes (Frias-Staheli et al., 2011; Plyusnin et al., 
2012; Lasecka and Baron, 2014). Several members of the genus cause severe disease 
(Table 1-1). Crimean-Congo haemorrhagic fever virus (CCHFV) is endemic in tick 
populations in parts of Africa, Asia and Southern and Eastern Europe (Papa et al., 
2009; Gergova et al., 2012; Tekin et al., 2012; Messina et al., 2015). CCHFV causes 
asymptomatic infection in livestock and wild herbivores; however, in humans it can 
cause severe morbidity, developing into a haemorrhagic fever with < 30% CFR 
(Ergönül, 2006). Conversely, Nairobi sheep disease virus (NSDV), which is also 
referred to as Ganjam virus, is associated with a benign febrile illness in man but severe 
gastroenteritis and abortion in sheep and goats, with a CFR close to 90% (Morrill et al., 
1990; Davies, 1997; Marczinke and Nichol, 2002; Sudeep et al., 2009).  
 
 
1.1.2.5 Tospovirus 
 
Tospoviruses are pathogenic plant viruses and there are currently 8 ICTV-recognised 
species with 13 additional virus isolates pending classification (Kormelink, 2011; 
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Plyusnin et al., 2012). Tospoviruses infect ornamental plants and economically 
important crops with annual crop losses estimated at > $ 1 billion (Goldbach and 
Peters, 1994). The type species of the genus, Tomato spotted wilt virus (TSWV), 
infects > 800 plant species, with disease presentation including wilted leaves, necrotic 
spotting, reduced vegetative output and plant death (Kormelink, 2011). Tospoviruses 
are transmitted and propagated by 13 species of thrips, which have a global 
distribution. Thrips are infected as larvae, and the virus then undergoes a period of 
latency and replication prior to transmission during the adult stages of the thrips life 
cycle (Kormelink, 2011). The only exception to this is Frankliniella occidentalis 
(Western flower thrips), which have been shown to transmit the virus from second 
larval instars stage onwards (Wijkamp et al., 1995). The viruses are transmitted to 
naïve plants during feeding, with virus particles injected into the host cell cytoplasm. 
Interestingly adult thrips that feed on infected plants do not propagate the virus, as the 
virus particles are retained in the thrips midgut (Ullman et al., 1992; Nagata et al., 
1999).  
 
 
1.1.2.6 Unclassified Bunyaviruses 
 
There are a number of serologically distinct bunyaviruses isolated during arbovirus 
surveillance that have yet to be assigned to a genus or virus species (Table 1-2). 
Furthermore, the number of unclassified bunyaviruses is rising as high-throughput 
sequencing (HTS) screens of insect pools and clinical samples identify probable 
bunyaviruses that challenge current classification methods (Table 1-2, Figure 1-1) (Li 
et al., 2015a). For example, Brazoran virus, isolated from mosquitoes in North America 
appears most similar to viruses in the orthobunyavirus genus (Lanciotti et al., 2013). 
However, it employs a unique coding strategy, in which the NSs ORF precedes that of 
the N protein (Lanciotti et al., 2013). An increasing number of insect-only viruses with 
limited homology to either the Phlebovirus or Orthobunyavirus and Tospovirus genera 
have also been discovered and it is proposed that they may form 2 new genera within 
the Bunyaviridae family (Marklewitz et al., 2011; Marklewitz et al., 2013). Many of 
the serologically characterised viruses lack sequencing information, and similarly, 
many of the new viruses identified by sequencing lack serological data. Sequencing 
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serologically classified viruses will aid virus classification and help unravel the 
complex relationships and evolutionary history of bunya-like viruses. 
 
 
1.1.3 Virion Structure 
 
Bunyaviruses have pleomorphic or spherical enveloped virus particles 80 nm - 120 nm 
in diameter when observed by cryo-electron microscopy (Holmes, 1971; Murphy et al., 
1973; Porterfield et al., 1975; Plyusnin et al., 2012). Glycoprotein projections of 5 nm 
to 10 nm, can be seen protruding from the host derived lipid bilayer, which is 5 - 7 nm 
thick (Figure 1-2) (Holmes, 1971; Talmon et al., 1987; Huiskonen et al., 2009; Battisti 
et al., 2010; Bowden et al., 2013). The glycoproteins are present in a 1:1 molar ratio 
and arranged in heterodimers, the exact arrangement of which varies between the 
different bunyavirus genera. Hantavirus Gn/Gc heterodimers are arranged in tetramers 
that have 4-fold symmetry and are unevenly distributed across the virion surface 
(Battisti et al., 2010; Huiskonen et al., 2010). In contrast, phlebovirus Gn/Gc 
heterodimers form round, closely packed capsomeres that display T=12 icosahedral 
symmetry (Freiberg et al., 2008; Huiskonen et al., 2009; Sherman et al., 2009). The 
glycoprotein heterodimers of orthobunyaviruses, tospoviruses and nairoviruses were 
thought to be disordered; however, high resolution cryo-electron microscopy of BUNV 
has recently identified a tripodal spike (Figure 1-2B) (Bowden et al., 2013). The virus 
genome is enclosed within the lipid envelope. Each RNA genome segment is 
encapsidated by the virus nucleocapsid protein (N) to form ribonucleocapsid protein 
(RNP) complexes that associate with small amounts of virus L protein. Bunyavirus 
RNPs lack helical symmetry and appear as non-condensed, imperfect circles due to 
base-pairing of complementary terminal sequences present in each genome segment 
(Figure 1-2A).   
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Figure 1-2: Bunyavirus Particle Structure 
A) Schematic representation of a typical bunyavirus particle showing host derived lipid 
envelope with projections of the virus glycoproteins, Gn and Gc, which are present as 
heterodimers. The lipid envelope surrounds the virus genome segments, S, M and L, which are 
encapsidated by virus nucleocapsid protein (N), forming ribonucleocapsid protein (RNP) 
complexes. Each RNP complex is associated with small amounts of the virus polymerase (L) 
protein and forms a panhandle structure due to complementarity in terminal untranslated 
regions (UTRs). B) Computational model of a Bunyamwera virus particle created by mapping 
averaged glycoprotein structures onto a tomographic reconstruction. Image taken from Bowden 
et al., 2013. C) Cryo-electron micrographs of Bunyamwera virions, Hantaan virions embedded 
in vitreous ice and Rift Valley fever virions. Scale bars represent 100 nm. Images were taken 
from Bowden et al., 2013, Battisti et al., 2010 and Huiskonen et al., 2009, respectively. 
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1.1.4 Genome Organisation and Coding Strategy 
 
Bunyaviruses have tripartite negative, or ambisense, single-stranded (ss) RNA 
genomes. Each genome segment comprises a coding region flanked by terminal 3’ and 
5’ untranslated regions (UTRs) of varying lengths. The RNA genome segments have 
genus-specific 3’ and 5’ terminal sequences (Table 1-3) (Elliott and Blakqori, 2011; 
Plyusnin et al., 2012). These sequences have inverted complementarity, allowing base 
pairing and the formation of the characteristic panhandle structure.  
 
The three genome segments, termed small (S), medium (M) and large (L), encode 4 
structural proteins; the S segment encodes the N protein, the M segment encodes 
glycoproteins Gn and Gc, and the L segment encodes the L protein, an RNA-dependent 
RNA polymerase (RdRp) (Table 1-3, Figure 1-3). In addition to the conserved 
structural proteins S and M genome segments may encode accessory proteins. These 
proteins lack conservation differing in their polarity, genome location and 
presence/absence (Figure 1-3) (Plyusnin et al., 2011). The S segments of 
phleboviruses, tospoviruses, hantaviruses and orthobunyaviruses may encode a non-
structural protein, NSs. The NSs proteins of hantaviruses and orthobunyaviruses are 
encoded in an overlapping reading frame that occurs within the N protein ORF. In 
contrast, phleboviruses and tospoviruses have an ambisense coding strategy with a 
negative sense ORF encoding the virus N protein and a separate positive sense ORF 
encoding the NSs protein (Figure 1-3). The M segments of orthobunyaviruses, sandfly 
fever group phleboviruses, and tospoviruses also encode a non-structural protein, NSm. 
Tospovirus NSm proteins are encoded in a separate ambisense ORF whilst 
orthobunyavirus and phlebovirus NSm proteins are encoded as part of the M 
polyprotein (Figure 1-3).  
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Table 1-3: Molecular Characteristics of the Bunyaviridae 
Genus Size of RNA Segments (kb) 
Size of Structural 
Proteins (kDa) 
3’ and 5’ consensus 
sequences 
Orthobunyavirus 
L    6.9 
M   4.5 
S    1.0 
 L             250 
 Gc, Gn   110, 35 
 N             25 
3‘ UCAUCACAUGA... 
...UCGUGUGAUGA 5’ 
Hantavirus 
L    6.5 
M   3.6 
S    1.7 
 L            250 
 Gc,Gn    55, 70 
 N            50 
3‘ AUCAUCAUCUG... 
......AUGAUGAU 5’ 
Phlebovirus  
L    6.4 
M   3.5 
S    1.7 
 L             250 
 Gc, Gn   65, 55-70 
 N            30 
3’ UGUGUUUC... 
...GAAACACA 5’ 
Nairovirus 
L  12.2 
M   4.9 
S    1.7 
 L            450 
 Gc, Gn   75, 35 
 N            50 
3’ AGAGUUUCU... 
...AGAAACUCU 5’ 
Tospovirus 
L    8.9 
M   4.8 
S    2.9 
 L             330 
 Gc, Gn   75, 45 
 N            30 
3’ UCUCGUUAAG... 
....CUAACGAGA 5’ 
 
Molecular characteristics of each bunyavirus genus are given. RNA sizes of genome segments 
small (S), medium (M) and large (L) rounded to the nearest 100 bases highlight genus specific 
features such as the large nairovirus L segment which encodes an L protein that is over 100 
kDa larger than that of viruses in other genera. Genus-specific terminal consensus sequences 
are also shown. Table adapted from Elliott and Blakqori, 2011.  
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Figure 1-3: Coding Strategy of Type Species 
Schematic representation of the virus genomes of Bunyamwera virus (BUNV), Hantaan virus 
(HTNV), Rift Valley fever virus (RVFV), Dugbe virus (DGUV) and tomato spotted wilt virus 
(TSWV), the type species of each bunyavirus genus. Viral genome RNA (vRNA) is depicted 
by capped lines, with size in nucleotides (nt) (S segments scaled at 1.5). Arrowed lines 
represent 5’ capped mRNA with the arrow indicating the direction of transcription. Coloured 
boxes represent virus proteins: nucleocapsid protein (N), non-structural proteins (NSs, NSm), 
glycoproteins (Gn, Gc) and viral polymerase (L). Figure adapted from Plyusnin et al., 2011. 
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1.1.5 Bunyavirus Gene Products 
 
1.1.5.1 Nucleocapsid Protein 
 
The N protein is the most abundant viral protein during virus replication, reflecting the 
multifactorial role of this protein in the virus life cycle (Elliott and Blakqori, 2011; 
Plyusnin et al., 2011). Bunyavirus N proteins range from 25 kDa – 50 kDa in size and 
although there is little sequence homology the proteins share common functions, the 
most well-studied of which is the encapsidation of nascent vRNA and cRNA to form 
RNPs. Bunyavirus RNPs are the template for genome replication and transcription by 
the virus L protein (Kolakofsky and Hacker, 1991). Cryo-electron microscopy shows 
RNPs as imperfect string-like circles that are wider than monomeric N protein, 
suggesting that the base unit for RNA encapsidation is N multimers (Figure 1-4). This 
has recently been confirmed by x-ray crystallography, with orthobunyavirus N proteins 
forming tetramers in the presence of RNA that are of corresponding diameter to native 
RNPs (Figure 1-4) (Ariza et al., 2013; Reguera et al., 2013; Niu et al., 2013; Dong et 
al., 2013b). In contrast, hantavirus and phlebovirus N proteins form stable trimers and 
hexamers, although due to inconsistencies with native RNP diameter the repeating unit 
of these RNPs is still debated (Mir and Panganiban, 2004; Raymond et al., 2010; 
Raymond et al., 2012; Guo et al., 2015b). Encapsidation of viral RNA by the N protein 
has been mapped to 5’ sequences in both the vRNA and cRNA, and 5’ vRNA 
sequences have been shown to be both sufficient and necessary to induce N protein 
binding (Osborne and Elliott, 2000; Severson et al., 2001; Ogg and Patterson, 2007). 
 
X-ray crystallography coupled with targeted mutagenesis has allowed detailed mapping 
of N protein functions, with distinct sites identified for N-N interactions, vRNA 
encapsidation and mRNA cap binding (Eifan and Elliott, 2009; Mir et al., 2010; Walter 
et al., 2011; Reguera et al., 2013). For example, hantavirus N proteins have been 
shown to interact with ribosomal protein S19, which forms part of the 40S subunit, 
functionally replacing the cellular cap binding complex eIF4F and initiating translation 
of viral mRNAs (Cheng et al., 2011; Mir and Panganiban, 2008). They have also been 
shown to sequester 5’mRNA caps stored in P bodies, enhancing viral transcription (Mir 
et al., 2008).   
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Figure 1-4: Bunyavirus RNP and N Protein Formation 
A) Electron micrographs of negative-stained Bunyamwera virus (BUNV) RNPs. 1) Purified 
(native) RNP from BUNV virions, scale bar represents 50 nm, 2) A single tetramer bound to 
synthetic 48-mer RNA, scale bar represents 10 nm. 3) Close-up image of purified (native) 
virion RNP highlighted by a black box in image 1, scale bar represents 10 nm. Images taken 
from Ariza et al. (2013). B) Crystal structure of tetrameric BUNV N protein, PDB 3ZLA 
(Ariza et al., 2013), images prepared in PyMol.  
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In addition to the functions described above, bunyavirus N proteins have been reported 
to interact with virus glycoproteins and the virus polymerase; however, the exact 
mechanisms and function of these interactions remain undefined. 
 
 
1.1.5.2 Glycoproteins 
 
Bunyaviruses encode 2 glycoproteins, Gn and Gc (previously known as G1 and G2), 
which are type I integral transmembrane proteins (Elliott and Blakqori, 2011). The 
glycoproteins are encoded as part of a polyprotein that is translated by ribosomes at the 
rough endoplasmic reticulum (RER). Full length polyprotein has never been detected in 
infected cells and the polyprotein is thought to undergo co-translational processing in 
the lumen of the ER (Fazakerley et al., 1988). The precise sites of polyprotein cleavage 
remain unknown for many bunyaviruses although sequence analysis identifies motifs 
that could be recognised by host cell, signal peptide peptidases (Elliott and Blakqori, 
2011; Frias-Staheli et al., 2011; Spiropoulou, 2011; Bouloy, 2011). Cleavage of 
hantavirus M polyproteins has been shown to occur at the conserved pentapeptide 
WAASA motif, and nairovirus CCHFV Gn protein is cleaved at an RRLL tetrapeptide 
sequence in the amino terminus of Gn by SKI-1 proteases (Löber et al., 2001; Sanchez, 
Vincent and Nichol, 2002; Vincent et al., 2003).  
 
During virus replication Gn and Gc accumulate at the Golgi and the Golgi 
targeting/retention signal has been mapped to the transmembrane domain of Gn, with 
Gc requiring Gn for Golgi localisation (Andersson et al., 1997; Gerrard and Nichol, 
2002; Shi et al., 2004a; Snippe et al., 2007). N-glycosylation and disulphide bond 
formation also play important roles in ensuring correct protein folding and trafficking 
(Shi et al., 2004b; Shi et al., 2005). Gn and Gc are N-glycosylated at asparagine 
residues and the position of cysteine residues is highly conserved within each genus, 
despite otherwise low sequence homology.  
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1.1.5.3 Polymerase 
 
The bunyavirus L protein acts as transcriptase, replicase and endonuclease, replicating 
the virus genome and transcribing viral mRNAs. Transcription is initiated by a ‘cap-
snatching’ mechanism in the host cell cytoplasm and the L protein acts as an 
endonuclease cleaving 5’ capped oligonucleotides from host mRNAs to prime viral 
mRNA transcription (Bishop et al., 1983; Patterson and Kolakofsky, 1984; Ihara et al., 
1985; Jin and Elliott, 1993; Reguera et al., 2010). Endonuclease activity maps to the 
amino terminal PD-(D/E)xK motif, which is conserved throughout the Bunyaviridae 
family (Reguera et al., 2010). Structure-based sequence alignments also indicate that 
similar motifs are present in the RdRp N terminus of all segmented negative sense 
RNA viruses, suggesting a common origin for the cap-snatching mechanism (Reguera 
et al., 2010).  
 
Bunyavirus L proteins also contain the conserved ‘polymerase module’, a group of 6 
motifs (designated pre-motif A, A, B, C, D, and E) present in all segmented RNA virus 
polymerases (Poch et al., 1989; Müller et al., 1994; Roberts et al., 1995). The critical 
role of the polymerase module in BUNV replication was confirmed by mutagenic 
studies, and the SDD motif present in domain C, which catalyses nucleotide 
polymerisation, shown to be essential for polymerase activity (Jin and Elliott, 1992). A 
seventh conserved region downstream of domain E has also been detected in 
bunyaviruses, the function of which has yet to be elucidated (Aquino et al., 2003).  
 
Nairoviruses encode larger L proteins than other bunyaviruses and, in addition to the 
conserved motifs already discussed, they contain an ovarian tumour (OTU) domain in 
their amino-terminal region (Honig et al., 2004; Kinsella et al., 2004). The OTU 
domain is part of a superfamily of ubiquitin-deconjugating cysteine proteases found in 
prokaryotes, eukaryotes, and viruses (Makarova et al., 2000). In nairoviruses the L 
protein OTU domain has been shown to have protease activity in vitro and it is 
hypothesised that it may play an anti-viral role, targeting the ubiquitin pathway to 
deactivate host proteins (Frias-Staheli et al., 2007; van Kasteren et al., 2012). 
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1.1.5.4 S Segment Non-structural Protein 
 
In addition to encoding the N protein, the S segment of phleboviruses, tospoviruses, 
and some members of the hantavirus and orthobunyavirus genera encode a non-
structural protein NSs. Two coding mechanisms are utilised; hantavirus and 
orthobunyavirus NSs proteins are encoded in overlapping reading frames downstream 
of N with transcription initiated by a leaky-scanning mechanism, whilst phlebovirus 
and tospovirus NSs proteins are encoded in a separate ambisense ORF (Figure 1-2). 
Cellular localisation of NSs proteins varies, RVFV NSs protein accumulates and forms 
filaments inside the nucleus whilst hantavirus NSs proteins display granular 
cytoplasmic localisation (ANDV) and perinuclear localisation (Tula virus) (Struthers 
and Swanepoel, 1982; Yadani et al., 1999; Virtanen et al., 2009; Vera-Otarola et al., 
2012). Orthobunyavirus NSs proteins are predominantly found in the cell cytoplasm 
but intranuclear inclusions have been detected in cells transfected with FLAG-tagged 
BUNV NSs expression plasmids (Weber et al., 2001; Thomas, 2004).  
 
Despite differing coding strategies, cellular localisation, and a lack of sequence 
homology, the primary role of all NSs proteins is thought to be that of a non-essential 
virulence factor. Tospovirus NSs proteins have been shown to suppress antiviral RNA 
silencing mechanisms in plants, with TSWV NSs protein inhibiting Dicer-mediated 
cleavage of long dsRNA in vitro (Takeda et al., 2002; Bucher et al., 2003; Schnettler et 
al., 2010). Phlebovirus RVFV clone 13, which has a large in-frame deletion in the NSs 
gene, replicates well in mosquitoes and Vero E6 cells, although unlike wild type (wt) 
virus it is a strong inducer of type I IFN (Bouloy et al., 2001). Similarly, recombinant 
orthobunyaviruses lacking an NSs protein show growth attenuation in IFN-competent 
cell lines and induce high levels of IFN compared to wt NSs encoding viruses. There is, 
as yet, no reverse genetics system for hantaviruses thus limiting studies into NSs 
function. However, hantaviruses encoding an NSs protein survive for more passages in 
IFN-competent cell lines than naturally occurring NSs deficient viruses (Jääskeläinen et 
al., 2008). Transient expression of hantavirus NSs proteins has also been shown to 
antagonise IFN-β promoter activity and IFN synthesis in vitro, albeit to a lesser degree 
than those of BUNV or RVFV (Jääskeläinen et al., 2007). The role of NSs as a 
virulence factor and the mechanisms of NSs interactions with the type I IFN system are 
discussed in greater detail in section 1.1.7. 
1: General Introduction 20 
 
1.1.5.4 M segment Non-structural Proteins 
 
The M segment encodes the virus glycoproteins Gn and Gc and, in phleboviruses, 
tospoviruses and orthobunyaviruses, the non-structural protein NSm (Figure 1-3). M 
segment non-structural proteins have key roles in protein maturation, virion assembly 
and release. The orthobunyavirus NSm protein is encoded between Gn and Gc as part 
of the M polyprotein and is thought to be cleaved by a furin-like enzyme due to the 
presence of a conserved RxxR motif in the C terminus of Gn (Briese et al., 2004; 
Fazakerley et al., 1988; Gerbaud et al., 1992). In contrast, sandfly fever group 
phleboviruses encode NSm pre-Gn and in RVFV alternate use of inframe AUG codons 
determines synthesis of either NSm1-Gc polyprotein, or NSm2-Gn-Gc polyprotein, 
which encode 78 kDa and 14 kDa NSm proteins respectively (Bouloy, 2011; Suzich et 
al., 1990). Phlebovirus and orthobunyavirus NSm proteins are thought to play an 
important role in virus assembly, acting as scaffolding proteins and localising to the 
Golgi independently of Gn and Gc (Fontana et al., 2008; Lappin et al,. 1994; Nakitare 
and Elliott, 1993; Shi et al., 2006). Tospovirus NSm proteins are encoded in an 
ambisense ORF and play a key role in cell-to-cell spread of virus RNPs in plant hosts, 
interacting directly with virus N protein (Soellick et al., 2000; Leastro et al., 2015).  
 
The M segments of nairoviruses encode 2 additional proteins, glycoprotein GP38 and a 
mucin-rich protein, the functions of which remain undefined. The additional proteins 
are located at the N terminal region, pre-Gn (Sanchez et al., 2002).  
 
 
1.1.6 Replication in Mammalian Cells 
 
The bunyavirus replication cycle comprises 4 main stages: virus attachment and cell 
entry; primary transcription and translation; genome replication; and virion assembly, 
maturation and release (Figure 1-5). 
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Figure 1-5: Bunyavirus Replication Cycle  
Schematic representation of bunyavirus replication in mammalian cells. 1) Infectious virus 
particles attach to cell surface receptors inducing receptor clustering and receptor-mediated 
endocytosis. 2) Virus particles dissociate from host cell receptors and following late endosomal 
acidification membrane fusion occurs releasing RNPs into the cytoplasm. 3) Virus replication 
begins with virion-associated L protein synthesising viral mRNAs and cRNAs. 4) S and L 
segment mRNAs are translated at free ribosomes into N, NSs (when encoded) and L proteins 
whilst the M segment mRNA is translated into viral glycoproteins and NSm (when encoded) by 
ribosomes at the rough endoplasmic reticulum (RER). 5) As viral replication continues viral 
tubes linked to the RER and mitochondria form in association with Golgi stacks. The L protein 
concentrates in the globular domain of viral tubes, synthesising viral mRNA transcripts and full 
length cRNAs and vRNA which associate with trimeric N. 6) N is present in abundance inside 
viral tubes and around the Golgi, facilitating RNP movement through the cytoplasm with 
assistance from actomyosin based motors. 7) RNPs associate with the cytoplasmic domain of 
Gn/Gc heterodimers which are concentrated in Golgi membranes due to the presence of the 
Golgi retention signal in Gn. 8) Once associated with Gc/Gn, RNP packaging occurs and new 
virus particles form and mature through budding. Figure adapted from Fontana et al., 2008 and 
Walter and Barr, 2011.  
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1.1.6.1 Cell Attachment and Cell Entry 
 
The key mediators of cell attachment are viral surface glycoproteins, Gn and Gc, which 
interact with host cell surface receptors (Shi et al., 2010). It has been proposed that 
hantavirus cell entry is mediated through interactions with integrins, and more 
specifically that pathogenic hantaviruses utilise β3 integrins (CD61), whilst non-
pathogenic hantaviruses use β1 integrin (Gavrilovskaya et al., 1998; Gavrilovskaya et 
al., 2002; Mou et al., 2006). However, pathogenic hantavirus ANDV exhibits robust 
entry in β3 integrin deficient cells and CD55 and gC1qR/p32 have also been implicated 
in HTNV cell entry (Choi et al., 2008; Krautkrämer and Zeier, 2008; Ray et al., 2010). 
Phlebovirus cell entry may be mediated through DC-SIGN, a C-type lectin shown to 
interact with high mannose N-glycans on phlebovirus glycoproteins Gn and Gc 
(Lozach et al., 2011; Hofmann et al., 2013). High mannose N-glycans are also present 
in nairovirus, hantavirus and orthobunyavirus glycoproteins and it is postulated that 
DC-SIGN mediated entry may occur (Schmaljohn et al., 1986; Sanchez et al., 2002; 
Shi et al., 2005). However, bunyaviruses infect a range of tissues that exceeds the 
cellular distribution of DC-SIGN, and additional receptors must therefore exist (Lozach 
et al., 2011). In addition to varying receptor specificity, the polarity of cell attachment 
varies across the Bunyaviridae, for example, in polarised epithelial cells CCHFV shows 
basolateral entry, BCCV apical entry, whilst RVFV and ANDV exhibit bidirectional 
entry (Ravkov et al., 1997; Gerrard et al., 2002; Rowe and Pekosz, 2006; Connolly-
Andersen et al., 2007). 
 
Following attachment, bunyaviruses undergo receptor-mediated endocytosis in a 
clathrin-dependent, caveolin-independent process (Jin et al., 2002; Santos et al., 2008; 
Simon et al., 2009; Lozach et al., 2011; Hollidge et al., 2012). However, some 
bunyaviruses, e.g. ANDV, utilise an alternative and undefined mechanism as both 
clathrin and caveolin inhibitors chlorpromazine and filipin fail to prevent virus entry 
(Ramanathan and Jonsson, 2008). Following internalisation, virus containing vesicles 
undergo acidification, inducing membrane fusion and releasing viral RNPs into the 
cytoplasm (Figure 1-5). Studies with LACV predict that a 22 amino acid (aa) 
hydrophobic domain in Gc (residues 1066-1087) acts as a class II fusion peptide 
undergoing pH-dependent conformational change associated with membrane fusion 
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(Plassmeyer et al., 2005; Plassmeyer et al., 2007). This region is conserved among 
other members of the Bunyaviridae and mutational analysis supports this hypothesis 
(Plassmeyer et al., 2007; Shi et al., 2009). However, studies with BUNV have also 
shown that the cytoplasmic tail of Gn also plays a pivotal role in membrane fusion (Shi 
et al., 2007).  
 
 
1.1.6.2 Primary Transcription and Translation 
 
Following cell entry, RNP complexes are released into the host cell cytoplasm, 
shielding the negative sense RNA genome from exposure to the host cell and initiating 
viral replication (Figure 1-5).  
 
Virion associated L protein initiates transcription of functional viral mRNAs via a ‘cap-
snatching’ mechanism whereby L exhibits endonuclease activity cleaving mature host 
cellular mRNAs present in the cytoplasm to generate short primers of 5’ capped mRNA 
(Figure 1-6) (Bishop et al., 1983; Patterson and Kolakofsky, 1984; Ihara et al., 1985; 
Jin and Elliott, 1993; Kukkonen et al., 2004; Reguera et al., 2010). Fully transcribed 
viral mRNAs are shorter than their genome counterparts and termination signals with 
conserved pentanucleotide motifs have been identified in the 5’ UTR of 
orthobunyavirus S and L segments and phlebovirus S and M segments (Barr et al., 
2006; Ikegami et al., 2007; Albariño et al., 2007). However, termination signals have 
yet to be characterised in the orthobunyavirus M segment, phlebovirus L segment or 
the hantavirus genera. 
 
Translation of viral mRNAs occurs concurrently with transcription and is required to 
prevent premature termination of transcription (Figure 1-6C) (Abraham and Pattnaik, 
1983; Barr, 2007; Lara et al., 2011). It is postulated that ribosome translocation blocks 
termination signals present in the coding region of viral mRNAs, disrupting RNA-RNA 
interactions and facilitating the progression of L (Barr, 2007). It is also important to 
note that, excluding the M segment of SNV, bunyavirus mRNAs are not 
polyadenylated; translation is therefore not enhanced via poly-A binding protein 
(PABP) and knockdown of PABP does not inhibit translation of viral mRNAs 
(Abraham and Pattnaik, 1983; Hutchinson et al., 1996; Blakqori et al., 2009).  
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Figure 1-6: Bunyavirus Transcription and Translation  
Schematic representation of bunyavirus mRNA transcription initiation and subsequent 
translation. A) The viral L protein, an RNA-dependent RNA polymerase, exhibits 
endonuclease activity, cleaving 5’ capped oligonucleotides from host cellular mRNAs. B) 
Cleaved 5’ capped oligonucleotides are used to prime transcription of viral mRNAs from the 
virus genome (vRNA). C) Translation occurs concurrently with transcription.   
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However, reduced levels of eukaryotic translation initiation factor (eIF) 4G has a 
marked effect on viral translation indicating a PABP-independent, eIF4G-dependent 
mechanism of translation (Blakqori et al., 2009).  
 
 
1.1.6.3 Genome Replication 
 
It is unclear what triggers the switch from transcription to replication in infected cells 
although increasing levels of N may play a role (Elliott and Blakqori, 2011). 
Replication and synthesis of the cRNA (also known as the antigenome) is initiated via 
5’ nucleoside triphosphates, therefore unlike viral mRNAs the cRNA lacks a 5’ primer 
extension (Kolakofsky and Hacker, 1991). The cRNA represents a full length copy of 
the viral genome, extending to the 5’ terminus of the genomic RNA template (Figure 1-
7) (Kolakofsky and Hacker, 1991). The mechanism by which the polymerase reads 
through mRNA transcription termination signals remains undefined; it may be that 
interactions with host proteins alter its function or that encapsidation of nascent 
antigenome prevents RNA RNA interactions, blocking mRNA termination signals 
(Elliott and Blakqori, 2011).  
 
 
1.1.6.4 Virion Assembly, Maturation and Release 
 
Bunyavirus maturation typically occurs at smooth membranes in the Golgi, the site of 
virus glycoprotein retention and accumulation, although maturation at the plasma 
membrane has been observed with New World hantaviruses and RVFV (Holmes, 1971; 
Zeller et al., 1989; Novoa et al., 2005; Fontana et al., 2008; Shi et al., 2010; Plyusnin 
et al., 2012). Glycoproteins Gc and Gn are cysteine rich and following cotranslational 
processing form a heterodimer in the ER prior to localisation at the Golgi due to a 
targeting sequence in Gn (Matsuoka et al., 1994; Matsuoka et al., 1996; Andersson et 
al., 1997; Gerrard and Nichol, 2002; Shi et al., 2004a; Snippe et al., 2007; Huiskonen 
et al., 2009).  
 
It is at the Golgi that glycoproteins associate with RNPs. Scanning mutagenesis of the 
phlebovirus Uukuniemi virus (UUKV) identified aa 76 - 81 in the Gn cytoplasmic tail   
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Figure 1-7: Translation and Replication  
Schematic representation of bunyavirus replication, transcription and translation. A) 5’ capped 
mRNA is transcribed from the viral genome (vRNA), whereas the virus genome replicates via 
full length complementary copies (cRNA), which is also referred to as the antigenome. B) 
Transcription and translation in viruses with an ambisense coding strategy. Transcription of the 
ambisense ORF occurs from the cRNA and not vRNA. 
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(CT) as essential for RNP binding and packaging (Overby et al., 2007). Furthermore, 
studies with RVFV indicate that Gn is sufficient for RNP packaging and hantavirus Gn 
CT has been shown to directly interact with N, supporting the hypothesis that the Gn 
CT of glycoprotein multimers interacts with N in RNP packaging (Wang et al., 2010; 
Piper et al., 2011). RNPs form throughout the replication cycle, and encapsidation is 
thought to be concomitant with RNA synthesis (Figure 1-5). Within RNPs the signal 
for encapsidation maps to the 5’ termini of vRNAs and cRNAs, with this region both 
necessary and sufficient for encapsidation of viral and non-viral RNAs (Osborne and 
Elliott, 2000; Severson et al., 2001; Ogg and Patterson, 2007). Furthermore, the 5’UTR 
of the M segment is key in ensuring the co-packaging of all 3 RNA segments, although 
interactions between the 3 RNAs are also involved (Elliott and Blakqori, 2011; 
Terasaki et al., 2011).  
 
Once RNPs are encapsidated and associated with viral glycoproteins, immature 
precursors assemble into dense intermediate virus particles at the Golgi stacks with 
glycoproteins becoming partially resistant to endo-B-N-acetylglucosaminidase H 
digestion prior to budding from the cell (Gerbaud et al., 1992; Novoa et al., 2005). In 
UUKV Gn protein aa 21 - 25 and 46 - 50 are key for the successful initiation of virus 
particle budding and trafficking from the ER to the Golgi, respectively. From the Golgi 
immature virus particles are transported within vacuoles to the cell surface via the 
exocytic pathway where fusion of the vacuole and plasma membrane releases the virus 
into the extracellular environment (Figure 1-5). The polarity of virion release varies 
and following release from the host cell bunyaviruses undergo a final stage of 
maturation and defined glycoprotein spikes become visible on the virion surface 
(Pekosz and González-Scarano, 1996; Gerrard et al., 2002; Rowe and Pekosz, 2006; 
Elliott and Blakqori, 2011). 
 
 
1.1.7 Bunyavirus Interaction With The Host Cell 
 
1.1.7.1 Activation of the Innate Immune Response  
 
The innate immune system is the first line of defence against pathogens, with pathogen 
recognition receptors (PRRs) recognising foreign particles through pathogen 
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association molecular patterns (PAMPs). The toll like receptors (TLRs) are a subset of 
PRRs and the expression of TLR3, an endosomal receptor which recognises dsRNA, 
has been shown to alter the pathogenesis of bunyavirus infection (Gowen et al., 2008; 
Jeong and Lee, 2011) (Figure 1-8). In Hantaan virus infections TLR3 is required for 
activation of MxA, and expression of TLR3 is linked with an attenuation in virus titre 
(Handke et al., 2009). TLR3 also plays a key role in the immune-modulated 
pathogenesis of phlebovirus Punta Toro virus (PTV) with TLR3-mediated upregulation 
of IL-6 and inflammatory mediators contributing to disease severity in mouse models 
(Gowen et al., 2006). TLR3 recognition of dsRNA is independent of RNA sequence, 
and once bound to dsRNA TLR3 forms dimers which act as a signalling complex, 
triggering activation of the type I IFN response (Alexopoulou et al., 2001; Doyle et al., 
2002; Leonard et al., 2008).  
 
Bunyavirus RNA may also be recognised by cytoplasmic PRRs, RIG-I (retinoic acid 
inducible gene I) and PKR (protein kinase R) (Streitenfeld et al., 2003; Nallagatla et 
al., 2007; Weber et al., 2013). RIG-I recognises dsRNA and ssRNA with polyuridine 
or 5’triphosphate sequences and bunyavirus RNPs with 5’ triphosphorylated panhandle 
structures have been shown to activate RIG-I in vitro (Figure 1-8) (Weber et al., 2013). 
Hantaviruses and nairoviruses process their viral RNA to form 5’monophosphorylated 
genomes, which in theory should minimise RIG-I activation (Habjan et al., 2008; 
Wang et al., 2011). Yet, Lee et al. (2011) demonstrated that expression of HTNV N 
ORF stimulates RIG-I and it is postulated that this may be due secondary structures 
within the vRNA. PKR, a serine-threonine kinase, also recognises dsRNA and ssRNA 
with 5’triphosphate groups and activates NFκB. In addition to acting as a PRR, PKR 
acts as an ISG. PKR-mediated suppression of mRNA translation is discussed in section 
1.1.7.2. 
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Figure 1-8: Interactions with Type I Interferon Response  
Schematic representation of bunyavirus interaction with type I interferon (IFN) response. 
Bunyavirus particles are recognised by pathogen recognition receptors including RIG-I, PKR 
and TLR3. Red crosses mark bunyavirus mechanisms to antagonise and evade the type I IFN 
system. 1) CCHFV has a 5’monophosorylated genome that is not recognised by RIG-I. 2, 3) 
Hantavirus Gn inhibits IKKε and TBK-1 kinases, preventing dimerisation and nuclear 
translocation of IRF-3. 4) The viral ovarian tumour domain in CCHFV L protein inhibits 
activation of NFκB. 5) Hantavirus N protein binds importin-alpha, blocking nuclear 
translocation of NFκB. 6,7) NSs proteins inhibit RNA polymerase II, blocking transcription of 
cellular mRNAs. 8,9) RVFV NSs protein activates SOCS-1a, a negative regulator of JAK-
STAT signalling pathway, and induces PKR degradation. Figure adapted from Haller et al., 
2006 with bunyavirus evasion and antagonism overlaid. 
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1.1.7.2 Evasion and Antagonism of the Type I IFN Response 
 
The type I IFN system is a powerful component of the innate immune response, 
activated by PRRs and capable of regulating hundreds of IFN-stimulated genes (ISGs). 
Many bunyaviruses suppress activation of this system. For example, orthobunyavirus 
and phlebovirus NSs proteins antagonise the type I IFN response at the transcriptional 
level, blocking RNA polymerase II (RNAPII) and inhibiting the transcription of 
cellular mRNAs (Weber et al., 2002; Billecocq et al., 2004; Thomas, 2004). This 
blockade has a profound effect on the IFN-β promoter and recombinant viruses lacking 
NSs show increased sensitivity to type I IFNs (Bridgen et al., 2001; Blakqori et al., 
2007). RVFV NSs has also been shown to interact with SAP30 (Sin3A associated 
protein 30), a cellular protein forming part of a Sin3A/NCoR/HDAC-3 co-repressor 
complex which binds to the IFN-β promoter (Le May et al., 2008). The binding of NSs 
to this complex inhibits histone acetylation and the recruitment of co-activator CREB 
binding protein and YY1 at the -122 site, preventing promoter activation (Le May et 
al., 2008). The importance of this interaction was shown by Le May et al. (2008) who 
created recombinant virus recZHD210-230 in which NSs lacked the SAP30 binding 
domain; this virus was unable to antagonise IFN-β expression and was avirulent in a 
mouse model. RVFV NSs has also been shown to activate SOCS-1, a negative 
regulator of the JAK-STAT pathway inhibiting STAT activation and subsequent 
induction of ISGs (Figure 1-8) (Haller et al., 2006). 
 
Hantavirus NSs proteins only partially inhibit IFN synthesis, and some pathogenic 
bunyaviruses do not encode an NSs protein, strongly suggesting additional mechanisms 
of IFN suppression (Jääskeläinen et al., 2007; Mohamed et al., 2009). Both pathogenic 
and non-pathogenic hantaviruses inhibit the IFN signalling pathway, suppressing 
phosphorylation and nuclear translocation of STAT-1 and 2 (Spiropoulou et al., 2007). 
However, pathogenic hantaviruses induce ISGs later than non-pathogenic hantaviruses 
in primary endothelial cells and IRF-3 dimerisation and nuclear translocation is also 
down-regulated (Kraus et al., 2004). The Gn proteins of pathogenic hantaviruses 
contain conserved ITAM (immunoreceptor tyrosine-based activation motif) sequences 
and have been shown to inhibit IKKe and TBK-1 kinases, suppressing IRF-3 
phosphorylation and nuclear translocation (Figure 1-8) (Geimonen et al., 2003; Alff et 
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al., 2006; Alff et al., 2008). The N proteins of Old World hantaviruses have also been 
shown to be involved in IFN suppression, binding importin-α and blocking nuclear 
translocation of NFκB (Taylor et al., 2009).  
 
In addition to suppressing IFN activation and signalling, bunyaviruses antagonise and 
evade ISG products. ISG products known to have anti-bunyavirus activity include 
MxA, the 2’-5’ OAS system, viperin, and IFI44 (MTAP44). Human MxA protein is a 
large (76 kDa) GTPase that accumulates in the cytoplasm of IFN-treated cells and acts 
as a defence against RNA viruses (Kochs, 2002; Haller and Kochs, 2002; Bridgen et 
al., 2004). Members of the orthobunyavirus, hantavirus, nairovirus and phlebovirus 
genera have been shown to be sensitive to MxA (Frese et al., 1996; Kanerva et al., 
1996; Andersson et al., 2004; Bridgen et al., 2004). Studies with LACV have found 
that MxA binds N, forming MxA/N copolymers that localise at the perinuclear 
compartment, inhibiting transport of N to the Golgi and reducing N protein availability 
at replication sites (Reichelt et al., 2004; Kochs and Haller, 2010). A decrease in viral 
N protein and viral RNA genome synthesis have also been shown to occur in Dugbe 
virus (DGUV) infected cells expressing MxA (Bridgen et al., 2004). However, not all 
bunyaviruses are sensitive to MxA, and it has little effect on BUNV (Bridgen et al., 
2004).  
 
The type I IFN response upregulates PKR expression which, in addition to acting as a 
PRR and activating NKκB pathways, inhibits translation of cellular and viral mRNAs. 
On binding RNA PKR forms homo-dimers which phosphorylate the α subunit of 
eukaryotic translation initiation factor eIF-2, inhibiting mRNA translation (Goodbourn 
et al., 2000; Nallagatla et al., 2007). PKR is activated in bunyavirus infection, yet it has 
limited anti-bunyavirus activity (Streitenfeld et al., 2003). In RVFV infections this may 
be attributed to NSs mediated PKR degradation. However, this activity is specific to 
RVFV NSs, and is not shared with other phleboviruses, or the orthobunyaviruses 
LACV and BUNV (Streitenfeld et al., 2003; Habjan et al., 2009; Ikegami et al., 2009).  
 
The 2’-5’ OAS system is a group of enzymes that recognise and process dsRNAs, 
producing a series of short 2’-5’oligoadenylates that bind and activate monomeric 
RNase L, inducing formation of the active RNase L homodimer (Stark et al., 1998). 
Activated RNase L catalyses cleavage of ssRNA and 28S ribosomal RNA, inhibiting 
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viral replication and levels of Oasl2 are significantly raised in BALB/cByJ mouse 
embryonic fibroblasts infected with RVFV (do Valle et al., 2010). However, RNase L 
does not seem to have activity against BUNV as there was no difference in disease 
progression in wild type and RNase L -/- mice inoculated intracerebrally with BUNV 
(Streitenfeld et al., 2003). 
 
Additional ISG products with anti-bunyavirus activity include viperin and IFI44 
(MTAP44) (Carlton-Smith and Elliott, 2012). Viperin localises at the ER membrane 
and impairs the formation of lipid rafts which are needed by some viruses for 
replication or budding (Weber and Mirazimi, 2008). IFI44 is a cytoplasmic protein 
previously associated with HCV infection (Kitamura et al., 1994). IFI44 contains a 
GTP binding site but lacks homology to GTPases or G proteins and it has been 
proposed that IFI44 may sequester intracellular GTP, preventing extracellular signal 
regulated kinase signalling, leading to cell cycle arrest inducing an antiproliferative 
state in vitro (Hallen et al., 2007). 
 
Polyubiquitin chains also play an important role in the type I IFN response, degrading 
IκB and activating RIG-I. The amino terminus of nairovirus L proteins contain a 
functional OTU domain capable of hydrolysing poly and non-linear ubiquitin chains 
(Frias-Staheli et al., 2007; van Kasteren et al., 2012). Moreover, CCHFV L protein has 
been shown to suppress activation of the NFκB responsive promoter in a dose-
dependent manner and to hydrolyse ISG15 conjugates and precursors (Figure 1-8) 
(Frias-Staheli et al., 2007). ISG15 is an antiviral ubiquitin-like protein that is thought to 
act co-translationally to inhibit viral proteins.  
 
 
1.1.7.3 Host Cell Shut Off  
 
As mentioned previously, orthobunyavirus NSs proteins antagonise the IFN response at 
the transcriptional level, blocking RNAPII and inhibiting host cell transcription. For 
example, the C terminus of BUNV NSs protein interacts with MED8 and strongly 
inhibits the phosphorylation of serine 2 in the RNAPII C terminal domain heptapeptide 
repeat YSPTSPS, blocking transcription elongation, whilst LACV NSs induces 
degradation of RNAPII subunit RPBI (Thomas, 2004; Léonard et al., 2006; 
1: General Introduction 33 
Verbruggen et al., 2011). Phleboviruses also antagonise RNAPII, and RVFV NSs 
protein has been shown to prevent formation of TFIIH, sequestering p44 and promoting 
degradation of p62 (Billecocq et al., 2004; Le May et al., 2004; Kalveram et al., 2011).  
 
As a consequence of NSs inhibiting host cell mRNA transcription, cellular mRNA 
levels fall leading to a decrease in translation. This is exacerbated by bunyavirus L and 
N proteins, which have been shown to decrease reporter gene expression 
independently, although not as extensively as NSs. L cleaves host cell mRNAs to 
generate 5’capped leader sequences to prime viral transcription, inducing cellular 
mRNA instability and further reducing availability of cellular mRNAs (Raju and 
Kolakofsky, 1988). BUNV N protein has also been shown to bind and colocalise with 
PABP in the cytoplasm before PABP is redistributed to the nucleus. PABP N protein 
binding is enhanced in the presence of NSs and it inhibits the translation of 
polyadenylated cellular mRNAs (Blakqori et al., 2009). 
 
 
1.1.7.4. Host Cell Apoptosis and Persistent Infections 
 
The ability to induce apoptosis in mammalian cells varies across the Bunyaviridae 
family and within each genus, for example, LACV is capable of inducing apoptosis 
whilst BUNV is not (Kohl et al., 2003; Blakqori and Weber, 2005). The NSs proteins 
of California serogroup orthobunyaviruses have been shown to bind apoptotic regulator 
Scythe and to trigger cytochrome C release and caspase 3 activation inducing 
apoptosis. Conversely, in BUNV infections deletion of NSs is required to induce 
apoptosis (Colón-Ramos et al., 2003; Kohl et al., 2003). In addition to NSs, NSm 
proteins have also been shown to influence the induction of apoptosis in vitro. RVFV 
NSm displays anti-apoptotic properties in vitro and deletion of NSm triggers apoptosis 
via caspases 3, 8 and 9 (Won et al., 2007). Virus yields are not significantly affected by 
cell death and blocking apoptosis through over-expression of anti-apoptotic factors 
does not prevent eventual cell death due to extensive cytopathic effect. It therefore 
appears that apoptosis of mammalian cells is not essential for virus replication but 
rather a consequence of replication and inhibition of the type I IFN response (Blakqori 
et al., 2007).  
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In contrast to the acute infections observed in mammalian cells, a key aspect of the 
bunyavirus life cycle is the establishment of persistent infections in arthropod and 
rodent vectors. It is thought that regulatory T cells may mediate hantavirus persistence 
in rodents, during which there is a selective reduction of the pro-inflammatory response 
in the lung, limiting host pathology and perhaps facilitating continued virus replication 
(Schountz et al., 2007). However, the underlying mechanisms of persistence remain 
unclear in both rodent and arthropod vectors. It has been shown that in arthropod 
vectors viral proteins can have different functions as NSs proteins fail to block host cell 
protein synthesis and the strength of viral promoters changes (Kohl et al., 2004). 
 
 
1.2 Orthobunyaviruses 
 
1.2.1 Orthobunyavirus Classification  
 
As discussed previously, orthobunyaviruses are the largest genus within the 
Bunyaviridae with 18 serogroups containing over 170 named virus isolates and a rising 
number of unclassified viruses (Table 1-4). The current gold standard for 
orthobunyavirus classification is the PRNT assay (Plaque Reduction Neutralisation 
Test), which detects neutralising antibodies targeting viral glycoproteins. To be 
classified as a distinct virus species viruses should have > 4-fold difference in 
heterologous (Ht) versus homologous (Ho) titres (Elliott and Blakqori, 2011; Plyusnin 
et al., 2012). Complement fixation tests (CFTs), which detect anti-N antibodies, are 
also often used, although due to the occurrence of reassortant viruses, they can give 
conflicting and sometimes confusing results (Figure 1-9) (Whitman and Shope, 1962; 
Casals, 1963; Zarate et al., 1968; Berge, 1975). Classification methods have also 
recently been updated to consider sequencing data, and when available, N protein aa 
sequences should be > 10% divergent for viruses to be considered as distinct virus 
species and not part of the same replicating lineage (Elliott and Blakqori, 2011; 
Plyusnin et al., 2012).  
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Table 1-4: Orthobunyavirus Species List 
Orthobunyavirus Serogroups, Virus species and Named Isolates 
Anopheles A serogroup Anopheles B serogroup Bakau serogroup 
Anopheles A virus  Anopheles B virus Bakau virus  
Anopheles A virus (ANAV) Anopheles B virus (ANBV) Bakau virus (BAKV) 
Arumateua virus (ARTV) Boracéia virus (BORV) Ketapang virus (KETV) 
Caraipé virus (CPEV) ------------------------------------------- Nola virus (NOLAV) 
ColAn 57389 (CA57389V) Bunyamwera serogroup Tanjong Rabok virus (TRV) 
Las Maloyas virus (LMV) Bunyamwera virus Telok Forest virus (TFV) 
Lukuni virus (LUKV)  Anadyr virus (ANADV) ------------------------------------------- 
Trombetas virus (TRMV)  Batai virus (BATV) Bwamba serogroup 
   Tucuruí virus (TUCV) Birao virus (BIRV) Bwamba virus 
Tacaiuma virus Bozo virus (BOZOV) Bwamba virus (BWAV) 
Tacaiuma virus (TCMV) Bunyamwera virus (BUNV) Pongola virus (PGAV) 
CoAr 1071 virus (CA1071V) Cache Valley virus (CVV) ------------------------------------------- 
CoAr 3627 virus (CA3626V) Fort Sherman virus (FSV) California serogroup 
   Virgin River virus (VRV) Germiston virus (GERV) California encephalitis virus 
------------------------------------------- Iaco virus (IACOV) California encephalitis virus (CEV) 
Capim serogroup Ilesha virus (ILEV) Khatanga virus (KHATV)R 
Acara virus  Lokern virus (LOKV) Inkoo virus (INKV) 
Acara virus (ACAV) Maguari virus (MAGV)  Jamestown Canyon virus (JCV) 
   Moriche virus (MORV) Mboke virus (MBOV) Jerry Slough virus 
Benevides virus  Ngari virus (NRIV)R Keystone virus (KEYV) 
   Benevides virus (BVSV) Northway virus (NORV) Khatanga virus 
Bushbush virus Playas virus (PLAV) La Crosse virus (LACV) 
Benfica virus Potosi virus (POTV) Lumbo virus (LUMV) 
Bushbush virus (BSBV) Santa Rosa virus (SARV) Melao virus (MELV) 
   Juan Diaz virus (JDV) Shokwe virus (SHOV) Morro Bay virus (MBV) 
Capim virus Stanfield virus San Angelo virus (SAV) 
   Capim virus (CAPV) Tensaw virus (TENV) Serra do Navio virus (SDNV) 
Guajara virus Tlacotalpan virus (TLAV) snowshoe hare virus (SSHV) 
   Guajara virus (GJAV) Tucunduba virus (TUCV) South River virus (SORV) 
------------------------------------------- Xingu virus (XINV) Tahyña virus (TAHV) 
Gamboa serogroup Guaroa virus Trivittatus virus (TVTV) 
Alajuela virus  Guaroa virus (GROV) ------------------------------------------- 
Alajuela virus (ALJV) Kairi virus Group C serogroup 
   San Juan virus (SJV) Kairi virus (KRIV)  Caraparú virus 
Gamboa virus Main Drain virus Apeú virus (APEUV) 
Gamboa virus (GAMV) Main Drain virus (MDV) Bruconha virus (BRUV) 
   Pueblo Viejo virus (PVV) Unclassified Caraparú virus (CARV) 
-------------------------------------------  Abbey Lake virus (Ab-BUNV) Ossa virus (OSSAV) 
Guama serogroup ------------------------------------------- Vinces virus (VINV) 
Bertioga virus  Kongool serogroup Madrid virus 
Bertioga virus (BERV) Koongol virus Madrid virus (MADV) 
Cananeia virus (CNAV) Koongol virus (KOOV) Marituba virus 
Guaratuba virus (GTBV) Wongal virus (WONV) Gumbo Limbo virus (GLV) 
Itimirim virus (ITIV) ------------------------------------------- Marituba virus (MTBV) 
   Mirim virus (MIRV) Minatitlan serogroup Murutucú virus (MURV) 
Bimiti virus Minatitlan virus Nepuyo virus (NEPV) 
   Bimiti virus (BIMV) Minatitlan virus (MNTV) Restan virus (RESV) 
Catu virus Palestina virus (PLSV) Zungarococha virus (ZUNV) 
   Catu virus (CATUV) ------------------------------------------- Oriboca virus 
Guamá virus Nyando serogroup Itaquí virus (ITQV) 
Ananindeua virus (ANUV) Kaeng Khoi virus Oriboca virus (ORIV) 
Guamá virus (GMAV) Kaeng Khoi virus (KKV) ------------------------------------------ 
Mahogany Hammock virus 
(MHV) Nyando virus Patois serogroup 
   Moju virus (MOJUV) Nyando virus (NDV) Patois virus 
Timboteua virus Eretmapodites virus (EREV) Abras virus (ABRV) 
   Timboteua virus (TBTV) Unclassified Babahoya virus (BABV) 
-------------------------------------------    Mojuí dos Campos virus (MDCV) Pahayokee virus (PAHV) 
Tete serogroup ------------------------------------------- Patois virus (PATV) 
Batama virus  Olifantsvlei serogroup Shark River virus (SRV) 
   Batama virus (BMAV) Botambi virus Zegla virus 
Tete virus Botambi virus (BOTV) Zegla virus (ZEGV) 
Bahig virus (BAHV) Olifantsvlei virus ------------------------------------------ 
Matruh virus (MTRV) Bobia virus (BIAV)  
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Tete virus (TETEV) Dabakala virus (DABV)  
Tsuruse virus (TSUV) Olifantsvlei virus (OLIV)  
   Weldona virus (WELV) Oubi virus (OUBIV)  
------------------------------------------------- -------------------------------------------------  
Simbu serogroup Turlock serogroup “Mapputta serogroup” 
Akabane virus  M’Poko vius Buffalo Creek virus (BUCV) 
Akabane virus (AKAV) M’Poko virus (MPOV) Gan Gan virus (GGV) 
Sabo virus (SABOV) Yaba-1 virus (Y1V) Mapputta virus (MAPV) 
Tinaroo virus (TINV) Turlock virus Maprik virus (MPKV) 
Yaba-7 virus (Y7V) Lednice virus (LEDV) Murrumbidgee virus (MURBV) 
Manzanilla virus Turlock virus (TURV) Salt Ash virus (SASHV) 
Buttonwillow virus (BUTV) Umbre virus (UMBV) Trubanaman virus (TRUV) 
Cat Que virus ------------------------------------------------- ------------------------------------------------- 
Ingwavuma virus (INGV) “Sedlec serogroup” “Wyemoyia serogroup” 
Inini virus (INIV) Sedlec virus Wyeomyia virus 
Manzanilla virus (MANV) I612045 virus Anhembi virus (AMBV) 
Mermet virus (MERV) Oyo virus (OYOV) BeAr 328208 virus (BAV) 
Oropouche virus Sedlec virus (SEDV) Cachoeira Porteira virus (CPOV) 
Facey’s Paddock virus (FPV) ------------------------------------------------- Iaco virus (IACOV) 
Iquitos virus (IQTV) No Probable Serogroup Macaua virus (MCAV) 
Madre de Dios virus    Brazoran virus (BRAZV) Rio Pracupi virus 
Oropouche virus (OROV) Estero Real virus (ERV) Sororoca virus (SORV) 
Perdões virus Enseada virus (ENSV) Taiassui virus (TAIAV) 
Pintupo virus Khurdun virus (KHURV) Tucunduba virus (TUCV) 
Utinga virus (UTIV) Kowanyama virus (KOWV) Wyeomyia virus (WYOV) 
Utive virus (UVV/UTVEV) Marambaia virus ------------------------------------------------- 
Sathuperi virus Pacui virus (PACV)  
Douglas virus (DOUV) Rio Preto da Eva virus (RPEV)  
Sathuperi virus (SATV) Shuangao insect virus 1  
Simbu virus Tapirapé virus (TPPV)  
Simbu virus (SIMV) Termeil virus (TERV)  
Shamonda virus Wuhan louse fly virus 1  
Peaton virus (PEAV) -------------------------------------------------  
Sango virus (SANV)   
Shamonda virus (SHAV)   
Shuni virus   
Aino virus (A(I)NOV)   
Kaikalur virus (KAIV)   
Shuni virus (SHUV)   
Thimiri virus   
Thimiri virus (THIV)   
Unclassified   
Leanyer virus (LEAV)   
Jatobal virus (JATV)R   
Schmallenberg virus (SBV)R   
 
Orthobunyavirus serogroups (bold), ICTV-recognised species (italics) and classified named 
isolates (indented) are listed. Recently proposed and not yet ICTV-approved serogroups are 
indicated by quotation marks. The Wyeomyia group currently forms part of the Bunyamwera 
serogroup, whilst Mapputta and Sedlec viruses branch alone on phylogenetic analysis 
(Chowdhary et al., 2012; Bakonyi et al., 2013; Gauci et al., 2015). (R) indicates reassortant 
virus. Virus abbreviations are also listed. Table adapted from Elliott and Blakqori (2011). 
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Figure 1-9: Antigenic Relationships between Orthobunyaviruses 
Adapted from Calisher 1988, with additional data from Mohamed 2007, Shope and Whitman 
1962, Zarate et al., 1968, Zeller et al., 1989 and Berge, 1975. Orthobunyavirus serogroups are 
highlighted in boxes and those linked by cross-reaction in either neutralisation or complement 
fixation tests are joined by a black line with an example of a virus with cross-reaction. The 
dotted line indicates questionable cross-reaction. Cross-reactions that have subsequently been 
supported by sequencing and phylogenetic analysis are highlighted in turquoise.  
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1.2.2 Orthobunyavirus Evolution 
 
The driving factors behind bunyavirus evolution are genetic drift and genetic shift 
(Figure 1-10). Genetic drift occurs through the accumulation of mutations in the virus 
genome during virus replication as the virus polymerase, an RdRp, has an intrinsic 
error rate and lacks proof reading capabilities (Figure 1-10A). It is postulated that the 
low fidelity of viral RdRps may play a key role in the virus life cycle as it leads to the 
rapid accumulation of mutations and the formation of quasispecies. Quasispecies 
represent a cloud of sequences genetically linked by mutations (Schneider and 
Roossinck, 2001; Lauring and Andino, 2010; Ojosnegros et al., 2011). Cloud size is a 
key property of quasispecies, occurring when the level of diversity in a replicating 
population reaches equilibrium (Lauring and Andino, 2010). Quasispecies are thought 
to be vital in the virus life cycle, providing a source of diversity to overcome 
bottlenecks in virus replication such as host switching. Although the error rate of 
orthobunyavirus RdRp has not yet been determined, the error rate for hantavirus S 
segments is approximately 10-3, which falls within the range estimated for other RNA 
viruses (10-3 - 10-5) (Plyusnin et al., 1995; Plyusnin et al., 1996). 
 
The second driver in orthobunyavirus evolution is genetic shift, or genetic 
reassortment. Reassortment occurs during mixed infections when genome segments 
from different parental strains are co-packaged to form progeny with mixed ancestry 
(Figure -10B). In dual orthobunyavirus infections 8 progeny may therefore be formed, 
6 reassortant viruses and 2 viruses matching the parental strains (Figure 1-10B). 
Reassortment occurs only between closely related viruses and may be considered when 
forming species classification, as distinct virus species should not be able to form 
recombinant progeny (Elliott and Blakqori, 2011). Reassortant orthobunyaviruses were 
first identified in the 1970s when co-infection experiments yielded progeny viruses 
with phenotypic profiles that did not match the parental strains, providing evidence that 
orthobunyavirus genomes may be segmented (Gentsch and Bishop, 1976; Gentsch et 
al., 1977). Naturally occurring reassortant viruses have now been documented in the 
Bunyamwera, Simbu, California, Group C and Patois serogroups (Briese et al., 2013). 
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Figure 1-10: Genetic Drift and Shift 
A) Genetic Drift. A schematic representation of quasispecies development during virus 
replication. Rounds of replication are represented by concentric circles and black lines connect 
variants linked by a point mutation. Although this schematic over simplifies quasispecies it 
represents how quickly the accumulation of mutations can lead to a diverse but related 
population of viruses. Adapted from Lauring et al., 2010. B) Genetic Shift. A schematic 
representation of virus reassortment during dual infection. Two distinct viruses (orange and 
purple) infect a host cell and during virus replication genome segments from either virus may 
be incorporated into mature virus particles, resulting in 8 possible progeny. In nature 
bunyavirus reassortment appears restricted with most reassortant viruses sharing a common 
ancestor for S and L segments. 
  
A)
B)
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As more reassortant viruses are identified there appears to be a genetic preference for 
co-inheritance of S and L segments, although this does not occur in California 
serogroup viruses, or when the parental strains are themselves reassortants (Gentsch et 
al., 1977; Gentsch et al., 1979). The molecular barrier for virus reassortment has not 
yet been determined, although the compatibility of the RNP and viral polymerase 
presumably plays a role.  
 
 
1.2.3 Orthobunyavirus Ecology 
 
Orthobunyaviruses are transmitted and maintained in the environment through 
arthropod vectors. Orthobunyaviruses have been isolated from a diverse range of 
arthropods, including midges, mosquitoes, biting flies, bed bugs and hard and soft 
bodied ticks. Arthropod vectors become infected by taking a blood meal on a viraemic 
host or through transovarial transmission (Figure 1-11). Transovarial transmission has 
been recorded in ticks, mosquitoes and midge species and is thought to be a key factor 
in the orthobunyavirus life cycle, sustaining orthobunyaviruses through winter months 
and acting as a reservoir of infection come Spring (Converse et al., 1974; Mclean, 
1975; Labuda and Kozuch, 1986; Dutary et al., 1989; Reese et al., 2010). Moreover, 
transovarial transmission can dramatically increase the virus reservoir as multiple 
infected progeny arise from a single adult female. Transovarial transmission has not 
been documented for all orthobunyaviruses but it is postulated that negative field 
studies may be skewed by an overall low incidence of infection in the test population 
(Allingham and Standfast, 1990; Scholte et al., 2014). 
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Figure 1-11: Epizoonotic Life Cycle of Orthobunyaviruses 
Schematic of the epizoonotic life cycle of orthobunyaviruses. Arthropod vectors include 
midges, mosquitoes, hard and soft bodied ticks, bedbugs and biting flies. Amplifying hosts 
include small and large mammals, marsupials and birds. Transovarial transmission of 
orthobunyaviruses has been reported in ticks, mosquitoes and midge species. Humans and other 
hosts may be incidentally infected and due to low levels of viraemia do not transmit the virus to 
non-infected biting arthropods.  
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In addition, a third, less documented, mode of transmission may occur. LACV has been 
shown to be transmitted horizontally from male to female Ae. triseriatus mosquitoes 
(Figure 1-11) (Thompson and Beaty, 1977). The male mosquitoes are infected 
transovarially and then as mature adults transmit the virus to female mosquitoes during 
copulation (Figure 1-11) (Thompson and Beaty, 1977).  
 
As arboviruses environmental conditions related to vector abundance and activity, such 
as elevation, host availability, changes in land use and meteorological conditions 
influence orthobunyavirus distribution and infection rates (Vasconcelos et al., 2001; 
Bessell et al., 2013). For example, wind-borne introduction of SBV-infected Culicoides 
midges from mainland Europe to the UK in 2011 is thought to account for the 
emergence of SBV in the UK, and the spread of OROV in Brazil has been linked with 
the construction of the Belem-Brasilia highway (Figure 1-12) (Vasconcelos et al., 
2001; Sedda and Rogers, 2013; Kluiters et al., 2015).  
 
Orthobunyaviruses tend to have a wide host range, which again facilitates virus spread 
and maintenance. However, some hosts are incidental, or dead-ends; this occurs when 
the level and/or duration of viraemia is not conducive to onward transmission of the 
virus to subsequent biting arthropods (Figure 1-11) (Calisher, 1994). 
 
A summary of current knowledge regarding orthobunyavirus vectors, geographic 
location, hosts and disease is detailed, by serogroup, in sections 1.2.3.1 to 1.2.3.19. 
 
 
1.2.3.1 Anopheles A Serogroup 
 
The Anopheles A serogroup contains 2 virus species, the Anopheles A virus species 
(sp.) and the Tacaiuma virus sp. (Table 1-4) (Calisher et al., 1973; Calisher et al.,  
1980; Calisher et al., 1985). Anopheles A virus sp. have been isolated from Anopheles 
and Aedes mosquitoes and equines in South America (Calisher et al., 1973; Calisher et 
al., 1980; Calisher et al., 1985). Tacaiuma virus sp. have a slightly larger geographical  
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Figure 1-12: Spread of Schmallenberg virus in Europe 
Schematic representation of geographical spread of Schmallenberg virus (SBV) in Europe. A) 
Location of confirmed SBV infection in large animals, image from Doceul et al., 2013. Dates 
of first isolations are summarised into three categories; September (Sep) 2011 - April (Apr) 
2012, May 2012 - August (Aug) 2012 and September (Sep) 2012 - October (Oct) 2012. B) 
Image from DEFRA and AHVLA depicting high risk wind for midge imports, overlaid on SBV 
map by Doceul et al., 2013. White stars indicate the first cases of UK SBV infection in 
ruminants.  
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distribution and have been isolated from Anopheles and Haemagogus mosquitoes in 
South and North America (Calisher et al., 1973; Berge, 1975; Calisher et al., 1980, 
Calisher et al., 1985). Named virus isolate TCMV has also been isolated from non-
human primates and is associated with a benign febrile illness in man (Berge, 1975; 
Calisher et al., 1980). Interestingly, S segment sequencing of ANAV, LUKV and 
TCMV revealed viruses in this serogroup lack a full length NSs ORF (Mohamed et al., 
2009; Shchetinin et al., 2015). 
 
 
1.2.3.2 Anopheles B Serogroup 
 
The Anopheles B serogroup has 1 recognised virus species, the Anopheles B virus sp., 
which contains 2 named virus isolates Anopheles B virus (ANBV) and Boraceia virus 
(BORV) (Table 1-4) (Elliott and Blakqori, 2011; Plyusnin et al., 2012). ANBV and 
BORV have been isolated from Anopheles mosquitoes in South America and 
neutralising antibodies to BORV have been found in cattle, dogs, equines, chickens, 
rodents and man (de Souza Lopes et al., 1966; de Souza Lopes and de Abreu Sacchetta, 
1974; Berge, 1975). BORV has not yet been linked with clinical disease as 16 subjects 
that underwent seroconversion during a short study period did not report symptoms (de 
Souza Lopes and de Abreu Sacchetta, 1974). Complete S segment sequences for 
ANBV and BORV were determined in 2009, and identified ANBV and BORV as 
viruses lacking a functional NSs ORF (Mohamed et al., 2009).  
 
 
1.2.3.3 Bakau Serogroup  
 
The Bakau serogroup comprises 1 virus species, the Bakau virus sp., which contains 5 
named virus isolates: Bakau virus (BAKV); Ketapang virus (KETV); Tanjong Rabok 
virus (TRV); Telok Forest virus (TFV); and Nola virus (NOLAV) (Table 1-4)  (Elliott 
and Blakqori, 2011). BAKV, KETV and TFV virus have been isolated from Culex 
mosquitoes and soft bodied ticks (BAKV only) in Malaysia (Berge, 1975). Neutralising 
antibodies to these viruses have also been detected in bats, birds, rodents, primates and 
man. Although no live virus has been isolated from man, TFV and TRV have been 
isolated from macaques (Berge, 1975). Interestingly, NOLAV appears to bridge the 
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Bakau and Simbu serogroups, as although it is listed as a member of the Bakau 
serogroup by Elliott and Blakqori (2011) it is classified as a member of the Simbu 
antigenic group in the ArboCAT (Berge, 1975). In neutralisation assays NOLAV had a 
Ht/Ho titre of 640 with Simbu group (pooled) hyperimmune ascitic fluid and a Ht/Ho 
titre of 40/1024 with Manzanilla antibody (Berge, 1975). However, with Bakau 
serogroup antibodies NOLAV had Ht/Ho titres of 40/320 in neutralisation assays, and 
16/1024 in CFTs with TFV antigen (Zeller et al., 1989). Perhaps most convincingly in 
enzyme linked immune assays (EIA) NOLAV had Ht/Ho titres of 1600/3200 to 
3200/3200 with BAKV and TFV respectively (Zeller et al., 1989). Interestingly, 
NOLAV has a different geographic distribution to other members of the Bakau virus 
sp., with the sole reported isolation of NOLAV from Culex mosquitoes in the Central 
African Republic (Berge, 1975).  
 
 
1.2.3.4 Bunyamwera Serogroup 
 
The Bunyamwera serogroup contains 4 virus species, the Bunyamwera, Guaroa, Kairi 
and Main Drain virus sp. (Table 1-4) (Plyusnin et al., 2012). The Bunyamwera virus 
sp., contains a large lineage of replicating isolates with 22 named virus isolates, whilst 
Guaroa, Kairi and Main Drain remain the sole named viruses in their species (Table 1-
4) (Elliott and Blakqori, 2011). Bunyamwera group viruses are predominantly 
transmitted by mosquitoes, although Lokern virus (Bunyamwera sp.) and Main Drain 
virus (Main Drain sp.) have also been isolated from biting flies (Berge, 1975). 
Bunyamwera group viruses have a wide geographical distribution with isolations in 
South and North America, Africa, Asia and Europe (Berge, 1975; L'vov et al., 1989; 
Lambert et al., 2014). Bunyamwera virus sp. are documented causes of abortion and 
foetal malformation in ruminants, abortion and encephalitis in equines, and febrile 
illness in man (Okuno, 1961; Chippaux et al., 1969; Chung et al., 1990; Chung et al., 
1991; Campbell et al., 2006; Tauro et al., 2012; Nguyen et al., 2013; Odhiambo et al., 
2015; Tauro et al., 2015). Ngari virus, a reassortant within the Bunyamwera virus sp., 
was first isolated in 1979, and caused a large outbreak of HF in East Africa in 1997 and 
1998 (Zeller et al., 1996; Bowen et al., 2001; Gerrard et al., 2004). Guaroa virus sp. 
have also been documented as a cause of a self-limiting febrile illness in man in South 
America, whilst Main Drain and Kairi virus sp. have been isolated from equines with 
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encephalitis (Emmons et al., 1983; Calisher et al., 1988; Tauro et al., 2009; Aguilar et 
al., 2010). 
 
 
1.2.3.5 Bwamba Serogroup 
 
The Bwamba serogroup contains Bwamba virus (BWAV) and Pongola virus (PGAV), 
which, due to high level of cross-reactivity in serological tests, were assigned to a 
single virus sp., Bwamba virus sp. (Table 1-4) (Smithburn et al., 1941; Kokernot et al., 
1957). However, recent sequencing data show that BWAV and PGAV share 
comparatively low levels of sequence identity and clearly diverge on phylogenetic 
analysis, supporting their re-classification into distinct virus sp. (Groseth et al., 2014). 
BWAV and PGAV are mosquito-borne viruses and serological surveys indicate 
BWAV and PGAV are widespread in Africa (Smithburn et al., 1941; Moore et al., 
1975; Berge, 1975; Lutwama et al., 1999). BWAV is associated with Bwamba fever, a 
non-specific febrile illness commonly associated with exanthema and occasionally 
meningeal involvement (Smithburn et al., 1941; Moore et al., 1975; Johnson et al., 
1978). However, BWAV can cause severe disease with haemorrhagic manifestations 
and 14 fatal cases were recorded during an outbreak among Rwandan refugees 
(Lutwama et al., 2002). PGAV has also been linked with human infection, with high 
levels of seropositivity in many African countries, and virus isolation from a febrile 
patient with myalgia and headache in Uganda (Berge, 1975). PGAV neutralising 
antibodies have been found in livestock and donkeys (Berge, 1975). Complete genome 
sequencing and phylogenetic analysis reveals Bwamba serogroup isolates are most 
closely related to the California serogroup, a relationship supported by antigenic cross-
reactions (Figure 1-9) (Groseth et al., 2014). 
 
 
1.2.3.6 California Serogroup 
 
The California serogroup contains 13 named viruses, all of which have been assigned 
to the California encephalitis virus sp. (Table 1-4). Viruses within this serogroup are 
predominantly vectored by mosquitoes although Jamestown Canyon virus (JACV) and 
Snowshoe hare virus (SSHV) have been isolated from biting flies (Berge, 1975; 
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Hubalek et al., 2014; Putkuri et al., 2014; Westby et al., 2015). California serogroup 
viruses are a recognised cause of febrile encephalitis in man, with infections occurring 
in North America (e.g. LACV, JACV, SSHV, Trivittatus virus), Europe (e.g. Inkoo 
virus (INKV), Tahyna virus (TAHV)), Africa and China (e.g. SSHV, TAHV) (Centers 
for Disease Control and Prevention (CDC), 2011; Li et al., 2014; Sonnleitner et al., 
2014; Pastula et al., 2015). California serogroup viruses have also been isolated in 
Siberia and, although no clinical cases have been reported, neutralising antibodies were 
detected in human sera  (L'vov et al., 1989; Mitchell et al., 1993; L'vov et al., 1998). 
 
 
1.2.3.7 Capim Serogroup  
 
Capim serogroup viruses have been isolated from Culex mosquitoes, rodents and 
marsupials in South America (Spence et al., 1967; Berge, 1975; Calisher et al., 1983a). 
The serogroup contains 4 virus species, Capim, Benevides, Acara and Bushbush (Table 
1-4) (Spence et al., 1967; Jonkers et al., 1968; Calisher et al., 1983a; Elliott and 
Blakqori, 2011). There is no evidence of infection in man with > 500 sera collected 
from areas with virus isolation in rodents, mosquitoes and marsupials negative by 
neutralisation assay for Capim virus (CAPV) (Berge, 1975).  
 
Capim serogroup viruses have been documented to cross-react with Guama group 
viruses in neutralisation and haemagglutination inhibition (HI) assays, but not CFT 
assays (Figure 1-9).  
 
 
1.2.3.8 Gamboa Serogroup  
 
The Gamboa serogroup contains 4 named isolates classified into 2 virus species, 
Alajuela virus sp. and Gamboa virus sp. (Table 1-4) (Calisher, Gutierrez, et al., 1983; 
Mitchell et al., 1987; Elliott and Blakqori, 2011). Gamboa virus sp., have been isolated 
from Aedeomyia mosquitoes, eggs and larvae in South America (Calisher, Gutierrez, et 
al., 1983; Mitchell et al., 1987; Dutary et al., 1989). Evidence for infection of 
vertebrate hosts is limited, with > 2200 sentinel mice collected from locations with 
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Gamboa virus (GAMV) infected mosquitoes testing negative by neutralisation assays, 
although an association with migratory birds has been reported (Berge, 1975).  
 
 
1.2.3.9 Group C Serogroup 
 
The Group C serogroup derives its name from the historical classification of viruses 
and its distinctive serological profile compared with group A (Togaviridae) and group 
B (Flaviviridae) viruses (Casals and Whitman, 1961; Calisher et al., 1983b). The 
Group C serogroup currently contains 4 recognised species, namely Caraparu, Madrid, 
Marituba and Oriboca, each of which contains a number of named isolates (Table 1-4) 
(Elliott and Blakqori, 2011). Group C viruses are predominantly vectored by 
mosquitoes in South America and Mexico, and are associated with a self-limited 
Dengue-like illness in man (Casals and Whitman, 1961; De Rodaniche et al., 1964; 
Iversson et al., 1987; Turell et al., 2005; Hontz et al., 2015). Deforestation and changes 
in land use throughout South America have been associated with increasing isolations 
of Group C viruses in man and the burden of disease is believed to be underestimated 
(Walder et al., 1984). 
 
 
1.2.3.10 Guama Serogroup 
 
The Guama serogroup contains 4 virus species, Bimiti, Bertioga, Catu and Guama 
(Table 1-4). In addition to the named species isolate, the Bertioga virus sp. contains 
Cananeia virus, Guaratuba virus, Itimirim virus, and Mirim virus, whilst Ananindeua 
virus, Moju virus and Mahogany Hammock virus (MHV) have been assigned to the 
Guama virus sp. (Whitman and Casals, 1961; Coleman et al., 1969; de Souza Lopes et 
al., 1975; Calisher et al., 1983b). Aside from MHV, which was isolated in Florida, 
USA, all Guama group viruses have been isolated in South America (Coleman et al., 
1969; Berge, 1975). Guama group viruses have been isolated from diverse species of 
mosquitoes, marsupials, bats, rodents and sentinel primates (Whitman and Casals, 
1961; Coleman et al., 1969; Berge, 1975; Calisher et al., 1983b). Two viruses, Catu 
virus and Guama virus, are associated with a self-limiting febrile illness with myalgia 
and headache, and have been isolated from febrile patients (Berge, 1975). Guama 
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serogroup viruses have been linked, by cross-reaction in serological assays, to viruses 
in the Capim and Minatitlan serogroups (Figure 1-9) (Zarate et al., 1968; Berge, 1975). 
Recent sequencing studies and phylogenetic analysis reveal close branching of Capim 
and Guama serogroup clusters but there are as yet no published sequences for 
Minatitlan serogroup viruses (Shchetinin et al., 2015). 
 
 
1.2.3.11 Koongol Serogroup 
 
The Koongol serogroup contains 1 virus species, Koongol virus sp., to which both 
Koongol virus (KOOV) and Wongal virus (WONV) belong (Table 1-4). KOOV and 
WONV were isolated from Culex annulirostris mosquitoes in Australia, and KOOV 
has subsequently been identified in New Guinea (Doherty et al., 1963; Berge, 1975; 
Wright et al., 1981; Marshall et al., 1982). A study into the plaque morphology of 
arboviruses found KOOV and WONV formed plaques ≤ 1 mm in diameter 15 and 10 d 
p.i., respectively, on Vero cells. KOOV formed slightly larger plaques (≤ 2 mm 10 d 
p.i.) on an additional cell line, LLC-MK2, whilst WOOV failed to plaque on these cells 
(Stim, 1968). Complete coding sequences for KOOV were published during 
preparation of this manuscript and phylogenetic analysis showed KOOV branching 
with Umbre virus, a Turlock serogroup virus (Shchetinin et al., 2015). The host range 
of Koongol serogroup viruses remains unclear. Sera from cattle, marsupials and birds 
has tested low-level positive by HI assays for KKOV and WONV; however, results 
were rarely confirmed by neutralisation tests and no clinical disease has been reported 
(Doherty et al., 1970). 
 
 
1.2.3.12 Minatitlan Serogroup 
 
To date the Minatitlan serogroup contains 2 named isolates, Minatitlan virus (MNTV) 
and Palestina virus (PLSV), both of which belong to the Minatitlan virus species (Table 
1-4). MNTV and PLSV have been isolated from Culex mosquitoes and sentinel 
hamsters in Mexico, Ecuador and Guatemala (Calisher et al., 1983a). Cross-reaction in 
serology based assays has been documented for the Minatitlan serogroup with both 
MNTV and PLSV cross-reacting with Capim, Guama and Group C serogroup viruses 
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in CFTs and Guama serogroup viruses in PRNT assays (Figure 1-9) (Berge, 1975; 
Calisher et al., 1983a).  
 
 
1.2.3.13 Nyando Serogroup 
 
Nyando serogroup viruses have been isolated from mosquitoes in Africa (Williams et 
al., 1965; Ardoin and Simpson, 1965; Lee and Moore, 1972; Lutwama et al., 1999). 
There is currently 1 recognised virus sp., the Nyando virus, which contains both 
Eretmapodites virus (EREV) and Nyando virus (NDV) isolates (Table 1-4) (Ardoin and 
Simpson, 1965; Berge, 1975; Elliott and Blakqori, 2011). There are limited 
documented isolations of NDV from febrile patients although serological surveys 
indicate a high prevalence in Kenya, Uganda and Senegal (Digoutte et al., 1972; 
Groseth et al., 2014). Frequent isolations from mosquitoes also indicate that the 
prevalence and disease burden of NDV may be underestimated (Berge, 1975; Groseth 
et al., 2014). 
 
 
1.2.3.14 Olifantsvlei Serogroup 
 
The Olifantsvlei serogroup contains 2 virus species: Botambi virus and Olifantsvlei 
virus (Table 1-4) (Plyusnin et al., 2012). The Olifantsvlei virus species contains 4 
named viruses, Olifantsvlei virus (OLIV), Bobia virus, Dabakala virus and Oubi virus, 
whilst Botambi virus remains the sole member of its species (Elliott and Blakqori, 
2011). Olifantsvlei serogroup viruses have been isolated from Culex mosquitoes in 
Africa (Berge, 1975; McIntosh, 1978). There is little published information on this 
group of viruses although Stim (1968) reported virus preparations of OLIV were fatal 
to new born mice despite failing to form plaques on Vero or LLC-MK2 cell lines.  
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1.2.3.15 Patois Serogroup 
 
The Patois serogroup contains 2 virus species, Zegla virus sp. and Patois virus sp., 
which contains 5 named virus isolates, Patois virus, Abras virus, Babahoya virus, 
Pahayokee virus and Shark River virus (Table 1-4) (Calisher et al., 1983a). Patois 
serogroup viruses have been predominately isolated from Culex mosquitoes and small 
rodents in South America, although Shark River virus was isolated in the Florida 
Everglades, USA, and from 1 pool of Anopheles mosquitoes (Berge, 1975). Antibodies 
to Patois virus and Zegla virus have been found in man, although there are no reports of 
clinical disease or virus isolation (Scherer et al., 1972). Viruses in the Patois serogroup 
cross-react with viruses in the Bunyamwera, California, Capim, Group C and Guama 
serogroups (Figure 1-9) (Ushijima et al., 1981).   
 
A sixth, currently unclassified virus, Estero Real virus has nominally been placed in the 
Patois serogroup (Shchetinin et al., 2015). However, Estero Real virus did not cross-
react with Abras, Babahoyo, Pahayokee, Patois, Zegla or Shark River virus in 
immunofluorescence tests (Zeller et al., 1989). In CFT assays Estero Real virus failed 
to cross-react with all Patois serogroup viruses except Zegla virus, which gave a Ht/Ho 
CFT titre of 32/1024 (Zeller et al., 1989). Moreover, Estero Real virus appears 
divergent from other Patois serogroup viruses as it was isolated from soft bodied ticks, 
and not mosquitoes, in South America (Málková et al., 1985). 
 
 
1.2.3.16 Simbu Serogroup 
 
The Simbu serogroup contains 8 ICTV-recognised species, Akabane, Shamonda, 
Shuni, Thimiri, Manzanilla, Oropouche, Sathuperi and Simbu virus, with each species 
representing a large lineage of named viruses (Table 1-4). Simbu serogroup viruses are 
vectored by both mosquitoes and midge sp. and are widely distributed with isolations in 
Africa, Asia, Australia, Europe and South and North America. The Simbu serogroup 
contains a number of clinically and economically important pathogens, such as OROV, 
Shuni virus, AKAV and SBV (Table 1-1). The emergence and rapid spread of SBV in 
Europe in 2011 exemplified the devastating impact emerging arboviruses can have 
(Gibbens, 2012).  
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1.2.3.17 Tete Serogroup 
 
The Tete serogroup contains 1 recognised species, the Tete virus sp., to which Tete, 
Bahig (BAHV), Matruh (MTRV), Tsuruse (TSUV) and Weldona (WELV) viruses have 
been assigned (Table 1-4) (Elliott and Blakqori, 2011). Tete serogroup viruses have 
been isolated from wild and domestic birds in Europe, Africa, Asia and North America, 
and there are no documented cases of human infection (Berge, 1975). The vectors of 
Tete serogroup viruses vary; MTRV and BAHV have been isolated from hard bodied 
ticks, whilst WELV has been isolated from Culicoides flies, and the vectors of TSUV 
and TETEV are, as yet, undetermined (Converse et al., 1974; Moussa et al., 1974; 
Berge, 1975; Calisher et al., 1990).  
 
The Batama virus sp., although currently listed as unclassified, is widely accepted as a 
member of the Tete serogroup and although no vector has been identified it has been 
isolated from diverse bird species (Table 1-4) (Berge, 1975; Elliott and Blakqori, 2011; 
Plyusnin et al., 2012).  
 
 
1.2.3.18 Turlock Serogroup 
 
Turlock serogroup viruses are associated with Culex mosquitoes and birds, and have a 
wide geographical distribution with isolations in Africa, Asia, Europe, South America, 
and North America (Berge, 1975; Calisher, Gutierrez, et al., 1983; Mitchell et al., 
1987). There are currently 2 virus species, Turlock virus sp. which contains Turlock 
(TURV), Lednice (LEDV) and Umbre (UMBV) viruses, and the M’Poko virus sp., 
which contains M’Poko virus (MPOV) and Yaba-1 virus (Table 1-4) (Calisher et al., 
1984). Neutralising antibodies to UMBV and MPOV have been found in man in 
Malaysia and the Central African Republic, respectively, although no virus isolations 
have been made (Berge, 1975). Moreover, experimental infection of non-human 
primates with LEDV led to the recovery of antibodies in regional lymph nodes but no 
viraemia or clinical signs (e.g. raised temperature) were detected (Málková et al., 
1976).  
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1.2.3.19 New Serogroups: Wyeomyia, Mapputta and Sedlec 
 
Three new serogroups have been proposed: Wyeomyia, Mapputta and Sedlec (Newton 
et al., 1983; Chowdhary et al., 2012; Bakonyi et al., 2013). The Wyeomyia serogroup 
includes viruses originally classified as members of the Wyeomyia virus sp. in the 
Bunyamwera serogroup (Chowdhary et al., 2012). Found in South America, Wyeomyia 
serogroup viruses are primarily vectored by mosquitoes and virus hosts remain largely 
undetermined with infrequent isolations in birds and rodents (Aitken et al., 1968; 
Berge, 1975; de Souza Lopes et al., 1975). Neutralising antibodies to Wyeomyia group 
viruses have been found in man and Wyeomyia virus (WYOV) has been documented 
as the aetiological agent in 2 cases of self-limiting febrile illness (Sirhongese and 
Johnson, 1965; Aitken et al., 1968; de Souza Lopes et al., 1975). Evidence that the 
Wyeomyia virus sp. should be considered a distinct complex from the Bunyamwera 
serogroup came from the complete genome sequencing of 8 named isolates belonging 
to the Wyeomyia virus sp. (Chowdhary et al., 2012). Phylogenetic analysis revealed 
that these isolates form a clade that is distinct from the Bunyamwera serogroup 
(Chowdhary et al., 2012). Additionally, Wyeomyia viruses lack a full length NSs ORF 
(Mores et al., 2009; Chowdhary et al., 2012).   
 
The Mapputta serogroup is a complex of antigenically distinct bunyaviruses that are 
currently unassigned within the Bunyaviridae family (Newton et al., 1983; Plyusnin et 
al., 2012). Mapputta serogroup viruses are vectored by mosquitoes, circulate in 
Australia and are associated with an acute febrile illness with polyarthritis (Doherty et 
al., 1963; Doherty et al., 1970; Gard et al., 1973; Wier, 2002). Recent complete 
genome sequencing of Mapputta serogroup viruses has revealed that these viruses lack 
a full length NSs ORF and form a distinct clade on phylogenetic analysis that lies 
within the orthobunyavirus genus (Gauci et al., 2015; Shchetinin et al., 2015).  
 
The Sedlec serogroup was proposed in 2013 following partial sequencing of Sedlec 
virus (SEDV) (Bakonyi et al., 2013). Originally isolated from a wild bird in the Czech 
Republic, SEDV did not cross-react with other bunyaviruses in CFTs but 
morphological characteristics placed it within the Bunyaviridae family (Hubalek et al., 
1990). Sequencing then revealed that SEDV clustered with 2 unclassified viruses 
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I612045 and Oyo virus on L segment analysis and branched with Simbu serogroup 
viruses on S segment analysis (Bakonyi et al., 2013).  
 
 
1.2.4 Orthobunyavirus Reverse Genetics 
 
Reverse genetics exploits recombinant DNA technology, utilising cloned DNA copies 
of virus genomes to create infectious recombinant virus particles (Figure 1-14). This 
allows mutagenesis of the virus genome via plasmid DNA clones and the correlation 
between genotype and phenotype to be studied. The first reverse genetics system for a 
segmented negative sense RNA virus was developed for BUNV (Bridgen and Elliott, 
1996). BUNV virus segments were cloned as full length cDNA copies into 
transcription plasmids under the control of a T7 promoter. Transcription of cDNA 
clones into vRNA was then achieved by transfecting cells expressing bacteriophage T7 
RNA polymerase (T7RNAP) and recombinant BUNV proteins (Bridgen and Elliott, 
1996). T7RNAP was provided by pre-infecting cells with vTF7-3, a recombinant 
vaccinia virus which expresses T7RNAP, and BUNV proteins from the transfection of 
BUNV N, M and L ORF expression plasmids (Jin and Elliott, 1991; Nakitare and 
Elliott, 1993; Dunn et al., 1995; Bridgen and Elliott, 1996). Rescue supernatants were 
then passaged in mosquito cells to remove vTF7-3 and enrich recombinant BUNV 
particles (Bridgen and Elliott, 1996). As reverse genetics systems have progressed the 
provision of T7RNAP by vTF7-3 has been replaced by transfection of a T7RNAP 
expression plasmid or by using cell lines that constitutively express T7RNAP, such as 
the BHK-21 derived cell line BSR-T7/5 (Buchholz et al., 1999; Lowen et al., 2004). 
 
T7RNAP is often the expression system of choice as it can be expressed in a wide 
range of cell types and localises to the cytoplasm, the site of bunyavirus replication. 
However, T7RNAP activity is enhanced by a guanosine residue +1 from the 3’ end of 
the T7 promoter sequence, which is incorporated into the vRNA transcript. Although 
many recombinant viruses tolerate the presence of an additional terminal nucleotide, it 
can affect recognition by the bunyavirus L proteins, with activity levels differing from 
non-recombinant viruses. Furthermore, transcription termination by T7RNAP is not 
precise, although the addition of self-trimming hepatitis-δ ribozyme sequences at the 3’ 
terminus of viral cDNAs can be used to maintain exact terminal sequences and 
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counteract problems associated with T7RNAP transcription. Alternatively, a parallel 
nuclear-based reverse genetics system which utilises cellular DNA-dependent RNA-
polymerase (Pol-I) to transcribe vRNA copies can be used (Ogawa et al., 2007). Pol-I 
is more precise than T7RNAP. However, it requires promoter sequences to be 
optimised for each species of cell line used and helper plasmids containing cell-specific 
Pol-II promoters for expression of virus N and L proteins.  
 
Orthobunyavirus reverse genetics systems have now been created for a number of 
viruses, including BUNV, LACV, AKAV and OROV. The technology has allowed 
recombinant viruses lacking NSs proteins to be extensively studied, unravelling 
molecular mechanisms behind virus pathogenesis. It has also enabled monitoring of the 
replication of fluorescently tagged viruses in real-time, and the creation of recombinant 
viruses with deletions or alanine substitutions has helped elucidate the role of NSm, Gn 
and Gc proteins in virus particle assembly and maturation. Furthermore, reverse 
genetics has enabled the function of UTR sequences in virus replication to be analysed 
and has provided a platform for the creation of chimeric orthobunyavirus vaccine 
candidates (Bennett et al., 2012). 
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2.1 Cell Lines 
 
Table 2-1: Cell Lines 
Cell Line Description and Cell Maintenance 
293FT 
Fast growing variant of the 293T cell line, maintained in DMEM 
supplemented with 10% (v/v) FCS, 1X NEAA and 500 µg ml-1 G418 
(Graham et al., 1977; Gama-Norton et al., 2011). 
293T 
Derived from primary human embryo kidney cells transformed with sheared 
human adenovirus type 5 DNA and SV40 T antigen, maintained in DMEM 
with 10% (v/v) FCS and 1X NEAA (Graham et al., 1977). 
A549 Derived from adenocarcinomic human alveolar basal epithelial cells and maintained in DMEM with 10% (v/v) FCS 
A549-NPro 
Derivative of A549 cells, which express the NPro protein of bovine viral 
diarrhea virus (BVDV). NPro induces proteasome-mediated degradation of 
IRF-3, abolishing IFN-β production (Hilton et al., 2006). A549-NPro cells 
were maintained in DMEM with 10% (v/v) FCS and 2 µg ml-1 puromycin. 
A549-IFITM 
Derived from the A549 cell line. As part of this study A549 cells were 
transduced with lentiviral vectors expressing either IFITM1, IFITM2, 
IFITM3 or empty SCRPSY vector. A549 IFITM cell lines were maintained 
in DMEM with 10% (v/v) FCS and 2 µg ml-1 puromycin to ensure selection 
of transduced cells. 
BHK-21 clone 
13 
Derived from baby hamster kidney fibroblast cells, maintained in GMEM 
with 10% (v/v) NCS and 10% (v/v) TPB (MacPherson and Stoker, 1962). 
BSR-T7/5 
BHK-21-derived cell line that constitutively expresses T7RNAP (Buchholz, 
Finke and Conzelmann, 1999). BSR-T7/5 cells were maintained in GMEM 
with 10% (v/v) FCS, 10% (v/v) TPB and 1 mg ml-1 G418 to maintain 
selection of cells expressing T7RNAP. 
Flp-InTM T-
RExTM 293 
MTAP44 and 
CAT 
Flp-InTM T-RExTM 293 cells co-transfected with pOG44 and 
pcDNA5/FRT/∆CAT containing FLAG-tagged full length MTAP44 
(microtubule associated protein 44, also known as IFI44) or untagged 
chloramphenicol CAT (chloramphenicol acetyltransferase) cDNA forming 
stable cells with tetracycline inducible expression of FLAG-tagged MTAP44 
or CAT (Jiang et al., 2008). Cells were maintained in DMEM with 10% (v/v) 
Tet System Approved FCS, 250 µg ml-1 hygromycin and 5 µg ml-1 
blasticidin. 
HEK-293 Human embryonic kidney cells, maintained in DMEM with 10% FCS (v/v). 
HeLa Derived from human epithelial cervical cancer cells, maintained in DMEM with 10% FCS (v/v) (Scherer et al., 1953). 
Huh7 Derived from human hepatic tumourigenic cells and maintained in DMEM with 10% FCS (v/v) and 1X NEAA. 
Huh7-Lunet T7 
Huh7 cells transduced to constitutively over-express T7RNAP, maintained in 
DMEM with 10% FCS (v/v), 1X NEAA and 5 µg ml-1 zeocin (Appel et al., 
2005; Koutsoudakis et al., 2006). 
Vero E6 Derived from African Green Monkey kidney cells and maintained in DMEM with 10% FCS (v/v). 
 
A description of cell lines used in this study is given. DMEM, Dulbecco’s modified Eagle 
medium; FCS, fetal calf serum; NEAA, non-essential amino acids; GMEM, Glasgow minimum 
essential medium; TPB, tryptose phosphate broth; NCS, newborn calf serum. 
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2.2 Virus Strains 
 
• Bunyamwera virus (BUNV), the type species of the Bunyamwera serogroup and 
orthobunyavirus genus as a whole, was kindly provided by Prof Richard M. Elliott 
(University of Glasgow).  
 
• rBUNdelNSs2, a recombinant BUNV that does not express NSs protein, was kindly 
provided by Dr Ingeborg van Knippenberg (University of Glasgow) (Bridgen et al., 
2001; Hart, Kohl and Elliott, 2009; van Knippenberg, Carlton-Smith and Elliott, 
2010). 
 
• Encephalomycocarditis virus (EMCV) is an IFN-sensitive virus that was used to test 
for the presence of biological IFN in infected cell supernatants.  
 
• 49 other orthobunyaviruses, as detailed in Table 2-2, were kindly provided by Dr 
Robert Tesh and the late Dr R.E. Shope, both University of Texas Medical Branch, 
Galveston, Texas. 
 
 
2.3 Bacterial strains and culture 
 
• Plasmids stocks were grown and maintained in Escherichia coli strain JM109: 
endA1, recA1, gyrA96, thi, hsdR17 (rk – mk +), relA1, supE44, ΔprolacAB), [F' 
traD36, proAB, laqIqZΔM15].  
 
• Transformations were carried out with competent JM109 cells, which were created 
using Mix & Go E. coli Transformation Kit & Buffer Set (Zymo Research). 
 
• Bacteria were cultured in liquid phase using 2.5% (w/v) LB Broth Miller 
(Formedium) and in solid phase using 4% (w/v) LB Agar Miller (Formedium). 
Dilutions were made with deionised water and transformants selected by the 
addition of 100 µg/ml ampicillin (Sigma-Aldrich). In addition to ampicillin 
selection, pGEM®-T easy recombinants were selected by blue/white screening in 
the presence of IPTG/X-gal.  
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Table 2-2: Virus Isolates 
Virus Name (ABBV) Serogroup Strain Information 
Date of freeze-
dried isolate 
Date of first 
isolation  
Anopheles A (ANAV) Anopheles A - DD.MM.1984 DD.MM.1940 
Anopheles A (ColAn57389) Anopheles A ColAn 57389 13.10.1981 - 
Anopheles A (CoAr1071) Anopheles A CoAr 1071 05.04.1985 25.03.1985 
Anopheles A (CoAr3624) Anopheles A CoAr 3624 22.09.1966 12.09.1966 
Arumateua (ARTV) Anopheles A BeAr 437811 08.12.1986 - 
Caraipe (CPEV) Anopheles A BeAr 428793 24.10.1984 - 
Las Maloyas (LMV) Anopheles A AG 80-14 10.09.1981 - 
Lukuni (LUKV) Anopheles A TR 10076 07.06.1965 - 
Tacaiuma Anopheles A Sp-Ar 2317 26.05.1971 30.04.1971 
Tacaiuma (TCMV) Anopheles A BeAn73 21.07.2001 DD.MM.1955 
Trombetas (TRMV) Anopheles A BeAn 306771 21.09.1981 - 
Tucurui (TUCRV) Anopheles A BeAR 422535 20.11.1985 - 
Virgin River (VRV) Anopheles A 743-366 13.10.1981 - 
Anopheles B (ANBV) Anopheles B DMC 1537 15.02.1963 - 
Boraceia (BORV) Anopheles B SP Ar395 06.12.1965 DD.MM.1962 
Bakau (BAKV) Bakau MM2325 09.05.1980 DD.MM.1956 
Ketapang (KETV) Bakau MM2549 15.05.1970 - 
Bwamba (BWAV) Bwamba M 459 DD.03.1980 - 
Pongola (PGAV) Bwamba - 17.03.1971 - 
Acara (ACAV) Capim BeAn 27639 26.06.1966 - 
Benevides (BVSV) Capim BeAn 153564 26.10.2011 - 
Benfica (BENV) Capim BeAn 84381 DD.MM.1966 - 
Bushbush (BSBV) Capim Tr. 26668 #22602 18.01.1985 21.12.1984 
Capim (CAPV) Capim - 26.06.1966 DD.MM.1961 
Guajara (GJAV) Capim BeAn 10615 27.03.1968 - 
Juan Diaz (JDV) Capim Maru 8563 12.06.2001 - 
Moriche (MORV) Capim - 17.11.1966 15.11.1966 
Gamboa (GAMV) Gamboa GML 438524 17.12.1990 - 
San Juan (SJV) Gamboa 78V 241 04.12.1981 - 
Bertioga (BERV) Guama - 28.09.1966 04.01.1966 
Guama (GMAV) Guama BeAn 277 13.01.1992 - 
Koongol (KOOV) Koongol MRM 31 20.06.1966 - 
Wongol (WONV) Koongol MRM 168 02.06.1966 06.06.1966 
Minatitlan (MNTV) Minatitlan 70439 #168 30.04.1974 25.04.1974 
Palestina (PLSV) Minatitlan 76V 1565 31.08.1982 - 
Eretmapodites (EREV) Nyando E147V 10.07.1966 - 
Nyando (NDV) Nyando - 11.10.2003 - 
Olifantsvlei (OLIV) Olifantsvlei SA Ar 5133 28.07.1964 - 
Botambi (BOTV) Olifantsvlei BA937 08.06.1970 - 
Pahayokee (PAHV) Patois - 25.09.1968 14.09.1968 
Patois (PATV) Patois - 22.12.1966 - 
Bahig (BAHV) Tete Eg B-90 #22607 07.01.1985 21.12.1984 
Batama (BMAV) Tete DAK AnB1292 15.12.1984 DD.MM.1970 
Matruh (MTRV) Tete EgAn 1047-61 12.07.1985 17.06.1985 
Tete (TETEV) Tete SA An3518 15.12.1984 DD.MM.1959 
Tsuruse-like (TSUV) Tete Magpie 271580 03.11.1999 - 
Weldona (WELV) Tete 76V 21935  30.04.2009 - 
M’Poko (MPOV) Turlock BA365 10.03.2003 - 
Turlock (TURV) Turlock MP847-32 09.02.1959 - 
 
Viruses used in this study that were obtained from the World Reference Center for Emerging 
Viruses and Arboviruses, University of Texas Medical Branch, Galveston, Texas, USA. Virus 
name (abbreviation), serogroup, and where available, strain information and isolate history are 
given. Dates are formatted as DD.MM.YYYY.   
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2.4 Plasmids 
 
• Plasmids were purified using the PureYieldTM Plasmid Miniprep System (Promega, 
A1223) and NucleoBond® Xtra Midi kit (Macherey-Nagel, 74041.50). 
 
• Expression plasmids, listed in Table 2-3, were used in 5 plasmid rescue systems, 
luciferase reporter assays, lentivirus construction and protein expression.  
 
• Transcription plasmids, described in Table 2-4, were used in viral rescue systems. 
Viral segments requiring sequence confirmation following HTS and de novo 
assemblies were also cloned into the pTvT7 backbone, as this would facilitate 
future development of rescue systems if needed.  
 
• pGEM®-T Easy vector was supplied as part of the pGEM®-T Easy Vector System 
I (Promega, A1360) and was used for sequence confirmation of viral fragments. 
The plasmid contains T7 and SP6 RNA polymerase promoters flanking a multiple 
cloning site located within the α-peptide coding region of the β-galactosidase 
enzyme, which undergoes insertional inactivation allowing the selection of 
recombinants by blue/white screening. The plasmid is supplied as linearised 
plasmid with single thymidine overhangs at both ends of the insertion site.  
 
 
2.5 Oligonucleotides 
 
Oligonucleotides were purchased from Integrated DNA technologies (IDT) at 25 
nmoles scale with standard desalt purification. Primer sequences are listed in Appendix 
1 and split into the following categories: 
A) Primers for RACE-PCR and UTR sequencing 
B) Primers for sequence confirmation (PCR products, pGEM-T easy) 
C) Primers for sequence confirmation (pTvT7 clones) 
D) Primers for BMAV reverse genetics and structural studies 
E) Primers for cloning virus ORFs into pCMV-empty  
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Table 2-3: Expression Plasmids 
Plasmid Description Source/Reference 
pTM1 
The pTM1 plasmid contains bacteriophage T7 promoter followed 
by encephalomyocarditis (EMCV) internal ribosome entry site 
(IRES), cloning site and a T7 terminator sequence. Transcripts 
contain the EMCV IRES element upstream of the cloned ORF to 
allow expression in mammalian cells lines expressing T7RNAP. 
Moss et al., 1990 
pTM1-BMAV  pTM1 backbone containing the complete coding sequence for 
BMAV N, M and L proteins respectively, under the control of the 
T7 promoter and EMCV IRES.  
This study pTM1-BMAV M 
pTM1-BMAV L 
pIFΔ(-125) lucter  Firefly luciferase under the control of the IFN-β promoter. Prof R.M Elliott, UoG 
phRL CMV Humanised Renilla luciferase under the control of a CMV immediate early promoter. Promega 
pCMV 
The coding sequence for humanised Renilla luciferase was removed 
from the phRL CMV plasmid by excision PCR to create a pCMV 
vector which could be used to drive expression of viral proteins in 
mammalian cells. 
This study 
pCAGGS-2CARD 
pCAGGS expression plasmid encoding 2 tandem amino-terminal 
caspase activation and recruitment domains (CARDs) of the 
Retinoic-acid-inducible gene-I (RIG-I). 
Dr Ben Hale, UoG 
pCMV-BUNVN pCMV backbone containing the complete coding sequence for 
BUNV N and NSs proteins respectively, under control of the CMV 
promoter. 
This study 
pCMV-BUNVNSs 
pCMV-27N pCMV backbone containing the complete coding sequence for 
BMAV N, M and L proteins respectively, under control of the CMV 
promoter. 
This study pCMV-27M 
pCMV-27L 
pCMV-22N 
pCMV backbone containing Weldona virus N and NSs ORFs. This study 
pCMV-22NSs 
pCMV-20ORF pCMV containing a predicted ORF in MTRV S segment (cRNA 465 – 665 bp). This study 
pCMV-34NSs pCMV backbone containing Eretmapodites virus NSs ORF. This study 
pCMV-29NSs pCMV backbone containing Nyando virus NSs ORF. This study 
pCMV-48NSs pCMV backbone containing M’Poko virus NSs ORF. This study 
pCMV-36NSs pCMV backbone containing Gamboa virus NSs ORF. This study 
pEHISTEV 
Expression vector derived from pET used for soluble protein 
expression for structural biology studies. The vector contains a 
multiple cloning site flanked by an amino terminal hexahistidine tag, 
and tobacco etch virus protease cleavage site. 
Liu and Naismith, 2009 
pSCRPSY-IFITM 
HIV-1 based gateway-compatible lentiviral vector that uses the 
endogenous splicing machinery of HIV-1 to co-express TagRFP, the 
puromycin resistance gene and either IFITM-1, -2 or -3 from a Tag-
RFP-IFITM-Puro cassette, which is downstream of a CMV promoter 
and EMCV IRES site. 
Schoggins et al., 2012 
pCMVR8.91 Packaging plasmid used in lentivirus construction, which expresses HIV-1 gag and pol proteins Zufferey et al., 1997  
pVSV-G Expression plasmid which encodes VSV-G (vesicular stomatitis virus envelope G protein) under a CMV promoter. Burns et al., 1993 
 
A description of expression plasmids used in this thesis is given. Unless stated, plasmids are 
ampicillin resistant in bacteria. University of Glasgow (UoG).  
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Table 2-4: Transcription Plasmids 
Plasmid Description Source 
pTvT7R(0,0) 
pTvT7R(0,0) plasmid is a T7 RNA polymerase transcription plasmid with an 
additional G in the +1 position upstream of the T7 promoter to facilitate 
efficient T7 transcription. The insert site is immediately followed by a 
hepatitis Delta ribozyme sequence and the T7 terminator sequence.  
Johnson et al., 
2000 
pTvT7-ANAVSS pTvT7R(0,0) plasmid containing full length Anopheles A virus antigenomic S segment sequence under control of the T7 promoter.  This study 
pTvT7-CA5739S 
pTvT7R(0,0) plasmid containing full length Anopheles A ColAn 57389 
antigenomic S segment sequences respectively, under control of the T7 
promoter. 
This study 
pTvT7-E147VS 
pTvT7R(0,0) plasmid containing full length Eretmapodites virus antigenomic 
S, M and L segment sequences respectively, under control of the T7 promoter.  This study pTvT7-E147VM 
pTvT7-E147VL 
pTvT7-JDVS pTvT7R(0,0) plasmid containing full length Juan Diaz virus antigenomic S segment sequences under control of the T7 promoter. This study 
pTvT7-LMVS  
pTvT7-LMVM 
pTvT7R(0,0) plasmid containing full length Las Maloyas virus antigenomic S 
and M segment sequences respectively, under control of the T7 promoter. This study 
pTvT7-MTRVS pTvT7R(0,0) plasmid containing full length Matruh virus antigenomic S segment sequences under control of the T7 promoter. This study 
pTvT7-TCMVS pTvT7R(0,0) plasmid containing full length Tacaiuma virus antigenomic S segment sequences under control of the T7 promoter. This study 
pTvT7-TETEVS pTvT7R(0,0) plasmid containing full length Tete virus antigenomic S segment sequences under control of the T7 promoter. This study 
pTvT7-TRMV pTvT7R(0,0) containing full length Trombetas virus antigenomic S segment sequence under control of the T7 promoter. This study 
pTvT7-TSUVS 
pTvT7-TSUVM 
pTvT7R(0,0) plasmid containing full length Tsuruse-like antigenomic S and M 
segment sequences respectively, under control of the T7 promoter. This study 
pTvT7-WELVS pTvT7R(0,0) containing full length Weldona virus antigenomic S segment sequence under control of the T7 promoter. This study 
pTvT7-BMAVS 
pTvT7R(0,0) plasmid containing full length Batama virus antigenomic S, M 
and L segment sequences respectively, under control of the T7 promoter.  This study pTvT7-BMAVM 
pTvT7-BMAVL 
rBMAVBu25N Modified pTvT7-BMAVS in which the N terminal 25 amino acids of the N protein have been modified to mimic the termini of BUNV N protein. This study 
rBMAVBu29N 
Modified pTvT7-BMAVS in which the N and C terminal amino acids of the N 
protein have been modified to mimic the termini of Bunyamwera virus N 
protein. 
This study 
rBMAVWelN Modified pTvT7-BMAVS in which the N and C terminal amino acids of the N protein have been modified to mimic the termini of Weldona virus N protein. This study 
rBMAVWelUN 
Modified pTvT7-BMAVS in which the N and C terminal amino acids of the N 
protein have been modified to mimic the termini of Weldona virus N protein 
and UTR sequences have been switched with those of Weldona virus. 
This study 
rBMAVn6A rBMAVn12A 
Modified pTvT7-BMAV S plasmid containing alanine 
substitutions at N protein amino acid residues 6, 12, 18 and/or 
24. Detailed descriptions in Table 7-1. 
This study 
rBMAVn18A rBMAVn24A 
rBMAVn2aA rBMAVn2bA 
rBMAVn2cA rBMAVn2dA 
rBMAVn2eA rBMAVn2fA 
rBMAVn3aA rBMAVn3bA 
rBMAVn3cA rBMAVn3dA 
rBMAVn4xA  
rBMAVn11∆ rBMAVn13∆ 
Modified pTvT7-BMAV S plasmid in which N protein amino 
acid residues 11, 13, 19 and/or 24 have been deleted. Detailed 
descriptions in Table 7-1. 
This study 
rBMAVn19∆ rBMAVn24∆ 
rBMAVn2a∆ rBMAVn2b∆ 
rBMAVn2c∆ rBMAVn2d∆ 
rBMAVn2e∆ rBMAVn2f∆ 
rBMAVn3a∆ rBMAVn3b∆ 
rBMAVn3c∆ rBMAVn3d∆ 
rBMAVn4x∆  
 
A description of transcription plasmids used in this thesis is given. rBMAV transcription 
plasmids are described in detail in Chapter 7, Table 7-1.  
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2.6 Antibodies 
 
Table 2-5: Primary Antibodies 
Target Antibody 
Dilutions 
WB IF 
BUNV N Rabbit anti-BUNV (non-commercial, bleed 593) 1:1000 1:2000 
BUNV NSs Rabbit anti-BUNV (non-commercial) 1:500 - 
FLAG epitope Mouse anti-FLAG M2 (Sigma-Aldrich) 1:2000 1:100 
IFI44 Mouse anti-IFI44 (Ab-cam) 1:500 1:50 
IFITM1 Rabbit anti-IFITM1 (Abgent) 1:1000 - 
IFITM2 Rabbit anti-IFITM2 (Abgent) 1:1000 - 
IFITM3 Rabbit anti-IFITM3 (Abgent) 1:1000 - 
MxA Rabbit anti-MxA (Santa-Cruz) 1:500 - 
Tubulin Mouse anti-tubulin (Cell Signaling) 1:3000 1:100 
 
A description of primary antibodies used in western blotting (WB) and immunofluorescence 
(IF). 
 
 
Table 2-6: Secondary Antibodies 
Target Antibody 
Dilutions 
WB IF 
Mouse IgG Anti-mouse HRP (New England BioLabs) 1:2000 - 
Rabbit IgG Anti-rabbit HRP (New England BioLabs) 1:3000 - 
Mouse IgG Anti-mouse IgG Cy5 (New England BioLabs) - 1:200 
Rabbit IgG Anti-rabbit IgG FITC (New England BioLabs) - 1:200 
 
A description of secondary antibodies used in western blotting (WB) and immunofluorescence 
(IF). 
 
 
2.8 Chemicals and Buffers 
 
2.8.1 Multipurpose Chemicals 
 
• Ethanol (Various, molecular grade) 
• Isopropanol (Various) 
• Formaldehyde (Fisher Scientific, F/1501/PB17) 
• Glycerol (BDH, 101186M) 
• Igepal CA-630: Gima I3021-500ML 
• HEPES: HEPES, free acid (Melford, B2001) 
• Methanol (Fisher Scientific, M/4000/17) 
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• Phosphate buffered saline (PBS) (Various) 
• Sodium azide (Sigma Aldrich, S2002-500G) 
• Sodium dodecyl sulphate (Sigma Aldrich L4509-500G) 
• Sucrose (Sigma Aldrich, S7903-1KG) 
• Tris-HCl (Sigma Aldrich, T5941-500G) 
 
 
2.8.2 Mammalian Cell Culture  
 
• Avicel RC/CL: Microcrystalline cellulose and sodium carboxymethylcellulose 
(CAS# 51395-75-6, FMC BioPolymer) 
• Avicel overlay 0.6% (w/v): 1.2% (w/v) Avicel RC/CL diluted at a ratio of 1:2 at 
time of use with 2X MEM (20% (v/v) 10X MEM, 2% (v/v) L-glutamine, 0.435% 
(v/v) sodium bicarbonate, 4% (v/v) FCS, diluted in sterile water 
• Blasticidin S (Life Technologies, A1113903)  
• Crystal violet solution: 1 g methyl violet (Fisher Scientific) dissolved in 200 ml 
ethanol and 10 ml methanol, and made up to a final volume of 1 L with distilled 
water. Stored at room temperature shielded from light. 
• Dulbecco’s modified Eagle media: DMEM (1X) (Life Technologies, 41966-029) 
• DMEM (Met-): DMEM without L-methionine, L-cysteine and L-glutamine (Sigma-
Aldrich, D0422-100ML) 
• DMSO (Sigma Aldrich, D8418-100ML) 
• Fetal calf serum (FCS) (Gibco, various) 
• Formaldehyde fixing buffer: 8% (v/v) formaldehyde in PBS 
• G418: GeneticinTM (Life Technologies, 10131035) 
• Glasgow minimum essential medium: G-MEM BHK-21 (1X) (Life Technologies, 
21710-025)  
• Hygromycin B (Calbiochem, Merck Millipore International, 400052-20ML) 
• Interferon: Universal type I IFN alpha (PBL, 11200-2)  
• L-glutamine (Life Technologies, 25030-024) 
• Minimum essential medium: MEM (10X) (Life Technologies, 21430-020) 
• Non-essential amino acids: MEM NEAA (100X) (Life technologies, 11140-035) 
• Newborn calf serum (NCS) (Gibco, various) 
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• Opti-MEM: Opti-MEM® I with GlutaMax-I (Life Technologies, 51985-026) 
• Pen/Strep (Life Technologies, 15140-122) 
• Plasticware: CELLSTAR® (VWR, various), Nunc® (Sigma-Aldrich, various) and 
Corning® (Sigma-Aldrich, various) 
• Puromycin (Life Technologies, A1113803) 
• Sodium bicarbonate 7.5% (Life Technologies, 25080-60) 
• Tet System Approved FCS (Clontech, 631101)  
• Tetracycline hydrochloride (Sigma-Aldrich, T-3383) 
• Trypsin EDTA 0.05% (Life Technologies, 25300-054) 
• Tryptose phosphate broth (TPB) (Life Technologies, 18050-039) 
 
 
2.8.3 Transfection of Cultured Cells 
 
• Dual luciferase® Reporter Assay System (Promega, E1960) 
• Lipofectamine 2000 (Life Technologies, 11668027) 
• TransIT®-LT1 (Mirus Bio, MIR 2300) 
• Polystyrene tubes: 5 ml polystyrene tubes, 12 x 75 mm style (SLS, 352054) 
 
 
2.8.4 Immunofluorescence 
 
• Mowiol® 4-88 (Calbiochem, 475904) 
• Permeabilisation buffer: PBS with 5% (v/v) FCS and 0.3% (v/v) Triton X-100 or 
PBS with 1% (w/v) BSA and 0.1% (w/v) saponin 
• Saponin (Sigma Life science, 84541-100G) 
• Triton X-100 (Sigma Aldrich, X100-100ML) 
 
 
2.8.5 Protein Analysis 
 
• Benzonase: Benzonase, purity >90% (Novagen®, 70746) 
• Bromophenol Blue: PlusOne bromophenol blue (Amersham Bioscience, 17-1329-
01) 
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• BSA: Bovine serum albumin (Sigma Aldrich, A2153-50G)  
• DTT: Dithiothreitol (Melford, MB1015) 
• Horseradish peroxidase (HRP) substrate: SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific, 34080) 
• MES SDS running buffer: NuPAGE® MES SDS Running Buffer (20X) (Life 
Technologies, NP0002-02) diluted to 1X in distilled water 
• Nitrocellulose membrane: Hybond-C Extra 0.45 µm (GE Healthcare, RPN303E) 
• Protein disruption buffer (PDB): 100 mM Tris-HCl, 20% (v/v) glycerol, 4% (w/v) 
SDS, 0.02% (w/v) bromophenol blue, 200 mM DTT and 125 U/ml benzonase 
• Protein gels: NuPAGE® SDS gel 4-12% Bis Tris (Life Technologies, various) 
• Protein ladder: PageRulerTM Plus Prestained Protein Ladder (Life Technologies, 
26619) 
• Transfer buffer: NuPAGE® Transfer Buffer (20X) (Life Technologies, NP0006-1) 
• Western blot blocking buffer: 5% (w/v) skimmed milk powder diluted in PBS, 
0.1% (v/v) Tween-20 
• Western blot washing buffer: PBS, 0.1% (v/v) Tween-20 
 
 
2.8.6 Nucleic Acid Isolation and Analysis 
 
• Agarose: Molecular grade agarose (Various)  
• DNA ladders: 100 and 1000 bp with loading dye (6X) (Promega, G2101 and 
G5711)  
• DNA polymerase: GoTaq® Hot Start polymerase (Promega, M5006) and KOD hot 
start DNA polymerase (Merck Millipore, 71086-4) 
• DNase: RQ1 RNase-Free DNase (Promega, M6101) 
• dNTP Mix: 10 mM dNTP Mix (Promega, U1511) 
• DpnI (Promega, R6231) 
• E-PAP: E. coli Poly(A) polymerase I (Life Technologies, AM1350) 
• Ethidium bromide solution (Various) 
• Klenow Fragment (3’→5’ exo-) (New England BioLabs, M0212S) 
• Magnetic bead DNA purification: Agencourt AMPre XP system (Beckman Coulter, 
A63880) 
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• PEG-8000, nuclease free (Sigma-Aldrich, P5413) 
• Poly(A) Tailing Kit (Life Technologies, AM1350) 
• QIAamp® Viral RNA Mini kit (Qiagen, 52904) 
• Random primers (Promega, C1181) 
• Reverse Transcriptase (RT): GoScriptTM RT (Promega, A5003), M-MLV (H-) Point 
mutant RT (Promega, M3681), and Transcriptor RT (Roche, 03531295001). 
• RNasin: Recombinant RNasin® Ribonuclease Inhibitor (Promega, N2511) 
• RNeasy Mini Kit (Life Technologies, 74104) 
• RNase (H) (Life Technologies, 18021014) 
• Sequencing library preparation: KAPA Library Preparation and Adapter Kits for 
Ion TorrentTM Platforms (Kapa Biosystems, KK8301, KK8331, KK8332, KK8333) 
• Series II RNA 6000 Nano Reagents (Agilent Technologies, 5067-1511)  
• SuperScript® III reverse transcriptase (Life Technologies, 18080044)  
• T4 DNA ligase (Promega, M1801) 
• T4 RNA ligase 1 (ssRNA Ligase) (New England BioLabs, M0204L) 
• TAE (Tris-acetic acid-EDTA) buffer: 40 mM Tris base (w/v), 12%(v/v) acetic acid, 
0.1mM (w/v) EDTA diluted in sterile water 
• TNE buffer: 10mM Tris pH 6.5, 1 mM EDTA, 100mM NaCl 
• TRIzol reagent (Life Technologies, 15596026) 
• Wizard® SV Gel and PCR Clean-Up System (Promega, A9282) 
 
 
  
 
 
 
 
 
 
 
 
Chapter 3: Methods 
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3.1 Cell Culture 
 
3.1.1 Cell Maintenance 
 
Cell cultures were maintained in vented 75 cm2 flasks and split every 3 - 4 days as 
required. Cell cultures were split by removing the cell culture medium and washing the 
cell monolayer with 5 ml sterile PBS. Cells were then washed in 5 ml of 0.05% trypsin-
EDTA and placed at 37°C with ≤ 0.5 ml residual trypsin remaining to aid cell 
detachment. Cells were resuspended in 10 ml cell culture media, seeded to new flasks 
at a final ratio of 1:10 with additional fresh cell culture medium and incubated at 37°C 
in a 5% CO2 humidified atmosphere.  
 
 
3.1.2 Liquid Nitrogen – Cell Storage and Resuscitation 
 
To maintain low passage stocks cell lines were stored in liquid nitrogen. Cell 
monolayers at low passage number in vented 75 cm2 flasks were trypsinised as per cell 
maintenance. The resuspended cells were then pelleted by centrifugation at 1700 x g 
for 5 minutes (min) and the supernatant discarded. The cells were then resuspended in 
5 ml cell culture medium containing 10% (v/v) DMSO and 20% (v/v) serum and stored 
overnight at -80°C, after which they were transferred for long term storage in liquid 
nitrogen. 
 
Cells from liquid nitrogen were rapidly thawed in 37°C water bath. To remove DMSO 
cells were washed twice in 12 ml ice cold medium by centrifugation at 200 x g for 5 
min. The cell pellet was then gently resuspended and cells seeded into vented 75 cm2 
flasks with the appropriate cell culture medium, selective antibiotic and 20% (v/v) 
serum. Cells were incubated overnight at 37°C in a 5% CO2 humidified atmosphere to 
allow cell attachment, and the cell culture media was then changed to remove dead 
cells and cell debris. Cells were then maintained with normal levels of serum as 
described in section 3.1.1. 
 
  
3: Methods 70 
3.1.3 Determination of Selective Antibiotic Concentration 
 
The optimal concentration of puromycin for the selection of transduced A549 cells was 
determined by kill curve experiment. A549 cells were seeded at 2 x 105 cells ml-1, 500 
µl per well, in 24-well cell culture plates. Six hours after seeding cells were checked for 
attachment and puromycin added at final concentrations of 0, 1, 2, 4, 8 and 10 µg ml-1 
to cell culture media. Concentrations were tested in triplicate and cells checked every 
24 hours (h) for cell death. At 3 days post antibiotic addition cell media was changed, 
with fresh antibiotic added. The optimal concentration was determined as the 
concentration needed to kill 90% of cells in 3 – 5 days. At day 4, 90% of cells in all 
wells with 2 µg ml-1 puromycin had died, and 2 µg ml-1 was chosen as the optimal 
concentration for antibiotic selection of A549-derived cell lines. 
 
 
3.2 Virus Propagation 
 
3.2.1 Preparation of Lentivirus Pseudoparticles 
 
SCRPSY plasmids encoding puromycin resistance and either TagRFP alone, or 
TagRFP and IFITM protein were kindly provided by Dr Sam Wilson, University of 
Glasgow. The SCRPSY-based plasmids were co-transfected into subconfluent 293FT 
cells in vented 75 cm2 flasks with pVSV-G and pCMVR8.91 plasmids at a ratio of 
5:3:3, respectively to create lentivirus pseudoparticles. Transfections were carried out 
with Lipofectamine 2000 as per manufacturer’s instructions in a total volume of 6 ml 
Opti-MEM for 5 h at 37 °C. Following incubation, the transfection mix was removed 
and the cell monolayer washed once with 5 ml DMEM 10% (v/v) FCS. Cells were then 
incubated at 37°C with 10 ml DMEM 10% (v/v) FCS and cell supernatant harvested 24 
h p.i. and stored at 4°C. Fresh medium was then added to the cell monolayer, and the 
cells incubated for a further 24 h; at this point the supernatant was harvested and 
pooled with that collected 24 h earlier. The pooled supernatant was then clarified by 
centrifuging at 1700 x g for 5 min, passed through a 0.45 µm Truffryn or PVDF filter 
and stored in 1.5 ml aliquots at -80°C.  
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3.2.2 Lentivirus Transduction 
 
Subconfluent A549 cells in vented 25 cm2 flasks were transduced with lentivirus 
pseudoparticles. Briefly, cells were washed with 2 ml serum free DMEM prior to the 
addition of 1 ml DMEM supplemented with 8 µg ml-1 polybrene and 500 µl lentivirus 
pseudoparticles or 500 µl DMEM for the mock-transduced control. Following 
incubation for 2 h at 37°C, 2 ml DMEM 10% (v/v) FCS was added directly to each 
flask, without removing the lentivirus inoculum. At 48 h p.i. cell culture medium was 
removed and replaced with DMEM 10% (v/v) FCS supplemented with 2 µg ml-1 
puromycin. Cells were then monitored for TagRFP expression and cultures split as 
required. 
 
 
3.2.3 Virus Rescue  
 
Recombinant viruses were created using a 3 plasmid rescue system. Five microlitres 
TransIT-LT1 was mixed with 175 µl Opti-MEM per reaction in a polystyrene tube, and 
incubated at room temperature for 5 min. Five hundred nanograms of 3 pTvT7 
plasmids encoding the complete S, M and L virus genome segments in the antigenome 
orientation were then mixed with 175 µl Opti-MEM and slowly added to the TransIT-
LT1 Opti-MEM mix. This solution was gently mixed by pipetting and incubated at 
room temperature for 30 min. Subconfluent BSR-T7/5 cells in 6-well cell culture plates 
were then washed with 1 ml Opti-MEM and 350 µl transfection mix/well pipetted 
directly onto the cell monolayer. Cells were then incubated at 37°C for 1 h, prior to the 
addition of 2 ml cell culture medium, and then moved to 33°C. Twenty-four hours 
post-transfection the cells were washed and fresh medium added to minimise 
transfection reagent toxicity. Supernatant was harvested 6 days post-transfection, 
clarified by centrifuging at 1700 x g for 5 min and stored at -80°C. Longer incubations 
of up to 14 days were tested for mutant viruses, although this did not increase the 
success of virus resuce. 
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3.2.4 Preparation of Virus Stocks 
 
Freeze-dried and lyophilised virus isolates were resuspended in 0.5 to 1 ml sterile PBS, 
as specified by isolate labels. Elite virus stocks were created by infecting subconfluent 
Vero E6 cells in 25 cm2 vented flasks with 100 µl inoculum (rescue supernatant or 
freeze-dried virus suspension) and 400 µl OptiMem for 1 h at 37°C, 5% CO2 in a 
humidified atmosphere. Four point five millilitres cell culture media was then added 
and cells incubated at 33°C, 5% CO2 in a humid atmosphere until cytopathic effect 
(CPE) reached 90% or for 7 days. When generating elite virus stocks from freeze-dried 
virus isolates, cell culture media and the first inoculum were supplemented with 100 U 
ml-1 Pen/Strep; all further passages of freeze-dried virus isolates were carried out in 
antibiotic-free media.  
 
Working stocks were then created by infecting subconfluent Vero E6 cells in vented 
150 cm2 flasks with 100 µl elite stock and 4 ml serum free medium for 1 h at 37°C 5% 
CO2 in a humidified atmosphere. Twenty-one millilitres cell culture medium was then 
added and cells incubated at 33°C, 5% CO2 in a humid atmosphere until CPE reached 
90% or for 7 days. 
 
 
3.2.5 Blind Passage of Virus Isolates 
 
Elite stocks of freeze-dried virus isolates were blind passaged in vented 25 cm2 flasks 
of subconfluent Vero E6 cells until the production of CPE or passage 8. Briefly, 7 days 
d p.i. elite stock supernatants were collected and centrifuged for 5 min at 1700 x g. One 
hundred microlitres clarified culture supernatant was then used to infect subconfluent 
Vero E6 cells as per the protocol for generating elite virus stocks. Additionally, 1 ml 
aliquots of each passage were stored at -80°C. 
 
 
3.2.6 Virus Titration by Plaque Assay 
 
Virus titre was determined by plaque assay on Vero E6 cells. Cells were seeded at 
5x105 cells per well in 6-well cell culture plates 18 - 22 h prior to infection. Cell culture 
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medium was then removed and replaced with 200 µl of virus supernatant that had been 
serially diluted in sterile PBS, 2% (v/v) FCS. Cells were then incubated for 1 h at 37°C 
in 5% CO2, and rocked every 15 min to prevent drying. Two millilitres 0.6% (w/v) 
Avicel overlay was then added and cells were incubated at 33°C for 6 to 14 days. The 
cell monolayers were then fixed for 1 h in 4% (v/v) formaldehyde, and monolayers 
stained in crystal violet for 15 min at room temperature. The stain was removed by 
rinsing the plates in water and virus titre calculated as number of plaque forming units 
(p.f.u) per ml using the formula: t = (p/d) x 5, where t = titre in p.f.u ml-1, p = number 
of plaques, d = dilution factor of counted well. 
 
 
3.2.7 Virus Yield Assays 
 
Virus yield assays were carried out in 6-well plates. For experiments with Flp-InTM T-
RExTM 293 cell lines, cells were induced with 1 µg ml-1 tetracycline or mock-induced 
with PBS for 48 h prior to infection. For all virus yield assays subconfluent cells were 
infected at the specified multiplicity of infection (MOI) for 1 h at 37°C in 5% CO2. 
Virus dilutions were carried out in Opti-MEM, which also acted as the negative control 
in mock infections. Following infection cell monolayers were washed three times with 
1 ml Opti-MEM prior to the addition of fresh medium and incubation at 37°C in 5% 
CO2. Cell monolayers and supernatants were harvested at specified time points. 
Supernatants were clarified by centrifuging at 1700 x g for 10 min and stored at -80°C 
for viral titre determination by plaque assay. Pellets were resuspended in 100 µl protein 
disruption buffer and pooled with the corresponding cell monolayer to which another 
200 µl protein disruption buffer was added. Cell lysates were stored at -20°C for 
analysis by Western Blot. 
 
 
3.3 Interferon Experiments 
 
3.3.1 Induction of Interferon-Stimulated Genes 
 
Cells were stimulated with IFN by the addition of universal IFN at a final concentration 
of 1000 U ml-1 for 4 h – 24 h. To test for ISG stimulation cell monolayers were 
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harvested at specified time points in 300 µl PDB and stored at -20°C for analysis by 
Western Blot.  
 
 
3.3.2 Resistance to Interferon 
 
Virus resistance to IFN was measured by treating Vero E6 cells seeded at 1.5 x 105 
cells ml-1 with 100, 1 000 and 10 000 U ml-1 IFN 24 hours prior to infection at MOI 
0.01. Supernatants were then harvested at 48 h p.i. and virus titre determined by plaque 
assay. 
 
 
3.3.3 Interferon-β Promoter Reporter Assays 
 
Two reporter assays measuring activation and antagonism of the IFN-β promoter were 
carried out using the Dual-Luciferase Reporter System. Luciferase activity was 
measured on the Glomax® 96 Microplate Luminometer (Promega) with a 2 s delay and 
1 s integration time. 
 
Induction of the IFN-β promoter during virus infection was assessed by transfecting 
subconfluent A549 cell monolayers in 6-well cell culture plates with 750 ng pIF∆(-
125)lucter and 5 ng phRL-CMV for 5 h at 37°C with rocking every 20 min to prevent 
drying of the cell monolayer. The transfection mix was then removed, cells washed 3 
times with 1 ml Opti-MEM and either infected at an MOI of 1 with the specified 
viruses or mock infected with Opti-MEM. Following infection cell monolayers were 
washed 3 times with 1 ml Opti-MEM prior to the addition of cell culture medium and 
incubation at 37°C in 5% CO2. Cell monolayers were harvested at 18 h p.i. in 1X 
passive lysis buffer as per manufacturer’s instructions and assayed for luciferase 
activity. 
 
A second reporter assay measuring antagonism of the IFN-β promoter by viral proteins 
was also performed using the Dual-Luciferase Reporter System. Subconfluent 293T 
cells in 12-well cell culture plates were transfected with 25 ng p2CARD-CAGGS to 
stimulate the IFN-β promoter, 750 ng p(-125)IFNlucter to measure activity of the IFN-
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β promoter, 5 ng phRL-CMV to allow normalisation to Renilla, 10 ng - 500 ng viral 
proteins under control of the CMV promoter, and empty pCMV plasmid to equalise the 
concentration of DNA across all reactions. Cells were harvested 18 h p.i. in passive 
lysis buffer as per manufacturer’s instructions. 
 
For reporter assays transfection reagent, Lipofectamine 2000 or TransIT-LT1 was 
mixed with Opti-MEM in polystyrene tubes, and incubated at room temperature for 5 
min. Plasmid DNA was mixed with Opti-MEM, added to the transfection/Opti-MEM 
solution, gently mixed by pipetting and incubated at room temperature for 30 min. The 
cell monolayer was then washed with 1 ml Opti-MEM and transfection mix added 
directly to cells. Cells were then incubated at 37°C in 5% CO2 for 1 h for all cell types 
except the A549 cell lines, which were incubated for 5 h. Following incubation 
transfection mix was removed and the appropriate cell culture medium added.  
 
 
3.3.5 Biological Interferon Assay 
 
Subconfluent A549 cells were infected at an MOI of 1 with the specified viruses, or 
mock infected with Opti-MEM, for 1 h at 37°C in 5% CO2. Following infection cell 
monolayers were washed 3 times with 1 ml Opti-MEM prior to the addition of cell 
culture medium and incubation at 37°C in 5% CO2. Forty-eight hours post infection 
supernatant was harvested and clarified by centrifugation at 1700 x g for 5 min. 
Clarified culture supernatant was then UV-inactivated by placing in a fresh 6-well cell 
culture plate and placing a UV light tube directly over the plate with no lid on for 2 
min. The plate was then agitated to mix the supernatant before exposure to UV light for 
a further 2 min. One hundred microlitres of 2-fold dilutions of the UV-irradiated 
supernatant were then applied to A549-NPro cells in 96-well cell culture plates and 
incubated for 24 h at 37°C. Without removing the UV-irradiated supernatant 
encephalomyocarditis virus (EMCV), which is sensitive to IFN, was then added to the 
A549-Npro cells at a final dilution of 1:10 000. Cell monolayers were then fixed in 4% 
(v/v) formaldehyde 72 h post EMCV infection and stained with crystal violet to 
measure cell death. Intact cell monolayers correspond with the death of EMCV and 
thereby the presence of IFN in the UV-inactivated supernatants. 
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3.4 Nucleic Acid Manipulation and Cloning 
 
3.4.1 Extraction of Total Cellular and Virion RNA 
 
Total cellular RNA for IFN-β mRNA PCR was extracted using TRIzol as per 
manufacturer’s instructions from A549 cells infected at MOI of 1, 18 h p.i. Virion 
RNA was extracted using the QIAamp® Viral RNA Mini kit (Qiagen), with carrier 
RNA as per manufacturer’s instructions. 
 
 
3.4.2 RNA Extraction for High-throughput Sequencing 
 
20 ml working virus stock was harvested and clarified by centrifugation at 1000 x g for 
10 min. The resulting supernatant was then further clarified by centrifugation at 3000 x 
g for 5 min in a fresh Falcon tube. The supernatant was then passed through a 0.2 µm 
filter and incubated at 4°C for 30 min with 10.8 ml sterile PEG-8000 in TNE buffer and 
1.56 ml sterile 5M NaCl. Virions were then precipitated by centrifugation at 4000 x g 
for 1 h 45 min at 4°C. The pellet was resuspended in 500 µl PBS, 25 U benzonase and 
incubated at 37°C for 30 min. RNA was then extracted with 2 ml TRIzol according to 
the manufacturer’s instructions. 
 
 
3.4.3 DNase Treatment 
 
Approximately 2 µg RNA was incubated with 2 µl (2 U) DNase in a total volume of 20 
µl at 37°C for 30 min, followed by heat inactivation at 65°C for 15 min.  
 
 
3.4.4 RNA Ligation 
 
Twelve microlitres virion RNA was denatured by heating at 90°C for 3 min and 
immediately cooled on ice. Twelve microlitres denatured RNA, 10 U rRNasin, 1X T4 
RNA ligase 1 buffer, 20 U T4 RNA ligase 1 (ssRNA ligase), and 20 mM ATP were 
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heated at 37°C for 2 h, followed by heat inactivation at 65°C for 15 min. Ligated RNA 
was then amplified by RT-PCR and sequenced as per section 3.4.5, 3.4.7 and 3.4.10. 
 
 
3.4.5 Standard Reverse-transcription  
 
For IFN-β mRNA RT-PCR with γ-actin controls, 10 µl DNase treated total cellular 
RNA was heated at 70°C for 5 min with 1 µl (500 ng) random primers. For all other RT 
reactions 12 µl virion RNA and 1 µl of 100 µM target-specific RT primer were heated 
at 70°C (90°C for ligated RNA) for 5 min and immediately cooled on ice. Standard RT 
reactions were carried out using M-MLV based systems: M-MLV (H-) Point mutant 
RT or GoScriptTM RT. The change from M-MLV (H-) Point mutant RT to GoScriptTM 
RT was made following relocation from The University of St Andrews to The 
University of Glasgow and the differing availability of kits at onsite stores. GoScriptTM 
reactions were carried out in a final volume of 25 µl with 13 µl heat-denatured 
RNA/Primer mix, 5 µl 5X GoScriptTM buffer, 3 µl 25 mM MgCl2, 1 µl 10 mM dNTPs, 
40 U rRNasin, 1 µl GoScriptTM RT. The RT reaction was incubated for 1 h at 42°C. M-
MLV (H-) Point mutant reactions were carried out in a final reaction volume of 20 µl 
with 13 µl heat denatured RNA/Primer mix, 4 µl 5X M-MLV buffer, 1 µl 10 mM 
dNTPs, 40 U rRNasin®, 200 U M-MLV (H-) Point mutant RT. The RT reaction was 
incubated for 1 h at 37°C. 
 
 
3.4.6 Rapid Amplification of cDNA Ends 
 
Virion RNA was poly-A tailed using the Poly(A) Tailing Kit (Ambion). Each 25 µl 
reaction contained 14 µl virion RNA, 5 µl 5X buffer, 2.5 µl 25 mM MnCl2 2.5 µl 10 
mM ATP and 1 µl EPAP. Reactions were incubated at 37 °C for 1 h and poly-A tailed 
RNA was then purified using the RNeasy minikit (Qiagen) and eluted in 30 µl nuclease 
free water as per manufacturer’s instructions. Twelve microlitres poly-A tailed RNA 
and 1 µl 100 µM oligo d(T) primer were then heat-denatured at 70°C for 5 min and 
immediately cooled on ice. Thirteen microlitres heat-denatured RNA/primer mix was 
then reverse transcribed in a 20 µl reaction containing 4 µl 5X Transcriptor RT reaction 
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buffer, 2 µl 10 mM dNTPs and 1 µl (20 U) Transcriptor RT for 40 min at 55°C. Five 
microlitres cDNA was then amplified by PCR using KOD polymerase, a virus specific 
primer and a primer targeting the oligo-d(T) anchor sequence. This technique was used 
to obtain sequences for both the 5’ and 3’ cRNA UTRs, as the 5’ cRNA UTR 
corresponds to the 3’ vRNA.  
 
 
3.4.6 Standard PCR 
 
PCRs, excluding colony PCR, were performed using KOD polymerase in a final 
reaction volume of 50 µl and contained 5 µl cDNA or 0.5 µl plasmid DNA, 5 µl 10X 
buffer, 5 µl dNTP mix (2 mM each), 3 µl 25 mM MgSO4, 2.5 µl 10 µM forward 
primer, 2.5 µl 10 µM reverse primer and 1 µl (1 U) KOD polymerase. PCR cycling 
conditions were initial denaturation at 95°C for 5 min followed by 35 cycles of 
denaturing at 95°C for 30 s, primer annealing at 50-60°C for 30 s, and extension at 
70°C for 30 s, and a final extension step at 70°C for 10 min. The primer annealing 
temperature was determined by primer characteristics, whilst the cycling extension 
time was determined by amplicon size (30 s per 1 kb amplicon). 
 
 
3.4.7 QuickChange® PCR 
 
QuickChange® site-directed mutagenesis (Stratagene) was performed according to the 
manufacturer’s instructions, with the exception that KOD polymerase and primers of 
standard salt purification were used. Following amplification template DNA was 
degraded by the addition of 20 U DpnI per reaction and incubation at 37°C for 1 h. 
treatment. Bacterial cells were then transformed with 2 µl of the QuickChange® 
reaction. 
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3.4.8 Agarose Gel Electrophoresis 
 
Gel electrophoresis was carried out in horizontal slab 1% (w/v) agarose gels in 1X TAE 
buffer supplemented with 0.004% (v/v) ethidium bromide. The volume of samples 
loaded ranged from 5 µl – 50 µl and loading dye was added to samples at a final 
concentration of 1X. Gels were run at 100 V for 30 – 45 min in 1X TAE running 
buffer. DNA fragments were visualised using a UV transilluminator. If required, gel 
bands were excised and purified using the Wizard® SV Gel and PCR Clean-Up System 
(Promega) as per manufacturer’s instructions. 
 
 
3.4.9 High-throughput Sequencing 
 
RNA samples from ANAV, CAPV, BORV, BMAV and TETEV virions were 
submitted to Glasgow Polyomics for sequencing on the illumina MiSeq platform. 
Insufficient reads were generated for ANAV and CAPV and these viruses, and all other 
viruses with HTS data were sequenced at the Center for Infection and Immunity, NY. 
Briefly, first strand cDNA synthesis was carried out on 11 µl virion RNA using random 
hexamer primers and superscript III reverse transcriptase enzyme. Samples were then 
RNAse(H) treated by 1 µl 37°C 20 min, 75°C 15 min. Second strand cDNA synthesis 
was performed using 600 ng random hexamer primers, 1X NEB buffer 2, 50 mM 
deoxynucleotides and 20 U Klenow Fragment, exo- in a total volume of 100 µl, 37°C 
45 min. The KAPA Library Preparation Kit for Ion Torrent Platforms was then 
followed as per manufacturer’s instructions, with sample clean-up using Agencourt 
AMPure XP reagent to prepare cDNAs for sequencing on the Ion Proton sequencer. 
Samples were quantified using the Qubit® 2.0 Fluorometer (Life Technologies) and 
2100 Bioanalyser (Agilent). 
 
 
3.4.10 Sanger Sequencing 
 
RACE-PCR products and purified plasmids were sent to GATC or Source BioScience 
for sequence confirmation by Sanger sequencing. The sample requirements 
recommended by the companies were followed.  
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3.4.11 Transformation of Bacterial Cells 
 
Competent JM109 E.coli bacteria were prepared using the Z-Competent E. coli 
Transformation kit and buffer set (Zymo Research) according to the manufacturer’s 
instructions and stored in 100 µl aliquots at -80°C. Prior to use cells were defrosted on 
ice for 5 min, plasmid DNA was then added and cells incubated on ice for 3-5 min. 
Transformed cells were then plated on pre-warmed LB agar with selective antibiotic 
and incubated overnight at 37°C. Colonies were then selected for confirmation by 
colony PCR and Sanger sequencing as required. 
 
 
3.4.12 Plasmid Propagation 
 
Transformed bacterial cells were grown on solid LB agar supplemented with ampicillin 
overnight at 37°C. Single colonies were then picked, inoculated into 5 ml LB broth 
containing ampicillin and incubated at 37°C with shaking at 225 rpm for 10 - 12 h. 
Plasmid purification was performed using the PureYieldTM Plasmid Miniprep System 
(Promega), as per the manufacturer’s instructions.  
 
 
3.4.13 Restriction-Free Cloning 
 
Plasmids were linearised by excision PCR with KOD polymerase and primers which 
flank the insertion site, followed by DpnI treatment. Inserts were prepared by KOD 
PCR with primers that contain a 5’ overhang of 15 bp, which is complementary to the 
desired insert site, followed by agarose gel electrophoresis and purification. Inserts and 
linearised vectors were then combined using the InFusion HD Cloning Kit (Clontech 
Laboratories Inc.). Reactions included 100 ng insert, 100 ng linearised vector, 1 µl 5X 
In Fusion enzyme pre-mix and nuclease free water in a total reaction volume of 10 µl, 
and were incubated at 50°C for 15 min prior to cooling on ice. The entire 10 µl reaction 
was then used to transform 100 µl competent JM109 cells as detailed in section 3.4.11. 
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3.4.14 pGEM-T Easy  
 
The pGEM-T easy vector is supplied as linearised plasmid with single thymidine 
overhangs at both ends of the insertion site. Therefore, adenine overhangs were added 
to agarose gel-purified PCR products to allow ligation between the vector and insert. 
Adenine overhangs were created using the following ‘Taq reaction’: 30 µl gel-purified 
PCR product, 5 µl 5X Flexi buffer, 1 µl 10 mM dNTPs, 5 µl 25 mM MgCl2, 0.5 µl 
GoTaq G2, 8.5 µl water, incubated at 72°C for 15 min and cooled on ice. Reaction 
products were then purified using Wizard® SV Gel and PCR Clean-Up System 
(Promega) and eluted in 35 µl nuclease free water as per manufacturer’s instructions. 
Overnight ligation reactions with T4 DNA ligase were carried out at 4°C with 
preliminary insert:vector ratios of 3:1 and 1:3, according to the manufacturer’s 
instructions. 
 
 
3.4.15 Colony PCR  
 
Colony PCR was used to screen transformants for the presence of a desired insert. 
Single colonies were resuspended in 14.5 µl sterile H2O and 2 µl used to dot inoculate 
an LB agar plate supplemented with ampicillin. The remaining 12.5 µl of the colony 
suspension was then used as the template in a 50 µl PCR reaction with final 
concentrations of 1X GoTaq PCR buffer, 200 nM dNTPs, 200 nM forward primer, 200 
nM reverse primer and 0.3 U GoTaq polymerase. PCR cycling conditions were 95°C 
for 5 min denaturation, followed by 30 cycles of 95°C for 30 s, primer annealing for 30 
s, extension at 72°C, and a final extension step at 72°C for 10 min. The primer 
annealing temperature and extension time were determined by primer characteristics 
and amplicon size (30 s per 1 kb amplicon), respectively. Colonies with PCR products 
of the correct size were then selected for plasmid propagation and confirmation by 
Sanger sequencing. 
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3.5 Protein Analysis  
 
3.5.1 Western Blotting 
 
Proteins were prepared for western blot analysis by removing cell culture media, 
rinsing cells in PBS, 2% (v/v) FCS and lysing cells in 30 µl PDB per cm2 cell 
monolayer. Lysates were stored at -20°C and then, prior to analysis, boiled at 100°C for 
3 min and immediately placed on ice. Samples (10 µl – 15 µl per well) were then size 
separated on NuPAGE 4-12% Bis-Tris gels, with 5 µl PageRule Plus pre-stained 
protein ladder, for approximately 50 min at 180 V in 1 X MES SDS running buffer. 
Proteins were transferred to nitrocellulose membrane (GE Healthcare) using the Bio-
Rad Trans-Blot Turbo Transfer System and 1x NuPAGE Transfer Buffer. Once transfer 
was complete membranes were blocked for 1 h at room temperature with 5% (w/v) 
skimmed milk in PBS, 0.1% (v/v) Tween-20. Membranes were then reacted with 
primary and secondary antibodies for 1 h using the specified dilutions (Table 2-4, Table 
2-5). Visualisation of proteins was achieved by the addition of SuperSignal West Pico 
Chemiluminescent Substrate as per manufacturer’s instructions. Blots were then 
exposed to x-ray films which were subsequently developed using KODOmat and 
Kograph Compact x4 automatic processors.  
 
 
3.5.2 Metabolic Labelling 
 
Metabolic labelling was carried out using subconfluent Vero E6 cells seeded in 6-well 
cell culture plates. Two hours prior to labelling cell culture medium was replaced with 
2 ml DMEM (Met-) to starve cells of methionine. Following methionine starvation 
DMEM (Met-) was replaced with 350 µl DMEM (Met-) supplemented with 15 µCi 
[35S]-methionine, and cells were incubated for a further 2 h at 37ºC in 5% CO2. 
Radiolabelled medium was then removed, cell monolayers lysed in PDB and stored at -
20°C prior to analysis. For analysis [35S]-methionine labelled proteins were size 
separated and transferred to nitrocellulose membrane as in 3.5.1. The protein gels were 
then dried and labelled products visualised by autoradiography.  
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3.6 Software Packages 
 
3.6.1 Bioinformatics 
 
• De novo assembly of high-throughput sequencing data was carried out in CLC 
genomics workbench v7.5.1 (Qiagen) [http://www.clcbio.com/products/clc-
genomics-workbench].  
 
• Mega 6.0 (for Mac) [http://www.megasoftware.net/] and NetNGlyc 1.0 
[http://www.cbs.dtu.dk/services/NetNGlyc] were used for sequence alignments, 
phylogeny and N-Glycosylation prediction respectively (Tamura et al., 2013; Gupta 
et al., 2004).  
 
• Disorder predictions and domain searches were carried out by Dismeta 
[http://www-nmr.cabm.rutgers.edu/bioinformatics/disorder] and InterPro Scan 
[http://www.ebi.ac.uk/interpro] (Huang et al., 2014; Mitchell et al., 2015). 
 
• Prediction of transmembrane topology and signal peptides were carried out by 
TMHMM server v2.0 [http://www.cbs.dtu.dk/services/TMHMM] and Phobius 
[http://phobius.sbc.su.se/]. 
 
 
• Structural models were generated by Phyre2 
[http://www.sbg.bio.ic.ac.uk/phyre2/html/page.cgi?id=index] and manipulated in 
PyMol v1.7.6 (for Mac) [https://www.pymol.org/] (Kelley and Sternberg, 2009). 
 
 
3.6.2 Graph Generation and Statistical Analysis 
 
Statistical analysis was carried out and graphs prepared using Prism v5.0a (for Mac OS 
X), GraphPad Software, La Jolla California, USA [http://www.graphpad.com/] 
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3.6.3 Imaging Programmes 
 
• IF images were prepared in ImageJ 1.45s 64-bit [http://imagej.nih.gov/ij].  
 
• Agarose gel electrophoresis and western blot images were prepared in Image Lab 
v5.0, Bio-Rad Laboratories [http://www.bio-rad.com/en-uk/product/image-lab-
software] 
 
• Graphical schematics were prepared in Autodesk® Graphic for Mac® v3.0.1 
[http://www.graphic.com/]  
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4.1 Introduction 
 
The World Health Organisation’s Collaborating Centre for Arbovirus Reference and 
Research has determined antigenic relationships between viruses collected by the 
Rockefeller Institute and collaborating centres since the late 1950s (Berge 1975; Elliott 
and Blakqori 2011). These data have shaped virus classification and our understanding 
of bunyavirus ecology and evolution, with Casals and Whitman proposing the 
formation of the Bunyamwera ‘group’ in 1960 (Casals and Whitman 1960). As 
complex interrelated antigenic relationships were discovered this was amended to the 
Bunyamwera ‘Supergroup’ in 1963 (Okuno 1961; Whitman and Casals 1961; Whitman 
and Shope 1962; Casals 1963). This proposal would go on to form the foundation of 
the Bunyaviridae family and orthobunyavirus genus, which now contains over 170 
named viruses, classified into 18 ICTV-recognised serogroups (Fenner 1976; King 
2012). However, for many of these viruses research stalled after their original isolation 
and antigenic classification, with detailed molecular studies focusing only on viruses in 
the Simbu, California, Bunyamwera and Group C serogroups (Dunn et al., 1994; 
Bowen et al., 1995; Nunes et al., 2005; Chowdhary et al., 2012; Ladner et al., 2014; 
Tilston-Lunel et al., 2015). Obtaining virus isolates from the less studied serogroups 
would allow further characterisation and improve genus wide knowledge. For example, 
the NSs protein has been identified as the primary virulence factor of 
orthobunyaviruses and was thought to be key in overcoming the vertebrate host 
immune response (Bridgen et al., 2001; Weber et al., 2002; Léonard et al., 2006; Barry 
et al., 2014). However, in 2009 Mohammed et al., utilised consensus primers to obtain 
S segment sequence data of viruses in the Anopheles A, Anopheles B and Tete 
serogroups, and in doing so identified viruses associated with human infection that 
contained severely truncated and non-functional NSs ORFs. Despite this discovery no 
further work has been carried out on viruses within these serogroups with no published 
information on growth kinetics, or plaque morphology. Furthermore, there are currently 
12 named virus isolates in the Anopheles A serogroup and only 2 viruses, ANAV and 
TCMV, were included in Mohamed et al., (2009) studies. 
 
In addition to documenting plaque morphology and growth kinetics determining the 
biochemical profile of virus isolates can act as a screen, confirming the presence of 
orthobunyavirus-like infectious agents. This is possible as orthobunyaviruses have a 
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unique biochemical profile that is distinct from other arboviruses and genera within the 
Bunyaviridae family (Table 1-3). Orthobunyaviruses typically encode an NSs protein 
of 12 ± 1 kDa, N protein of 22 ± 3 kDa, NSm protein of 16 ± 2 kDa, Gn and Gc 
proteins of 37 ± 8 kDa and 115 ± 7 kDa, respectively, and a 259 kDa L protein. 
However, this orthobunyavirus protein profile is based on viruses from only 10 
serogroups, namely the Anopheles A, Anopheles B, Bunyamwera, California, Capim, 
Group C, Guama, Patois, Simbu, and Turlock serogroups (White, 1975; Gentsch et al., 
1977; Pennington et al., 1977; Gentsch et al., 1979; Klimas et al., 1981; McPhee and 
Westaway 1981; Ushijima et al., 1981; Short et al., 1982; Elliott, 1985; McPhee and 
Della-Porta, 1988). Furthermore, the unclassified orthobunyavirus Brazoran virus has 
an N protein of 49.8 kDa and NSs protein of 19.6 kDa demonstrating that there is 
greater diversity in the orthobunyavirus genus than previously thought (Lanciotti et al., 
2013). It would therefore be of interest to determine the protein profiles of viruses in 
the remaining 8 recognised serogroups, which are the Bakau, Bwamba, Gamboa, 
Koongol, Minatitlan, Nyando, Olifantsvlei and Tete serogroups.  
 
 
4.2 Aims  
 
The aims of this part of my studies were to create a panel of orthobunyaviruses capable 
of replication in mammalian cell culture with information on plaque morphology, virus 
protein profiles and virus growth kinetics in IFN-competent and incompetent cell lines. 
In addition to the virus panel, I would create a spreadsheet detailing geographical 
distribution, known vectors, and host species for all ICTV-recognised orthobunyavirus 
species and all named orthobunyaviruses with complete genome sequences. 
 
 
4.3 Results 
 
4.3.1 Virus Propagation and Plaque Morphology 
 
Fifty orthobunyavirus isolates, supplied as freeze-dried infected mouse brain 
homogenates or freeze-dried low passage tissue culture samples were resuspended and 
blind passaged on Vero E6 cells until the production of CPE, or passage 10 (Table 4-1). 
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In total 25 viruses developed CPE during virus passage, 2 on passage 1, 13 on passage 
2, 7 on passage 3, 1 on passage 4, 1 on passage 5 and 1 on passage 6 (Table 4-1).  
 
Of the 26 viruses that developed CPE 7 belonged to the Anopheles A serogroup. 
ANAV, ColAn57389, CPEV and LMV developed CPE at passage 2, whilst TRMV and 
TUCV required further passaging, developing CPE at passage 4 and passage 6, 
respectively (Table 4-1). ColAn57389, LMV and TRMV formed plaques 2 mm - 3 mm 
in diameter that remained slightly opaque, with incomplete clearing of the cell 
monolayer (Figure 4-1). The plaques of CPEV, TUCV and TCMV were smaller at only 
1 mm - 2 mm in diameter at 6 d p.i. (Figure 4-1). Viruses in the Anopheles B 
serogroup, ANBV and BORV, both developed CPE at passage 2 and formed semi 
opaque/turbid plaques 2 mm - 3 mm in diameter at 6 d p.i. (Table 4-1, Figure 4-1).   
 
Nine viruses in the Capim serogroup were passaged, however, only 4 developed CPE, 
GJAV and JDV at passage 2 and CAPV and MORV at passage 3 (Table 4-1). CAPV, 
GJAV and JDV formed sharp clear pin-prick plaques of 1 mm - 2 mm in diameter, 
whilst MORV formed slightly larger plaques of ≤ 3 mm at 6 d p.i. (Table 4-1, Figure 4-
1). GMAV, the sole member of the Guama serogroup to show evidence of infection, 
developed CPE on passage 2 and formed large clear plaques of 4 mm - 5 mm in 
diameter which were comparable to those of BUNV (Figure 4-2). The only other virus 
to form large plaques comparable to BUNV was MPOV, a member of the Turlock 
serogroup, which produced CPE on passage 1 and formed large clear plaques 2 mm – 5 
mm in size (Table 4-1, Figure 4-2). 
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Table 4-1: Virus Propagation in Vero E6 Cells 
   Virus Classification    Isolates In This Study  In the Literature 
Virus Name ABBV Passage Number CPE 
Virus Titre 
(p.f.u ml-1) 
Plaque Morphology 
(d p.i., size [mm]) 
Anopheles A Serogroup 
Anopheles A  ANAV p3 + 1.80 x 106 (4, 2) 
ColAn 57389 ColAn57389 p2 + 2.20 x 105 N/A 
CoAr 1071 CoAr1071 p10 - N/A N/A 
CoAr 3624 CoAr3624 p10 - N/A N/A 
Arumateua ARTV p10 - N/A N/A 
Caraipe CPEV p2 ++ 3.65 x 106 N/A 
Las Maloyas LMV p2 ++ 1.00 x 107 (5, <1) 
Lukuni LUKV p10 - N/A (13, 0.5-1) 
Tacaiuma TCMV p10 - N/A (N/A,1) 
Tacaiuma BeAn73 BeAn73 p5 + 9.00 x 105 (N/A,1) 
Trombetas TRMV p4 ++ 4.50 x 106 N/A 
Tucurui  TUCV  p6 + 6.50 x 105 N/A 
Virgin River  VRV p10 - N/A (12, 3) 
Anopheles B Serogroup 
Anopheles B ANBV p2 + 1.00 x 106 (9,3) 
Boraceia BORV p2 + 4.50 x 107 (2,3) 
Bakau Serogroup      
Bakau  BAKV  p10 - N/A (4,2) 
Ketapang  KETV p10 - N/A (4,2) 
Bwamba Serogroup 
Bwamba BWAV p2 ++ 8.50 x 106 (5,1) 
Pongola PGAV p10 - N/A (3,1) 
Capim Serogroup 
Acara ACAV p10 - N/A (6,1) 
Acara ACAV p10 - N/A (6,1) 
Benevides BVSV p10 - N/A CPE 
Benfica BENV p10 - N/A CPE 
Bushbush BSBV p10 - N/A (6,1) 
Capim CAPV p3 + 3.65 x 106 (3,1) 
Guajara  GJAV  p2 + 8.50 x 105 N/A 
Juan Diaz JDV p2 ++ 5.50 x 104 (5, N/A) 
Moriche MORV p3 ++ 1.65 x 106 (4,1) 
Gamboa Serogroup      
Gamboa GAMV p2 ++ 1.75 x 105 (4-6, N/A) 
San Juan SJV p3 ++ 3.55 x 106 (5, N/A) 
Guama Serogroup      
Bertioga BERV p10 - N/A (2,1) 
Guama GMAV p2 + 2.50 x 105 (5, 1-1.5) 
Koongol Serogroup      
Koongol KOOV p10 - N/A (15,1) 
Wongal WONV p10 - N/A (10,2) 
Minatitlan Serogroup 
Minatitlan MNTV p10 - N/A N/A 
Palestina PLSV p2 +++ 2.60 x 107 (7, N/A) 
Nyando Serogroup      
Eretmapodites  EREV p2 +++ 2.60 x 107 N/A 
Nyando NDV p1 + 1.80x 107 (5,2) 
Olifantsvlei Serogroup 
Botambi BOTV p10 - N/A N/A 
Olifantsvlei OLIV p10 - N/A N/A 
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Patois Serogroup      
Pahayokee PAHV p10 - N/A N/A 
Patois PATV p10 - N/A No plaques 
Tete Serogroup      
Bahig  BAHV  p10 - N/A (3,3) 
Batama BMAV p2 ++ 3.10 x 108 N/A 
Matruh MTRV p3 ++ 1.70 x 107 (3,7) 
Tete TETEV p3 ++ 3.95 x 107 N/A 
Tsuruse-like TSUV p3 ++ 3.25 x 107 N/A 
Weldona WELV p2 + N/A N/A 
Turlock Serogroup      
M’Poko MPOV p1 ++ 5.50 x 106 N/A 
Turlock TURV p10 - N/A (6,3) 
 
Virus names and abbreviations (ABBV) of isolates passaged in this study are given. Viruses 
were passaged on Vero E6 cells until the development of cytopathic effect (CPE) or passage (p) 
10. Level of CPE signified by + or -; +++, 90% disruption of cell monolayer by 4 days post 
infection (d p.i.); ++, 90% disruption of cell monolayer by 7 d p.i.; +, evidence of cell death but 
<90% at 7 d p.i.; -, no evidence of CPE at 7 d p.i., cells comparable to mock. The virus titre of 
working stocks determined by plaque assay on Vero E6 cells is also listed. Lastly, a summary 
of evidence of replication in Vero cells as listed in the International Catalog of Arboviruses 
(ArboCAT) section VI – Biologic Characteristics is given (Berge 1975); plaque morphology is 
reported as incubation time (days), followed by plaque size (mm). N/A no information 
available, CPE information on cytopathic effect only. 
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GAMV and SJV, members of the Gamboa serogroup, developed CPE at passage 2 and 
passage 3, respectively. GAMV formed clear plaques 2 mm - 4 mm in diameter whilst 
SJV formed smaller plaques at 1 mm - 2 mm at 6 d p.i. (Table 4-1, Figure 4-2). 
Similarly, 2 viruses in the Nyando serogroup, NDV and EREV, developed CPE at 
passage 1 and passage 2, respectively, and formed plaques on Vero E6 cells (Table 4-
1). However, NDV caused notably less CPE than EREV, and further passaging of NDV 
did not increase CPE formation to that of EREV. NDV plaques were also difficult to 
distinguish at 6 d p.i. and required incubation for 9 days (Figure 4-2). PLSV, a member 
of the Minatitlan serogroup produced strong CPE at passage 2 and formed clear 
plaques of 2 mm - 3 mm (Figure 4-2).   
 
In total 6 named virus isolates from the Tete serogroup were passaged in cell culture 
with 5 viruses, BMAV, MTRV, TETEV, TSUV and WELV, producing CPE (Table 4-
1). All of which, except WELV, formed distinct plaques in Vero E6 cells at 6 d p.i. 
(Figure 4-2). WELV failed to form clear plaques on Vero E6 cells with indistinct 
hazing of the cell monolayer only (Figure 4-2, Figure 4-3). Further passaging of WELV 
did not improve plaque formation or increase the level of CPE beyond that observed at 
passage 2, with cell rounding and cell death at 5 d p.i. (Figure 4-3). 
 
Viruses in the Bakau (Bakau, Ketapang), Koongol (Koongol, Wongol), Olifantsvlei 
(Olifantsvlei, Botambi) and Patois (Pahayokee, Patois) serogroups failed to produce 
CPE by passage 10 (Table 4-1). All passage 10 isolates were also negative by plaque 
assay at 6 d p.i. (Table 4-1) and 14 d p.i. (data not shown). 
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Figure 4-1: Plaque Morphology of Viruses in the Anopheles A, Anopheles B and 
Capim Serogroups 
Plaque morphology at 6 days post infection on Vero E6 cells with a 0.6% (w/v) Avicel overlay. 
 
Virus abbreviations: Anopheles A virus (ANAV), Caraipe virus (CPEV), ANAV strain 
ColAn57389 (ColAn57389), Las Maloyas (LMV), Trombetas virus (TRMV), Tucurui virus 
(TUCV), Tacaiuma virus (TCMV), Anopheles B virus (ANBV), Boraceia virus (BORV), 
Bunyamwera virus (BUNV), Bwamba virus (BWAV), Capim virus (CAPV), Guajara virus 
(GJAV), Juan Diaz virus (JDV) and Moriche virus (MORV).  
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Figure 4-2: Plaque Morphology of Gamboa, Guama, Minatitlan, Nyando, Tete and 
Turlock Serogroup Viruses 
Plaque morphology at 6 days post infection (d p.i.) unless stated, on Vero E6 cells with a 0.6% 
(w/v) Avicel overlay. 
 
Virus abbreviations: Bunyamwera virus (BUNV), Gamboa virus (GAMV), San Juan virus 
(SJV), Guama virus (GMAV), Palestina virus (PLSV), Nyando virus (NDV), Eretmapodites 
virus (EREV), Tete virus (TETEV), Batama virus (BMAV), Matruh virus (MTRV), Tsuruse-
like virus (TSUV), Weldona virus (WELV) and M’Poko virus (MPOV).  
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Figure 4-3: Weldona Virus Cytopathic Effect in Vero E6 Cells 
Weldona virus (WELV) cytopathic effect 5 days post infection in Vero E6 cells. Cells were 
inoculated with 100 µl clarified culture supernatant from passage 1 virus stocks or mock 
infected with 100 µl PBS 2% (v/v) FCS. Widespread cell rounding and cell death is present 
only in WELV infected cells. Scale bars represent 1000 µm, 400 µm and 200 µm at x4, x10 
and x20 magnification, respectively.  
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4.3.2 Virus Growth Kinetics 
 
Growth kinetics in A549 and Vero E6 cell lines were determined for the 25 viruses 
titrated by plaque assay in section 4.3.1., the type species of the genus, BUNV, and 
rBUNdelNSs2. BUNV grew to similar titres in both cell lines at all time points, with 
titres of 4.0 x 106 p.f.u ml-1 and 5.0 x 106 p.f.u ml-1 in A549 and Vero E6 cells 
respectively at 72 h p.i. (Figure 4-4). However, growth of rBUNdelNSs2 was 
suppressed in A549 cells with > 1 log drop in virus titre at 24 h p.i., 48 h p.i. and 72 h 
p.i. compared with Vero E6 cells (Figure 4-4). 
 
 
 
Figure 4-4: Growth Kinetics of Wild Type and Recombinant Bunyamwera Virus 
Growth kinetics of wild type Bunyamwera virus (BUNV) and recombinant virus 
rBUNdelNSs2, which lacks a functional NSs protein. A549 and Vero E6 cells were infected at 
multiplicity of infection 0.01 and virus titre determined by plaque assay on clarified culture 
supernatant harvested at specified time points post infection. 
 
 
With the exception of TCMV, all viruses in the Anopheles A serogroup showed 
reduced titres in A549 cells in comparison to Vero E6 cells, with a > 1 log drop in virus 
titre at 48 h p.i. and 72 h p.i. (Figure 4-5). In contrast the virus titre of TCMV remained 
within < 1 log at all time points when the 2 cell lines were compared, with final titres of 
8.5 x104 p.f.u ml-1 and 2.25 x105 p.f.u ml-1 in A549 and Vero E6 cells at 72 h p.i. 
(Figure 4-5). BWAV, a member of the Bwamba serogroup, also displayed similar 
growth kinetics in both cell lines, with no notable difference in virus titre at any time 
point tested (Figure 4-6).   
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Figure 4-5: Growth Kinetics of Viruses in the Anopheles A Serogroup 
Growth kinetics in A549 and Vero E6 cell lines. Cells were infected at multiplicity of infection 
0.01 and clarified culture supernatant harvested at specified hours (h) post infection. Virus titre 
was then determined by plaque assay on Vero E6 cells.  
 
Virus abbreviations: Anopheles A virus (ANAV), Caraipe virus (CPEV), ANAV strain 
ColAn57389 (ColAn57389), Las Maloyas (LMV), Tacaiuma virus (TCMV), Trombetas virus 
(TRMV) and Tucurui virus (TUCV).   
4: Orthobunyavirus Growth Characteristics and Protein Profiles 97 
Titres of the Anopheles B serogroup viruses ANBV and BORV were > 1 log lower in 
A549 cells at 48 h p.i. and 72 h p.i. (Figure 4-6). Reduced growth in A549 cells was 
also detected in Capim serogroup viruses although the degree of growth suppression 
varied (Figure 4-6). CAPV only showed > 1 log difference at 72 h p.i. with final titres 
of 2.65 x105 p.f.u ml-1 and 6.85 x106 p.f.u ml-1 in A549 and Vero E6 cells (Figure 4-6). 
The titre of GJAV in A549 cells was >1 log lower at 48 h p.i. and 72 h p.i. compared 
with Vero E6 cells (Figure 4-6). JDV titres were lower at all time points, although this 
difference was > 1 log only at 72 h p.i. (Figure 4-6). The titre of MORV in A549 cells 
was >1 log lower at 24 h p.i., 48 h p.i. and 72 h p.i. with a final titre of only 3.50 x103 
p.f.u ml-1 at 72 h p.i. in A549 cells (Figure 4-6).   
 
Viruses in the Gamboa serogroup, GAMV and SJV, replicated in Vero E6 cells with 
titres of 2.50 x 105 p.f.u ml-1 and 2.60 x x106 p.f.u ml-1, respectively, at 72 h p.i. (Figure 
4-7). The titre of SJV in A549 cells at 72 h p.i. was only 500 p.f.u ml-1 and no plaques 
of GAMV were detected at 48 h p.i. or 72 h p.i. (Figure 4-7).  
 
GMAV, a member of the Guama serogroup, had ≥ 1 log reduction in A549 cells at 48 
and 72 h p.i. with final titres of only 1.00 x 103 p.f.u ml-1 and 5.80 x 104 p.f.u ml-1 in 
A549 and Vero E6 cell lines at 72 h p.i., respectively (Figure 4-7). Virus titres of 
PLSV, a member of the Minatitlan serogroup, were also reduced across all time points 
in A549 cells with ≥ 1 log drop at 18 h p.i., 24 h p.i. and 72 h p.i.. Final virus titres of 
PLSV were 1.00 x 105 p.f.u ml-1 and 2.60 x 106 p.f.u ml-1 in A549 and Vero E6 cell 
lines, respectively (Figure 4-7). Virus titres of the Nyando serogroup viruses NDV and 
EREV were reduced across all time points in A549 cells, although titres remained 
within 1 log of those in Vero E6 cells (Figure 4-7).  
 
Virus titres of MPOV were severely suppressed with > 2 log drop at 48 h p.i. and 72 h 
p.i. in A549 cells compared with Vero E6 cells (Figure 4-8). There was also a > 2 log 
reduction in the titre of BMAV, a member of the Tete serogroup, at 72 h p.i. in A549 
cells compared with Vero E6 cells. Other members of the Tete serogroup, TETEV, 
MTRV and TSUV, also showed lower levels of virus titre in A549 cells, however there 
was < 2 log reduction at all time points tested (Figure 4-8).  
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Figure 4-6: Growth Kinetics of Viruses in the Anopheles B, Bwamba and Capim 
Serogroups  
Growth kinetics in A549 and Vero E6 cell lines. Cells were infected at multiplicity of infection 
0.01 and clarified culture supernatant harvested at specified hours (h) post infection. Virus titre 
was then determined by plaque assay on Vero E6 cells.  
Virus abbreviations: Anopheles B virus (ANBV), Boraceia virus (BORV), Bwamba virus 
(BWAV), Capim virus (CAPV), Guajara virus (GJAV), Juan Diaz virus (JDV) and Moriche 
virus (MORV).   
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Figure 4-7: Growth Kinetics of Viruses in the Gamboa, Guama, Minatitlan and 
Nyando Serogroups.  
Growth kinetics in A549 and Vero E6 cell lines. Cells were infected at multiplicity of infection 
0.01 and clarified culture supernatant harvested at specified hours (h) post infection. Virus titre 
was then determined by plaque assay on Vero E6 cells.  
 
Virus Abbreviations: Gamboa virus (GAMV), San Juan virus (SJV), Guama virus (GMAV), 
Palestina virus (PLSV), Nyando virus (NDV), and Eretmapodites virus (EREV).  
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Figure 4-8: Growth Kinetics of Viruses in the Tete and Turlock Serogroups 
Growth kinetics in A549 and Vero E6 cell lines. Cells were infected at multiplicity of infection 
0.01 and clarified culture supernatant harvested at specified hours (h) post infection. Virus titre 
was then determined by plaque assay on Vero E6 cells.  
 
Virus abbreviations: Tete virus (TETEV), Batama virus (BMAV), Matruh virus (MTRV), 
Tsuruse-like virus (TSUV) and M’Poko virus (MPOV). 
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4.3.3 Metabolic Labelling 
 
Metabolic labelling of proteins during virus infection in Vero E6 cells was carried out 
for the 26 viruses described in section 4.3.1, with BUNV and rBUNdelNSs2 as 
controls. In BUNV infected cells clear bands at approximately 11 kDa, 15 kDa, 25 kDa 
and 115 kDa, that were not present in mock infected cells, were detected (Figure 4-9). 
These bands correspond in molecular weight to the virus proteins NSs, NSm, N and Gc 
proteins. A high molecular weight band (>180 kDa) was also detected and may 
represent the virus L protein, which has a predicted molecular weight of 259 kDa 
(Figure 4-9). An additional band at approximately 32 kDa, the predicted molecular 
weight of the virus Gn protein, was also present in infected cells at 48 h p.i. (Figure 4-
9). At 48 h p.i. and 72 h p.i. there is a dramatic reduction in the number and intensity of 
bands as virus induced protein shut-off and cell death occurs. rBUNdelNSs2 gave a 
similar protein profile to BUNV, although bands corresponding to the molecular weight 
of virus Gn or NSs proteins were not visualised (Figure 4-9).  
 
 
 
Figure 4-9: Metabolic Labelling of BUNV and rBUNdelNSs2 Viruses 
Vero E6 cells were infected at multiplicity of infection 1 with Bunyamwera virus (BUNV), 
recombinant BUNV rBUNdelNSs2, or mock infected with PBS 2% (v/v) FCS. Cells were 
radiolabelled with 35 S methionine cysteine for 2 hours prior to harvesting at 24, 48 and 72 
hours post infection Black arrows indicate bands not present in mock infected cells, and where 
possible are labelled with the virus protein of corresponding molecular weight. BUNV and 
rBUNdelNSs2 were included as controls. Black lines on the right hand side of the protein gels 
indicate the migration of the non-labelled protein ladder with sizes of approximately 10, 15, 25, 
30, 50, 65, 80, 115 and 180 kDa in 4-12% Bis-Tris gels with 1xMES running buffer.  
Gn 
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In cells infected with Anopheles A serogroup viruses, excluding TCMV, clear strong 
bands at approximately 26 kDa, the size of orthobunyavirus N proteins, were present at 
24 h p.i. and 48 h p.i. and, at reduced intensity, 72 h p.i. (Figure 4-10). In TCMV 
infected cells a band at approximately 26 kDa was detected, although it was very faint 
at 24 h p.i., increasing in intensity at 48 h p.i. and 72 h p.i. (Figure 4-10). Bands at 
approximately 117 kDa, which is analogous to the size of the virus Gc protein, were 
detected in ANAV, CPEV, ColAn57389, LMV and TUCV infected cells (Figure 4-10). 
In TRMV and TCMV only very faint bands, which were difficult to differentiate from 
bands in mock infected cells, were present within the 115 kDa - 125 kDa molecular 
weight range (Figure 4-10). Bands corresponding to the size of Gn could not be 
detected in any cells infected with Anopheles A serogroup viruses. High molecular 
weight bands, >180 kDa, that were distinct from those in mock infected cells were 
present only in TCMV infected cells at 24 h p.i., 48 h p.i. and 72 h p.i. (Figure 4-10). 
Low molecular weight bands corresponding to the molecular weight of NSm proteins, 
16 ± 2 kDa, were only present in LMV infected cells at 24 h p.i. and 48 h p.i. (Figure 4-
10). Bands conforming to the NSs protein size 11 kDa – 13 kDa were not detected at 
any time point in cells infected with Anopheles A serogroup viruses (Figure 4-10). 
 
In cells infected with Anopheles B serogroup viruses, ANBV and BORV, only bands at 
approximately 26 kDa and 117 kDa were detected, corresponding to virus N and Gc 
proteins (Figure 4-11). In Capim serogroup viruses CAPV, GJAV and JDV the band 
presumed to represent virus N protein migrated to approximately 24 kDa. However, in 
cells infected with MORV, which also belongs to the Capim serogroup, 2 bands within 
the molecular weight range for orthobunyavirus N proteins were detected (Figure 4-
11). Bands at approximately 115 kDa, thought to be virus Gc protein, were detected in 
CAPV, GJAV, JDV and MORV infected cells (Figure 4-11). High molecular weight 
bands not present in mock infected cells and possibly representing virus L protein were 
only present in MORV infected cells (Figure 4-11). Low molecular weight bands 
within the range of orthobunyavirus NSm or NSs proteins were not present in any 
Capim or Anopheles B serogroup viruses (Figure 4-11).  
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Figure 4-10: Metabolic Labelling of Viruses in the Anopheles A Serogroup 
Vero E6 cells were infected at multiplicity of infection 1 or mock infected with PBS 2% (v/v) 
FCS. Cells were radiolabelled with 35 S methionine cysteine for 2 hours prior to harvesting at 
24, 48 and 72 hours post infection Black arrows indicate bands not present in mock infected 
cells, and where possible are labelled with the virus protein of corresponding molecular weight. 
BUNV was included as a control. Black lines on the right hand side of the protein gels indicate 
the migration of the non-labelled protein ladder with sizes of approximately 10, 15, 25, 30, 50, 
65, 80, 115 and 180 kDa in a 4-12% Bis-Tris gel with 1xMES running buffer. 
 
Virus abbreviations: Bunyamwera virus (BUNV), Anopheles A virus (ANAV), Caraipe virus 
(CPEV), Anopheles A virus strain ColAn57389 (ColAn57389), Las Maloyas virus (LMV), 
Trombetas virus (TRMV), Tucurui virus (TUCV) and Tacaiuma virus (TCMV). 
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Figure 4-11: Metabolic Labelling of Viruses in the Anopheles B and Capim 
Serogroups 
Vero E6 cells were infected at multiplicity of infection 1 or mock infected with PBS 2% (v/v) 
FCS. Cells were radiolabelled with 35 S methionine cysteine for 2 hours prior to harvesting at 
24, 48 and 72 hours post infection Black arrows indicate bands not present in mock infected 
cells, and where possible are labelled with the virus protein of corresponding molecular weight. 
BUNV was included as a control. Black lines on the right hand side of the protein gels indicate 
the migration of the non-labelled protein ladder with sizes of approximately 10, 15, 25, 30, 50, 
65, 80, 115 and 180 kDa in a 4-12% Bis-Tris gel with 1xMES running buffer. 
 
Virus abbreviations: Bunyamwera virus (BUNV), Anopheles B virus (ANBV), Boraceia virus 
(BORV), Capim (CAPV), Guajara virus (GJAV), Juan Diaz virus (JDV), and Moriche virus 
(MORV). 
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In cells infected with the Gamboa serogroup viruses, GAMV and SJV, bands 
corresponding to the size of orthobunyavirus N (25 kDa) and Gc (120 kDa) proteins 
were detected (Figure 4-12). In GMAV and PLSV infected cells the only band distinct 
from those in mock infected cells migrated at approximately 25 kDa, analogous with 
the size of orthobunyavirus N proteins (Figure 4-12). Bands of 25 kDa were also 
present in NDV and EREV infected cells. In addition, bands corresponding in size to 
virus NSs, Gn, Gc and L proteins were also detected in EREV infected cells, and NSs 
protein in NDV infected cells (Figure 4-12). 
 
 
Bands corresponding in size to orthobunyavirus N and Gc protein could be detected in 
cells infected with Tete and Turlock serogroup viruses (Figure 4-13). In BMAV, 
MTRV, TETEV and TSUV infected cells the band posited as N protein migrated at 
approximately 27/28 kDa, whilst in WELV infected cells it migrated slightly faster at 
approximately 25 kDa and was only visible at 24 h p.i. (Figure 4-13). A band predicted 
to be virus Gc protein migrated at 115 kDa - 120 kDa in all Tete serogroup viruses, 
although it was only present in WELV infected cells at 24 h p.i. (Figure 4-13). In 
MPOV infected cells bands corresponding in size to virus N and Gc proteins at 25 kDa 
and 115 kDa were clearly visible only at 24 h p.i., with very faint bands at 48 h p.i. 
(Figure 4-13).  
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Figure 4-12: Metabolic Labelling of Viruses in the Gamboa, Guama, Minatitlan 
and Nyando Serogroups 
Vero E6 cells were infected at multiplicity of infection 1 or mock infected with PBS 2% (v/v) 
FCS. Cells were radiolabelled with 35 S methionine cysteine for 2 hours prior to harvesting at 
24, 48 and 72 hours post infection Black arrows indicate bands not present in mock infected 
cells, and where possible are labelled with the virus protein of corresponding molecular weight. 
BUNV was included as a control. Black lines on the right hand side of the protein gels indicate 
the migration of the non-labelled protein ladder with sizes of approximately 10, 15, 25, 30, 50, 
65, 80, 115 and 180 kDa in a 4-12% Bis-Tris gel with 1xMES running buffer. 
 
Virus abbreviations: Bunyamwera virus (BUNV), San Juan virus (SJV), Gamboa virus 
(GAMV), Guama virus (GMAV), Palestina virus (PLSV), Eretmapodites virus (EREV) and 
Nyando virus (NDV).  
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Figure 4-13: Metabolic Labelling of Viruses in the Tete and Turlock Serogroups 
Vero E6 cells were infected at multiplicity of infection 1 or mock infected with PBS 2% (v/v) 
FCS. Cells were radiolabelled with 35 S methionine cysteine for 2 hours prior to harvesting at 
24, 48 and 72 hours post infection Black arrows indicate bands not present in mock infected 
cells, and where possible are labelled with the virus protein of corresponding molecular weight. 
Black arrows indicate bands not present in mock infected cells and where possible labelled 
with the virus protein of corresponding molecular weight. BUNV was included as a control. 
Black lines on the right hand side of the protein gels indicate the migration of the non-labelled 
protein ladder with sizes of approximately 10, 15, 25, 30, 50, 65, 80, 115 and 180 kDa in a 4-
12% Bis-Tris gel with 1xMES running buffer. 
 
Virus abbreviations: Bunyamwera virus (BUNV), Tete virus (TETEV), Batama virus (BMAV), 
Matruh virus (MTRV), Tsuruse-like virus (TSUV), and M’Poko virus (MPOV).  
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4.4 Discussion  
 
4.4.1 Virus Propagation and Plaque Morphology 
 
In this study only 26 of 50 freeze-dried orthobunyaviruses were successfully 
propagated in Vero E6 cells giving a recovery rate of 52%. Passaging virus isolates on 
only 1 cell line introduced a clear restriction factor and possible barrier to virus growth 
as Vero E6 cells may not be permissive to all of the viruses that were screened. The 
Vero E6 cell line was selected as it was the most frequently documented permissive 
cell line in the ArboCAT for the viruses included in this study (Table 4-1) (Berge, 
1975). However, ArboCAT contained no information on cell line permissiveness for 7 
of the 24 viruses that failed to show CPE or form plaques at 6 d p.i. or 14 d p.i.. These 
were Anopheles A ColAr1071 and CoAr3624, Arumateua, Botambi, Olifantsvlei, 
Minatitlan and Pahayokee viruses (Berge, 1975). In 1968 T.B. Stim carried out a 
detailed investigation into arbovirus plaque morphology on 2 simian kidney-derived 
cell lines, Vero cells and LLC-MK2 cells. In disagreement with ArboCAT records, Stim 
(1968) reported that LUKV, a virus that failed to form plaques or CPE by passage 10 in 
this study, did not form plaques on Vero cells. Furthermore, it was reported that 
although mouse passage 5 Olifantsvlei virus SAAr 5133  did not form plaques the virus 
preparation was fatal to infant mice (Stim 1968). Therefore, the failure of viruses to 
show CPE or form plaques on Vero cells does not rule out the presence of infectious 
particles. For all isolates the residual freeze-dried resuspension, passage 1 cell 
monolayers harvested in Trizol, and clarified culture supernatant from each blind 
passage were stored at -80°C. This will facilitate future studies by providing RNA for 
possible screening by HTS and resuspended freeze-dried isolates for passaging on 
alternative cell lines. 
 
In addition to the choice of cell line, sample viability will also have impacted on virus 
recovery. Information on the date isolates were freeze-dried was available for all 
(n=50) of the isolates passaged in this study. Freeze-dried dates ranged from 1959 for 
TURV to 2011 for BVSV (Table 2-1). Comparing the year in which samples were 
freeze-dried revealed a significant difference between viruses that were successfully 
propagated (n=27, median 1984, range 1963 - 2009) and those which were not (n=23 
median 1970, range 1959 - 2011) (t-test, p<0.05).  However, it should be noted that 
4: Orthobunyavirus Growth Characteristics and Protein Profiles 109 
sample age was not an absolute predictor of recovery success as viruses freeze-dried in 
1963 (ANBV), 1966 (EREV, MORV) and 1968 (CAPV) were successfully propagated, 
whilst BVSV, which is documented as causing CPE in Vero cells and freeze-dried in 
2011, failed to produce CPE or plaques in this study. Pastorino et al., (2015) 
investigated the thermostability and infectivity of freeze-dried viruses, observing < 2 
log drop in TCID50 values for freeze-dried Chikungunya virus (CHIKV), an enveloped 
ssRNA virus, when it was stored at +20°C for 7 days. The viruses included in this 
study were shipped from the United States of America at room temperature and may 
have undergone loss in infectivity due to thermal instability. Furthermore, 27 of the 
viruses included in this study were originally received in the laboratory in 2003. The 
samples were resuspended and stored at -20°C, however, prior to this study they have 
been subject to at least 3 freeze-thaw cycles due to power failures and freezer 
breakdown, possibly further impacting negatively on sample viability. Fourteen of the 
viruses that failed to form CPE or plaques belonged to this group. 
 
In total 26 viruses, belonging to 10 serogroups, developed CPE on virus passage, 
however only 25 could be titrated by plaque assay. Despite forming clear CPE WELV, 
a member of the Tete serogroup, could not be titrated by plaque assay (Figure 4-2, 
Figure 4-3). Altering the length of incubation (3 days - 12 days), temperature (32°C, 
33°C and 37°C), cell type (BHK-21, Vero E6 or CPT-Tert cells) or overlay 
concentration (0.6% (w/v) - 1.2% (w/v)) did not improve plaque formation. 
Interestingly, 4 other viruses in the Tete serogroup, formed clear plaques and grew to a 
titre of 1.0 x 107 p.f.u ml-1 - 3.10 x 108 p.f.u ml-1 (Figure 4-2, Table 4-1). WELV was 
isolated from Culicoides flies whilst other Tete serogroup viruses (BAHV and MTRV) 
have been found in Hyalomma marginatum ticks (Table 4-2) (Converse et al., 1974; 
Moussa et al., 1974). Divergent vectors and plaque phenotype suggest that WELV may 
be distant from other viruses in the Tete serogroup. 
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Table 4-2: Orthobunyavirus Ecology 
Virus ABBV Geographical Vector Subfamily Hosts Human Infection 
Anopheles A Serogroup 
ANAV South America N/A N/A N/A 
ColAn57389 N/A N/A N/A N/A 
CPEV N/A N/A N/A N/A 
LMV South America Anophelinae N/A N/A 
TCMV South America Anophelinae and Culicinae 
Bats, birds, horses, 
primates and rodents Y 
TRMV South America N/A N/A N/A 
TUCV  N/A N/A N/A N/A 
Anopheles B Serogroup 
ANBV South America Anophelinae N/A N/A 
BORV South America Anophelinae and Culicinae N/A NtAb 
Bwamba Serogroup 
BWAV Africa Anophelinae N/A Y 
Capim Serogroup 
CAPV South America Culicinae Rodent N/A 
GJAV  N/A N/A N/A N/A 
JDV South America N/A Sentinal mice N/A 
MORV South America Culicinae N/A N/A 
Gamboa Serogroup 
GAMV South America Culicinae N/A N/A 
SJV N/A N/A N/A N/A 
Guama Serogroup 
GMAV South America Anophelinae and Culicinae 
Bats, marsupials and 
rodents Y 
Minatitlan Serogroup 
PLSV South America Culicinae Sentinal hamster N/A 
Nyando Serogroup 
EREV Africa Anophelinae N/A N/A 
NDV Africa Anophelinae N/A Y 
Tete Serogroup 
BMAV Africa N/A Birds N/A 
MTRV Egypt, Italy Hyalomminae Birds N/A 
TETEV Africa N/A Birds N/A 
TSUV Japan N/A Birds N/A 
WELV USA Ceratopogonidae N/A N/A 
Turlock Serogroup 
MPOV Africa Culex N/A NtAb 
 
Exert from Orthobunyavirus spreadsheet. Published information on the geographical location, 
virus vector, host and association with human infection is summarised. Unless stated 
information was sourced from the International Catalog of Arboviruses (ArboCAT). Vector 
information is given at the subfamily level; Anophelinae or Culicinae (mosquitoes), 
Ceratopogonidae (Culicoides flies) and Hyalomminae (hard bodies Hyalomma ticks). 
Association with human infection is indicated by “Y” symbolising yes, for clinical cases and 
isolation of virus from man, where no clinical cases have been detected but neutralising 
antibodies are present “NtAb”.  
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Plaque morphology has been linked with virus attenuation in orthobunyaviruses as 
rBUNdelNSs2, a recombinant BUNV that lacks the NSs protein, forms smaller plaques 
than the parental wt virus BUNV (Bridgen et al., 2001; Hart et al., 2009; van 
Knippenberg et al., 2010). In this study the only viruses to form plaques of a 
comparable size to that of BUNV were MPOV and GMAV, both of which have been 
linked with human infection (Figure 4-2, Table 4-2). The other known human 
pathogens, BWAV, TCMV, NDV and EREV formed small plaques of only ≤ 1 mm in 
diameter at 6 d p.i. (Figure 4-1, Figure 4-2, Table 4-2). Moreover, the plaque size of 
Guaroa virus, an orthobunyavirus in the Bunyamwera serogroup, does not correlate 
with pathogenicity as small and large plaque variants had similar pathogenicity in 
suckling mice inoculated intracranially (Tauraso 1969). Consequently, plaque size of 
orthobunyaviruses on Vero E6 cells cannot be correlated with in vivo pathogenicity or 
virulence. 
 
 
4.4.2 Virus Growth Kinetics 
 
BUNV, BWAV, TCMV, NDV and EREV were the only viruses with < 1 log reduction 
in virus titre in A549 cells compared with Vero E6 cells. The A549 cell line, originally 
derived from human alveolar cells, is IFN-competent whilst the simian kidney derived 
cell line Vero E6 is IFN-deficient having lost the IFNA and IFNB1 genes (Mosca and 
Pitha, 1986; Diaz et al., 1988). BUNV, BWAV, TCMV, and Nyando serogroup viruses 
have all been documented as causing clinical disease in humans (Smithburn et al., 1941 
Digoutte et al., 1972; Moore et al., 1975; Johnson et al., 1978; Calisher et al., 1980; 
Lutwama et al., 2002). It is therefore perhaps to be expected that virus replication 
would not be severely attenuated in an IFN-competent cell line. However, the virus 
titres of BORV, GMAV and MPOV were suppressed by > 1 log in A549 cells despite 
their association with human infection (Figure 4-5, Figure 4-7, Figure 4-8) (Whitman 
and Casals, 1961; de Souza Lopes and de Abreu Sacchetta, 1974; Berge, 1975). 
Therefore, virus pathogenicity cannot be extrapolated from comparative growth 
kinetics in IFN-competent A549 cells and IFN-deficient Vero E6 cells. 
 
Viruses in the Anopheles A, Anopheles B and Tete serogroup (excluding TCMV) also 
showed >1 log drop in virus titres in A549 cells at 72 h p.i.. Six viruses in these 
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serogroups, ANAV, TCMV, ANBV, BORV, BMAV and TETEV, have previously 
been shown to lack an NSs protein (Mohamed et al., 2009). The NSs protein is the 
primary virulence factor of orthobunyaviruses, blocking RNA polymerase II and 
antagonising the type I IFN response (Léonard et al., 2006; Thomas 2004; van 
Knippenberg et al., 2010). This leads to the hypothesis that non-NSs viruses would be 
vulnerable to the IFN response as this action of antagonism is not present. This 
hypothesis is supported by the growth kinetics of rBUNdelNSs2, a recombinant virus 
in which the expression of NSs has been abolished through the introduction of 6 
mutations that are synonymous for the BUNV N protein (Figure 4-6) (van Knippenberg 
et al., 2010; Bridgen et al., 2001). However, TCMV opposes this theory, showing 
similar growth kinetics in both IFN-competent and IFN-deficient cell lines, despite 
lacking an NSs protein (Figure 4-4). Furthermore, Gamboa serogroup viruses, GAMV 
and SJV, showed > 2 log drop in virus titre in A549 cells, yet Nunes et al. (2014) 
published complete coding sequence data for 4 Gamboa serogroup viruses and all were 
predicted to contain full length NSs ORFs. Therefore, the presence or absence of an 
NSs ORF can no longer act as a predictor of virus growth in IFN-competent cell lines. 
 
 
4.4.3 Protein Labelling 
 
The titrated viruses had protein profiles corresponding to the characteristic biochemical 
footprint of orthobunyaviruses with N and Gc protein bands at approximately 24 ± 3 
kDa and 117 ± 3 kDa respectively. The higher molecular weight of Tete serogroup N 
proteins corroborates S segment sequencing data published by Mohamed et al., (2009) 
that reported BMAV and TETEV encode N proteins of 258 aa, in comparison to the 
233 aa N protein of BUNV. However, the N protein of WELV was smaller than that of 
the other Tete serogroup viruses at 25 kDa, and only visible at 24 h p.i. (Figure 4-12). 
WELV failed to form clear plaques on virus titration and protein labelling was carried 
out at an unknown MOI with 200 µl neat working stock, whilst all other viruses were 
tested at an MOI of 1. If Vero E6 cells were not permissive for WELV infection the 
titre of the working stock preparation used in this experiment would be approximately a 
1 in 6.25 x 105 dilution of the original freeze-dried suspension, or 160 p.f.u ml-1 if the 
freeze-dried suspension contained 1 x 108 p.f.u ml-1. Non-replicating residual cell 
bound virus at this titre would be insufficient to form visible bands on radiolabelling, 
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therefore some level of virus propagation in Vero E6 cells must have occurred. Vero 
E6 cells are also IFN-deficient and apparent virus clearance at 48 h p.i. or 72 h p.i. 
would be highly unusual. In contrast to WELV, the intensity of all other virus protein 
bands increased over time and only reduced in intensity in conjunction with a reduction 
of host protein bands, most probably due to host protein shut-off and/or cell death.  
 
There was very low detection of bands corresponding to the Gn and L proteins in 
infected cells. This was partly due to masking by host cellular protein bands of a 
similar molecular weight. Radiolabelling concentrated virions instead of infected cell 
supernatants may therefore improve detection of these proteins, especially Gn, which 
frequently gives rise to much fainter bands than the other structural proteins (Gentsch 
et al., 1979; Ushijima et al., 1980; Short et al., 1982). In concordance with previous 
studies, the detection of non-structural proteins was also poor with both NSm and NSs 
proteins identified only in BUNV infected cells (Figure 4-9) (Gentsch et al., 1977; 
Gentsch et al., 1979; Ushijima et al., 1980; Klimas et al., 1981; Stuckly and Wright 
1983). The NSs protein of BUNV undergoes lysine-dependent degradation by the 
proteasome and the addition of proteasome inhibitors such as MG132 leads to 
improved detection of NSs by western blot analysis (van Knippenberg et al., 2013). 
The addition of proteasome inhibitors may also increase the detection of NSs by 
radiolabelling. However, not all orthobunyaviruses encode an NSs protein as viruses in 
the Anopheles A, Anopheles B, Mapputta, Simbu and Bunyamwera serogroup have 
been shown to contain severely truncated and presumably non-functional NSs ORFs 
(Mohamed et al., 2009; Chowdhary et al., 2012; Ladner et al., 2014; Gauci et al., 
2015). It will therefore be of interest to determine if the viruses in the Capim, Guama, 
Gamboa, Minatitlan and Turlock serogroups, which had no detectable NSs protein 
band on radiolabelling, are in fact lacking a full length NSs ORF. 
 
 
4.4.4 Concluding Remarks 
 
In conclusion, a panel of 25 orthobunyaviruses representing 10 serogroups of the 
orthobunyavirus genus was created. The presence of replicating virus was confirmed by 
virus titration on Vero E6 cells and metabolic labelling of proteins during virus 
infection. Growth kinetics in IFN-competent A549 cells and IFN-deficient Vero E6 
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cells at low MOI were also determined. A spreadsheet collating information on vector, 
geographical location and vertebrate hosts was also created to facilitate result 
interpretation and complement future sequencing studies (Table 4-2, Appendix 2). 
 
  
 
 
 
 
 
 
 
 
Chapter 5: Orthobunyavirus Genome 
Sequencing  
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5.1 Introduction 
 
Orthobunyaviruses, the largest of the 5 bunyavirus genera, are transmitted by 
arthropods, a feature that contributes to their continual evolution and geographical 
spread. This was exemplified by the emergence of SBV, a novel orthobunyavirus 
causing abortion and foetal abnormalities in cattle and sheep, that spread rapidly 
throughout Europe in 2011 (van den Brom et al., 2012; Gibbens, 2012; Rasmussen et 
al., 2012). There are currently 48 ICTV-registered orthobunyavirus species but over 
170 named viruses in the literature, with ‘new’ viruses increasingly described by HTS 
screens (Elliott and Blakqori, 2011; Plyusnin et al., 2012; Lanciotti et al., 2013; 
Bakonyi et al., 2013; Li et al., 2015). In addition to HTS, consensus primers targeting 
the conserved termini of orthobunyavirus genome segments have been used for PCR 
amplification and Sanger sequencing (Yandoko et al., 2007; Mohamed et al., 2009) . 
 
Utilising consensus primers targeting the orthobunyavirus S segment Mohammed et al., 
(2009) identified viruses within the Anopheles A, Anopheles B and Tete serogroups 
that naturally lack a functional NSs ORF. Subsequently, viruses within the Mapputta, 
Simbu and Wyeomyia groups have also been found to contain severely truncated and 
presumably non-functional NSs ORFs (Mores et al., 2009; Chowdhary et al., 2012; 
Ladner et al., 2014; Gauci et al., 2015). The NSs protein has been identified as the 
major virulence factor of orthobunyaviruses, blocking RNAPII and inhibiting the 
transcription of cellular mRNAs (Bridgen et al., 2001; Thomas, 2004). The 
transcriptional blockade has a profound effect on the IFN-β promoter and viruses 
genetically engineered to lack a functional NSs show increased sensitivity to type I 
IFNs (Bridgen et al., 2001; Blakqori et al., 2007). Studying naturally occurring “non-
NSs” bunyaviruses will further our understanding of bunyavirus evolution and 
replication, and may reveal previously unidentified mechanisms by which 
orthobunyaviruses can overcome or subvert the host’s innate immune system. As yet, 
no complete genome sequences are available for viruses within the Anopheles A, 
Anopheles B or Tete serogroups. Furthermore, complete genome sequencing of 
orthobunyaviruses as a whole is extremely limited with 12 out of the 18 recognised 
orthobunyavirus serogroups lacking a single, published, complete genome sequence. 
Full genome sequence information will enable the relationships between 
orthobunyaviruses to be established and their evolutionary history tracked. Moreover, 
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at a practical level, it will provide essential information for the rational classification of 
bunyaviruses as well contributing to our understanding of bunyavirus emergence and 
facilitating in depth molecular research on virus replication and interactions with the 
host cell.  
 
 
5.2 Aims 
 
The aim of the research presented in this chapter was to carry out complete genome 
sequencing of orthobunyaviruses belonging to serogroups with no published complete 
genome sequences1 . Viruses in serogroups identified by S segment sequencing to 
contain isolates lacking a full length NSs ORF, namely the Anopheles A, Anopheles B, 
Capim and Tete serogroups, were prioritised (Mohamed, 2007).  
 
 
5.3 Results 
 
In total 21 viruses were selected for HTS with viruses belonging to serogroups known 
to contain non-NSs isolates preferentially picked (n=15) (Table 5-1). The remaining 
viruses belonged to serogroups containing isolates with full length NSs ORFs (n=4) or 
no sequence information (n=2) (Table 5-1). Twenty-one viruses were selected as this 
made optimal use of sequencing reagents. To confirm the presence of replicating virus 
in each sample, an aliquot of the clarified and filtered cell culture supernatant processed 
for HTS was titrated by plaque assay on Vero E6 cells (Table 5-1). 
 
HTS on virion RNA was carried out on the illumina® MiSeq and Ion ProtonTM 
platforms followed by de novo genome assembly in CLC Genomics Workbench v7.5.1  
  
                                                
1 Complete genome and coding sequences were published for Nyando and Gamboa serogroup 
viruses during data analysis and have been included in data analysis (Groseth et al., 2014; 
Nunes et al., 2014). Schetinin et al., (2015) have also determined complete coding sequence for 
viruses in the Anopheles A, Capim, Guama, Tete and Turlock serogroups, although sequences 
were not available on GenBank® on 3rd December 2015, and are therefore not included in data 
analysis. 
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Table 5-1: Virus Isolates for Genome Sequencing 
Virus Name Serogroup Date of isolate (DD.MM.YYYY) 
Strain  
Information 
NSs 
ORF 
Sample Titre 
(p.f.u. ml-1) 
ANAV Anopheles A 23.12.1984 Isolated 1940 N 1.4 x 105 
57389 Anopheles A 13.10.1981 ColAn 57389 N/A 2.1 x 105 
LMV Anopheles A 10.09.1981 AG 80-14 N/A 7.0 x 105 
TCMV Anopheles A 21.07.2001 BeAn73 N 4.1 x 105 
TRMV Anopheles A 21.09.1981 BeAn 306771 N/A 2.6 x 106 
ANBV Anopheles B 15.02.1963 DMC 1537 N 1.0 x 106 
BORV Anopheles B 21.06.1965 SP Ar395 N 8.6 x 105 
CAPV Capim 08.02.1994 N/A N 1.5 x 106 
JDV Capim 12.06.2001 Maru 8563 N/A 1.5 x 105 
MORV Capim 17.11.1966 N/A N/A 3.0 x 105 
GAMV Gamboa 17.12.1990 GML 438524 Y 4.5 x 105 
GMAV Guama 13.01.1992 BeAn 277 N/A 3.5 x 104 
PLSV Minatitlan 31.08.1982 76V 1565 N/A 3.0 x 105 
EREV Nyando 10.07.1966 E147V Y 4.1 x 105 
NDV Nyando 11.10.2003 Mp401 Y 2.7 x 105 
BMAV Tete 15.12.1984 DAK AnB1292 N 2.2 x 107 
MTRV Tete 12.07.1985 An 1047-61 N/A 1.1 x 107 
TETEV Tete 12.07.1984 SA An3518 N 3.5 x 106 
TSUV Tete 03.11.1999 Magpie 271580 N/A 1.2 x 107 
WELV Tete 30.04.2009 76V 21935 N/A N/A 
MPOV Turlock 10.03.2003 BA365 Y 4.2 x 106 
 
Details of the 21 viruses selected for genome sequencing. Isolates were obtained from the 
Emerging Viruses and Arboviruses Reference Collection, University of Texas Medical Branch 
and propagated as detailed in Chapter 4. The presence of an NSs ORF as known in December 
2013 is also given; (N) none or severely truncated, (Y) putative complete NSs ORF, (N/A) not 
available (Mohamed, McLees and Elliott, 2009; Mohamed, no date). The virus titre of RNA 
cultures after filtration was determined by plaque assay on Vero E6 cells with a 0.6% (w/v) 
Avicel overlay.  
 
Virus abbreviations: ANAV (Anopheles A virus), 57389 (ColAn 57389 virus), LMV (Las 
Maloyas virus), TCMV (Tacaiuma virus), TRMV (Trombetas virus), ANBV (Anopheles B 
virus), BORV (Boracéia virus), CAPV (Capim virus), JDV (Juan Diaz virus), MORV (Moriche 
virus), GAMV (Gamboa virus), GMAV (Guama virus), PLSV (Palestina virus), EREV 
(Eretmapodites virus), NDV (Nyando virus), BMAV (Batama virus), MTRV (Matruh virus), 
TETEV (Tete virus), TSUV (Tsuruse-like virus), WELV (Weldona virus), MPOV (M’Poko 
virus). 
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(Qiagen). HTS data were trimmed by quality score and adapter sequences removed 
prior to contig assembly with word and bubble size optimised for average HTS read 
length. Contigs were then assembled into genome scaffolds through BLASTn and 
BLASTx comparisons with cyclical rounds of read mapping. Regions of low coverage 
(< 100 reads) and terminal UTR sequences were confirmed by Sanger sequencing and 
RACE PCR (Table 5-2). 
 
 
5.3.1 N and NSs Coding Sequences 
 
All S segment sequences contained bunyavirus nucleocapsid domain pfam00952. 
Capim, Guama, Gamboa, Minatitlan, Nyando and Turlock serogroup viruses are 
predicted to encode N proteins of 233 - 238 aa, whereas viruses belonging to the 
Anopheles A, Anopheles B and Tete serogroups encode larger N proteins at 244 – 245 
aa, 247 aa, and 248 - 258 aa, respectively (Table 5-2). In the Anopheles A and 
Anopheles B serogroup the additional amino acids align at the C terminus of the N 
protein. In Tete serogroup N proteins the additional amino acids form a 25 - 26 aa 
insertion at the N terminus, with only 3 - 4 aa aligning to the C terminus of the N 
protein (Figure 5-1). The BUNV N protein E128A change associated with a small-
plaque, high-titre phenotype in BUNV was only present in MPOV. All other viruses in 
this study retained the E residue at this position. N protein residues that remain fully 
conserved within the orthobunyaviruses are at alignment positions K77, T119 and 
G180 (BUNV N protein K50, T91, 147G) (Figure 5-1).  
 
In addition to the N protein ORF a second ORF, that identifies as bunyavirus NSs 
pfam01104 by BLASTx and is in a plus 1 reading frame relative to N, was identified in 
5 viruses. The NSs encoding viruses are Nyando serogroup viruses NDV and EREV, 
Gamboa serogroup virus GAMV, Turlock serogroup virus MPOV and Tete serogroup 
virus WELV (Table 5-2). All sequenced viruses in the Anopheles A, Anopheles B, 
Capim, Guama and Minatitlan serogroups lacked an NSs ORF, and contained no 
additional or severely truncated (< 40 aa) ORFs (Table 5-2). 
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Table 5-2: Virus Genome Size 
 Nucleotide sequence (nt)  Amino acid sequence 
(aa) Virus S segment  M segment  L segment  
 5’ UTR ORF 
3’ 
UTR  
5’ 
UTR ORF 
3’ 
UTR  
5’ 
UTR ORF 
3’ 
UTR  N NSs M L 
ANAV 53† 738 155¥  52† 4224 339¥  33† 6729 119†  244 N/D 1405 2242 
57389 53† 738 208¥  43† 4218 124†  32† 6723 94†  245 37* 1405 2240 
LMV 54† 738 210¥  51† 4236 109¥  32† 6723 100†  245 37* 1411 2240 
TCMV 42† 738 134¥  35† 4278 124†  33† 6723 93†  245 27* 1425 2240 
TRMV 44† 738 203¥  34† 4248 118†  32† 6723 94†  245 37* 1415 2240 
ANBV 35† 744 212¥  38† 4296 280†  48† 6729 180†  247 24* 1431 2242 
BORV 35† 744 203†  32† 4293 224†  39† 6729 91†  247 38* 1430 2242 
CAPV 49† 708 307¥  51† 4293 454¥  58† 6759 162†  235 11* 1430 2252 
JDV 44† 705 323¥  42† 4296 478¥  61† 6752 188†  234 10* 1431 2253 
MORV 44† 705 379¥  42† 4329 434¥  61† 6792 154†  234 10* 1442 2253 
GAMV 86† 717 438  42† 4779 236†  47† 6822 79†  238 130 1592 2273 
GMAV 70† 714 355¥  139† 4320 240  57 6753 178  237 18* 1439 2250 
PLSV 89† 711 >167  62† 4335 >145†  51† 6726 181†  236 21* 1444 2241 
EREV 70¥ 702 169¥  34¥ 4338 135¥  30¥ 6798 111¥  233 92 1445 2265 
NDV 45† 702 155¥  48† 4299 102†  29† 6807 121†  233 92 1432 2268 
BMAV 73† 777 171†  39† 4302 110†  57† 6843 93†  258 33* 1433 2280 
MTRV 58† 777 228¥  39† 4299 115†  58† 6843 125†  258 36* 1432 2280 
TETEV 73† 777 172¥  39† 4299 116†  57† 6846 92†  258 20* 1432 2281 
TSUV 58¥ 777 183¥  39† 4302 111¥  57† 6843 124†  258 23* 1433 2280 
WELV 60† 747 185†  N/A N/A N/A  N/A N/A N/A  248 114 N/A N/A 
MPOV 117† 711 247  77† 4386 266†  73† 6828 118†  236 79 1461 2275 
BUNV 85 702 174  56 4302 100  50 6717 108  233 101 1433 2238 
 
Size of virus genomes and predicted proteins are listed. Viruses sequenced in this study are 
highlighted in bold. The genome details of Bunyamwera virus (BUNV) NC001927 are given 
for comparison. UTR; untranslated region, ORF; open reading frame, nt; nucleotide, aa; amino 
acid. N/D; not detected, † Confirmed by RACE PCR. ¥ Confirmed by cloning into pGEM®-T 
Easy or pTVT7 vectors, terminal 15 nucleotides primer/HTS sequence data only. * truncated 
and presumably non-functional ORF.  
 
Virus abbreviations: ANAV (Anopheles A virus), 57389 (ColAn 57389 virus), LMV (Las 
Maloyas virus), TCMV (Tacaiuma virus), TRMV (Trombetas virus), ANBV (Anopheles B 
virus), BORV (Boracéia virus), CAPV (Capim virus), JDV (Juan Diaz virus), MORV (Moriche 
virus), GAMV (Gamboa virus), GMAV (Guama virus), PLSV (Palestina virus), EREV 
(Eretmapodites virus), NDV (Nyando virus), BMAV (Batama virus), MTRV (Matruh virus), 
TETEV (Tete virus), TSUV (Tsuruse-like virus), WELV (Weldona virus), MPOV (M’Poko 
virus). 
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Figure 5-1: N Protein Conservation 
N protein sequences of viruses sequenced in this study were aligned with previously published 
orthobunyavirus sequences; when more than 1 sequence for a named virus was available 1 was 
selected. Sequences were aligned in CLC Genomics Workbench v7.5.1 (Qiagen) using 
MUSCLE algorithm. Fully conserved residues are highlighted in red. Residues present in > 
90% of named virus are marked in blue. Functional annotations as per Reguera et al., (2013).  
(*) Oyo, I612045 and Tete serogroup viruses only. (†) Mermet, M’poko, Brazoran viruses and 
Anopheles A, Anopheles B, Tete serogroup only. (**) Brazoran virus only. 
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The Nyando serogroup viruses EREV and NDV were predicted to encode a 93 aa NSs 
protein, which contains conserved SS, LxL and IxI sequence motifs (Figure 5-2). 
MPOV was predicted to encode an NSs protein of only 79 aa, which lacks the 
conserved LxL motif, containing FxL at this position. GAMV was predicted to encode 
a much larger NSs protein at 130 aa (Table 5-2). The additional aa in GAMV, and 
published Gamboa serogroup NSs proteins, align to the C terminus and form an 
incredibly serine-rich region (Figure 5-2) (Nunes et al., 2014). WELV was predicted to 
encode a 114 aa NSs protein and although it contained the conserved LxL and IxI it 
lacked the conserved serine residues and had a 10 aa insertion in this region. WELV 
was the only member of the Tete serogroup predicted to contain an NSs ORF, with 
BMAV, TETEV, MTRV and TSUV containing severely truncated and presumed non-
functional second ORFs. To confirm correct assembly of the WELV S segment, the 
complete S segment was amplified from virion RNA in a single RT-PCR reaction with 
primers targeting RACE-PCR confirmed terminal UTR sequences. The amplified 
segment was then cloned into a plasmid backbone for Sanger sequencing, confirming 
HTS data and the presence of an NSs ORF.  
 
 
5.3.2 M Coding Sequences 
 
The M segments of the viruses sequenced in this study are predicted to encode a single 
polyprotein that will be post-translationally cleaved to form the 2 virus glycoproteins, 
Gn (pfam03563) and Gc (pfam03557), and the non-structural protein NSm 
(TIGR04210). M polyproteins of Anopheles B, Capim, Guama, Nyando, Minatitlan, 
Tete and Turlock serogroups were 1430–1454 aa in length. The Anopheles A 
serogroup virus M polyproteins, excluding TCMV, were slightly smaller at 1405 - 1415 
aa (Table 5-2). In agreement with complete coding sequences published for Gamboa 
serogroup viruses, GAMV encodes a larger M polyprotein at 1592 aa with a 149 aa 
insertion at the start of the NSm domain, which manifests as a clear drop in 
conservation in the M polyprotein alignment (Figure 5-3A) (Nunes et al., 2014).  
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A) 
 
 
B) 
 
Figure 5-2: NSs Protein Conservation 
A) NSs protein sequences of viruses sequenced in this study were aligned with previously 
published orthobunyavirus sequences; when more than 1 sequence for a named virus was 
available 1 was selected. Sequences were aligned in CLC Genomics Workbench v7.5.1 
(Qiagen) using MUSCLE algorithm. Fully conserved residues are highlighted in red. Residues 
present in > 75% of named virus isolates are marked in blue. (*) Brazoran virus only, (**) 
Brazoran virus and Gamboa serogroup NSs proteins only. B) C terminal alignment of Gamboa 
serogroup NSs proteins, published sequences are named by their accession number, (GAMV) 
Gamboa virus sequenced in this study. Orthobunyavirus conserved motifs are highlighted in 
blue, serine residues in red. 
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Figure 5-3: M Polyprotein Conservation 
A) M polyprotein sequences of viruses sequenced in this study were aligned with previously 
published orthobunyavirus sequences; when more than 1 sequence for a named virus was 
available 1 was selected. Sequences were aligned in CLC Genomics Workbench v7.5.1 
(Qiagen) using MUSCLE algorithm. Cysteine residues are highlighted in blue, fully conserved 
residues, excluding cysteine, are highlighted in red. (*) Gn zinc finger motif, (**) Gc fusion 
peptide. B) Gn zinc finger (ZF1 and ZF2) and Gc fusion peptide motifs of the viruses 
sequenced in this study. Sequences were aligned in CLC Genomics Workbench v7.5.1 
(Qiagen) using MUSCLE algorithm. Black bars represent percentage conservation at each 
alignment position. 
 
Virus abbreviations: ANAV (Anopheles A virus), 57389 (ColAn 57389 virus), LMV (Las 
Maloyas virus), TCMV (Tacaiuma virus), TRMV (Trombetas virus), ANBV (Anopheles B 
virus), BORV (Boracéia virus), CAPV (Capim virus), JDV (Juan Diaz virus), MORV (Moriche 
virus), GAMV (Gamboa virus), GMAV (Guama virus), PLSV (Palestina virus), EREV 
(Eretmapodites virus), NDV (Nyando virus), BMAV (Batama virus), MTRV (Matruh virus), 
TETEV (Tete virus), TSUV (Tsuruse-like virus), WELV (Weldona virus), MPOV (M’Poko 
virus).  
TCMV   255 - 
BORV   255 - 
ANBV   252 - 
TRMV   251 - 
57389   251 - 
ANAV   255 - 
LMV      253 - 
PLSV    251 - 
GMAV   255 - 
CAPV   248 - 
JDV      250 - 
MORV  256 - 
TETEV 252 - 
BMAV  252 - 
MTRV  252 - 
TSUV   252 - 
EREV  256 - 
NDV    250 - 
GAMV 249 - 
MPOV  254 - 
 
Conservation  
ZF 1 ZF 2 Fusion peptide 
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The alignment also demonstrates striking conservation of cysteine residues, with 53 of 
73 cysteine residues fully conserved across all sequences and 63 conserved in 90% of 
published M proteins (Figure 5-3A). Zinc finger motifs located in the Gn cytoplasmic 
tail and the Gc fusion peptide were readily detected in all sequences and were highly 
conserved (Figure 5-3B). N-glycosylation patterns remained largely conserved within 
serogroups (Figure 5-4). For example, all Anopheles A serogroup viruses lack a single 
glycosylation site in Gn, whilst GMAV and PLSV lack any glycosylation sites in the 
Gc C terminus (Figure 5-4). 
 
 
5.3.3 L Coding Sequences 
 
The characteristic domains of bunyavirus L proteins, namely the endonuclease domain 
(pfam15518) and ‘polymerase module’ (pfam04196) were present in all sequences and 
all sequences were of comparable length to those previously published for 
orthobunyavirus L segments (Table 5-2). Within the polymerase module premotif A, 
motifs A, B, C (containing the catalytic site S1633DD), D, and E were readily detected 
and highly conserved (Figure 5-5B). Two drops in aa conservation at alignment 
positions 604-607 and 2241-2253 can be attributed to an insertion of 4 aa (FxSD) by 
viruses in the Gamboa serogroup and 23 aa insertion by Tete serogroup viruses, 
respectively (Figure 5-5A).  
 
  
5: Orthobunyavirus Genome Sequencing 126 
0 1500
0.0
0.2
0.4
0.6
0.8
1.0 LMV TRMV57389
0 1500
0.0
0.2
0.4
0.6
0.8
1.0
MPOV
0 1500
0.0
0.2
0.4
0.6
0.8
1.0 EREV NDV
0 1500
0.0
0.2
0.4
0.6
0.8
1.0 ANBV BORV
0 1500
0.0
0.2
0.4
0.6
0.8
1.0 JDV MORVCAPV
0 1500
0.0
0.2
0.4
0.6
0.8
1.0 GAMV
0 1500
0.0
0.2
0.4
0.6
0.8
1.0 MTRV TSUV
0 1500
0.0
0.2
0.4
0.6
0.8
1.0 GMAV PLSV
0 1500
0.0
0.2
0.4
0.6
0.8
1.0 TETEV BMAV 
0 1500
0.0
0.2
0.4
0.6
0.8
1.0 ANAV TCMV
Anopheles A              Tete 
 
 
 
 
 
 
 
 
 
Anopheles B              Capim 
 
 
 
 
 
Gamboa              Guama and Minatitlan 
 
 
 
 
 
 
Turlock              Nyando 
 
 
 
 
 
Figure 5-4: Predicted M Polyprotein N-glycosylation   
N-glycosylation patterns as predicted by NetNGlyc 1.0. Viruses grouped into serogroups, with 
the exception of GMAV and PLSV, members of the Guama and Minatitlan serogroups, which 
are grouped together. Capped lines indicate Gn, NSm and Gc. 
Virus abbreviations: ANAV (Anopheles A virus), 57389 (ColAn 57389 virus), LMV (Las 
Maloyas virus), TCMV (Tacaiuma virus), TRMV (Trombetas virus), ANBV (Anopheles B 
virus), BORV (Boracéia virus), CAPV (Capim virus), JDV (Juan Diaz virus), MORV (Moriche 
virus), GAMV (Gamboa virus), GMAV (Guama virus), PLSV (Palestina virus), EREV 
(Eretmapodites virus), NDV (Nyando virus), BMAV (Batama virus), MTRV (Matruh virus), 
TETEV (Tete virus), TSUV (Tsuruse-like virus), WELV (Weldona virus), MPOV (M’Poko 
virus).  
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Figure 5-5: L Protein Conservation  
A) L protein sequences of viruses sequenced in this study were aligned with previously 
published orthobunyavirus sequences; when more than 1 sequence for a virus species was 
available 1 was selected. Sequences were aligned in CLC Genomics Workbench v7.5.1 
(Qiagen) using MUSCLE algorithm. Fully conserved residues are shown in red. 1. 
Endonuclease domain (pfam15518) with conserved nuclease superfamily motif marked. 2. 
Polymerase module (pfam04196) with pre-motif A and motifs A, B, C, D and E marked. B) 
Polymerase module of L proteins sequenced in this study. Sequence were aligned CLC 
Genomics Workbench v7.5.1 (Qiagen) using MUSCLE algorithm. * 3’ vRNA binding site   ** 
Nucleotide addition sites.  
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5.3.4 Untranslated Sequences 
 
The archetypal conserved orthobunyavirus termini (AGUAGUGUA, CACACUACU) 
were present in the S, M and L segments of ANAV, ANBV, BORV, GAMV, NDV, 
EREV, PLSV, BMAV, MTRV, TSUV and MPOV. However, members of the Capim 
and Guama serogroups contained changes at the 8th nucleotide position in both the S 
and M segments, and Anopheles A serogroup viruses, ColAn57389, LMV and TRMV 
contained a change in the M segment only (Table 5-3). When additional segment 
specific conserved residues are considered (S segment 10-13, M segment 10-12, L 
segment 10-13) even greater diversity is seen (Table 5-3). In addition to diversity in 
terminal sequences, there was a large range in the length of UTRs amongst the viruses 
sequenced in this study. MPOV S segment cRNA 5’UTR was 117 nt, in comparison to 
35 nt for ANBV and 85 nt for BUNV, the type species of the genus (Table 5-2). 
Moreover, the cRNA 3’UTRs of JDV S, M segments were 323 and 478 nt long and 
incredibly A rich, UTRs of a similar length were also present in both MORV and 
CAPV (Table 5-2). 
 
Despite the variation in UTR length and conserved termini sequences some 
conservation remains. The conserved motif UGGGUGGGUGGU, present in the S 
segment antigenomic 3’UTR of California, Bunyamwera and Wyeomyia group viruses, 
was detected in Anopheles A (excluding TCMV), Anopheles B, Gamboa and Nyando 
serogroups (Dunn et al., 1994; Bowen et al., 1995; Campbell and Huang, 1996; 
Chowdhary et al., 2012). Slightly modified versions were also present in the Tete 
serogroup ([GW]GGUGGGUGGU), Capim and Guama serogroups 
([W]GGGU[U]GGGUGGU) and TCMV (UGGG[A]GGGUGGU). The only virus 
found to lack even a truncated version of this motif was MPOV, a member of the 
Turlock serogroup.  
 
 
 Table 5-3: Variation in Conserved UTR Terminal Sequences 
 
 
 
 
S Segment cRNA  M Segment cRNA  L Segment cRNA  
 5’UTR 3’UTR 5’UTR 3’UTR 5’UTR 3’UTR 
Virus AGU AGU GUA C-UC C G GAG CAC ACU ACU AGU AGU GUA CUA C G UAG CAC ACU ACU AGU AGU GUA C-UC C G GAG CAC ACU ACU 
57389 ... ... ... .-.. . . ... ... ... ... ... ... .A. ... . . ... ... ... ... ... ... ... ... . ... ... ... ... 
LMV ... ... ... .-.. . . ... ... ... ... ... ... .A. ... . . ... ... ... ... ... ... ... ... . ... ... ... ... 
TRMV ... ... ... .-.. . . ... ... ... ... ... ... .A. ... . . ... ... ... ... ... ... ... ... . ... ... ... ... 
CAPV ... ... .A. .-.U . . A.A G.. ... ... ... ... .A. .CG . . CG. A.. ... ... ... ... ... .C. U A .G. ... ... ... 
MORV ... ... .A. .-.U . . A.A ... ... ... ... ... .A. .CG . . CG. A.. ... ... ... ... ... .C. U A .G. ... ... ... 
JDV ... ... .A. .-.U . . A.A ... ... ... ... ... .A. .CG . . CG. A.. ... ... ... ... ... .C. U A .G. ... ... ... 
GMAV ... ... .A. U-.U . . A.A ... ... ... ... ... .A. .CG . . CG. A.. ... ... ... ... ... .C. U A .G. ... ... ... 
PLSV ... ... ... .-.. . . ... ... ... ... ... ... ... .C. . N/A ... ... ... .C. U A .G. ... ... ... 
TETE ... ... ... .-.. . . ... U.. ... ... ... ... ... ... . . ... ... ... ... ... ... ... .C. C . .G. ... ... ... 
BMAV ... ... ... .-C. . . ... ... ... ... ... ... ... .C. . . ... ... ... ... ... ... ... .C. C . .G. ... ... ... 
MTRV ... ... ... .-.. . . ... ... ... ... ... ... ... ... . . ... ... ... ... ... ... ... .C. C . .G. ... ... ... 
TSUV ... ... ... .-C. . . ... ... ... ... ... ... ... ... . . ... ... ... ... ... ... ... .C. C . .G. ... ... ... 
Brazoran* ... ... .A. .U.. . . A.A ... ... ... ... ... .A. ..G . . C.. A.. ... ... ... ... ... ... . ... ... ... ... 
Nyando* ... ... ... .A.. . . ... ... ... ... ... ... ... ... . . ... ... ... ... ... ... ... ... . ... ... ... ... 
Apeu * ... ... ..G .-.. . . ... ... ... ... ... ... ... ... . . ... ... ... ... ... ... ... ... . ... ... ... ... 
La Crosse* ... ... ... .-C. . . .G. ... ... ... ... ... ... ... . . ... ... ... ... ... ... ... ... . ... ... ... ... 
Akabane* ... ... .A. .-.. . . ... ... ... ... ... ... .A. ... . . ... A.. ... ... ... ... ... ... . ... ... ... ... 
SBV* ... ... .A. .-.. . . ... A.. ... ... ... ... .A. ... . . ... A.. ... ... ... ... ... ... . ... ... ... ... 
Jatobal* ... ... ... .-.. . . ... ... ... ... ... ... ... ..C . . ... ... ... ... ... ... ... ... . ... ... ... ... 
Pongola* ... ... ... .-.. . . ... ... ... ... ... ... ... ..G . . C.. ... ... ... ... ... ... ... . ... ... ... ... 
Buttonwillow* ... ... ... .-.. . . A.. ... ... ... ... ... ... ... . . ... ... ... ... ... ... ... ... . ... ... ... ... 
 
Sequences with variations in conserved termini are shown. Non-canonical base pairing in red; -, denotes a gap. * Variation in published sequences limited to 1 example 
per virus species. Virus abbreviations: ANAV (Anopheles A virus), 57389 (ColAn 57389 virus), LMV (Las Maloyas virus), TCMV (Tacaiuma virus), TRMV 
(Trombetas virus), ANBV (Anopheles B virus), BORV (Boracéia virus), CAPV (Capim virus), JDV (Juan Diaz virus), MORV (Moriche virus), GAMV (Gamboa 
virus), GMAV (Guama virus), PLSV (Palestina virus), EREV (Eretmapodites virus), NDV (Nyando virus), BMAV (Batama virus), MTRV (Matruh virus), TETEV 
(Tete virus), TSUV (Tsuruse-like virus), WELV (Weldona virus), MPOV (M’Poko virus). 
 5.3.5 Sequence Identity and Phylogeny 
 
To investigate evolutionary relationships and virus classification, phylogenetic analysis 
and aa identity were investigated. Phylogenetic analysis largely supports traditional 
virus classifications with N, M and L ORFs of all viruses, excluding TCMV, branching 
within serogroup designations (Figure 5-6, Figure 5-7, Figure 5-8).  
 
Anopheles A and Anopheles B serogroups formed neighbouring clusters on N, M and 
L ORF phylogenetic trees. However, the placement of TCMV, an Anopheles A 
serogroup virus, varied, branching with the Anopheles B serogroup on N and M 
analysis, but branching as ancestral to the Anopheles A and Anopheles B serogroups on 
L analysis (Figure 5-6, Figure 5-7, Figure 5-8). This also occurred in neighbour-joining 
phylogenetic analyses (Figure 5-9). Furthermore, TCMV shares very low sequence 
identity with other Anopheles A serogroup viruses, with aa identities of ≤ 55.1%, ≤ 
39.9% and ≤ 60.6% for the N, M and L proteins, respectively (Table 5-4A). Indeed, 
TCMV shared slightly higher aa identity with ANBV M (41.1%) and L (61.3%) 
proteins (Table 5-4B). Interestingly, unclassified bunyavirus Tataguine, which causes 
febrile disease in man, branched ancestrally to the Anopheles A and Anopheles B 
serogroups, with high bootstrap values on N and L analyses.  
 
Capim, Guama and Minatitlan serogroups branched very closely on phylogenetic 
analysis and share high aa identity (Figure 5-6, Figure 5-7, Figure 5-8, Table 5-4C). N, 
M and L phylogeny shows PLSV, a member of the Minatitlan serogroup, as ancestral 
to both the Guama and Capim serogroups. However, the phylogenetic relationships 
between GMAV and the Capim serogroup viruses are less clear, and only supported by 
high bootstrap values in the L ORF analysis (Figure 5-6, Figure 5-7, Figure 5-8). 
 
Tete serogroup viruses formed a single clade, supported by high bootstrap values for 
each ORF (Figure 5-6, Figure 5-7, Figure 5-8). Moreover, unclassified virus I612045 
fell within the Tete serogroup cluster and showed high levels of identity to Tete 
serogroup N, M and L proteins (Table 5-4D). N ORF phylogeny also reveals that Oyo 
may fall within the Tete serogroup cluster, with WELV, a member of the Tete virus sp. 
and Tete serogroup, branching basally to the group (Figure 5-6).  
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Figure 5-6: N ORF Phylogeny 
Nucleotide sequences for complete N ORFs were aligned with previously published* 
sequences using the MUSCLE algorithm in MEGA 6.06 (Mac). Maximum likelihood 
phylogenies were then implemented in MEGA 6.06 (Mac) with 1000 pseudoreplicates, 
bootstrap values > 60% are shown. Clades containing isolates sequenced in this study are 
highlighted whilst large clades lacking novel sequences have been compressed. When > 1 
published sequenced for a named virus isolate was available 1 was selected. A complete list of 
virus names and accession numbers are shown in non-compressed trees (Appendix 4).  
 
*Published sequences available 3rd December 2015.  
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Figure 5-7: M ORF Phylogeny 
Nucleotide sequences for complete M ORFs were aligned with previously published* 
sequences using the MUSCLE algorithm in MEGA 6.06 (Mac). Maximum likelihood 
phylogenies were then implemented in MEGA 6.06 (Mac) with 1000 pseudoreplicates, 
bootstrap values > 60% are shown. Clades containing isolates sequenced in this study are 
highlighted whilst large clades lacking novel sequences have been compressed. When > 1 
published sequenced for a named virus isolate was available 1 was selected. A complete list of 
virus names and accession numbers are shown in non-compressed trees (Appendix 4). 
 
*Published sequences available 3rd December 2015. 
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Figure 5-8: L ORF Phylogeny 
Nucleotide sequences for complete L ORFs were aligned with previously published* sequences 
using the MUSCLE algorithm in MEGA 6.06 (Mac). Maximum likelihood phylogenies were 
then implemented in MEGA 6.06 (Mac) with 1000 pseudoreplicates, bootstrap values > 60% 
are shown. Clades containing isolates sequenced in this study are highlighted whilst large 
clades lacking novel sequences have been compressed. When > 1 published sequenced for a 
named virus isolate was available 1 was selected. A complete list of virus names and accession 
numbers are shown in non-compressed trees (Appendix 4). 
 
*Published sequences available 3rd December 2015. 
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Figure 5-9: N, M and L ORF Neighbour-Joining Phylogeny 
Nucleotide sequences for complete N (A), M (B) and L (C) ORFs were aligned with previously published sequences using the MUSCLE algorithm in MEGA 6.06 
(Mac). Neighbour-Joining phylogenies were then implemented in MEGA 6.06 (Mac) with 1000 pseudoreplicates, bootstrap values > 60% are shown. Clades 
containing isolates sequenced in this study are highlighted whilst large clades lacking novel sequences have been compressed. When > 1 published sequenced for a 
named virus isolate was available 1 was selected. 
A)       B)       C) 
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Table 5-4: Amino Acid Identity within Serogroups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
D)                                               TETE SEROGROUP AMINO ACID PERCENTAGE IDENTITY 
 
N  M  L 
BMAV MTRV TSUV WEL I612045  BMAV MTRV TSUV I612045  BMAV MTRV TSUV I612045 
TETEV 88.8 68.3 68.7 45.2 83.0  75.8 74.5 75.0 76.8  94.1 83.3 82.4 91.6 
BMAV  67.2 67.6 44.8 83.7   75.2 76.3 80.5   83.0 83.0 91.1 
MTRV   76.4 43.6 67.9    85.6 76.8    92.1 82.4 
TSUV    41.7 69.9     76.9     81.6 
WEL     45.6     -     - 
 
E) NYANDO SEROGROUP AMINO ACID PERCENTAGE IDENTITY 
  N    M    L  
 EREV ERET147 MP401  EREV ERET147 MP401  EREV ERET147 MP401 
NDV 85.4 85.4 100.0  56.6 56.7 100.0  61.8 61.8 99.9 
EREV  100.0 85.4   100.0 56.7   100.0 61.8 
ERET147   85.4    56.7    61.8 
 
F) GAMBOA SEROGROUP AMINO ACID PERCENTAGE IDENTITY 
 
N  M  L 
GML MPOV MARU  GML MPOV MARU  GML MPOV MARU 
GAMV 99.6 42.9 99.6  76.6 33.0 99.6  99.9 58.4 99.7 
GML  42.9 100   40.4 76.8   58.4 99.8 
 
Amino acid sequences were aligned using the MUSCLE algorithm in in CLC Genomics 
Workbench v7.5.1 (Qiagen) using MUSCLE algorithm and pairwise identity calculated. 
Accession numbers for previously published sequences are listed. A) Anopheles A serogroup. 
B) Anopheles B serogroup and TCMV. C) Capim, Guama and Minatitlan serogroups. D) Tete 
serogroup, I612045 virus (HM627180, HM627181, HM627179). E) Nyando serogroup, 
ERET147 (KJ867194, KJ867195, KJ867196), NDV strain MP401 (KJ867188, KJ867189, 
KJ867190). F) Turlock and Gamboa serogroup, GML; Gamboa virus (KM272176, KM272175, 
KM272174), MARU; Alajuela virus (KM272188, KM272187, KM272186).  
A)                       ANOPHELES A SEROGROUP AMINO ACID PERCENTAGE IDENTITY 
 
N  M  L 
57389 LMV TRMV TCMV  57389 LMV TRMV TCMV  57389 LMV TRMV TCMV 
ANAV 72.3 75.6 73.6 53.0  45.3 47.0 37.8 37.8  76.9 77.3 76.8 59.6 
57389  98.4 97.2 54.3   46.7 41.1 35.6   94.3 98.4 60.6 
LMV   97.2 55.1    39.9 38.7    94.3 60.6 
TRMV    54.3     39.9     60.3 
B)             ANOPHELES B SEROGROUP (+ TCMV) 
 
N  M  L 
BORV TCMV  BORV TCMV  BORV TCMV 
ANBV 82.6 51.0  48.4 41.1  83.3 61.3 
BORV  48.6   39.2   62.0 
C)           CAPIM, GUAMA, MINATITLAN SEROGROUP AMINO ACID PERCENTAGE IDENTITY 
 
N  M  L 
JDV MORV GMAV PLSV  JDV MORV GMAV PLSV  JDV MORV GMAV PLSV 
CAPV 74.9 76.2 67.5 56.8  65.0 64.3 65.1 59.0  84.0 83.7 79.1 72.4 
JDV  93.2 67.5 58.5   65.4 63.6 56.5   92.1 78.1 71.8 
MORV   65.4 59.3    64.0 59.9    77.5 71.8 
GMAV    59.5     62.4     74.8 
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Phylogenetic analysis also suggests that BMAV, I612045 and TETEV belong to 1 
replicating lineage whilst MTRV and TSUV form another (Figure 5-6, Figure 5-7, 
Figure 5-8). 
 
Nyando serogroup viruses branched with sequences published by Groseth et al., (2014) 
forming 2 replicating lineages which correspond to the classical NDV and EREV 
classifications (Figure 5-6, Figure 5-7, Figure 5-8).  
 
Turlock serogroup virus MPOV shares only 29.3% aa identity with the published N 
protein sequence of MPOV strain ArB365, accession number AM711133, and shares 
higher aa identity with Gamboa serogroup viruses (Table 5-4F). MPOV also branches 
in a distant clade from MPOV ArB365, accession AM711133, branching with the 
Gamboa serogroup on N, M and L ORF phylogenetic analysis (Figure 5-6, Figure 5-7, 
Figure 5-8, Appendix 4).  
 
It should also be noted that there was evidence of reassortants among all serogroups 
with ≥ 3 sequenced isolates, namely the Anopheles A, Capim, and Tete serogroups. For 
example, within the Capim serogroup CAPV N and L proteins are ancestral to those of 
MORV and JDV, whereas M protein phylogeny shows JDV as ancestral to CAPV and 
MORV. 
 
 
5.4 Discussion 
 
5.4.1 Protein Conservation 
 
In this study complete genome sequences of 20 orthobunyaviruses, representing the 
first complete genomes for 8 orthobunyavirus serogroups, were determined, unearthing 
greater genetic diversity in viral UTRs and coding regions, thus calling current 
classifications into question. 
 
In 2009 Eifan et al., detected 46 conserved aa in orthobunyavirus N proteins; today 
only 3 of these residues, alignment positions K77, T119 and G180, remain fully 
conserved (Figure 5-1) (Eifan and Elliott, 2009). K77 is flanked by RNA and N-N 
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interaction domains and T119 has been shown to directly interact with RNA in LACV 
crystallography studies, whilst G180 falls within a region of high conservation that 
currently has no assigned function (Figure 5-1) (Reguera et al., 2010). Mutagenic 
analysis of BUNV N by Eifan and Elliott (2009) identified BUNV N protein residues 
141, 144 and 158 (alignment positions 174, 177 and 191) as having potentially 
important roles in the virus life cycle. Mutants Y141C, F144A and Y158N displayed 
only 2%, 29% and 30% activity in a minigenome assay with respect to wt BUNV, and 
N-L co-precipitation of Y141C was only 36% with respect to wt BUNV (Eifan and 
Elliott, 2009). Further investigation of this region with regards to mapping N-L 
interactions would therefore be warranted. Additionally, L protein alignment residues 
2241-2253 which contain a 23 aa insertion by Tete serogroup viruses, may also be of 
interest. Tete serogroup viruses encode larger N proteins and the L protein alignment 
2241-2253 is flanked by fully conserved residues (Figure 5-3A). High levels of 
conservation were also present in L protein alignment residues 1441-1463 (88.8%) and 
1493-1546 (83.2%), compared with 60.6% conservation across the complete L protein. 
This region is not yet associated with any known motif or function. 
 
In this study only 5 viruses, GAMV, WELV, MPOV, NDV and EREV were found to 
encode ORFs containing NSs pfam domain 01104. Excluding Brazoran virus, which 
encodes an NSs protein of 173 aa in an overlapping reading frame that precedes that of 
the N protein, ‘traditional’ orthobunyavirus NSs proteins previously ranged from 83 – 
109 aa (Mohamed et al., 2009; Lanciotti et al., 2013). Sequencing of the ‘neglected’ 
serogroups reveals greater diversity in NSs protein size as Gamboa serogroup viruses 
are predicted to encode NSs proteins at 130 - 137 aa, whilst the shortest at only 79 aa is 
encoded by MPOV a member of the Turlock serogroup (Nunes et al., 2014). Despite 
this large variation in size small conserved sequence motifs are still present, with 
additional conserved aa within serogroups. The conserved motifs map to NSs aa 
alignment positions 95-114, a region with 57.3% conservation, in comparison to only 
28.9% when the entire NSs protein is considered. Conservation within NSs proteins 
may arise as a consequence of conservation within the overlapping N protein ORF. 
However, the conserved NSs sequence motifs map to regions of the genome not 
associated with high N protein conservation. For example, NSs alignment residues 95-
114 share coding sequence with aa 75-93 in BUNV N protein, a region with only 
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57.7% conservation compared to the 81.0% conservation for BUNV N residues 68 - 87, 
which are associated with RNA binding.  
 
Studying the conserved motifs within NSs proteins may help elucidate the mechanisms 
by which NSs proteins act. The interaction of BUNV NSs with Med8 has been mapped 
to alignment residues 110-118, which contains the Bunyamwera serogroup conserved 
sequence VLPSTxxVD. A truncated version of this motif (xLPSTxxxD) is also present 
in Bwamba and California serogroups, whilst MPOV NSs truncates prior to this region 
and Gamboa serogroup NSs proteins contain a divergent sequence (xxPxTxxxD). 
Moreover, BUNV NSs is subject to proteosomal degradation yet Gamboa viruses and 
some Simbu serogroup NSs proteins lack a single lysine residue. 
 
Truncated NSs ORFs were first identified in Bunyamwera (Wyeomyia) group viruses 
in 2009 and have subsequently been detected in the Anopheles A, Anopheles B, 
Mapputta and Tete serogroups (Mohamed et al., 2009; Mores et al., 2009). Mohamed 
et al. (2009) also demonstrated that the severely truncated NSs ORFs of Anopheles A, 
Anopheles B and Tete serogroup viruses were non-functional when S segment clones 
were expressed in cell free expression systems. This study now reports that viruses 
belonging to the Capim, Guama and Minatitlan serogroups also contain severely 
truncated and presumably non-functional NSs ORFs (Table 5-2). We also report that 
the presence/absence of the NSs ORF is not conserved within current serogroups, as a 
full length NSs ORF (114 aa) was detected in WELV, a member of the Tete serogroup 
that was previously thought to contain only non-NSs viruses. It has been hypothesised 
that non-NSs viruses may exhibit greater diversity in N protein sequences as the S 
segment ORF is no longer constrained by the need to encode both N and NSs proteins 
(Mohamed et al., 2009). There is, as yet, no evidence of this as there is greater 
sequence diversity amongst the N proteins of Simbu serogroup viruses (e.g. 49.8% aa 
identity between Leanyer virus and Facey’s Paddock virus) than non-NSs viruses of the 
same serogroup. However, it should be noted that the largest non-NSs serogroup, 
Wyeomyia, contains only 7 named viruses with sequence data and low levels of 
sequencing may mask true levels of diversity (Chowdhary et al., 2012). 
 
Prior to the work of Mohamed et al, (2009), NSs, the primary virulence factor of 
orthobunyaviruses, was thought to be essential in overcoming vertebrate innate 
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immune defence (Hart et al., 2009). However, 6 non-NSs viruses (TCMV, BORV, 
GMAV, Tataguine virus, BUCV and Tucunduba virus) belonging to the Anopheles A, 
Anopheles B, Guama, Mapputta, and Wyeomyia serogroups have been linked with 
human infection (de Souza Lopes and de Abreu Sacchetta, 1974; Moore et al., 1975; 
Calisher et al., 1980; Chowdhary et al., 2012; Gauci et al., 2015). The mechanism by 
which these viruses are able to overcome the human innate immune response is yet to 
be identified. It was initially postulated that the N or M protein of non-NSs 
orthobunyaviruses may play a role in IFN antagonism as the N proteins of hantaviruses 
have been shown to antagonise the type I IFN response through the inhibition of PKR 
dimerisation (Wang and Mir, 2015). Additionally, the cytoplasmic tails of Gn proteins 
in virulent hantaviruses suppress ISRE and IFN-β promoter activation in a mechanism 
thought to involve regulation of the TBK-1 complex (Alff et al., 2008). Viruses in the 
Anopheles A, Anopheles B and Tete serogroups encode larger N proteins (243-258 aa) 
than NSs encoding orthobunyaviruses; however, this characteristic is not conserved 
among the other non-NSs viruses. Interestingly, viruses within the Capim, Guama, 
Minatitlan and Wyeomyia viruses have incredibly long A-rich antigenomic 3’UTRs 
and it is unclear what role these play in the virus replication (Table 5-2). Although 
more prevalent in non-NSs viruses, they are not exclusive to this subset of 
orthobunyaviruses with GAMV, a member of the Gamboa serogroup, encoding an S 
segment UTR of 438 nt (Table 5-2). Therefore, there is no clear conserved genome trait 
in the newly sequenced non-NSs viruses that may account for pathogenicity in man. 
 
The M polyprotein of orthobunyaviruses is post-translationally cleaved to form the 2 
virus glycoproteins, Gn and Gc, and the non-structural protein NSm. There is striking 
conservation of cysteine residues throughout the polyprotein and Gn zinc finger motifs 
and the Gc fusion peptide remain fully conserved (Figure 5-3). It is also of note that of 
the 5 conserved histidine residues present in the ectodomain of orthobunyavirus Gc 
proteins studied by Shi et al. (2005) only alignment position 1267 (BUNV 1029), the 
histidine residue closest by sequencing to the Gc fusion peptide, remains conserved in 
all orthobunyaviruses with the exception of Khurdun virus. 
 
Bunyavirus glycoproteins form Gn Gc heterodimers and both Golgi-targeting and 
Golgi-retention signals map to the Gn protein. Further to this, N-glycosylation of Gn 
has been demonstrated to have an essential role in virus replication with BUNV N60Q 
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mutants misfolding and being retained in the ER (Shi et al., 2005). However, this study 
has found that viruses in the Anopheles A serogroup are predicted to lack a single 
glycosylation site in the Gn protein, a feature that has only previously been reported for 
Maprik virus (MPKV), a member of the Mapputta serogroup. Anopheles A serogroup 
M proteins, excluding TCMV, are also smaller than those of other orthobunyaviruses at 
1405 - 1415 aa, a feature they also share with Mapputta serogroup viruses (1370-1379 
aa). However, unlike the severely truncated M proteins of Khurdun virus and the insect 
only bunyaviruses Herbert, Tai and Kibale, Anopheles A and Mapputta serogroup 
viruses are still predicted to encode full length NSm proteins (Figure 5-4) (Marklewitz 
et al., 2013).  
 
The role of NSm proteins in virus replication has yet to be fully elucidated. NSm 
localises to the Golgi complex and is thought to act as a scaffold protein as the N 
terminal region of BUNV NSm has been shown to be important in glycoprotein folding 
and virus assembly (Shi et al., 2006). Yet recombinant viruses with large NSm 
deletions are able to replicate in cell culture and remain virulent in animals, with 
rSBVΔNSm causing viraemia and seroconversion comparable to wt SBV in cattle 
(Kraatz et al., 2015). In this study all viruses were found to encode NSm proteins but of 
note is GAMV, which encodes an M polyprotein of 1592 aa. This finding is in 
agreement with Nunes et al. (2014) who published complete coding sequences for 5 
members of the Gamboa serogroup. Analysis now shows the additional aa map to the N 
terminal region of NSm with a 149 aa insertion at alignment positions 350 - 498 
(Figure 5-3A). Moreover, Gamboa serogroup viruses are predicted to have altered 
transmembrane topology, with 2 additional transmembrane domains located in the 
predicted NSm protein (Appendix 3). Gamboa serogroup viruses have been isolated 
from Aedeomyia sp. of mosquitoes in South America, although little is known about 
their host range and it remains unclear what role the additional aa in NSm may play. 
Further studies of the non-NSm viruses, such as Khurdun virus and Gamboa serogroup 
viruses, would therefore be of interest, especially in studying mechanisms of 
glycoprotein folding and trafficking. 
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5.4.2 Impact on Orthobunyavirus Classification 
 
Orthobunyavirus species are primarily defined by cross neutralisation and complement 
fixation relationships, with viruses considered distinct when Ht/Ho titres differ by ≥ 4-
fold. Further to this N protein aa sequences, if available,  should differ by > 10% and 
current data implies that 1 species should not be able to reassort with any other (Elliott 
and Blakqori, 2011; Plyusnin et al., 2012). Applying this to viruses within the Capim 
serogroup highlights problems with current classification methods. JDV, CAPV and 
MORV are currently classified as members of distinct Capim serogroup species: JDV 
(Bushbush sp.), CAPV (Capim sp.), MORV (Acara sp.). There is no cross-reaction 
between the viruses in neutralisation (NT) assays, supporting their distinct 
classification. However, JDV and MORV are indistinguishable in CFTs and their N 
proteins show only 6.8% aa difference (Table 5-4C). Phylogeny supports the 
serological data, with JDV and MORV N and L proteins branching together, whilst 
their M proteins are separated by CAPV (Figure 5-6, Figure 5-7 and Figure 5-8). 
Moreover, although CAPV does not cross-react in either NT or CFT assays with JDV 
and MORV, it does cross-react with GMAV (CFT Ht/Ho 1/64) and PLSV (CFT Ht/Ho 
1/16), members of the Guama and Minatitlan serogroups (Berge, 1975; Calisher et al., 
1983). Cross-reaction between serogroups has long been known, complicating 
classification by serological methods and highlighting the complicated interrelatedness 
of orthobunyaviruses (Srihongse et al., 1966; Zarate et al., 1968; Zeller et al., 1989). 
As more sequencing data for closely related and serologically characterised viruses 
become available it may be possible to map antigenic sites, shedding light on antigenic 
cross-reactions and crucially facilitating the development of a robust method of 
orthobunyavirus classification. 
 
As the classification of orthobunyaviruses is reviewed phylogenetics will play a key 
role in unravelling the genetic relationships within the orthobunyavirus genus. 
Orthobunyaviruses have long been known to reassort, with classical reassortment 
studies utilising viruses in the Bunyamwera and California serogroups yeilding novel 
viruses from mixed infections (Gentsch et al., 1979). More recently, sequencing and 
phylogenetic analysis has provided evidence of reassortants in the Bunyamwera, 
Wyeomyia, Simbu, Group C and California groups (Yanase et al., 2006; Yanase et al., 
2010; Aguilar et al., 2011; Blitvich et al., 2012; Chowdhary et al., 2012; Yanase et al., 
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2012; Briese et al., 2013; Hontz et al., 2015; Tilston-Lunel et al., 2015). This study 
continues to detect reassortant viruses, with evidence of reassortment in the Anopheles 
A, Tete and, as described above, Capim serogroups. In agreement with previous studies 
S and L segments share a common ancestor with divergence occurring at the M 
segment. However, classification by phylogenetics alone is not without its constraints 
as due to the prevalence of reassortant viruses, the provision of complete sequences for 
all 3 virus segments is essential in elucidating true genetic relatedness.  
 
There have been well documented but conflicting findings regarding the phylogenetic 
placement of Group C viruses. The resolution of these discrepancies is hindered by the 
viruses innate capability to reassort, the lack of complete genome sequences for all 
isolates concerned, different sources of virus isolates, and the ever changing 
name/classification of these viruses (Nunes et al., 2005; Forshey et al., 2014; Hang et 
al., 2014; Hontz et al., 2015). This study also reports divergent findings with 
previously published sequences. MPOV strain ArB365 and NDV strain ArB16055 N 
protein sequences, accession numbers AM711133 and AM70978, fell within the 
Bunyamwera serogroup on phylogenetic analysis, sharing 81.9% and 86.4% identity 
with BUNV N protein (NC001927), respectively (Yandoko et al., 2007) (Appendix 4). 
However, in this study MPOV branched separately, sharing a common ancestor with 
Gamboa serogroup viruses, and Nyando serogroup viruses NDV and EREV branched 
with the NDV sequences published by Groseth et al., (2014). MPOV strain ArB365 
(AM711133) and NDV strain ArB16055 (AM70978) were sourced from the Institut 
Pasteur de Bangui, Central African Republic, whereas all viruses sequenced in this 
study were sourced from the Emerging Viruses and Arboviruses Reference Collection, 
University of Texas Medical Branch (Yandoko et al., 2007). 
 
Furthermore, it has been proposed that I612045, Oyo and Sedlec viruses form a new 
serogroup termed the Sedlec serogroup (Bakonyi et al., 2013). However, at the time of 
the proposed classification only S segment sequences were available for Tete serogroup 
viruses and, although I612045 virus grouped with these on phylogenetic analysis, the 
classification was taken forward on the phylogenetic relationship of partial L segment 
sequences for I612045, Sedlec and Oyo only. It is now clear that I6120245 not only 
shares genetic and biological features comparable to viruses within the Tete serogroup 
(N protein of 258 aa, truncated NSs ORF, isolated from birds), it also has high 
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sequence identity across all 3 genome segments and clusters on phylogenetic analysis 
within the Tete serogroup (Shchetinin et al., 2015). Unfortunately, there is no 
serological data relating to I612045 but genomic data strongly support the classification 
of I612045 as a member of the Tete serogroup. Complete sequencing of WELV M and 
L segments, along with complete sequencing of Sedlec virus, will further clarify the 
relationships within this group of viruses and emphasises the need to determine genome 
sequences for recognised orthobunyavirus species across all serogroups prior to the 
creation of new groups.  
 
In addition to phylogenetic analysis, the presence of conserved invertedly 
complimentary terminal sequences has provided a quick and simple method of 
identifying bunyavirus genera. However, as predicted by Elliott and Blakqori (2011), as 
more viruses are sequenced diversity in previously conserved sites is uncovered with 
changes at the 8th nt position in S and M segment reported for AKAV, SBV, Brazoran 
and MPKV (Table 5-3). The viruses sequenced in this study further contribute to UTR 
sequence divergence and support the reduction of conserved terminal sequences from 9 
to 7 nucleotides in the S and M segments of orthobunyaviruses, and the removal of 
segment specific sequences (Table 5-3). Crucially, the presence of terminal sequences 
can no longer be relied upon as a quick method of classification. This can be shown by 
the out grouping of Khurdun virus on phylogenetic analysis. Khurdun virus isolated 
from a Eurasian coot, Fulica atra, in Russia in 2001 contains complete orthobunyavirus 
terminal sequences in the S, M and L segments, with only a single change at the 8th nt 
position in the S segment (Galkina et al., 2005; Al'kovskhovskiĭ et al., 2013). Khurdun 
is phylogenetically distant from other orthobunyaviruses, branching as an outlier in N, 
M and L phylogenetic trees. Moreover, it encodes a severely truncated M polyprotein 
that lacks the NSm domain, a feature shared with the, as yet, unclassified insect only 
bunyaviruses Kibale, Tai and Herbert. Kibale, Tai and Herbert viruses also contain 
terminal sequences comparable to those of orthobunyaviruses yet branch equidistant 
between tospoviruses and orthobunyaviruses on phylogenetic analysis (Marklewitz et 
al., 2013). 
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5.4.3 Concluding Remarks 
 
Complete genome sequences for viruses in the Anopheles A, Anopheles B, Capim, 
Gamboa, Guama, Gamboa, Minatitlan, Nyando, Tete and Turlock serogroups were 
determined prior to the publication of sequences by Groseth et al., (2014), Nunes et al., 
(2014) or Al’kovskohovskii (2015). Sequencing viruses from the lesser studied 
serogroups challenges current classification methods and perceptions regarding NSs, as 
increasing numbers of orthobunyaviruses associated with human disease are found to 
lack a full length NSs ORF. 
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6.1 Introduction 
 
In this study, sequencing confirmed the presence of an NSs ORF in 5 of 20 sequenced 
orthobunyaviruses. The NSs positive viruses were Nyando serogroup viruses NDV and 
EREV, Gamboa serogroup virus GAMV, Turlock serogroup virus MPOV, and WELV, 
a Tete serogroup virus. In addition to these viruses, BWAV and SJV, which both 
belong to virus species with published sequences that contain full length NSs ORFs, 
were successfully propagated (Groseth et al., 2014; Nunes et al., 2014). The NSs 
protein is the primary virulence factor of orthobunyaviruses, antagonising the type I 
IFN system at the transcriptional level (Bridgen et al., 2001; Weber et al., 2002). The 
transcriptional blockade exerted by BUNV and LACV NSs proteins occurs, at least 
partly, at the mRNA elongation stage with inhibition of C-terminal domain serine 2 
phosphorylation, blocking RNAPII activity and protein synthesis in mammalian cells 
(Thomas, 2004; Verbruggen et al., 2011). The transcriptional blockade of the IFN-β 
promoter is profound and recombinant viruses lacking an NSs protein show increased 
sensitivity to type I IFNs (Blakqori et al., 2007; Bridgen et al., 2001). Indeed it was 
thought that the NSs protein was a key factor in determining the zoonotic potential of 
orthobunyaviruses, enabling the virus to overcome the mammalian innate immune 
response (Hart et al., 2009).  
 
However, an increasing number of orthobunyaviruses that naturally lack an NSs ORF 
have been identified in sequencing studies. Through published reports and the work 
presented in this thesis non-NSs viruses have now been detected in the Anopheles A, 
Anopheles B, Bunyamwera (Wyeomyia), Capim, Guama, Minatitlan, Mapputta, Simbu 
and Tete serogroups (Chowdhary et al., 2012; Gauci et al., 2015; Ladner et al., 2014; 
Mohamed et al., 2009). Moreover, a small number of these non-NSs viruses have been 
linked with human infection, either through the presence of neutralising antibodies or, 
in the case of TCMV, GMAV and BUCV, virus isolation from febrile patients (Berge, 
1975; Calisher et al., 1980; Wier, 2002). The mechanism by which these non-NSs 
viruses can overcome the host innate immune response has yet to be identified. It has 
been reported that TCMV antagonises the type I IFN system, whilst ANAV, another 
non-NSs orthobunyavirus in the Anopheles A serogroup that is not linked with human 
infection, induces high levels of IFN in vitro (Mohamed et al., 2009). To date this 
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remains the sole publication investigating non-NSs orthobunyaviruses and the type I 
IFN system. 
 
 
6.2 Aims 
 
The aims of this part of my studies were to investigate the activation and antagonism of 
the type I interferon response by NSs encoding and naturally occurring non-NSs 
orthobunyaviruses. This would enable the correlation of the presence of an NSs ORF, 
the ability to antagonise the type I IFN system, and reported pathogenicity in man to be 
studied.  
 
 
6.3 Results 
 
To test for statistical significance, the results presented in this chapter were analysed by 
t-test or one-way ANOVA, followed by the Dunnett’s multiple comparison test, with 
either BUNV or rBUNdelNSs2 as the control. Unless indicated, all p values in this 
chapter refer to these analyses and not any other form of statistical analysis.  
 
 
6.3.1 Activation and Antagonism of the Type I IFN System by Viruses with 
an NSs ORF 
 
Induction of biological IFN by viruses predicted to encode an NSs protein was tested in 
vitro. Briefly, serial dilutions of UV-inactivated supernatant from infected A549 cells 
were assayed for the presence of IFN by their ability to induce an anti-viral state in 
recipient cells, protecting them from subsequent infection by EMCV. The first dilution 
to show CPE, and therefore susceptibility to infection, was marked as the endpoint for 
each sample. BUNV, BWAV, NDV and EREV induced very low levels of biological 
IFN, ≤ 16 relative IFN U ml-1 (rIFN U ml-1), during virus infection (Figure 6-1). 
Although > 3-fold higher levels were observed in MPOV infections, the level of IFN 
remained significantly lower (p < 0.05) than for rBUNdelNSs2, which induced 
approximately 256 rIFN U ml-1 (Figure 6-1).  
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Figure 6-1: Biological Induction of Interferon by NSs Encoding Viruses 
Relative levels of biological interferon (rIFN U ml-1) produced by A549 cells 48 hours post 
induction with universal IFN (U ml-1) or 48 hours post infection at multiplicity of infection 1. 
rIFN was measured by the level of protection given to A549-NPro cells from EMCV infection 
by 2-fold dilutions of UV-irradiated supernatant from IFN-induced and virus infected A549 
cells. Mean ± standard deviation of triplicate experiments is shown. Samples with significantly 
lower levels of rIFN than rBUNdelNSs2 are marked with an asterisk, ** p < 0.001, * p < 0.05. 
 
Virus abbreviations: Bunyamwera virus (BUNV), recombinant BUNV lacking an NSs protein 
(rBUNdelNSs2), Bwamba virus (BWAV), Nyando virus (NDV), Eretmapodites virus (EREV), 
M’Poko virus (MPOV), Gamboa virus (GAMV), San Juan virus (SJV) and 
encephalomyocarditis virus (EMCV) 
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In GAMV and SJV infections approximately 512 rIFN U ml-1 were produced, 
significantly higher (p < 0.0001) than the other NSs encoding viruses and 2-fold higher 
than rBUNdelNSs2 (Figure 6-1). 
 
Activation of the IFN-β promoter in a dual luciferase reporter assay mirrored the levels 
of biological IFN produced during virus infection (Figure 6-2A). Firefly activity, and 
thereby activation of the IFN-β promoter, was normalised to CMV-driven Renilla 
expression and relative light units (RLU) were adjusted so that mock equals 1. Using 
this formula activity of the IFN-β promoter in rBUNdelNSs2 infected cells (14.8 RLU) 
was significantly higher (p < 0.01) than in BUNV infections (0.7 RLU) (Figure 6-2A). 
This was despite similar levels of viral replication as mean virus titres were within 0.2 
logs (Figure 6-2B). Indeed, IFN-β promoter activity in BUNV and BWAV, NDV and 
EREV infected cells was below background at only 0.45 – 0.85 RLU (Figure 6-2A). 
Although activity in MPOV infected cells was higher than in BUNV infected cells, 
values remained significantly lower (p < 0.002) than in rBUNdelNSs2 infected cells at 
only 4.29 ± 0.40 RLU (Figure 6-2A). GAMV and SJV infections induced significantly 
higher IFN-β promoter activity than rBUNdelNSs2 (p < 0.002) (Figure 6-2A).  
 
To confirm that the low levels of IFN induction were due to antagonism of the type I 
IFN system, the reporter assay was repeated in the presence of exogenous IFN to prime 
the type I IFN response (Figure 6-3). In the presence of 10 U ml-1 IFN activation of the 
IFN-β promoter was significantly higher (p < 0.005) than in untreated cells at 
approximately 7.5 RLU (Figure 6-3A). BUNV and BWAV significantly antagonised 
activation of the IFN-β promoter in the presence exogenous IFN with RLU readings of 
only 2 ± 0.5 (p < 0.005). Antagonism by NDV and EREV was less pronounced with 
IFN-β promoter activity 4.5 ± 0.6 RLU higher than in infected, IFN untreated cells 
(Figure 6-3B). There was no evidence of antagonism by MPOV, with 10.5 ± 0.8 RLU 
in the presence of exogenous IFN, > 6.3 RLU higher than in MPOV infected IFN 
untreated cells (Figure 6-3). In GAMV and SJV infections IFN-β promoter activity was 
higher than in rBUNdelNSs2 infections, and > 7.3 RLU higher than in IFN untreated 
infected cells (Figure 6-3).  
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Figure 6-2: Activation of the Interferon-β Promoter in Virus Infection 
A549 cells were co-transfected with IFN-β firefly and CMV Renilla reporter plasmids pIF∆(-
125)lucter and phRL-CMV. Cells were then infected at multiplicity of infection 1. A) At 18 
hours post infection the cells were assayed for luciferase activity (relative light units, RLU). 
Mean ± standard deviation of triplicate experiments is shown. Samples with significantly lower 
levels of luminescence than rBUNdelNSs2 are marked with an asterisk, **p < 0.001, * p < 
0.002. B) In addition to measuring luciferase activity virus titres of the corresponding cell 
supernatants were determined by plaque assay on Vero E6 cells. Mean ± standard deviation of 
triplicate experiments is shown. 
 
Virus abbreviations: Bunyamwera virus (BUNV), recombinant BUNV lacking an NSs protein 
(rBUNdelNSs2), Bwamba virus (BWAV), Nyando virus (NDV), Eretmapodites virus (EREV), 
M’Poko virus (MPOV), Gamboa virus (GAMV), and San Juan virus (SJV).  
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Figure 6-3: Antagonism of the Type I Interferon Response in Virus Infection 
A549 cells were co-transfected with interferon (IFN)-β firefly and CMV Renilla reporter 
plasmids pIF∆(-125)lucter and phRL-CMV. Cells were then infected at multiplicity of 
infection 1) or mock infected with an equal volume of PBS 2% (v/v) FCS. Two hours post 
infection (h p.i.) the mock infected positive control (PC) and virus infected cells were treated 
with 10 U ml-1 universal IFN. The mock infected negative control (NC) was treated with an 
equal volume of PBS in place of IFN. A) At 18 h p.i. cells were assayed for luciferase activity 
(relative light units, RLU). Mean ± standard deviation of triplicate infections is shown. B) To 
facilitate result interpretation RLU from infected cells not treated with IFN (Figure 6-2A) were 
subtracted from those presented in Figure 6-3A, thereby showing the difference in IFN-β 
promoter activity between infected and infected IFN treated cells. Mean ± standard deviation of 
triplicate experiments is shown.  
 
Virus abbreviations: Bunyamwera virus (BUNV), recombinant BUNV lacking an NSs protein 
(rBUNdelNSs2), Bwamba virus (BWAV), Nyando virus (NDV), Eretmapodites virus (EREV), 
M’Poko virus (MPOV), Gamboa virus (GAMV), and San Juan virus (SJV).  
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To assess whether the type I IFN antagonism observed during virus infection could be 
attributed to the NSs protein the NSs ORFs of BUNV, NDV, EREV, MPOV, GAMV, 
and WELV were cloned into CMV-driven expression plasmids. Due to time 
constraints, only viruses that were sequenced as part of my studies were included, 
therefore BWAV and SJV were omitted whilst WELV, a Tete serogroup virus that 
could not be titrated by plaque assay and was therefore not tested in previous assays, 
was included. The NSs expression plasmids were co-transfected with luciferase 
reporter plasmids and a plasmid encoding the 2CARD domain of RIG-I to activate the 
type I IFN system. Induction of the type I IFN response in this assay was confirmed by 
the positive control with ≥ 219-fold increase in IFN-β promoter activity compared with 
non-induced cells (Figure 6-4). In this assay BUNV, NDV and EREV NSs expression 
plasmids exerted strong antagonism, with significant (p ≤ 0.0002) reductions in IFN-β 
promoter activity at only 10 ng (Figure 6-4). 
 
Antagonism by the BUNV NSs expression plasmid significantly (p < 0.01) increased 
with transfection of 50 ng compared to 10 ng, and then levelled off with no significant 
differences in IFN-β promoter activity at higher concentrations (Figure 6-4). The 
antagonism exerted by the EREV NSs expression plasmid was dose-dependent with a 
steady increase in antagonism with increasing plasmid concentration (Figure 6-4). The 
NDV NSs expression plasmid showed strong antagonism at all concentrations (Figure 
6-4). The putative NSs protein of WELV also had a strong antagonistic effect, in a 
dose-dependent manner, with a 2.5-fold reduction (p < 0.004) at 10 ng and a 16.8-fold 
reduction (p ≤ 0.0001) at 250 ng (Figure 6-4). The MPOV NSs expression plasmid 
displayed weaker antagonistic activity than BUNV, NDV, and EREV, with only a 3.1-
fold reduction (p < 0.003) in IFN-β promoter activity at 500 ng (Figure 6-4). Strikingly, 
the NSs ORF of GAMV showed no activity in this assay with no significant reductions 
in luciferase activity at any of the concentrations tested (Figure 6-4).  
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Figure 6-4: Antagonism of the Interferon-β Promoter by Virus NSs Proteins 
293T cells were co-transfected with: interferon (IFN)-β firefly and CMV Renilla reporter 
plasmids, pIF∆(-125)lucter and phRL-CMV; pCAGGs-2CARD to stimulate the type I IFN 
pathway; pCMV NSs encoding plasmids at specified concentrations; and pCMV-empty to 
normalise plasmid DNA concentrations across all reactions. At 18 hours post transfection cells 
were assayed for luciferase activity (relative light units, RLU). The NSs ORFs of BUNV, 
WELV, NDV, EREV, MPOV and GAMV were tested. The mean ± standard deviation of 
triplicate transfections is shown. The positive control (PC) contains IFN-β and CMV promoter 
reporter plasmids, pCAGGs-2CARD to stimulate type I IFN pathway and pCMV-empty in 
place of an NSs expression plasmid. The negative control (NC) contains IFN-β and CMV 
promoter reporter plasmids and pCMV-empty only, with no NSs expression plasmid or IFN 
induction plasmid, pCAGGs-2CARD. 
 
Virus abbreviations: Bunyamwera virus (BUNV), Weldona virus (WELV), Nyando virus 
(NDV), Eretmapodites virus (EREV), M’Poko virus (MPOV) and Gamboa virus (GAMV). 
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6.3.2 Sensitivity of Viruses with an NSs ORF to Pre-treatment with IFN 
 
Viruses predicted to encode an NSs protein were tested for sensitivity to exogenous 
IFN. Vero E6 cells were pre-treated with universal IFN for 24 hours prior to infection 
and virus replication measured by plaque assay on clarified culture supernatant 48 h 
p.i.. BUNV underwent a dose-dependent reduction in virus titre with ≥ 1.3 log 
reduction at 100 IFN U ml-1, a 2.2 log reduction at 1 000 IFN U ml-1 and ≥ 2.4 log 
reduction at 10 000 IFN U ml-1 (Figure 6-5). The Nyando serogroup viruses, NDV and 
EREV, underwent similar reductions with ≥ 1.1 log drop at 100 IFN U ml-1, ≥ 2.3 log 
drop at 1000 IFN U ml-1 and ≥ 2.6 log drop at 10 000 IFN U ml-1 (Figure 6-5). Gamboa 
serogroup viruses, GAMV and SJV, were also sensitive to IFN pre-treatment with > 2 
log and > 3 log reductions in virus titres at 1 000 IFN U ml-1 and 10 000 IFN U ml-1, 
respectively (Figure 6-5). BWAV, a member of the Bwamba serogroup, was slightly 
more resistant to IFN pre-treatment, with only a 0.8 log reduction in virus titre at 100 
IFN U ml-1 and 1.7 log reduction at 1 000 IFN U ml-1 (Figure 6-5). However, of the 
NSs encoding viruses, MPOV showed the greatest resistance to IFN pre-treatment with 
< 1 log drop at 1 000 IFN U ml-1, and < 2 log drop at 10 000 IFN U ml-1 (Figure 6-5). 
 
To facilitate result interpretation and summarise the in vitro IFN phenotype of viruses 
predicted to encode an NSs protein the results presented thus far are collated in Table 
6-1.  
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Figure 6-5: Virus Growth in Interferon Treated Cells 
Vero E6 cells were pre-treated with universal interferon (IFN) (U ml-1) 24 hours prior to 
infection at multiplicity of infection 1. Cell supernatants were collected 48 hours post infection 
and virus titre determined by plaque assay on Vero E6 cells. Mean ± range of duplicate 
experiments is shown. 
 
Virus abbreviations: Bunyamwera virus (BUNV), recombinant BUNV lacking an NSs protein 
(rBUNdelNSs2), Bwamba virus (BWAV), Nyando virus (NDV), Eretmapodites virus (EREV), 
M’Poko virus (MPOV), Gamboa virus (GAMV) or San Juan virus (SJV). 
  
BU
NV
rB
un
de
lNS
s2
BW
AV
ND
V 
ER
EV
MP
OV
GA
MV SJ
V
1 
2 
3 
4 
5 
6 
7 
0 
100
1 000
10 000
Vero E6 cells treated with 0, 100, 1000 or 10 000 U of universal IFN 24 hours prior to infection.
Cells then infected at MOI 0.1 and viral titre determined 48 hours post infection by plaque assay.
Graph depicts duplicate experiments, mean and standard deviation shown.
IFN Pretreatment
(U ml-1)
Virus
Vi
ru
s 
Ti
tr
e 
(L
og
10
 p
.f.
u 
m
l-1
)
6: Orthobunyaviruses and the Type I Interferon Response 156	
 
Table 6-1: In vitro Interferon Phenotype of Viruses with an NSs ORF 
Virus Serogroup NSs ORF 
Induction of 
Biological IFN 
Activation of 
IFN-β Promoter 
Sensitivity 
to IFN 
Antagonism of 
IFN-β Promoter 
BUNV Bunyamwera + - - +++ ++++ 
BWAV Bwamba + - - ++ N/A 
NDV Nyando + - - +++ +++ 
EREV Nyando + + - +++ +++ 
MPOV Turlock + ++ + + + 
GAMV Gamboa + ++++ ++++ +++ - 
SJV Gamboa + ++++ ++++ ++ N/A 
WELV Tete + N/A N/A N/A +++ 
 
A summary of interferon (IFN) results for viruses predicted to encode an NSs protein. N/A; not 
available. 
• Induction of biological IFN in virus infection: -, ≤ 10 rIFN U ml-1; +, > 10 ≤ 50 rIFN U ml-1;  
   ++, > 50 ≤ 150 rIFN U ml-1; +++, > 150 ≤ 300 rIFN U ml-1; +++, > 300 rIFN U ml-1.  
• Activation of IFN-β promoter in virus infection: -, ≤ 1 RLU; +, 1 - 5 RLU; ++, 5 - 10 RLU;  
   +++, 10 - 15 RLU; ++++, > 15 RLU.  
• Sensitivity to IFN, lowest concentration IFN for ≥ 1 log reduction in virus titre: +++, 100 IFN  
   U ml-1; ++, 1 000 IFN U ml-1; +, 10 000 IFN U ml-1; -, <1 log reduction at 10 000 IFN U ml-1. 
• Antagonism of the IFN-β promoter by NSs expression plasmids at 250 ng: ++++, ≤ 10  RLU;    
   +++, > 10 ≤ 25 RLU; ++, > 25 ≤ 100 RLU; +, > 100 ≤ 200 RLU; -, > 200 RLU. 
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6.3.3 Activation and Antagonism of the Type I IFN System by Viruses 
Lacking an NSs ORF 
 
Activation of the type I IFN system was measured using the biological EMCV assay 
and IFN-β promoter reporter assays described in section 6.3.1. Anopheles A serogroup 
viruses, CPEV, LMV, TRMV and TUCV, induced approximately 128 rIFN U ml-1 to 
256 rIFN U ml-1, which was equal to, or within 1 dilution factor, of rBUNdelNSs2 
(Figure 6-6). ANAV induced far higher levels of IFN at > 1 000 rIFN U ml-1, whereas, 
TCMV, another Anopheles A serogroup virus, induced significantly lower (p < 0.01) 
levels of biological IFN than rBUNdelNSs2 at approximately 50 rIFN U ml-1 (Figure 6-
6). Anopheles B serogroup viruses, ANBV and BORV, induced approximately 512 
rIFN U ml-1.  
 
The Minatitlan serogroup virus, PLSV and Capim serogroup viruses, CAPV, JDV and 
MORV, induced a similar level of IFN as rBUNdelNSs2 at approximately 128 rIFN U 
ml-1 - 256 rIFN U ml-1 (Figure 6-6). The remaining Capim serogroup virus, GJAV, 
induced lower levels of biological IFN at approximately 64 rIFN U ml-1 (Figure 6-6). 
GMAV, a member of the Guama serogroup, induced approximately 27 rIFN U ml-1, 
significantly less (p < 0.01) than rBUNdelNSs2. Tete serogroup viruses also induced 
low levels of IFN compared with rBUNdelNSs2, with significant reductions (p < 0.01) 
in BMAV, TETEV and TSUV infections (Figure 6-6).  
 
Activation of the IFN-β promoter in a dual luciferase assay largely mirrored the results 
of the biological IFN assay. Anopheles A serogroup viruses CPEV, LMV, TRMV and 
TUCV induced similar levels of IFN-β promoter activity as rBUNdelNSs2, at 15.3 ± 
3.0 RLU versus 14.9 ± 1.1 RLU (Figure 6-7A). ANAV induced significantly higher 
activity (p < 0.02) than rBUNdelNSs2, at approximately 33.5 RLU, and TCMV 
induced significantly lower levels (p < 0.002) at ≤ 4 RLU (Figure 6-7A). Differences in 
the level of induction by Anopheles A serogroup viruses could not be attributed to 
variation in virus replication as the mean virus titres of corresponding cell supernatants 
were within 0.2 logs (Figure 6-7B).   
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Figure 6-6: Biological Induction of Interferon by Non-NSs Viruses 
Relative levels of biological interferon (IFN) (rIFN U ml-1) produced by A549 cells 48 hours 
post induction with universal interferon (U ml-1) or 24 hours post infection at multiplicity of 
infection 1. rIFN was measured by the level of protection given to A549-NPro cells from 
EMCV infection by 2-fold dilutions of UV-irradiated supernatant from induced and infected 
A549 cells. Mean ± standard deviation of triplicate infections is shown. Samples with 
significant (p < 0.01), ≥ 4-fold, lower induction of IFN are marked with a black asterisk (*). 
 
Virus abbreviations: Bunyamwera virus (BUNV), recombinant BUNV lacking an NSs protein 
(rBUNdelNSs2), Anopheles A virus (ANAV), Caraipe virus (CPEV), Las Maloyas virus 
(LMV), Trombetas virus (TRMV), Tucurui virus (TUCV), Tacaiuma virus (TCMV), 
Anopheles B virus (ANBV), Boraceia virus (BORV), Capim virus (CAPV), Guajara virus 
(GJAV), Juan Diaz virus (JDV), Moriche virus (MORV), Guama virus (GMAV), Palestina 
virus (PLSV), Batama virus (BMAV), Tete virus (TETEV), Matruh virus (MTRV), Tsuruse-
like virus (TSUV) and encephalomyocarditis virus (EMCV). 
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Figure 6-7: Activation of the Interferon-β Promoter in Non-NSs Virus Infection 
A549 cells were transfected with interferon (IFN)-β and CMV promoter reporter plasmids 
pIF∆(-125)lucter and phRL-CMV. Cells were then infected at multiplicity of infection 1. A) At 
18 hours post infection cells were assayed for luciferase activity. Mean ± standard deviation of 
triplicate infections is shown, samples with significantly lower activity than rBUNdelNSs2 are 
marked with asterisks: **, p ≤ 0.002; *, p ≤ 0.02. B) In addition to measuring luciferase 
activity, virus titres of the corresponding cell supernatants were determined by plaque assay on 
Vero E6 cells, mean ± standard deviation are shown. 
 
Virus abbreviations: Bunyamwera virus (BUNV), recombinant BUNV engineered to lack an 
NSs protein (rBUNdelNSs2), Anopheles A virus (ANAV), Caraipe virus (CPEV), Las Maloyas 
virus (LMV), Trombetas virus (TRMV), Tucurui virus (TUCV), Tacaiuma virus (TCMV), 
Anopheles B virus (ANBV), Boraceia virus (BORV), Capim virus (CAPV), Guajara virus 
(GJAV), Juan Diaz virus (JDV), Moriche virus (MORV), Guama virus (GMAV), Palestina 
virus (PLSV), Batama virus (BMAV), Tete virus (TETEV), Matruh virus (MTRV), and 
Tsuruse-like virus (TSUV).  
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Anopheles B serogroup viruses, ANBV and BORV, induced significantly higher levels 
(p < 0.005) of IFN-β promoter activity than rBUNdelNSs2 at 22.1 ± 2.0 RLU. Capim 
and Minatitlan serogroup viruses induced lower levels of activity than rBUNdelNSs2 
and, in contrast to the biological IFN assay, reductions were significant for CAPV, 
GJAV, JDV and MORV (p<0.005) (Figure 6-7A). Guama serogroup virus GMAV 
induced the lowest level of IFN-β promoter activity at only 2.8 ± 1.5 RLU (Figure 6-
7A). Tete serogroup viruses also induced significantly lower (p < 0.02) levels of 
activity and, as with the biological assays, the biggest reductions were seen in BMAV, 
TETE and TSUV infected cells (Figure 6-7A). 
 
Non-NSs viruses with lower activation of the type I IFN system in both the biological 
and IFN-β promoter reporter assay were tested for antagonism of the type I IFN 
response. The IFN-β promoter assay was repeated in the presence of 10 U ml-1 
exogenous IFN, with BUNV and rBUNdelNSs2 as controls. In the presence of 
exogenous IFN BUNV antagonises the IFN response with IFN-β promoter activity of 
only 2.5 ± 0.2 RLU, notably lower than in the uninfected positive control (Figure 6-
3A). In contrast, IFN treated cells infected with rBUNdelNSs2 virus had higher activity 
at 30.7 ± 1.5 RLU, approximately 15 RLU higher than infected cells that had not been 
treated with IFN (Figure 6-8). This also occurred in Tete serogroup infected cells, with 
no evidence of IFN antagonism by BMAV, MTRV, TETEV or TSUV as IFN-β 
promoter activity increased to > 15 RLU in the presence of exogenous IFN (Figure 6-
8A). There was also no evidence of antagonism by Capim, Guama and Minatitlan 
serogroup viruses (Figure 6-8). However, in TCMV infected cells the difference in 
RLU between IFN treated and untreated cells was 5.8 ± 0.5, which was lower than that 
of the IFN PC (Figure 6-8B).  
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Figure 6-8: Antagonism of the Type I Interferon Response in Virus Infection 
A549 cells were transfected with interferon (IFN)-β and CMV promoter reporter plasmids 
pIF∆(-125)lucter and phRL-CMV. Cells were then infected at multiplicity of infection 1 and 2 
hours post infection (h p.i.) 10 U ml-1 universal IFN, or an equal volume of PBS, were added to 
the cell supernatant. A) At 18 h p.i. cells were assayed for luciferase activity. Mean ± standard 
deviation of triplicate infections are shown, RLU (relative light units). B) To facilitate result 
interpretation normalised firefly luciferase values from infected cells not treated with IFN 
(Figure 6-6A) were subtracted from those presented in Figure 6-7A, mean ± standard deviation 
are shown. 
 
Virus abbreviations: Bunyamwera virus (BUNV), recombinant BUNV engineered to lack an 
NSs protein (rBUNdelNSs2), Tacaiuma virus (TCMV), Guajara virus (GJAV), Juan Diaz virus 
(JDV), Guama virus (GMAV), Palestina virus (PLSV), Batama virus (BMAV), Tete virus 
(TETEV), Matruh virus (MTRV) and Tsuruse-like virus (TSUV).  
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6.3.4 Sensitivity of non-NSs viruses to Pre-treatment with IFN 
 
Non-NSs encoding viruses were tested for sensitivity to IFN pre-treatment as described 
in section 6.3.2. rBUNdelNSs2 had a similar sensitivity profile to BUNV with dose-
dependent reduction in virus titre and 2.2 log reduction at 1 000 IFN U ml-1 (Figure 6-
9A). Anopheles A serogroup viruses, excluding TCMV, were sensitive to IFN with 
titres > 1 log lower at 1 000 IFN U ml-1 (Figure 6-9A). TCMV however, was highly 
resistant, with virus titres at 1 000 IFN U ml-1 and 10 000 IFN U ml-1 within 1 log of 
untreated cells (Figure 6-9A). The Anopheles B serogroup viruses, ANBV and BORV, 
were also highly resistant to IFN with titres remaining within 1.5 logs of untreated 
cells, even at 10 000 IFN U ml-1 (Figure 6-9A).  
 
Capim serogroup viruses CAPV, GJAV and JDV were sensitive to IFN with titres ≥ 1.5 
log lower at 1 000 IFN U ml-1 (Figure 6-9B). MORV, also a member of the Capim 
serogroup, and PLSV, a Minatitlan serogroup virus, were more resistant with < 0.7 log 
reduction in virus titres at 1 000 IFN U ml-1 (Figure 6-9B). Guama serogroup virus 
GMAV and Tete serogroup viruses, excluding MTRV, were sensitive to IFN with a ≥ 2 
log drop in virus titres at 1 000 IFN U ml-1. MTRV was slightly more resistant with 
approximately a 1 log drop at 1 000 IFN U ml-1 (Figure 6-9B). To aid result 
interpretation IFN sensitivity and IFN activation data were collated and summarised in 
Table 6-2.  
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Figure 6-9: Virus Growth in Interferon Treated Cells 
Vero E6 cells were pre-treated with universal interferon (IFN) (U ml-1) 24 hours prior to 
infection at multiplicity of infection 1 with the specified viruses. Cell supernatants were 
collected 48 hours post infection and virus titre determined by plaque assay on Vero E6 cells. 
Mean ± range of duplicate experiments is shown. A) Viruses in the Anopheles A and Anopheles 
B serogroups were tested. B) Viruses in the Capim, Guama, Minatitlan and Tete serogroups were 
tested. 
 
Virus abbreviations: Bunyamwera virus (BUNV), recombinant BUNV lacking an NSs protein 
(rBUNdelNSs2), Anopheles A virus (ANAV), Caraipe virus (CPEV), Las Maloyas virus 
(LMV), Trombetas virus (TRMV) and Tucurui virus (TUCV), Tacaiuma virus (TCMV), 
Anopheles B virus (ANBV) and Boraceia virus (BORV), Capim virus (CAPV), Guajara virus 
(GJAV), Juan Diaz virus (JDV), Moriche virus (MORV), Guama virus (GMAV), Palestina 
virus (PLSV), Batama virus (BMAV), Tete virus (TETEV), Matruh virus (MTRV), and 
Tsuruse-like virus (TSUV).   
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Table 6-2: In vitro Interferon Phenotype of Viruses lacking an NSs ORF 
Virus Serogroup NSs ORF 
Induction of 
Biological IFN 
Activation of 
IFN-β Promoter 
Sensitivity 
to IFN 
Antagonism of 
IFN-β Promoter 
BUNV Bunyamwera + - - +++ +++ 
rBUNdelNSs2 - +++ +++ +++ - 
ANAV Anopheles A - ++++ ++++ ++++ N/A 
CPEV Anopheles A - ++ +++ ++ N/A 
LMV Anopheles A - ++ +++ ++ N/A 
TRMV Anopheles A - ++ ++++ ++ N/A 
TUCV Anopheles A - +++ +++ +++ N/A 
TCMV Anopheles A - + + - + 
ANBV Anopheles B - ++++ ++++ - N/A 
BORV Anopheles B - ++++ ++++ + N/A 
CAPV Capim - +++ ++ ++ N/A 
GJAV Capim - ++ ++ ++ N/A 
JDV Capim - +++ ++ ++ - 
MORV Capim - +++ ++ + - 
GMAV Guama - + + ++ - 
PLSV Minatitlan - +++ ++ + - 
TETEV Tete - + + +++ - 
BMAV Tete - + + +++ - 
MTRV Tete - ++ ++ ++ - 
TSUV Tete - + + +++ - 
 
A summary of interferon (IFN) results for viruses predicted to lack an NSs open reading frame 
(ORF). N/A; not available. 
• Induction of biological interferon in virus infection: -, ≤ 10 rIFN U ml-1; +, > 10 ≤ 50 rIFN
   U ml-1; ++, > 50 ≤ 150 rIFN U ml-1; +++, > 150 ≤ 300 rIFN U ml-1; +++, > 300 rIFN U 
   ml-1.  
• Activation of IFN-β promoter during virus infection: -, ≤ 1 RLU; +, 1 - 5 RLU; ++, 5 - 10  
   RLU; +++, 10 - 15 RLU; ++++, >15 RLU.  
• Sensitivity to IFN, lowest concentration IFN for ≥ 1 log reduction in virus titre: +++, 100 
   IFN U ml-1; ++, 1 000 IFN U ml-1; +, 10 000 IFN U ml-1; -, < 1 log reduction at 10 000  
   IFN U ml-1.  
• Antagonism of IFN-β promoter in the presence of exogenous IFN, Figure 6-8B: (-) ≥ 7 
   RLU; +, > 5 ≤ 7 RLU; ++, > 2 ≤ 5 RLU; +++, > 1 ≤ 2; ++++, ≤ 1 RLU. 
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6.4 Discussion 
 
6.4.1 Viruses with an NSs ORF and Interferon 
 
The NSs proteins of pathogenic orthobunyaviruses, including AKAV, BUNV, LACV, 
OROV (Personal communication, Natasha Tilston-Lunel, University of St Andrews) 
and SBV, have been shown to be potent antagonists of the type I IFN system and 
remain the primary virulence factor of orthobunyaviruses (Bridgen et al., 2001; Weber 
et al,. 2002; Blakqori et al., 2007; Ogawa et al., 2007; Barry et al., 2014). In this study 
7 viruses predicted to encode an NSs protein by genome sequencing were studied for 
activation, antagonism, and sensitivity to type I IFN. Bwamba serogroup virus, BWAV, 
mirrored the in vitro behaviour of BUNV, the type species of the genus, inducing 
undetectable levels of biological IFN and below background activation of the IFN-β 
promoter in a reporter assay (Figure 6-1, Figure 6-2). BWAV was also a strong 
antagonist of the IFN-β promoter in the presence of exogenous IFN (Figure 6-3). 
BWAV is widespread in Africa and causes a self-limiting febrile illness with 
exanthema and frequent meningeal involvement that is often misdiagnosed as malaria 
(Smithburn et al., 1941; Smithburn, 1952; Lutwama et al., 2002). Expression of an NSs 
protein with potent anti-IFN activity would agree with our current understanding of 
orthobunyavirus pathogenicity.  
 
Like BWAV, the Nyando serogroup viruses have been isolated from across Africa and 
are associated with a self-limiting febrile illness (Williams et al,. 1965; Digoutte et al., 
1972; Lutwama et al., 1999; Groseth et al,. 2014). In this study Nyando serogroup 
viruses NDV and EREV, were found to induce very low levels of IFN during virus 
infection of A549 cells (Figure 6-1, Figure 6-2). Moreover, expression of the NSs ORF 
in a reporter assay significantly antagonised activation of the IFN-β promoter (Figure 
6-4). Groseth et al. (2012) published the first complete sequences for Bwamba and 
Nyando serogroup viruses and studied the growth of these viruses in a range of 
mosquito (C6/36), mammalian (Vero E6) and bat (Tbu-L1 and RE05) cell lines. 
However, this is the first study confirming IFN antagonism by viruses in the Nyando   
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Figure 6-10: NSs Conservation 
Schematic representation of NSs protein conservation highlighting Bunyamwera virus (BUNV) 
(NC001927), the type species of the genus and the viruses included in this study. Bwamba 
virus (BWAV) and Gamboa virus (GAMV) are representative of all sequenced Bwamba 
serogroup and Gamboa serogroup viruses (n=2, n=6). **, highlights the extended sequence of 
Gamboa serogroup viruses compared with other putative orthobunyavirus NSs proteins. 
Nyando serogroup viruses (n=6) are represented by Nyando virus (NDV) and Eretmapodites 
virus (EREV). Weldona virus (WELV) and M’Poko virus (MPOV) are the only sequenced 
viruses with NSs ORFs in the Tete and Turlock serogroups respectively. Published putative 
NSs protein sequences ≥ 50 amino acids (aa) for all named orthobunyaviruses isolates were 
combined with those obtained during this study. When more than 1 sequence for a named 
isolate was available 1 was selected. A complete list of virus isolates and accession numbers is 
detailed in Appendix 2. Protein sequences were aligned in CLC Genomics Workbench v7.5.1 
(Qiagen) using the MUSCLE algorithm. A dashed box highlights the proposed Med8 
interaction domain (BUNV NSs aa 81 - 93)(Léonard et al., 2006). Non-conserved aa are 
highlighted in red.  
 
 
 
  
MPOV
BWAV **
GAMV  M         L                 xxS                        LxL          IxI                 xPxT
 L          L                 SSS                       FxL          IxI                 
 L         L                  xSS                        LxL          IxI                LPST
NDV  L         L                  SSS                        LxL          IxI                LxST
BUNV  L         L                   SSx                        LxL          IxI                LPST
Conservation 
(%)
0
100
Virus
NSs Protein Alignment (aa)0                                154
WELV  L         L                   SSx                        LxL          IxI                LPSx
 L         L                  SSS                        LxL          IxI                x x x xEREV
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and Bwamba serogroups. The NSs proteins of viruses in the Bwamba and Nyando 
serogroups are 92 aa in length, terminating just 1 aa short of the complete Med8 
interaction domain, and all sequenced isolates contain the highly conserved LxL and 
IxI motifs (Figure 6-10). 
 
The NSs protein of WELV, the only member of the Tete serogroup predicted to encode 
an NSs protein, also contains the highly conserved LxL and IxI motifs and the 
proposed Med8 interaction domain (Figure 6-10). Unfortunately, WELV could not be 
titrated by plaque assay and was therefore omitted from all experiments requiring virus 
titration. However, expression of the WELV NSs ORF in a reporter assay did provide 
evidence that, if expressed, the NSs protein would antagonise the IFN-β promoter 
(Figure 6-4). WELV has not yet been associated with human infection but limited 
prevalence studies in Colorado detected neutralising antibodies in birds and live virus 
in unidentified ceratopogonid midge species (Calisher et al., 1990). It would be of 
interest to determine expression of the predicted NSs ORF during virus replication and 
to contrast the biological characteristics of WELV with those of the non-NSs Tete 
serogroup viruses.  
 
The NSs protein of MPOV, a member of the Turlock serogroup, terminates prior to the 
Med8 interaction domain and contains FxL in place of the conserved LxL motif (Figure 
6-10). MPOV induced higher levels of biological IFN and IFN-β promoter activity than 
BUNV, BWAV, NDV and EREV (Figure 6-1, Figure 6-2). Moreover, the putative 
MPOV NSs protein appeared less active than the other NSs proteins when expressed in 
an IFN-β reporter assay (Figure 6-4). Expression of the NSs ORF in this assay was not 
confirmed as no antibodies were available, and expression levels would need to be 
assessed prior to drawing conclusions about actual NSs activity. To circumvent the lack 
of NSs antibodies, tagged proteins could be made but this was not done due to time 
constraints. Interestingly, of the NSs encoding viruses MPOV showed the greatest 
resistance to pre-treatment with IFN in vitro (Figure 6-8, Table 6-1). This may play a 
compensatory role in virus infection if the NSs protein is unable to completely shut 
down the cellular type I IFN response. 
 
Gamboa serogroup viruses GAMV and SJV induced high levels of biological IFN and 
IFN-β promoter activity during virus infection in vitro (Figure 6-1, Figure 6-2). 
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Moreover, the GAMV NSs ORF expressed under a CMV promoter failed to show any 
activity in a IFN antagonism assay (Figure 6-4). Although expression of NSs in this 
assay was not confirmed as no antibodies targeting GAMV NSs were available, the 
results correspond with experiments utilising infectious virus, as GAMV induced high 
levels of IFN with no antagonism of IFN-β promoter activity (Figure 6-2). It is also of 
note that GAMV and SJV struggled to replicate at low MOI in the IFN-competent 
A549 cell line (Figure 4-7). Interestingly, all sequenced Gamboa viruses contain the 
highly conserved LxL and IxI motifs and at 130-137 aa extend past the Med8 
interaction domain, although there is sequence variation in this region (Figure 6-10). 
There is a high level of conservation in the extended C-terminus, with 6 out of 6 
sequenced isolates encoding a serine-rich sequence that terminates in STGSMEQ 
(Figure 5-2B) (Nunes et al., 2014). To further investigate the NSs ORF of Gamboa 
serogroup viruses, priority should be given to establishing NSs expression during virus 
infection. If expression is confirmed, development of a reverse genetics system would 
greatly facilitate protein function studies, allowing recombinant viruses with NSs 
deletions and substitutions to be made. There are no reported cases of human infections 
caused by Gamboa serogroup viruses. Neutralising antibodies to Calchaqui virus have 
been found in horses although it is unclear if these relate to the Gamboa serogroup 
Calchaqui virus sequenced by Nunes et al. (2014) or the Calchaqui virus reported to 
belong to the Vesicular stomatitis antigen group (Berge, 1975).  
 
 
6.4.2 Viruses without an NSs ORF and Interferon 
 
Naturally occurring non-NSs viruses were first discovered in 2009 (Mohamed et al., 
2009; Mores et al., 2009). These viruses would be predicted to induce high levels of 
IFN, but one, TCMV, induced significantly lower levels of IFN than rBUNdelNSs 
(Mohamed et al., 2009; Mores et al., 2009). Moreover, co-infection assays with TCMV 
and rBUNdelNSs implied an as yet unidentified NSs-independent mechanism of IFN 
antagonism by TCMV (Mohamed et al., 2009). To date, Mohamed et al. (2009) 
remains the only published study investigating activation of the type I IFN response by 
naturally occurring non-NSs viruses. To expand our understanding of non-NSs viruses, 
viruses predicted to lack an NSs ORF from the Anopheles A (n=6), Anopheles B (n=2), 
Capim (n=4), Guama (n=1), Minatitlan (n=1) and Tete (n=4) serogroups were 
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investigated for type I IFN induction and antagonism. Strikingly, 8 viruses were found 
to induce significantly lower levels of biological IFN and IFN-β promoter activity than 
rBUNdelNSs2 during virus infection. These were the Anopheles A serogroup virus 
TCMV, Capim serogroup viruses GJAV and JDV, Guama serogroup virus GMAV, and 
the Tete serogroup viruses BMAV, TETEV, MTRV, and TSUV (Figure 6-6, Figure 6-
7, Table 6-1).  
 
TCMV was the only virus in the Anopheles A and Anopheles B serogroups to induce 
significantly lower levels of biological IFN and IFN-β promoter activity than 
rBUNdelNSs2 (Figure 6-6, Figure 6-7). Moreover, in support of the antagonism 
reported by Mohamed et al. (2009), TCMV antagonised IFN-β promoter activation in 
the presence of exogenous IFN (Figure 6-8). As discussed in Chapter 5, sequence 
analysis revealed TCMV lacks homology to other Anopheles A serogroup viruses, and 
appears to bridge the Anopheles A and Anopheles B serogroups on phylogenetic 
analysis. However, there are no clear genome characteristics that could account for the 
IFN phenotype observed in vitro, as sequence variation among Anopheles A and 
Anopheles B serogroup viruses occurs throughout the genome with no clear region of 
divergence. TCMV circulates in South America and remains the only Anopheles A 
serogroup virus associated with human disease (Calisher et al., 1980). In addition to 
antagonism of the type I IFN system, TCMV was highly resistant in vitro to pre-
treatment with universal IFN (Figure 6-9). Previous studies have also shown that i.p. 
administration of ≤ 100 000 IU ml-1 IFN-α 24 hours before infection failed to protect 
new born mice from fatal infection with TCMV, despite protecting 16/16 mice infected 
with OROV, a pathogenic NSs encoding orthobunyavirus (Livonesi et al., 2007).  
 
In this study resistance to pre-treatment with IFN was also observed for viruses in the 
Anopheles B serogroup (Figure 6-9). Anopheles B serogroup viruses have been 
isolated in South America and BORV has been linked with human infection (Lopes et 
al., 1966; de Souza Lopes and de Abreu Sacchetta, 1974). BORV induced high levels 
of IFN and IFN-β promoter activity during virus infection and resistance to IFN may 
therefore play a key role in virus pathogenicity (Figure 6-6, Figure 6-7, Table 6-2).  
 
Capim and Guama serogroup viruses GJAV, JDV and GMAV induced lower levels of 
biological IFN and IFN-β promoter activity during virus infection than rBUNdelNSs2. 
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However, there was no clear evidence of IFN antagonism in the presence of exogenous 
IFN, suggesting lower induction or evasion of the IFN pathway rather than active 
antagonism (Figure 6-7). Complete genome sequencing revealed viruses in the Capim 
and Guama serogroups contain exceptionally long M and/or S segment UTR sequences 
leading to the hypothesis that these may contribute to the observed IFN phenotype. 
However, other Capim serogroup viruses, CAPV and MORV, induced the same level 
of IFN as rBUNdelNSs2 during virus infection, which suggests that the presence of 
long UTRs in itself does not account for the observed in vitro IFN phenotype of GJAV, 
JDV and GMAV. It may be that RNA sequence and structure in the extended UTRs 
play a role (Davis et al., 2012). Interestingly, of the Capim and Guama serogroup 
viruses only those belonging to the Guama group have been associated with human 
infection (Berge, 1975). GMAV and Catu virus (CATUV) have been isolated from 
sentinel primates and human sera in Brazil and are associated with fever and myalgia in 
man. Antibodies to a third Guama serogroup virus, Bimiti virus, have also been 
detected in human sera in Trinidad (Berge, 1975).  
 
Viruses in the Tete serogroup were also found to induce lower levels of IFN and IFN-β 
promoter activity than rBUNdelNSs2 (Figure 6-6, Figure 6-7, Table 6-2). BMAV, 
TETEV, MTRV and TSUV encode larger N proteins than NSs encoding 
orthobunyaviruses. As discussed in Chapter 5, the additional amino acids align to the 
amino terminal, a region shown through x-ray crystallography of BUNV, SBV, LACV 
and LEAV N proteins to bind RNA (Ariza et al., 2013; Dong et al., 2013a; Dong et al., 
2013b; Reguera et al., 2013). It is hypothesised that the larger N proteins of Tete 
serogroup viruses may bind RNA with differing topology, altering RNP formation 
which may in turn decrease activation of type I IFN by shielding viral RNA from host 
PRRs. This hypothesis is further investigated and discussed in Chapter 7 “Batama 
Virus Reverse Genetics and Interferon Induction”. 
 
 
6.4.4 Concluding Remarks 
 
The NSs proteins from orthobunyavirus, phlebovirus and hantavirus share a common 
function, antagonising the type I IFN response at the transcriptional level (Weber et al., 
2002; Billecocq et al., 2004; Jääskeläinen et al., 2007). This is despite differing coding 
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strategies and large divergence in sequence, with no pan-bunyavirus conserved 
domains. However, the results presented in this chapter may challenge this dogma as 
there was no evidence of IFN antagonism by MPOV or Gamboa serogroup viruses. 
Lack of antagonism by MPOV NSs may be attributed to truncation prior to the 
proposed Med8 interaction. However, the Gamboa serogroup viruses are predicted to 
encode full length NSs proteins with a conserved serine-rich C terminus. To fully 
challenge our current understanding expression of the Gamboa serogroup NSs proteins 
must first be confirmed in virus replication, work could then begin to elucidate their 
role in virus replication. 
 
Characterising activation and antagonism of the type I IFN system by divergent 
orthobunyaviruses also revealed that TCMV is not the only non-NSs orthobunyavirus 
to induce low levels of IFN during virus infection in vitro. Viruses in the Capim, 
Guama and Tete serogroup also showed significantly lower activation of the IFN-β 
promoter. Interestingly, these viruses did not appear to antagonise the type I IFN 
system in the presence of exogenous IFN suggesting a strategy of evasion rather than 
antagonism. TCMV on the other hand did show evidence of antagonism, supporting the 
findings of Mohammed et al. (2009), and highlighting the need for further research into 
NSs-independent mechanisms of IFN antagonism.  
 
 
 
  
 
 
 
 
 
 
 
Chapter 7: Batama Virus Reverse Genetics 
and Interferon Induction 
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7.1: Introduction 
 
The Tete serogroup currently contains 2 virus species, Tete and Batama. The Batama 
virus species contains only 1 named isolate, BMAV, whilst the Tete virus species 
contains BAHV, MTRV, TETEV, TSUV and WELV (Plyusnin et al., 2012). Tete 
serogroup viruses have been isolated from wild and domestic birds although very little 
is known of their ecology (Berge, 1975). WELV, the only Nearctic Tete serogroup 
virus, has been isolated from unidentified pools of biting midges. BAHV and MTRV 
have been isolated from hard bodied ticks in Egypt and Italy (Converse et al., 1974; 
Moussa et al., 1974; Calisher et al., 1990). 
 
Genome sequencing of BMAV, MTRV TETEV, TSUV, and WELV revealed that all, 
except WELV, lacked a full length NSs ORF (Table 5-2). The orthobunyavirus NSs 
protein is a strong antagonist of the type I IFN system and it was therefore surprising 
that BMAV, and other non-NSs Tete serogroup viruses, induced only low levels of IFN 
and IFN-β promoter activity during virus infection in vitro (Figure 6-6, Figure 6-7). 
Moreover, there was no evidence of IFN-β promoter antagonism, leading to the 
hypothesis that Tete serogroup viruses may be low inducers rather than antagonists of 
the type I IFN system.  
 
In addition to the unexpected IFN phenotype a notable feature of non-NSs Tete 
serogroup viruses is the size of their N protein, which at 258 aa is larger than that of 
most other orthobunyaviruses (Table 5-2). Moreover, WELV, the only sequenced Tete 
serogroup virus with a full length NSs ORF, encodes a smaller N protein (248 aa) and 
branches ancestrally to the group on N protein phylogeny (Figure 5-6). This suggests 
that the larger N proteins of non-NSs Tete serogroup viruses, such as BMAV, may 
have evolved over time as loss of the NSs ORF occurred. Investigating the role of the 
larger N protein in virus replication and IFN induction would therefore be of interest. 
 
 
7.2 Aims 
 
The aims of this part of my studies were to further investigate activation of type I IFN 
by Tete serogroup viruses and to determine the role of the virus N protein in this 
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context. This would be facilitated by the development of a reverse genetics system and 
the creation of recombinant viruses containing N protein mutations. These 
investigations were carried out using BMAV, the first Tete serogroup virus with a 
complete genome sequence.  
 
 
7.3 Results 
 
To test for statistical significance the results in this chapter were analysed by one-way 
ANOVA and the Dunnett’s multiple comparison test with either BUNV or 
rBUNdelNSs2 as the control, or by t-test. Unless indicated all p values in this chapter 
refer to this analysis only and not any other form of statistical analysis.  
 
 
7.3.1 Interferon Antagonism by Batama Virus Proteins 
 
In Chapter 6 it was shown that BMAV induced significantly lower levels of IFN than 
other non-NSs viruses yet there was no evidence of IFN antagonism in the presence of 
exogenous IFN (Figure 6-6, Figure 6-7, Figure 6-8). To follow up on this observation, 
the ORFs encoding BMAV N, M and L proteins were cloned into CMV-driven 
expression plasmids and tested using a reporter assay for antagonism of the IFN-β 
promoter (Figure 7-1). Expression plasmids encoding the N and NSs proteins of 
WELV, a Tete serogroup virus with a full length NSs ORF, were included as controls. 
The WELV NSs expression plasmid significantly (p < 0.01) inhibited IFN-β promoter 
activity in a dose-dependent manner, with approximately a 2.3-fold reduction at 10 ng, 
5.2-fold reduction at 50 ng, and 15.4-fold reduction at 250 ng (Figure 7-1). However, 
there was no clear evidence of antagonism by the expression plasmids encoding WELV 
N protein or BMAV N, M or L proteins (Figure 7-1). Although there was a small drop 
in IFN-β promoter activity at high concentrations (≥ 250 ng), values remained within 2-
folds of the positive control at ≥ 130 RLU (Figure 7-1).  
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Figure 7-1: Interferon-β Promoter Antagonism by Batama Virus Proteins 
293T cells were co-transfected with: Interferon (IFN)-β firefly and CMV Renilla reporter 
plasmids, pIF∆(-125)lucter and phRL-CMV; pCAGGs-2CARD to stimulate the type I IFN 
pathway; pCMV plasmids encoding the virus proteins; and pCMV-empty to normalise plasmid 
DNA concentrations across all reactions. Eighteen hours post transfection cells were assayed 
for luciferase activity. The NSs and N ORFs of Weldona virus (WELV), and the N, M and L 
ORFs of Batama virus (BMAV) were tested. The positive control (PC) contains IFN-β and 
CMV promoter reporter plasmids, pCAGGs-2CARD to stimulate type I IFN pathway and 
pCMV-empty in place of an NSs expression plasmid. The negative control (NC) contains IFN-
β and CMV promoter reporter plasmids and pCMV-empty only, with no NSs expression 
plasmid or IFN induction plasmid, pCAGGs-2CARD. The mean ± standard deviation of 
triplicate transfections is shown. Significance (p < 0.01) is indicated by a black asterisk (*). 
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7.3.2 Batama Virus N Protein Structural Model 
 
BMAV and the other non-NSs Tete serogroup viruses, TETEV, MTRV, and TSUV, 
encode N proteins of 258 aa. As discussed in Chapter 5.3.1, N protein alignments show 
the additional aa form a 22 aa - 25 aa extension at the N terminus and a short, 3 aa, 
extension at the C terminus relative to other orthobunyaviruses (Figure 7-2A). A 
structural model of BMAV N protein with high coverage (88%) and confidence (100%) 
was generated by Phyre2 using the published crystal structure of Bunyamwera N 
protein (Figure 7-2B) (Kelley and Sternberg, 2009; Li et al., 2013a). Overlaying the 
BMAV N protein structural model on the crystal structure of SBV N protein bound to 
RNA (PDB 4JNG) emphasises the high level of homology that BMAV N protein is 
predicted to share with other orthobunyavirus N proteins (Figure 7-2B) (Dong, et al. 
2013a). However, the model omits the first 25 aa of the BMAV N protein, beginning 
only at I26 (Figure 7-2B). The first 25 aa of BMAV N protein are also omitted in 
structural models based on the solved crystal structures of BUNV, LACV and LEAV N 
proteins (data not shown). Interestingly, the N and C terminal aa of BMAV that are 
excluded from structural models are predicted to be highly disordered, whereas the rest 
of the protein displays a similar disorder prediction to BUNV N protein (Figure 7-2C). 
 
To fully elucidate the role of the larger N protein in virus replication and to direct 
future mutagenesis studies structural determination of the full length protein, including 
the highly disordered termini, is required. To that end the BMAV N protein ORF was 
cloned into the expression vector pEHISTEV and sent to Professor Changjiang Dong, 
University of East Anglia for structural studies. Unfortunately, due to changes in 
research staff, commencement of structural studies was delayed and results are not yet 
available.  
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Figure 7-2: Structural Modelling of Batama Virus N Protein 
A) Scaled schematic of N protein amino acid (aa) alignment showing N terminal and C 
terminal extensions of viruses in the Tete, Anopheles A and Anopheles B serogroups. (*) Tete 
serogroup viruses, except Weldona virus (WELV), which is shown separately as it encodes a 
smaller protein at 248 aa, are represented by a single bar, as are viruses from the Anopheles A 
and Anopheles B serogroups. (**) Viruses from the Bunyamwera, Bwamba, California, Capim, 
Gamboa Group C, Guama, Minatitlan, Nyando, Simbu and Turlock serogroups with 231 – 239 
aa N proteins align together and are shown as single bar labelled Misc serogroups. B) Phyre2 
model of Batama virus (BMAV) N protein based on Bunyamwera virus (BUNV) N protein 
(PDB 4IJS, chain B) aligned to the RNA-bound Schmallenberg virus (SBV) N protein (PDB 
4JNG) in PyMOL, Molecular Graphics System, Version 1.7.4 Schrödinger, LLC (Kelley and 
Sternberg, 2009). C) Disorder predictions of BMAV, BUNV (NC001927) and SBV 
(JX853181) by Dismeta (Huang et al., 2014). 
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7.3.3 Batama Virus Reverse Genetics 
 
Viral genome segments were amplified by RT-PCR on virion RNA and cloned, in the 
antigenomic sense, into the pTVT7 backbone (Figure 7-3A). The N and L protein 
ORFs were also cloned into pTM-1 expression plasmids to allow both the 3 and 5 
plasmid rescue systems to be tested. Plasmids were co-transfected into subconfluent 
BSRT-7 cells and clarified culture supernatant collected at > 80% CPE or 7 days post 
transfection (Figure 7-3B). Rescue supernatant was then screened for infectious 
particles by plaque assay on Vero E6 cells (Figure 7-3C). The 3 plasmid rescue system 
was robust and recombinant wild type BMAV (rBMAV) was rescued from 8 out of 8 
independent experiments, with variations in plasmid concentration (500 ng - 1000 ng), 
cell density (1 x 105 cells ml-1 - 5 x 105 cells ml-1) and transfection reagent (LT1, 
Lipofectamine 2000). Virus titres in rBMAV p1 stocks were comparable to wild type 
BMAV, referred to simply as BMAV from this point forward, at > 1 x 107 p.f.u ml-1. 
Plaque morphology of rBMAV and BMAV on Vero E6 cells was also comparable, at 2 
mm - 4 mm in diameter, with complete clearing of the cell monolayer and blurred 
edges (Figure 7-3C). However, it should be noted that the 5 plasmid rescue consistently 
failed, with no evidence of CPE and no plaques on virus titration. Moreover, both the 3 
and 5 plasmid rescue systems failed when Huh7-Lunet T7 cells were used in place of 
BSRT-7 cells (Figure 7-3B). 
 
Once the reverse genetics system had been established a panel of recombinant viruses 
was made by QuickChange® PCR and excision PCR (Figure 7-4, Table 7-1). The 
recombinant viruses contained mutations in the N protein N and C termini to allow the 
role of the larger N protein in virus replication to be studied. As the N protein termini 
of orthobunyavirus N proteins are known to be involved in RNA binding and N-N 
protein interactions a number of approaches were tested. These included the 
introduction of point mutations, deletions at conserved sites, and bulk aa deletions 
coupled with aa substitution to mirror the terminal aa sequence of BUNV and WELV N 
proteins (Figure 7-4).  
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Figure 7-3: Batama Virus Rescue System 
A) Batama virus (BMAV) genome segments were amplified by RT-PCR on virion RNA. PCR 
products were visualised by gel electrophoresis and gel-purified for restriction free cloning into 
the pTVT7 plasmid. B) pTVT7 plasmids encoding BMAV S, M and L cRNA were co-
transfected into BSRT-7 and Huh7-Lunet T7 cells. Cytopathic effect (CPE) 7 days post 
transfection is shown, scale bars represent 1 000 µm. No L control, pTVT7-BMAVS and 
pTVT7-BMAVM only; recombinant BMAV (rBMAV), pTVT7-BMAVS, pTVT7-BMAVM 
and pTVT7-BMAVL. C) Plaque morphology of rescue supernatant (Rescue), Vero E6 passage 
1 (p1) and wild type BMAV (BMAV) on Vero E6 cells 7 days post infection with a 0.6% (w/v) 
Avicel overlay. 
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Figure 7-4: Batama Virus N Protein Constructs for Virus Rescue 
Scaled schematic of cRNA S segment constructs for virus rescue. Wild type (wt) Batama virus 
(BMAV), Weldona virus (WELV) and Bunyamwera virus (BUNV, NC001927) S segments are 
shown for comparison. Recombinant viruses are grouped into those with BUNV or WELV N 
protein termini (Switch), and those with point mutations (Point). A complete list of 
recombinant viruses is detailed in Table 7-1 and S segment cRNA nucleotide sequences are in 
Appendix 5. 
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Table 7-1: Recombinant Batama Virus Titres 
 
The virus titres (p.f.u ml-1) of recombinant Batama viruses (rBMAV) are listed. N protein 
mutations include: point mutations, amino acid substitutions and deletions (∆), which are 
numbered by the amino acid position in the wild type N protein; termini switched, recombinant 
viruses with N protein termini modified to match those of Bunyamwera virus (BUNV) or 
Weldona virus (WELV). Virus titre was determined by plaque assay on Vero E6 cells, (-) no 
plaques at 6 or 14 days post infection. 
  
rBMAV N protein Mutation Rescue Titre Working Stock Titre 
rBMAV - 2.75 x 106 1.70 x 107 
Point Mutations 
rBMAVn6A R6A 1.10 x 106 8.50 x 107 
rBMAVn12A S12A 6.00 x 104 3.50 x 107 
rBMAVn18A S18A 5.00 x 104 8.50 x 107 
rBMAVn24A D24A 5.00 x 105 5.50 x 107 
rBMAVn2aA R6A.S12A 3.85 x 106 9.50 x 106 
rBMAVn2bA R6A.S18A 2.73 x 106 7.00 x 107 
rBMAVn2cA R6A.D24A 1.10 x 107 5.95 x 107 
rBMAVn2dA S12A.S18A 5.00 x 106 1.05 x 108 
rBMAVn2eA S12A.D24A 6.50 x 106 3.85 x 107 
rBMAVn2fA S18A.D24A 9.00 x 105  6.00 x 107 
rBMAVn3aA R6A.S12A.S18A 8.00 x 106 3.73 x 107 
rBMAVn3bA R6A.S12A.D24A 7.50 x 106 1.60 x 107 
rBMAVn3cA R6A.S18A.D24A 2.30 x 107 3.50 x 107 
rBMAVn3dA S12A.S18A.D24A 2.80 x 106 9.50 x 107 
rBMAVn4xA R6A.S12A.S18A.D24A 8.00 x 106 6.50 x 107 
rBMAVn11∆ P11∆ 5.50 x 104 5.50 x 107 
rBMAVn13∆ I13∆ 6.00 x 102 - 
rBMAVn19∆ A19∆ 2.10 x 105 9.50 x 107 
rBMAVn24∆ D24∆ 9.75 x 103 3.50 x 107 
rBMAVn2a∆ P11∆.I13∆ - - 
rBMAVn2b∆ P11∆.A19∆ 1.80 x 106 5.30 x 107 
rBMAVn2c∆ A19∆.D24∆ 2.75 x 106 6.20 x 107 
rBMAVn2d∆ I13∆.A19∆ - - 
rBMAVn2e∆ I13∆.D24∆ - - 
rBMAVn2f∆ P11∆.D24∆ 2.15 x 106 5.45 x 107 
rBMAVn3a∆ P11∆.I13∆.A19∆ - - 
rBMAVn3b∆ P11∆.I13∆.D24∆ - - 
rBMAVn3c∆ P11∆.A19∆.D24∆ 1.55 x 106 3.00 x 107 
rBMAVn3d∆ I13∆.A19∆.D24∆ - - 
rBMAVn4x∆ P11∆.I13∆.A19∆.D24∆ - - 
Termini Switched 
rBMAVBu25N BUNV N terminal - - 
rBMAVBu29N BUNV N and C termini - - 
rBMAVWelN WELV N and C termini - - 
rBMAVWelUN 
WELV N and C termini and 
UTRs 
- - 
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Firstly, recombinant ‘switch’ viruses with large mutations in the N protein termini, and 
UTRs for rBMAVWelUN, were tested (Figure 7-4, Table 7-1). All ‘switch’ 
recombinant virus rescues failed, with no CPE at 7 days post transfection and no 
plaques at 6 or 14 d p.i. (data not shown).  
 
Virus rescues with point mutants were then tested (Figure 7-4, Table 7-1). The rescue 
supernatant from rBMAVn13∆, containing a virus in which N protein aa I13 had been 
deleted, produced small pinprick plaques that diluted out on titration (Figure 7-5A). 
However, p1 and p2 stocks were negative by plaque assay (Figure 7-5B). This 
happened repeatedly, with separate plasmid stocks, and increasing the length of 
incubation to 14 days did not notably increase plaque size or improve visualisation. 
Passaging rescue supernatant on BSRT-7 cells, instead of Vero E6 cells, also failed to 
propagate rBMAVn13Δ further (data not shown).  
 
 
A) 
 
 
 
 
 
 
 
B)  
 
 
 
 
 
Figure 7-5: rBMAVn13∆ Plaque Morphology 
A) rBMAVn13Δ rescue supernatant titrated on Vero E6 cells with a 0.6% (w/v) Avicel overlay, 
7 days post infection. B) rBMAVn13Δ passage 1 supernatant titrated on Vero E6 cells with a 
0.6% (w/v) Avicel overlay, 10 days post infection. Box 1 and 2 show an enlarged images of 
selected regions, white arrows highlight pin-prick clearings in the cell monolayer.  
1        1 
2                                     2 
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All other recombinant viruses with ≤ 4 point mutations showed strong CPE 6 – 7 days 
post transfection, formed clear plaques on virus titration and p1 stocks had titres ≥ 9.5 x 
106 p.f.u ml-1 (Table 7-1, Figure 7-6, Figure 7-7).  
 
Plaque morphology of recombinant viruses with alanine substitutions varied. 
rBMAVn2fA and rBMAVn3dA formed plaques comparable to rBMAV, whilst 
rBMAVn24A, rBMAVn3bA, rBMAVn3cA and rBMAVn4xA formed clear plaques 
that were slightly reduced in size at 1.5 mm - 3 mm (Figure 7-6). rBMAVn6A, 
rBMAVn12A, rBMAVn18A, rBMAVn2bA, rBMAVn2dA, rBMAVn2eA and 
rBMAVn3aA formed plaques 1 mm - 2 mm, with indistinct serrated edges. 
rBMAVn2aA formed the smallest plaques at ≤ 1 mm with incomplete clearing of the 
cell monolayer. 
 
Recombinant viruses with point deletions also showed variations in plaque 
morphology. rBMAVn3c∆ formed large clear diffuse plaques whilst rVMAVn2b∆ 
formed small sharp plaques approximately 1.5 mm in size. (Figure 7-7). The remaining 
recombinant viruses with point deletions, rBMAVn11∆, rBMAVn19∆, rBMAVn24∆, 
rBMAVn2c∆, and rBMAVn2f∆, formed plaques 1.5 mm - 3 mm in diameter (Figure 7-
7).  
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Figure 7-6: Plaque Morphology of Recombinant Viruses with Alanine 
Substitutions 
Plaque morphology of passage 1 recombinant Batama viruses (BMAV) with alanine 
substitutions are shown. Viruses were titrated on Vero E6 cells with a 0.6% (w/v) Avicel 
overlay and fixed and stained 7 days post infection. Recombinant virus names are given, 
descriptions of mutations are listed in Table 7-1, and S segment sequences are included in 
Appendix 5.  
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Figure 7-7: Plaque Morphology of Recombinant Viruses with Point Deletions 
Plaque morphology of passage 1 recombinant Batama viruses (BMAV) with point deletions are 
shown. Viruses were titrated on Vero E6 cells with a 0.6% (w/v) Avicel overlay and fixed and 
stained 7 days post infection. Recombinant virus names are given, descriptions of mutations are 
listed in Table 7-1, and complete S segment sequences are included in Appendix 5. 
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7.3.5 Growth Kinetics of Recombinant Batama Viruses 
 
To further characterise the recombinant viruses, growth kinetics in IFN-competent 
A549 and IFN incompetent Vero E6 cell lines were determined. rBMAV displayed 
similar growth kinetics as BMAV in both A549 and Vero E6 cells, growing to 6.5 x 104 
p.f.u ml-1 and 8.5 x 106 p.f.u ml-1 at 48 h p.i. (Figure 7-8).  
 
 
 
 
 
Figure 7-8: Growth Kinetics of Wild Type Batama Viruses 
A549 and Vero E6 cell lines were infected at multiplicity of infection 0.01 with wild type 
Batama virus (BMAV) and recombinant wild type BMAV (rBMAV). Clarified culture 
supernatants were harvested at specified hours (h) post infection and virus titre determined by 
plaque assay on Vero E6 cells.  
 
 
 
At early time points recombinant viruses with single point mutations demonstrated 
delayed growth, with lower titres than rBMAV in both A549 and Vero E6 cells. 
However, at 48 h p.i. titres for all viruses, except rBMAVn6A and rBMAVn11∆, were 
within 0.5 log of rBMAV in both Vero E6 and A549 cells (Figure 7-9). At 48 h p.i 
rBMAVn6A and rBMAVn11∆ virus titres were > 1 log lower than rBMAV in Vero E6 
cells, at 5.0 x 105 p.f.u ml-1 and 2.1 x 105 p.f.u ml-1, respectively. At 48 h p.i. in A549 
cells rBMAVn6A and rBMAVn11∆ virus titres were 0.5 log lower than rBMAV titres 
(Figure 7-9).  
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Figure 7-9: Growth Kinetics of Recombinant Viruses with Single Point Mutations 
A549 and Vero E6 cell lines were infected at multiplicity of infection 0.01. Clarified culture 
supernatants were harvested at specified hours (h) post infection and virus titre determined by 
plaque assay on Vero E6 cells. Descriptions of recombinant viruses are listed in Table 7-1. 
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Recombinant viruses with 2 alanine substitutions generally exhibited greater 
attenuation in virus growth than single point mutants (Figure 7-10, Figure 7-11). 
rBMAVn2aA and rBMAVn2fA showed the largest reductions, with a > 1 log decrease 
in both Vero E6 and A549 cells at 48 h p.i. compared with rBMAV (Figure 7-10). 
Whereas rBMAVn2cA and rBMAVn2dA had lower titres in both Vero E6 and A549 
cells at early time points, at 48 h p.i. only titres in A549 cells remained ≥ 0.5 log lower 
than rBMAV (Figure 7-10). rBMAVn2bA and rBMAVn2eA virus titres were only 
slightly suppressed at early time points and equalled or exceeded titres of rBMAV in 
Vero E6 cells at 48 h p.i., although titres remained approximately 0.4 log lower in 
A549 cells at 48 h p.i. (Figure 7-10). 
 
Recombinant viruses with 3 or 4 alanine substitutions, excluding rBMAVn3cA, 
showed evidence of growth attenuation with lower titres in Vero E6 and A549 cells < 
48 h p.i. (Figure 7-11). rBMAVn3aA had the greatest attenuation with a 1.4 log 
reduction in virus titre in A549 cells at 48 h p.i. At early time points (< 48 h p.i.) in 
Vero E6 cells rBMAVn3aA virus titre was also > 1 log lower than rBMAV (Figure 7-
11). rBMAVn3bA also showed evidence of attenuation with a ≥ 1 log drop in virus titre 
at early time points in both Vero E6 and A549 cells and a 0.7 log reduction in A549 
cells at 48 h p.i. (Figure 7-11). rBMAVn3dA and rBMAVn4xA had evidence of 
attenuation early in infection, although at 48 h p.i virus titres were within 0.5 log of 
rBMAV in both Vero E6 and A549 cells (Figure 7-11).  
 
Interestingly, recombinant viruses with 2 and 3 point deletions had comparable titres to 
rBMAV in Vero E6 cells at 48 h p.i. At early time points (< 48 h p.i.) rBMAVn2b∆, 
rBMAVn2f∆ and rBMAVn3c∆ showed attenuation with ≥ 1 log reduction in virus titre 
(Figure 7-12). In A549 cells only rBMAVn2f∆, which contains deletions at P11 and 
D24, showed reduced growth at 48 h p.i. with a 0.9 log reduction in virus titre 
compared with rBMAV, although other deletant viruses showed attenuation at earlier 
time points (Figure 7-12). 
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Figure 7-10: Growth Kinetics of Recombinant Viruses with Double Alanine 
Substitutions 
A549 and Vero E6 cell lines were infected at multiplicity of infection 0.01. Clarified culture 
supernatants were harvested at specified hours (h) post infection and virus titre determined by 
plaque assay on Vero E6 cells. Descriptions of recombinant viruses are listed in Table 7-1. 
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Figure 7-11: Growth Kinetics of Recombinant Viruses with Triple and Quadruple 
Alanine Substitutions 
A549 and Vero E6 cell lines were infected at multiplicity of infection 0.01. Clarified culture 
supernatants were harvested at specified hours post infection and virus titre determined by 
plaque assay on Vero E6 cells. Descriptions of recombinant viruses are listed in Table 7-1.   
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Figure 7-12: Growth Kinetics of Recombinant Viruses with Multiple Point 
Deletions 
A549 and Vero E6 cell lines were infected at multiplicity of infection 0.01. Clarified culture 
supernatants were harvested at specified hours (h) post infection and virus titre determined by 
plaque assay on Vero E6 cells. Descriptions of recombinant viruses are listed in Table 7-1. 
  
rBMAVn2cdel
0 20 40 60
 1
 2
 3
 4
 5
 6
 7
 8
Time Post Infection (h)
Vi
ru
s 
Ti
tr
e 
(L
og
10
 p
.f.
u 
m
l-1
)  
rBMAVn2bdel
0 20 40 60
 1
 2
 3
 4
 5
 6
 7
 8
Time Post Infection (h)
Vi
ru
s 
Ti
tr
e 
(L
og
10
 p
.f.
u 
m
l-1
)  
rBMAVn2fdel
0 20 40 60
 1
 2
 3
 4
 5
 6
 7
 8
Time Post Infection (h)
Vi
ru
s 
Ti
tr
e 
(L
og
10
 p
.f.
u 
m
l-1
)  
rBMAVn3cdel
0 20 40 60
 1
 2
 3
 4
 5
 6
 7
 8
Time Post Infection (h)
Vi
ru
s 
Ti
tr
e 
(L
og
10
 p
.f.
u 
m
l-1
)  
Wild type rBMAV rBMAV with point deletions 
  
  
Δ         Δ 
Δ         Δ 
7: Batama Virus Reverse Genetics and Interferon Induction 194	
 
7.3.6 Interferon Induction by Recombinant Batama Viruses 
 
Recombinant viruses were tested for the induction of biological IFN and the IFN-β 
promoter during virus infection of A549 cells. The level of biological IFN and IFN-β 
promoter activity induced by rBMAV infection was comparable to BMAV, at 
approximately 16 rIFN U ml-1 and 5.4 RLU respectively (Figure 7-13).  
 
Recombinant viruses with N protein mutations induced higher levels of biological IFN 
than rBMAV and BMAV in vitro (Figure 7-13A). The largest rise in IFN production (> 
4-fold) occurred in rBMAVn2aA, rBMAVn3aA and all recombinants with ≥ 2 point 
deletions (Figure 7-13A). In agreement with the biological IFN assay rBMAVn2aA and 
rBMAVn3aA induced high levels of IFN-β promoter activity, ≥ 13.5 RLU (Figure 7-
13B). The only other recombinant viruses with higher activity were rBMAVn3cA, 
rBMAVn4xA, and 2 deletant viruses rBMAVn24∆ and rBMAVn2f∆. Interestingly 
rBMAVn2f∆ induced approximately 18.7 RLU, which was higher than rBUNdelNSs2 
which induced only 17.2 RLU (Figure 7-13B). 
 
To aid interpretation of results plaque size, growth kinetics in A549 cells and induction 
of biological IFN and IFN-β promoter activity have been scored relative to rBMAV 
and summarised in Table 7-2. 
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Figure 7-13: Interferon Induction by Recombinant Batama Viruses 
Descriptions of recombinant viruses are listed in Table 7-1. A) Relative levels of biological 
interferon (rIFN U ml-1) produced by A549 cells 48 hours post induction with universal IFN (U 
ml-1) or 48 hours post infection (h p.i.) at multiplicity of infection (MOI) 1. Mean ± standard 
deviation of triplicate experiments is shown. B) A549 cells were co-transfected with IFN-β 
firefly and CMV Renilla reporter plasmids pIF∆(-125)lucter and phRL-CMV, respectively, and 
infected at MOI 1. At 18 h p.i. the cells were assayed for luciferase activity (relative light units, 
RLU). Mean ± standard deviation of triplicate experiments is shown.  
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Table 7-2: Biological Characteristics of Recombinant Batama Viruses 
rBMAV Plaque Size in Vero E6 cells 
Reduced Titres  
in A549 cells 
Biological IFN 
Production 
IFN-β Promoter 
Activity 
rBMAV 2 – 4 mm 1.25 x 104 p.f.u ml-1 16 rIFN U ml-1 5.4 RLU 
rBMAVn6A ++ + + - 
rBMAVn12A ++ + + - 
rBMAVn18A ++ + + ++ 
rBMAVn24A + - + ++ 
rBMAVn2aA +++ +++ ++ ++ 
rBMAVn2bA +++ + + + 
rBMAVn2cA ++ +++ + - 
rBMAVn2dA ++ +++ + + 
rBMAVn2eA +/++ + ++ ++ 
rBMAVn2fA - ++ ++ ++ 
rBMAVn3aA + +++ + ++ 
rBMAVn3bA + ++ ++ + 
rBMAVn3cA + - +++ ++ 
rBMAVn3dA - - + ++ 
rBMAVn4xA + ++ ++ +++ 
rBMAVn11∆ + ++ ++ ++ 
rBMAVn19∆ + - + + 
rBMAVn24∆ + - ++ ++ 
rBMAVn2b∆ ++ ++ +++ ++ 
rBMAVn2c∆ - ++ +++ ++ 
rBMAVn2f∆ + +++ +++ +++ 
rBMAVn3c∆ - ++ +++ + 
 
• Plaque morphology of passage 1 isolates on Vero E6 cells: -, comparable to rBMAV;  
  2 mm – 4 mm; +, 2 mm – 3 mm; ++, 1 mm – 2 mm; +++, ≤ 1 mm.  
• Virus titres in A549 cells 18 hours post infection, multiplicity of infection 0.01, compared  
   with rBMAV: -, ± 0.5 log; +, 0.5 – 0.75 log lower; ++, 0.75 -1 log lower; +++, > 1 log lower.  
• Induction of biological IFN during virus infection compared with rBMAV: -, < 2-fold  
   difference; +, 2-fold higher; ++, 4-fold higher; +++, 8-fold higher.  
• IFN-β promoter activity, relative light units (RLU): -, ≤ 8 RLU; +, > 8 RLU; ++, > 10 RLU;  
   +++, > 15 RLU. 
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7.4 Discussion 
 
Bunyavirus N proteins play a critical role in virus replication encapsidating nascent 
cRNA and vRNA to form the RNP, which is the template for genome transcription and 
replication, and interacting with virus glycoproteins and the viral polymerase (Elliott, 
2014). The crystal structure of orthobunyavirus N proteins from viruses in the 
Bunyamwera, Simbu and California serogroups have been determined both in the 
presence and absence of RNA (Ariza et al., 2013; Dong et al., 2013a; Dong et al., 
2013b; Niu et al., 2013; Reguera et al., 2013). Strikingly, despite low sequence identity 
(39.7% - 43.2% aa identity) structural confirmation is highly conserved with the 
presence of a unique fold that has not been seen in the N proteins of other negative 
sense viruses (Li et al., 2013a). In the presence of RNA the N protein assembles into 
tetramers with RNA binding occurring within the positively charged inner ring (Ariza 
et al., 2013; Dong et al., 2013a; Dong, et al., 2013b; Niu et al., 2013; Reguera et al., 
2013). Oligomerisation of the tetramer occurs via protruding N and C terminal arms; 
the C terminal arm binds the hydrophobic cavity in the neighbouring N molecule, 
whilst the N terminal arm extends away from the inner ring to interact with the adjacent 
N monomer, stabilising the tetramer and shielding viral RNA. Access to viral RNA for 
virus replication is then thought to occur via a hinge like mechanism, with assembly of 
the initiation complex triggering further release of viral RNA (Ariza et al., 2013; Dong 
et al., 2013a; Dong et al., 2013b; Niu et al., 2013; Reguera et al., 2013). Given the 
critical role the N terminal arm plays in N-N oligomerisation and RNA binding it was 
hypothesised that the larger N proteins found in Tete serogroup viruses may possess a 
novel mechanism of RNA binding, and possibly N-N oligomerisation, as the additional 
amino acids align to the N-terminal arm of the protein (Figure 7-2A, Figure 7-2B). 
 
 
7.4.1 Structural Modelling of Batama Virus N Protein 
 
BMAV N protein shares ≤ 35% aa sequence identity with the N proteins of non-Tete 
serogroup orthobunyaviruses. Despite low sequence identity a structural model with 
high confidence and high homology to other orthobunyavirus N proteins was generated 
(Figure 7-2B). However, the model does not cover the first 25 aa of BMAV N protein. 
The N terminal arm of orthobunyavirus N proteins has been shown to be disordered in 
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RNA-free solutions; however, upon the addition of RNA N proteins oligomerise and 
the previously disordered N terminal arm interacts with RNA and the neighbouring N 
protomer to form an ordered structure that stabilises the oligomer and shields RNA 
from the external environment. The N terminal arm of Tete serogroup N proteins are 
predicted to be highly disordered and it would therefore be of great interest to 
determine the role of these aa in RNA binding and RNP formation (Figure 7-2C). To 
this end the BMAV N protein ORF was cloned into the pEHISTEV expression vector 
for structural studies by Professor Changjiang Dong at The University of East Anglia, 
UK, whilst a reverse genetics system was developed to allow functional studies of 
recombinant viruses with mutations targeting the N terminal arm of the N protein. 
 
 
7.4.2 Batama virus Reverse Genetics and Recombinant Virus Rescue 
 
Utilising the complete genome sequence of BMAV, obtained in the course of my 
studies, a 3 plasmid reverse genetics system was successfully established. However, 
recombinant viruses with large deletions in the N and C terminal arms could not be 
rescued. This is perhaps not surprising given the crucial role these domains play in 
RNP formation, although rescue of a recombinant BUNV encoding an additional 10 aa 
at the C terminal arm (BUNV ts19) has been reported (Ariza et al., 2013).  
 
The only other recombinant virus in this study that could not be propagated was 
rBMAVn13Δ, which contained a single point deletion at I13. I13 is conserved within 
sequenced Tete serogroup viruses, namely BMAV, TETEV, MTRV, TSUV and 
WELV, although it is not present in I612045 virus. As discussed in Chapter 5, the 
unclassified, I612045 virus shares high sequence identity to Tete serogroup viruses and 
falls within the Tete serogroup clade on phylogenetic analysis (Figure 5-6). 
Determining the structure of BMAV N protein may shed light on the critical role I13 
has in virus replication. Eifan et al., (2009) carried out targeted mutagenesis of 
conserved aa in BUNV N protein and were unable to rescue a virus containing a F17A 
point mutation. Structural studies subsequently mapped F17 to the RNA binding 
groove and it is hypothesised that mutating this residue would decrease RNA binding 
affinity (Ariza et al. 2013). Interestingly recombinant viruses which contained single 
point deletions A19 and D24, which are conserved in all Tete serogroup viruses and 
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I612045, showed little attenuation in either plaque morphology or growth kinetics. 
Thus, the conservation of single amino acids does not always correlate with a critical 
role in virus replication in vitro. 
 
 
7.4.3 Recombinant Viruses Growth Kinetics and Plaque Morphology 
 
All rescued recombinant viruses, at p1, had comparable titres to BMAV and rBMAV at 
≥ 9.5 x 106 p.f.u ml-1 (Table 7-1). However, the titres of rescue supernatant for 
rBMAVn12A, rBMAVn18A, rBMAVn24A, rBMAVn11Δ, rBMAVn19Δ and 
rBMAVn24Δ were ≤ 5.0 x 105 p.f.u ml-1, with p1 titres increasing by > 2 logs. In 
comparison, the virus titre of all other recombinant viruses increased by only 1 log 
between rescue supernatants and p1 (Table 7-1). In this study only the N protein ORF 
of p1 recombinant viruses was confirmed by sequencing and mutations in the UTRs, M 
or L segments will not have been detected. It would therefore be prudent to carry out 
complete genome sequencing of the recombinant viruses to ensure that observed 
phenotypes are due to the intended mutations only and not mutations acquired during 
virus replication, especially in viruses that underwent a large rise in virus titre in 1 
passage.  
 
Recombinant viruses generally showed attenuation in plaque morphology with respect 
to BMAV and rBMAV, with smaller or more opaque plaques than wild type virus 
(Figure 7-6, Figure 7-7). The exception, however, was rBMAVn3cΔ which formed 
large clear plaques that were bigger than those of BMAV or rBMAV (Figure 7-7). 
rBMAVn3cΔ contains 3 point deletions, P11, A19 and D24, whilst recombinant viruses 
with only 1 or 2 of these mutations formed smaller slightly opaque plaques. Plaque 
morphology of recombinant viruses with multiple point mutations can therefore not be 
predicted by the behaviour of recombinant viruses containing the corresponding single 
point mutations. Plaque size also failed to correlate with virus titre as although 
rBMAVn2aA formed the smallest plaques at ≤ 1 mm in size and had a virus titre of 9.5 
x 106 p.f.u ml-1, and rBMAVn3cΔ, which formed the largest plaques  had a titre of 3.0 x 
107 p.f.u ml-1, rBMAVn2dA, which formed plaques < 2 mm in size had a titre of 1.05 x 
108 p.f.u ml-1.  
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Additionally, some recombinant viruses gave mixed plaque morphology (e.g. 
rBMAVn2fΔ), a phenomenon that has been previously reported in the literature (Figure 
7-7). Eifan et al (2009) rescued a panel of recombinant Bunyamwera viruses with N 
protein point mutations, and plaques of mixed size were repeatedly found on virus 
titration despite plaque purification. It was postulated that mutations in BUNV N 
protein may influence polymerase fidelity. This warrants further investigation, and 
complete genome sequencing of virus inoculum and isolated plaques over virus 
passage would help address this hypothesis. 
 
Looking in more detail at the growth kinetics of recombinant viruses in Vero E6 cells it 
is notable that although titres of p1 isolates were comparable to those of BMAV and 
rBMAV titres of all except rBMAVn2bA and rBMAVn2cdel were reduced early in 
infection. The greatest reductions occurred in rBMAVn11Δ, rBMAVn2aA and 
rBMAVn2fA infections with ≥ 1.4 log reduction in virus titre at 48 h p.i. compared 
with rBMAV (Figure 7-9, Figure 7-10). In IFN-competent A549 cells BMAV and 
rBMAV grew to lower titres than in IFN-deficient Vero E6 cells (Figure 7-9). In this 
study the growth kinetics of recombinant viruses were also attenuated in A549 cells 
when compared to growth in Vero E6 cells. Furthermore, all except rBMAVn24A and 
rBMAVn2cΔ had lower titres than rBMAV (Figure 7-10, Figure 7-11, Figure 7-12, 
Figure 7-13). The largest decrease (> 0.9 log at 48 h p.i.) was observed in recombinant 
viruses with ≥ 2 point mutations, namely rBMAVn2aA, rBMAVn2dA, rBMAVn2fA, 
rBMAVn3aA, rBMAVn3bA and rBMAVn2fΔ (Figure 7-11, Figure 7-12).  
 
The N protein and RNP plays a crucial role in virus infection, and subtle modifications 
in N protein structure may lead to sub-optimal primary transcription by the virion 
associated RdRp. Structural information would greatly aid the interpretation of 
biological phenotypes, although in the absence of this replicon assays with agarose-
urea gel electrophoresis could be used to investigate and differentiate between 
disruption to transcription or genome replication (Barr and Wertz, 2005; Ariza et al., 
2013). Moreover, protein-protein interactions, including N-N oligomerisation and N-L 
interactions could be investigated using chemical cross-linking and co-
immunoprecipitation assays (Eifan and Elliott, 2009). These experiments should be 
conducted only on single point mutants as the combined effect of multiple mutations 
cannot be predicted without structural information. To fully map the role of each amino 
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acid additional mutants with single point mutations could easily be constructed through 
QuickChange® PCR.  
 
 
7.4.4 Recombinant Viruses and the Type I IFN System 
 
BMAV and other non-NSs Tete serogroup viruses induce very low levels of IFN 
during virus infection in vitro, significantly lower than rBUNdelNSs2 and other non-
NSs viruses (Table 6-2). However, there was no evidence of active antagonism of the 
type I IFN system, leading to the hypothesis that Tete serogroup viruses may be low 
inducers rather than active antagonisers of the IFN response (Figure 6-8, Figure 7-1). 
Recombinant viruses were therefore investigated for their induction of biological IFN 
and activation of the IFN-β promoter during virus infection of A549 cells. There was a 
general trend with the level of IFN induction increasing as the number of N protein 
point mutations increased, with the highest induction by rBMAVn4xA and 
rBMAVn3cΔ (Table 7-2, Figure 7-13). This would agree with the hypothesis that 
disrupting RNA binding and or RNP formation by the N terminal arm of the N protein 
increases the exposure of viral RNA to the host cell, leading to increased induction of 
the type I IFN system. Transfecting purified RNPs and measuring the induction of type 
I IFN would help address this theory, whilst sensitivity of RNA-bound in RNPs to 
RNase treatment may also help assess exposure of RNA to the external environment 
(Ariza et al., 2013; Li et al., 2013a; Reguera et al., 2013).  
 
 
7.4.5 Concluding Remarks 
 
Altering BMAV N protein sequence and presumably structure through the introduction 
of point mutations in the N terminal extension led to attenuation in growth kinetics and 
increased induction of type I IFN. In lieu of structural data a number of experimental 
methods, as discussed above, could be employed to further investigate the role of this 
protein in virus replication and the function of the extended N terminal domain. 
However, it is hoped that the crystal structure of BMAV N protein will be available 
soon, allowing a more targeted approach to future experiments.  
  
 
 
 
 
 
 
 
Chapter 8: Antagonism by Interferon 
Stimulated Genes 
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8.1 Introduction  
 
The type I IFN response is a key anti-viral component of the innate immune response, 
stimulating the expression of hundreds of ISGs. ISG products known to have anti-
bunyavirus activity include MxA, the 2’-5’ OAS system and viperin (Frese et al., 1996; 
Kanerva et al., 1996; Hefti et al., 1999; Andersson et al., 2004; Bridgen et al., 2004; 
Carlton-Smith and Elliott, 2012). The activity of these proteins has been widely studied 
and varies across the Bunyaviridae family. For example, MxA binds LACV N protein 
forming copolymers that localise to the perinuclear compartment, reducing the 
availability of N and inhibiting virus replication (Haller and Kochs, 2002; Kochs, 2002; 
Reichelt et al., 2004). Yet MxA has little activity against BUNV, the type species of 
the Orthobunyavirus genus and Bunyaviridae family (Bridgen et al., 2004). An ISG 
recently identified as possibly having anti-BUNV activity is IFN-induced protein 44 
(IFI44) (Carlton-Smith and Elliott, 2012).  
 
IFI44, also known as microtubule aggregate protein 44 (MTAP44), is highly conserved 
amongst mammals (Hallen et al., 2007). A previous study utilising Flp-InTM T-RExTM 
293 cells with tetracycline inducible expression of individual ISGs identified IFI44 as 
inhibiting BUNV replication in a virus release assay (Carlton-Smith and Elliott, 2012). 
However, very little is known about the structure or function of IFI44. First identified 
in 1990 as a protein physically associated with microtubule aggregates in the liver of 
chimpanzees infected with hepatitis C virus (HCV) it was not until 1994 that IFI44 was 
characterised as an ISG (Honda et al., 1990; Kitamura et al., 1994). Kitamura et al., 
(1994) identified 2 ISREs in the 5’ flanking region and demonstrated that expression 
was induced by IFNα but not IFNγ in a PLC/PRF/5 human hepatoma-derived cell line. 
IFI44 has since been shown to be significantly upregulated in a number of clinical 
conditions including infections and inflammatory autoimmune conditions, such as 
systemic lupus erythematosus (SLE) and Sjogrens syndrome (Nzeusseu Toukap et al., 
2007; Wildenberg et al., 2008; Bochkov et al., 2010; Farina et al., 2010). In 2007 IFI44 
was identified as a cytoplasmic protein with a GTP binding site, leading to the 
hypothesis that IFI44 may sequester intracellular GTP, inhibiting extracellular signal-
regulated kinases (ERK) and leading to cell cycle arrest and establishment of an 
antiproliferative state (Hallen et al., 2007).  
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In addition to IFI44, 2 groups of membrane bound ISGs, bone marrow stromal antigen 
2 (BST2) and the IFITM family (IFN-induced transmembrane protein), have been 
shown to have inhibitory roles in the replication of enveloped RNA viruses. IFITM1, 
IFITM2 and IFITM3 are transmembrane proteins that are upregulated by type I and 
type II IFN (Friedman et al., 1984; Jaffe et al., 1989; Lewin et al., 1991). The proteins 
have been shown to have wide ranging anti-viral activities, restricting the replication of 
influenza A virus (IAV), SARS coronavirus (CoV), Ebola, Dengue, HIV-1 and the 
bunyaviruses ANDV, HTNV, LACV and RVFV (Brass et al., 2009; Huang et al., 
2011; Lu et al., 2011; Mudhasani et al., 2013). IFITM proteins also interact with 
VAPA (vesicle-membrane-protein-associated protein A), antagonising the VAPA-
OSBP (VAPA-oxysterol-binding protein) interaction, which leads to the accumulation 
of cholesterol in late endosomal compartments (Amini-Bavil-Olyaee et al., 2013). 
Disrupted cholesterol homeostasis and increased membrane rigidity inhibits membrane 
fusion, leading to the retention of virus particles in endosomal compartments, thus 
inhibiting virus entry (Feeley et al., 2011; Amini-Bavil-Olyaee et al., 2013; Li et al., 
2013b). 
 
In contrast to the IFITM proteins which act early in the virus life cycle BST2, also 
known as tetherin or CD317, antagonises a later stage, inhibiting the release of virus 
particles from infected cells. BST2 is a type I IFN-induced type II transmembrane 
protein that localises to lipid rafts in the plasma membrane, endocytic compartments 
and trans-Golgi network (Kupzig et al., 2003; Blasius et al., 2006). It has a broad 
activity against enveloped viruses and expression of BST2 leads to the accumulation of 
virions at the cell surface (Neil et al., 2008; Jouvenet et al., 2009; Sakuma et al., 2009; 
Radoshitzky et al., 2010; Weidner et al., 2010; Mangeat et al., 2012). It is hypothesised 
that BST2 simultaneously spans both viral and cellular membranes ‘tethering’ viruses 
to the host cell, and thereby inhibiting virus spread and release. In addition, it has been 
proposed that BST2 may play a role in host restriction as over-expression of human 
BST2, but not ovine BST2, leads to a reduction in titres of SBV, an orthobunyavirus 
that infects ruminants but has no association with human infection (Personal 
communication, Dr Mariana Varela, University of Glasgow). 
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8.2 Aims 
 
The aims of the research presented in this chapter were first to confirm the anti-
bunyavirus activity of IFI44 by studying the effects of IFI44 over-expression on the 
replication of BUNV and rBUNdelNSs2, a recombinant BUNV that lacks a functional 
NSs protein (Bridgen et al., 2001). My second aim was to investigate possible antiviral 
mechanisms of IFI44 and finally I aimed to investigate the anti-orthobunyavirus 
activity of the membrane bound IFITM and BST2 proteins.  
 
 
8.3 Results 
 
To test for statistical significance the results in this chapter were analysed by either an 
individual t-test or one-way ANOVA followed by the Dunnett’s multiple comparison 
test. The t-test was used to determine statistical significance of differences when 2 
conditions at 1 time point were being compared. One-way ANOVA and the Dunnett’s 
multiple comparison test were used when there were > 2 data sets, for example when 
virus titres from 4 cell lines were being compared. The cut-off for significance was set 
at p < 0.05. Unless indicated all p values in this chapter refer to these analyses only and 
not any other form of statistical analysis. 
 
 
8.3.1 Inducible Expression of IFI44 
 
Following on from the work presented by Carlton-Smith and Elliott (2012) a Flp-InTM 
T-RExTM 293 cell line with tetracycline inducible expression of FLAG-tagged IFI44 
(T-REx IFI44) was used to investigate IFI44 orthobunyavirus antagonism. Tetracycline 
induced expression of FLAG-tagged IFI44 was confirmed by western blot anaylsis 
with anti-FLAG and anti-IFI44 antibodies, with a clear band at approximately 50 kDa 
(Figure 8-1A). Expression of IFI44 was detected with the anti-FLAG antibody as early 
as 8 h after the addition of tetracycline, with band strength increasing over the 48 h 
induction period. An additional band at approximately 115 kDa was also visible and 
present in both induced and non-induced cells (Figure 8-1A). This protein was also 
intermittently detected by the anti-IFI44 antibody, which detected IFI44 48 h after the 
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addition of tetracycline to the cell culture medium (Figure 8-1A). Detection by anti-
IFI44 required the primary antibody to be incubated for 2 to 4 h at room temperature. 
Incubation for less than 2 h at room temperature, or over night incubation at 4°C, failed 
to result in detection (data not shown). Altering the blocking buffer to BSA or PBS 
with 2% (w/v) skimmed milk and 0.01% (v/v) Tween-20 also failed to improve 
detection (data not shown). Following induction, FLAG-tagged IFI44 remained 
detectable by western blot analysis with anti-FLAG antibody for at least 72 h with a 
clear band visible at approximately 50 kDa (Figure 8-1B). No proteins were detected 
by either anti-FLAG or anti-IFI44 antibodies in T-REx CAT cells, the control Flp-InTM 
T-RExTM 293 cell line which contains chloramphenicol acetyl transferase (CAT) in 
place of a FLAG-tagged ISG (Figure 8-1C). 
 
To investigate the cellular localisation of FLAG-tagged IFI44 immunofluorescence (IF) 
and cellular fractionation, followed by western blot analysis, were carried out. In 
tetracycline induced cells IF with the anti-FLAG antibody showed predominantly 
cytoplasmic staining (Figure 8-2A). However, cross-reaction with the anti-FLAG 
antibody can occur and cellular fractionation was therefore carried out to confirm this 
observation. Cellular fractionation on induced and non-induced cells again indicated 
that FLAG-tagged IFI44 localises to the cytoplasm in uninfected cells, with a clear 
band at approximately 50 kDa (Figure 8-2B). However, IFI44 was not detected in 
either the cytoplasmic or nuclear fraction of cells infected at MOI 3 with BUNV 
(Figure 8-2A). Failure to detect FLAG-tagged IFI44 is unlikely to be due to 
experimental error as BUNV N protein and tubulin were detected in the cytoplasmic 
fraction, and uninfected and infected cell lysates were probed for FLAG-tagged IFI44 
on the same membrane during western blotting.  
 
In addition to the tetracycline inducible system human cell lines were screened for IFN 
inducible expression of IFI44 by western blot analysis. Cells were treated with 1 000 U 
ml-1 IFN-2α and harvested at 4, 8, 12 and 24 h post IFN treatment. Endogenous IFI44 
expression following IFN treatment was undetectable in Huh7, HeLa, A549 or HEK-
293 cells (Figure 8-3). This was despite confirmation of an active IFN response by 
detection of MxA in A549 and Huh7 cells (Figure 8-3). As no cell line with detectable 
expression of IFI44 following IFN treatment was available the T-REx IFI44 cell line 
with tetracycline inducible IFI44 expression was used for all future work.  
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Figure 8-1: Tetracycline Induction of IFI44 
A) Expression of IFI44 was induced by the addition of tetracycline at a final concentration of 1 
µg ml-1 to cell media, or an equal volume of PBS in non-induced cells, for 48 h. Expression of 
FLAG-tagged IFI44 during the 48 h induction period was monitored by harvesting cell lysates 
at the specified time points. Cell lysates were then probed with anti-FLAG and anti-IFI44 
antibodies. B) Following 48 h induction with 1 µg ml-1 tetracycline T-REx IFI44 cells were 
harvested at specified time points post induction and FLAG-tagged IFI44 expression detected 
with anti-FLAG antibody. C) T-REx CAT cell lysates were collected 48 h after the addition of 
1 µg ml-1 tetracycline, or an equal volume of PBS, to the cell medium. Cell lysates were tested 
for FLAG-tagged gene expression using anti-FLAG antibody, with tetracycline induced T-REx 
IFI44 cell lysate included as a positive control.  
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Figure 8-2: Cellular Localisation of FLAG-tagged IFI44 
A) T-REx IFI44 cells were induced with 1µg ml-1 tetracycline or PBS for 48 h. Cells were then 
fixed and stained with anti-FLAG antibody to detect IFI44 expression. Coverslips were 
mounted in Mowiol, supplemented with DAPI, for nuclear staining. Scale bars represent 100 
µm. B) T-REx IFI44 cells were induced with 1µg ml-1 tetracycline for 48 h. Cells were then 
infected with Bunyamwera virus (BUNV) at multiplicity of infection 3 and monolayers 
harvested at 0 and 24 h post infection (h p.i.). Cell lysates were then fractionated and tested by 
western blot analysis the presence of FLAG-tagged IFI44 using anti-FLAG antibody. Samples 
were also probed with anti-N and anti-tubulin antibodies to detect BUNV N protein and 
tubulin, respectively.   
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Figure 8-3: Investigation of IFN Inducible Expression of IFI44 
A549, Huh7, HeLa and HEK 293 cells were treated with 1 000 U ml-1 IFN2α for 4, 8, 12, and 
24 h. Cells were then harvested and analysed for expression of IFI44 and MxA by western blot 
analysis using anti-IFI44 and anti-MxA antibodies. Samples were also probed with anti-tubulin 
antibody to detect tubulin as a loading control. A Positive control (PC) of IFN-stimulated A549 
cell lysate was included in HeLa and HEK 293 blots.  
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8.3.2 IFI44 Expression and Virus Replication 
 
Following induction by tetracycline FLAG-tagged IFI44 was detected during low MOI 
with BUNV and rBUNdelNSs2 in T-REx IFI44 cells (Figure 8-4A, Figure 8-5A). 
During virus infection a reduction in the detection of viral N protein occurred, with 
fainter bands in both BUNV and rBUNdelNSs2 infections at 24 h p.i. and 36 h p.i. in 
induced cells compared to non-induced cells (Figure 8-4B, Figure 8-5B). A reduction 
in viral N protein was not detected in the T-REx CAT control cells (Figure 8-6). 
Induced T-REx IFI44 cells over-expressing FLAG-tagged IFI44 also displayed a 
reduction in virus release, quantified by plaque assay of clarified culture supernatants, 
when compared to non-induced cells (Figure 8-4C, Figure 8-5C). The reduction in 
virus titre was most evident and statistically significant (p<0.05) early in infection, with 
no virus detected at 8 h p.i. in induced cells infected with BUNV (Figure 8-4C). This 
was followed by a significant 9-fold reduction in virus titre at 12 h p.i. (p < 0.05). This 
reduction was not maintained at later time points, with titres equalling or exceeding that 
of non-induced cells (Figure 8-4C). The reduction in virus yield during rBUNdelNSs2 
infection was also most notable early in infection with a 5-fold reduction at 12 h p.i. 
(Figure 8-5C). rBUNdelNSS2 virus titres remained suppressed in induced cells until 48 
h p.i, when titres then equalled those of non-induced cells (Figure 8-5C).    
 
To further investigate the effect of IFI44 over-expression during BUNV infection the 
virus release assay was carried out at a range of MOIs (0.001, 0.01, 0.1, 1 and 10). 
Once again at MOI 0.01 there was a reduction in virus titre at early time points with a 
16-fold lower virus titre in induced cells at 8 h p.i. (Figure 8-7). The only other notable 
reduction in virus release occurred at the lower MOI of 0.001 with no virus detected at 
8 h p.i. in T-REx IFI44 induced cells. This was followed by a 6-fold reduction in virus 
titre at 16 h p.i., however, virus titres equalled those of non-induced cells at 24 h p.i 
(Figure 8-7). In agreement with these virus titre results a reduction in the level of virus 
N protein detected by western blotting was visible only at low MOI (Figure 8-8). At 
MOI 0.1, 1 and 10 a reduction in the amount of IFI44 detected occurred. The level of 
FLAG-tagged IFI44 detected decreased with increasing MOI, with no visible bands at 
24 h p.i. or 48 h p.i. at MOI 10, suggesting degradation of IFI44 upon virus infection 
(Figure 8-8). 
  
8: Antagonism by Interferon Stimulated Genes 211	
55 kDa - 
55 kDa - 
25 kDa - 
4 8 12 24 36 48 72
1 
2 
3 
4 
5 
6 
7 
8 
9 
Induced
Non-induced
Time Post Infection (h)
Vi
ru
s 
Ti
tr
e 
(L
og
10
 p
.f.
u 
m
l-1
)
 
A) 
 
 
 
 
B)  
 
 
 
 
 
 
 
C)  
 
 
 
 
 
 
 
 
 
 
Figure 8-4: Low MOI with BUNV in Cells Over-Expressing IFI44 
T-REx IFI44 cells were induced for 48 hours (h) with 1µg ml-1 tetracycline or an equal volume 
of PBS and infected with BUNV at multiplicity of infection (MOI) 0.01. At specified h post 
infection (h p.i.) cell monolayers and cell supernatants were collected for analysis of protein 
levels and virus release, respectively. A) Cell lysates were probed with anti-FLAG antibody to 
confirm the expression of FLAG-tagged IFI44 throughout the time course. B) Cell lysates were 
probed with an antibody targeting BUNV N (anti-N) to monitor virus protein production, 
whilst anti-tubulin antibody was used to detect cellular tubulin as a loading control for each 
sample. C) Virus release at specified time points was quantified by plaque assay on clarified 
culture supernatants, mean ± standard deviation of triplicate infections are shown. 
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Figure 8-5: Low MOI with rBUNdelNSs2 in Cells Over-Expressing IFI44 
T-REx IFI44 cells were induced for 48 hours (h) with 1µg ml-1 tetracycline or an equal volume 
of PBS and infected with rBUNdelNSs2 at multiplicity of infection (MOI) 0.01. At specified h 
post infection (h p.i.) cell monolayers and cell supernatants were collected for analysis of 
protein levels and virus release, respectively. A) Cell lysates were probed with anti-FLAG 
antibody to confirm the expression of FLAG-tagged IFI44 throughout the time course. B) Cell 
lysates were probed with an antibody targeting BUNV N (anti-N) to monitor virus protein 
production, whilst anti-tubulin antibody was used to detect cellular tubulin as a loading control 
for each sample. C) Virus release at specified time points was quantified by plaque assay on 
clarified culture supernatants, mean ± standard deviation of triplicate infections are shown. 
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Figure 8-6: BUNV and rBUNdelNSS2 Low MOI in T-Rex CAT Control Cells 
T-REx CAT cells were induced for 48 hours (h) with 1µg ml-1 tetracycline or an equal volume 
of PBS and infected at multiplicity of infection (MOI) 0.01 with either wild type Bunyamwera 
virus (BUNV) or the recombinant virus rBUNdelNSs2. At specified time points cell 
monolayers were collected for analysis of protein levels by western blot analysis. Antibodies 
targeting the virus N protein (anti-N) and cellular tubulin (anti-tubulin) were used. 
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Figure 8-7: BUNV MOI Screen in T-REx IFI44 Cells, Virus Release Assay 
T-REx IFI44 cells were induced for 48 hours (h) with 1µg ml-1 tetracycline or an equal volume 
of PBS and infected with wild type Bunyamwera virus (BUNV) at the specified multiplicity of 
infection (MOI). Cell supernatants were collected at specified time points and virus release 
measured by plaque assay. Cell lysates were also collected at 0, 24 and 48 h post infection 
(Figure 8-8).   
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Figure 8-8: BUNV MOI Screen in T-REx IFI44, Cells Protein Expression 
T-REx IFI44 cells were induced for 48 hours (h) with 1µg ml-1 tetracycline or an equal volume 
of PBS and infected with BUNV at specified multiplicity of infection (MOI). At specified time 
points cell supernatants (Figure 8-7) and cell monolayers were collected for analysis of virus 
release and protein levels, respectively. Cell lysates were probed with antibodies targeting 
FLAG-tagged IFI44 (anti-FLAG), virus N and NSs proteins (anti-N, anti-NSs) and, as a 
loading control, tubulin (anti-tubulin). 
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To ensure the selection of IFI44 inducible cells T-REx IFI44 cells were passaged with 
increased concentrations of selective antibiotics (20 µg ml-1 blasticidin and 1000 µg ml-
1 hygromycin versus 5 µg ml-1 and 250 µg ml-1 respectively). This did not noticeably 
enhance antiviral activity as no significant decrease in virus release was detected in 
induced cells at > 12 h p.i. in BUNV or rBUNdelNSs2 infected cells (MOI 0.01 and 
0.001 tested, data not shown). Incubating cells at 33°C following tetracycline induction 
and infection with BUNV at an MOI of 0.01 also failed to elicit a significant decrease 
in virus yield when compared to non-induced cells (data not shown).  
 
To investigate the loss of detectable FLAG-tagged IFI44 observed during high MOI 
experiments, parallel high MOI experiments with BUNV and rBUNdelNSs2 were 
carried out. It was confirmed, that in contrast to low MOI experiments, there was no 
clear difference in the level of viral N protein for either BUNV or rBUNdelNSs2 in 
induced and non-induced cells. Once again, there was a reduction in the level of 
detectable IFI44 (Figure 8-9). Reduction in IFI44 levels occurred faster during BUNV 
infections than rBUNdelNSs2 infections, where it remained clearly detectable at 24 h 
p.i., with a faint band at 36 h p.i. in comparison to no detectable bands at either 24 h p.i. 
or 36 h p.i. in BUNV infected cells (Figure 8-9). Treating induced T-Rex IFI44 cells 
with the proteasome inhibitor, MG132, increased IFI44 levels during high MOI with 
BUNV and rBUNdelNSs2 virus (Figure 8-10). MG132 treatment also increased 
detection of BUNV NSs protein, whilst having no detectable affect on levels of BUNV 
N protein (Figure 8-10).   
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Figure 8-9: Expression of IFI44 and Virus N Protein in High MOI 
T-REx IFI44 cells were induced with 1 µg ml-1 tetracycline or an equal volume of PBS for 48 
hours (h) prior to infection with Bunyamwera virus (BUNV) or the recombinant rBUNdelNSs2 
virus at multiplicity of infection 3. Cell lysates were collected at specified h post infection (h 
p.i.) and analysed by western blotting for expression of FLAG-tagged IFI44 (anti-FLAG), virus 
N protein (anti-N), and tubulin (anti-tubulin). 
.  
h p.i. 
Induced (+) Non-induced (-) 
anti-FLAG
anti-tubulin 
anti-N
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Figure 8-10: Inhibition of the Proteasome in T-Rex IFI44 Cells 
A, B) T-REx IFI44 cells were induced with 1µg ml-1 tetracycline for 48 hours (h) prior to 
infection with Bunyamwera virus (BUNV) (A) or the recombinant virus rBUNdelNSs2 (B). 
Cells were infected at multiplicity of infection 3 and the proteasome inhibitor MG132 added at 
a final concentration of 10 µM at 5 h post infection (h p.i.). Cell lysates were harvested at 
specified time points and probed with antibodies targeting FLAG-tagged IFI44 (anti-FLAG), 
virus NSs protein (anti-NSs), virus N protein (anti-N) and cellular tubulin (anti-tubulin). C) 
Cells were mock infected with PBS supplemented with 2% (v/v) FCS and cell lysates probed 
for tubulin to monitor MG132 toxicity levels.  
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8.3.4 Anti-Orthobunyavirus Activity of Membrane Bound ISGs 
 
To enable screening for anti-orthobunyavirus activity A549 cell lines constitutively 
over-expressing TagRFP and either IFITM1, IFITM2, or IFITM3 were constructed by 
lentivirus transduction (Figure 8-11). An empty vector control cell line, A549-
SCRPSY, over-expressing TagRFP alone was also created (Figure 8-11). The optimal 
concentration of the selective agent, puromycin, was determined by killing assay on 
non-transduced A549 cells to be 2 µg ml-1 (data not shown). The level of transduction, 
as measured by image based cytometry of TagRFP expression, was > 98% for all cell 
lines (Figure 8-11A). Over-expression of IFITM2 and IFITM3, but not IFITM1, was 
also confirmed by western blot analysis (Figure 8-11C). It should be noted that IFITM2 
and IFITM3 proteins are highly homologous and both proteins were detected by anti-
IFITM2 (data not shown) and anti-IFITM3 antibodies. The IFITM3 antibody gave 
slightly better signal for both proteins and was therefore used for all future work.  
 
To study the effect of IFITM over-expression on virus replication infections were 
carried out with rBUNGc-eGFP and rBUNdelNSs-GcGFP, recombinant viruses with 
GFP-tagged glycoproteins (Shi et al., 2010). Cells were then analysed using image 
based cytometry, a technique that gives quantitative measurements of GFP and RFP 
expression in cells, allowing the percentage of infected and transduced cells to be 
counted. Over-expression of IFITM1 (p < 0.005) and IFITM3 (p < 0.0005) were found 
to significantly inhibit rBUNGc-eGFP virus replication (Figure 8-12). At 24 h p.i. and 
48 h p.i. only 32.8% and 38.0% of A549-IFITM3 cells were positive for rBUNGc-
eGFP, in comparison to 78.4% and 82.8% of empty vector control cells (Figure 8-12). 
In A549-IFITM1 cells 67.0% and 69.2% were positive for rBUNGc-eGFP at 24 h p.i. 
and 48 h p.i., respectively (Figure 8-12). A similar pattern was observed in 
rBUNdelNSs-GcGFP infections, with significant (p<0.005) reductions in GFP 
detection in A549-IFITM1 and -IFITM3 cell lines at 24 h p.i. and 48 h p.i. compared 
with the empty vector control cells (Figure 8-12). However, overall rates of infection 
were greatly reduced in comparison to rBUNGc-eGFP (Figure 8-12).  
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Figure 8-11: A549 Cells Constitutively Expressing IFITM Proteins 
A549 cells were transduced with lentivirus vectors encoding TagRFP (empty vector) or 
TagRFP and IFITM1, IFITM2, or IFITM3. A) Passage (p) 2 cells were treated with trypsin to 
form single cell suspensions, which were then analysed on the Tali® Image Cytometer (Life 
Technologies) to determine the proportion of transduced cells. B) Fluorescent microscopy on 
adherent p2 cell monolayers showing expression of TagRFP. Scale bars represent 400 µm. C) 
Western blot analysis of p2 cell lysates with anti-IFITM3 antibody; due to high homology 
between proteins IFITM2 is recognised by the anti-IFITM3 antibody.   
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Figure 8-12: BUNGc-eGFP rBUNdelNSs-GcGFP 
A549-IFITM cell lines and empty vector control, A549-SCRPSY, were infected at multiplicity 
of infection 1 with green fluorescent viruses rBUNGc-eGFP and rBUNdelNSs-GcGFP. Cell 
monolayers were harvested at 24 h post infection (h p.i.) and 48 h p.i. and analysed for GFP 
and RFP fluorescence by image based cytometry on the Tali® Image Cytometer (Life 
Technologies). Mean ± standard deviation of triplicate samples is shown, with significant 
differences from empty vector cells indicated by asterisks: *, p<0.005; **, p<0.0005.  
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To further investigate virus antagonism fluorescent microscopy was carried out. At 7 h 
p.i. rBUNGc-eGFP virus replication was clearly visualised in empty vector and A549-
IFITM2 cells, with the aggregation of GFP signal in the perinuclear region (Figure 8-
13). However, in A549-IFITM1 and -IFITM3 cells only isolated fluorescent spots were 
seen, indicating that virus replication and the trafficking of GFP-tagged glycoproteins 
to the Golgi has not yet occurred (Figure 8-13).  
 
In addition to fluorescence-based studies with GFP-tagged viruses, antagonism of virus 
replication was investigated using wild type BUNV and rBUdelNSs2 virus. In a virus 
release assay over-expression of IFITM1 and IFITM3 was, once again, associated with 
significant inhibition of virus replication. In A549-IFITM3 cells antagonism was most 
evident early in infection, with a significant reduction in BUNV titre at 8 h p.i (p < 
0.005) and 12 h p.i (p < 0.01) (Figure 8-14A). Virus titres remained suppressed at 24 h 
p.i. and 36 h p.i., although not to significant levels. In A549-IFITM1 cells the titre of 
BUNV was also significantly lower than control cells at 8 h p.i. (p<0.05) and 12 h p.i. 
(p<0.01), although the level of antagonism was lower than that observed in cells over-
expressing IFITM3 (Figure 8-14A). The reductions in virus titre were also supported 
by decreased detection of BUNV N protein by western blot analysis at 24 h p.i. in both 
A549-IFITM1 and -IFITM3 cells (Figure 8-14B).  
 
rBUNdelNSs2 virus replication was also antagonised in A549-IFITM1 and IFITM3 
cells. In A549-IFITM3 cells there were small but significant reductions in 
rBUNdelNSs2 virus titre at 8 h p.i. (p<0.01), 12 h p.i. (p<0.05) and 24 h p.i. (p<0.05) 
(Figure 8-15A). This was coupled with a reduction in the detection of virus N protein 
by western blot analysis in A549-IFITM3 cells at 24 h p.i. (Figure 8-15B). In A549-
IFITM1 cells the reduction in rBUNdelNSs2 virus was only significant at 8 h p.i. 
(p<0.05) and there was no apparent antagonism of viral N protein levels (Figure 8-15).  
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Figure 8-13: Fluorescent Microscopy of rBUNGc-eGFP in Cells Over-Expressing 
IFITM Proteins 
A549-IFITM cell lines and empty vector control, A549-SCRPSY, were infected at multiplicity 
of infection 5 with the green fluorescent virus rBUNGc-eGFP. Cells were fixed 7 hours post 
infection and coverslips mounted in Mowiol supplemented with DAPI to stain cell nuclei. 
TagRFP, eGFP and DAPI fluorescence were captured by fluorescent microscopy (EVOS® FL, 
Life Technologies), scale bars represent 100 µm. A, B and C show enlarged images of selected 
regions, white arrows highlight regions with GFP signal.   
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Figure 8-14: BUNV Replication in A549-IFITM Cells 
A549-SCRPSY and A549-IFITM cell lines were infected, in triplicate, with Bunyamwera virus 
(BUNV) at multiplicity of infection 0.01 and cell supernatants and cell lysates collected at 
specified hours post infection (h p.i.). A) Virus release was quantified by plaque assay of 
clarified culture supernatants on Vero E6 cells. Mean values ± standard deviation of triplicate 
infections are shown, with significant differences versus empty vector control cells, A549-
SCRPSY, indicated by asterisks: *, p<0.05; **, p<0.01. B) Cell lysates from A549-
SCRPSY(V), -IFITM1 (1), -IFTIM2 (2), -IFITM3 (3) were analysed by western blotting. 
Antibodies targeting BUNV N protein (anti-N), IFITM2 and IFITM3 proteins (anti-IFITM3) 
and tubulin (anti-tubulin) were used.  
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Figure 8-15: rBUNdelNSs2 in A549-IFITM Cells 
A549-SCRPSY and A549-IFITM cell lines were infected, in triplicate, with recombinant virus 
rBUNdelNSs2 at multiplicity of infection 0.01 and cell supernatants and cell lysates collected 
at specified hours post infection (h p.i.). A) Virus release was quantified by plaque assay of 
clarified culture supernatants on Vero E6 cells. Infections were carried out in triplicate and 
graphs depict mean values ± standard deviation. Significant differences versus empty vector 
control cells, A549-SCRPSY, are indicated by asterisks: *, p<0.05; **, p<0.01. B) Cell lysates 
from A549-SCRPSY(V), -IFITM1 (1), -IFTIM2 (2), -IFITM3 (3) were analysed by western 
blotting. Antibodies targeting BUNV N protein (anti-N), IFITM2 and IFITM3 proteins (anti-
IFITM3) and tubulin (anti-tubulin) were used.  
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To explore the spectrum of anti-orthobunyavirus activity A549-IFITM cell lines were 
tested with viruses from the Anopheles A serogroup (ANAV and TCMV), Anopheles 
B serogroup (BORV) and Tete serogroup (BMAV). Antibodies against these viruses 
were not available, therefore only virus release was measured. In contrast to BUNV, 
ANAV virus yield was significantly reduced (p < 0.05) in A549-IFITM1, -IFITM2, and 
-IFITM3 cells at 8 h p.i. (Figure 8-16). Virus yields remained significantly lower in 
A549-IFITM2 and -IFITM3 cell lines at 12 h p.i. (p<0.01, p<0.01) and 24 h p.i. 
(p<0.05, p<0.01) (Figure 8-16). In TCMV infected cells a significant (p<0.01) 
reduction in virus titre occurred only at 12 h p.i. in A549-IFITM3 cells, with no 
evidence of antagonism at other time points or in A549-IFITM1 or A549-IFITM2 cell 
lines (Figure 8-16).  
 
The Anopheles B serogroup virus, BORV, grew to significantly higher titres than the 
Anopheles A serogroup viruses, ANAV and TCMV, at early time points with titres > 3 
log10 p.f.u ml-1 at 8 h p.i. in A549-SCRPSY cells (Figure 8-16). Despite this, BORV 
replication was still significantly lower in A549-IFITM1, -IFITM2, and -IFITM3 cells 
at 8 h p.i. (p<0.05) and A549-IFITM2 and IFITM3 cells at 12 h p.i. (p<0.05) (Figure 8-
16).  
 
Lastly, replication of BMAV, a member of the Tete serogroup, was antagonised by 
IFITM2 and IFITM3 over-expression, with significantly (p<0.05) lower virus titres at 8 
h p.i., 12 h p.i. and 24 h p.i. in A549-IFITM2 and -IFITM3 cells with respect to A549-
SCRPSY control cells (Figure 8-16). 
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Figure 8-16: Replication of Anopheles A, Anopheles B and Tete Serogroup 
Viruses in A549-IFITM Cell Lines 
A549-SCRPSY and A549-IFITM cell lines were infected with Anopheles A serogroup viruses, 
Anopheles A virus (ANAV) and Tacaiuma virus (TCMV), the Anopheles B serogroup virus 
Boraceia virus (BORV) and Batama virus (BMAV), a member of the Tete serogroup. 
Infections were carried out in triplicate at multiplicity of infection 0.01 and cell supernatants 
collected at specified hours (h) post infection for quantification by plaque assay on Vero E6 
cells. Mean values ± standard deviation are shown, with significant differences versus empty 
vector control cells, A549-SCRPSY indicated by asterisks: *, p<0.05; **, p<0.01. 
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In addition to antagonising orthobunyavirus replication at low MOI it was noted that 
levels of detectable IFITM2 and IFITM3 proteins decreased during high MOI with 
BUNV and, to a lesser extent, with rBUNdelNSs2 (Figure 8-17A). To further 
investigate this observation naive A549 cells were infected with BUNV and 
rBUNdelNSs2 at MOI 10 and cell lysates tested for IFN-induced IFITM2 and IFITM3 
expression. Neither IFITM2 nor IFITM3 was detected in BUNV or rBUNdelNSS2 
infections at 24 h p.i. (Figure 8-17B). In contrast IFITM3 was clearly detected in cells 
infected with BMAV or BORV at 24 h p.i. (Figure 8-17B). As BUNV antagonises the 
type I IFN system A549 cells were treated with exogenous IFN to induce expression of 
the IFITM proteins. However, even in the presence of exogenous IFN IFITM2 and 
IFITM3 proteins were not detected in BUNV or rBUNdelNSs2 cell lysates, despite the 
detection of MxA, another ISG product (Figure 8-17C).  
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Figure 8-17: Expression of IFITM2 and IFITM3 in high MOI Virus Infection 
A) A549 cells constitutively over-expressing IFITM2 or IFITM3 were infected at multiplicity 
of infection (MOI) 1 and MOI 10 with Bunyamwera virus (BUNV) and rBUNdelNSs2 virus 
(delNSs). Cell monolayers were harvested 24 hours post infection (h p.i.) and probed with 
antibodies targeting virus N protein (anti-N), IFITM2 and IFITM3 proteins (anti-IFITM3) and 
tubulin (anti-tubulin). V, 1, 2 and 3 refer to empty vector (A549-SCRPSY), A549-IFITM1, 
A549-IFITM2 and A549-IFITM3 cell lines, respectively. B) A549 cells were infected at MOI 
10 with BUNV, rBUNdelNSs2 (delNSs), Boraceia virus (BORV) or Batama virus (BMAV). 
Cell monolayers were collected at 12 h p.i. and 24 h p.i. and probed with antibodies targeting 
BUNV-N protein, IFITM3 and tubulin. No antibodies for BORV or BMAV N were available, 
but virus infection was confirmed by titration (data not shown). C) A549 cells were stimulated 
with 1000 U ml-1 IFN (+) , or an equal volume of PBS (-) and infected with BUNV or 
rBUNdelNSs2 (delNSs) at MOI 10. Cell lysates were collected 24 h p.i. and probed with 
antibodies targeting MxA (anti-MxA), virus N protein (anti-N), IFITM2 and IFITM3 proteins 
(anti-IFITM3) and tubulin (anti-tubulin).  
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In contrast to IFITM proteins, which act early in the virus life cycle, BST2 (tetherin, 
CD317) inhibits virus replication by tethering newly produced virus particles to the cell 
surface, antagonising virus release. To study the effect of BST2 over-expression on 
orthobunyavirus replication 293T cells constitutively over-expressing human (h) or 
ovine (o) BST2 proteins were kindly provided by Dr Mariana Varela, University of 
Glasgow. BUNV did not appear to be strongly affected by the over-expression of 
hBST2 or oBST2 proteins, with no large differences in virus titre at any of the time 
points tested (Figure 8-18A). There was however, a 24-fold reduction in the virus titre 
of rBUNdelNSs2 in cells over-expressing hBST2 at 24 h p.i. in comparison to the 
empty vector control (Figure 8-19A). The decrease in viral titre, although not 
statistically significant, was supported by a drop in viral N protein levels, with 
detection of a fainter band at 36 h p.i. than in the control cell sample, despite no notable 
difference in the level of tubulin (Figure 8-19B). It should also be noted, that in both 
BUNV and rBUNdelNSs2 infections there was a decrease in detection of virus N 
protein in cells over-expressing oBST2A, despite no clear antagonism of virus titre 
(Figure 8-18, Figure 8-19).  
 
Viruses from the Anopheles A serogroup (ANAV and TCMV), Anopheles B serogroup 
(BORV) and BMAV, a member of the Tete serogroup, were also screened using the 
BST2 cell lines. As no antibodies against these viruses were available, only virus 
release was measured. There was slight suppression of ANAV virus release at early 
time points, with 3.7-fold – 9.6-fold reductions in virus titre at 12 h p.i. in cells over-
expressing hBST2, oBST2A or oBST2B (Figure 8-20). This was followed by a 6.3-fold 
reduction in oBST2A cells at 24 h p.i., and titres from oBST2A and oBST2B remained 
slightly lower than empty vector controls or hBST2 at 36 h p.i. and 48 h p.i. (Figure 8-
20). TCMV replication did not appear to be antagonised by over-expression of either 
human or ovine BST2 proteins. There was a slight reduction in virus titre at 36 h p.i. in 
cells over-expressing hBST2, but there were no clear differences at any other time 
point (Figure 8-20).  
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Figure 8-18: BUNV Replication in Cells Over-Expressing BST2 
293T cells over-expressing human, ovine A or ovine B BST2 proteins were infected at 
multiplicity of infection 0.01 with wild type Bunyamwera virus (BUNV). A) Clarified culture 
supernatants were collected at specified hours post infection (h p.i.) and virus release quantified 
by plaque assay. Infections were carried out in duplicate and mean ± range are shown. B) Cell 
lysates were collected and analysed by western blotting, samples were probed with antibodies 
targeting BUNV N protein (anti-N) and tubulin (anti-tubulin). 
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Figure 8-19: rBUNdelNSs2 Replication in Cells Over-Expressing BST2 
293T cells over-expressing human, ovine A or ovine B BST2 proteins were infected at 
multiplicity of infection 0.01 with the recombinant rBUNdelNSs2 virus. A) Clarified culture 
supernatants were collected at specified hours post infection (h p.i.) and virus release quantified 
by plaque assay. Infections were carried out in duplicate and mean ± range are shown. B) Cell 
lysates were collected and analysed by western blotting, samples were probed with antibodies 
targeting BUNV N protein (anti-N) and tubulin (anti-tubulin). 
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Figure 8-20: Replication of Anopheles A, Anopheles B and Tete Serogroup 
Viruses in Cells Over-Expressing BST2 
293T cells over-expressing human or ovine BST2 proteins were infected at multiplicity of 
infection 0.01 with Anopheles A virus (ANAV), Tacaiuma virus (TCMV), Boraceia virus 
(BORV) or Batama virus (BMAV). Clarified culture supernatants were collected at specified 
hours (h) post infection and virus release quantified by plaque assay on Vero E6 cells. 
Infections were carried out in duplicate and mean ± range are shown.  
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Over-expression of hBST2 or oBST2A proteins also appeared to have no effect on 
BORV replication. However, over-expression of oBST2B did appear to stall virus 
release in BORV infections with reductions in virus titre at 24 h p.i. and 36 h p.i. 
(Figure 8-20). BMAV, a member of the Tete serogroup, showed greater evidence of 
antagonism by BST2, with lower virus titres in hBST2, oBST2A and oBST2B cell 
lines at 12 h p.i.. This was followed by a 28-fold and 10-fold reduction in virus titres at 
24 h p.i. in hBST2 and oBST2B cell lines, respectively (Figure 8-20). 
 
 
8.4 Discussion 
 
8.4.1 IFI44 and Bunyamwera virus Antagonism 
 
This work confirmed tetracycline inducible expression of FLAG-tagged IFI44 in T-
REx IFI44 cells (Figure 8-1A). However, in concurrence with Hallen et al., (2007) the 
only published paper citing use of an anti-IFI44 antibody, intermittent cross-reaction 
with a higher molecular weight protein occurred. Hallen et al, (2007) utilised an 
antibody raised in rabbits against a peptide conjugate of IFI44 (aa 271 - 285), which in 
addition to detecting IFI44 detected an unknown protein at approximately 70 kDa in 
both IFN-induced and non-induced cells. In this study an anti-FLAG and anti-IFI44 
antibody raised against the complete IFI44 protein were used. Cross-reaction with an 
unidentified protein at approximately 115 kDa occurred in both tetracycline induced 
and non-induced cells with both anti-FLAG and anti-IFI44 antibodies (Figure 8-1A). 
Cross-reactive proteins are therefore unlikely to be IFI44 oligomers.  
 
Carlton-Smith and Elliott (2012) reported a reduction in BUNV and rBUNdelNSs2 
virus release in T-REx IFI44 cells over-expressing IFI44. More specifically an 18-fold 
and 6-fold reduction in BUNV virus titre at 36 h p.i. and 72 h p.i., respectively, and a 
12-fold reduction in rBUNdelNSs2 virus titre at 72 h p.i. (Carlton-Smith, 2012; 
Carlton-Smith and Elliott, 2012). Despite replicating the published experimental 
conditions, the level of antagonism exerted by IFI44 over-expression was lower in this 
study. Initially, problems ensuring maintenance of an intact cell monolayer throughout 
the 72 h time course (the cell line is loosely adherent) prevented the acquisition of 
consistent or reliable results. This was resolved by seeding cells in 35 mm dishes rather 
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than 6-well plates and carrying out virus dilutions and washes with warmed Opti-
MEM, not PBS. Furthermore, utilising a single dish for each time point in place of a 
single monolayer for the whole time course allowed both protein expression and virus 
release to be measured. Following these amendments, a significant (p<0.05) reduction 
in virus titre at 8 h p.i. and 12 h p.i. was detected at MOI 0.01 in BUNV infected cells. 
However, there was no evidence of inhibition of virus release at later time points 
(Figure 8-4C). Collecting cell monolayers allowed the presence of IFI44 during 
infection to be confirmed by western blot analysis (Figure 8-4A, Figure 8-5A). Failure 
to replicate previous findings was therefore not due to IFI44 degradation or failure of 
IFI44 induction. An additional stock of BUNV was also grown up from an alternative 
source of elite virus and tested at MOI of 0.01 and 0.001 (data not shown), reducing the 
likelihood that differences in virus preparations could account for the differing levels of 
virus antagonism by IFI44 over-expression. Despite failing to show significant 
inhibition of virus release at later time points (> 12 h p.i.), there was a reduction in viral 
N protein at 24 h p.i. and 36 h p.i in cells over-expressing FLAG-tagged IFI44 during 
low MOI experiments with both BUNV and rBUNdelNSs2 (Figure 8-4B, Figure 8-5B). 
This reduction was not due to differences in cell quantity as there were no clear 
differences in the level of the cell loading control, tubulin, when N and tubulin were 
stained for on the same gel (Figure 8-4B, Figure 8-5B). This reduction can also not be 
accounted for by the pre-treatment of cells with tetracycline as there was no reduction 
in the level of N protein in T-REx CAT control cells induced with tetracycline 
compared to those mock induced by the addition of PBS in place of the antibiotic 
(Figure 8-6). The reduction in virus N protein, coupled with significant reductions in 
virus titre early in infection supports the hypothesis that IFI44 has anti-bunyavirus 
activity (Carlton-Smith and Elliott, 2012).  
 
The inability to detect evidence of anti-bunyavirus activity during high MOI infections, 
with no reduction in viral titre or viral N protein, suggests that the anti-BUNV activity 
of IFI44 can be overcome by high levels of infection (Figure 8-7, Figure 8-8, Figure 8-
9). There was, however, a reduction in the detection of IFI44 during high MOI 
experiments (Figure 8-2A Figure 8-8, Figure 8-9). This reduction was most apparent in 
BUNV infections, with no FLAG-tagged IFI44 detected 24 hp.i. in induced T-REx 
IFI44 cells infected with BUNV at MOI 3 (Figure 8-2A, Figure 8-9). The level of 
FLAG-tagged IFI44 during high MOI experiments was prolonged by inhibition of the 
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proteasome (Figure 8-10). BUNV NSs has been linked with degradation of host 
RNAPII and an attractive hypothesis would be that NSs mediates proteosomal 
degradation of IFI44 (van Knippenberg et al., 2010). However, as a reduction in 
FLAG-tagged IFI44 was also detected in rBUNdelNSs2 infections, albeit at a later time 
point and to a lesser degree, it is likely that an alternative or additional NSs 
independent mechanism exists (Figure 8-9).  
 
IFI44 is reportedly significantly upregulated in a number of clinical conditions and 
upon IFN treatment in vitro (Nzeusseu Toukap et al., 2007; Wildenberg et al., 2008; 
Bochkov et al., 2010; Farina et al., 2010). However, this study failed to detect IFI44 in 
4 human cell lines (Huh7, A549, HeLa and HEK-293) following IFN treatment. Hallen 
et al., (2007) found IFI44 to be upregulated in 2 cell lines (ME15 and D10) following 
treatment with IFNα. It was also reported that IFI44 was virtually uninducible in A549 
cells supporting the results of this study. Unfortunately, Huh7, HeLa or HEK-293 cells 
were not included in the Hallen et al., (2007) paper. However, it would be premature to 
classify these cell lines as not possessing IFN inducible IFI44 expression as the anti-
IFI44 antibody was shown to lack sensitivity in western blots detecting FLAG-tagged 
IFI44 (Figure 8-1A). Screening cells by quantitative RT-PCR for significant 
upregulation of IFI44 mRNA may therefore be a more suitable methodology (Hallen et 
al., 2007; Farina et al., 2010; Gautam et al., 2011).  
 
It has been proposed that IFI44 may induce an anti-proliferative state by binding and 
thereby reducing the availability of GTP, inhibiting the ERK pathway. Cellular 
fractionation, supported by IF, showed FLAG-tagged IFI44 localised in the cytoplasm, 
corroborating published data on IFI44 localisation (Figure 8-2) (Hallen et al., 2007; 
Power et al., 2015). Analysis of IFI44 sequences reveals a Walker A motif 
(GxxxxGKS) at residues 193 to 200. However, IFI44 has not yet been shown to bind 
GTP, and is said to lack homology to any known GTPases or G proteins (Hallen et al., 
2007). A structural model of IFI44 with 99.9% confidence is obtained when the 
sequence was entered into Phyre2 (Kelley and Sternberg, 2009). However, this model, 
which was based on the crystal structure of GIMAP2 (GTPase of immunity associated 
proteins 2, protein database identifier 2xtp), has only 15% amino acid (aa) sequence 
identity and 48% coverage, with only 213/444 aa residues aligned (Figure 8-21).  
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Figure 8-21: Structural Model of IFI44 
Computational modelling of IFI44, accession number NP006408.3. A) The IFI44 amino acid 
sequence was analysed by Phyre2, the highest ranking model was based on the crystal structure 
of GIMAP2, a GTPase of immunity associated proteins 2 (PDB ID code 2xtp) (Kelley and 
Sternberg, 2009). Using this model, 3D ligand identified a possible binding site with GTP and 
magnesium acting as ligands. The Phyre2 and 3D ligand data were then combined in 
MacPyMOL to create the model shown. B) Phyre2 alignment data. The Walker A motif, 
highlighted in a black box, was predicted to be flanked by a β-sheet and α-helix. T=Hydrogen 
bond, S=bend. C) Aligned regions of the top 10 ranking structural models generated by Phyre2, 
against full length IFI44 are highlighted in blue. There was no coverage of the first 186 aa in 
any of the 499 hits generated by Phyre2. 
  
Predicted Binding Site 
Residue Mean distance (Å) 
199 Lys 0.18 
200 Ser 0.00 
219 Leu 0.56 
228 Ser 0.27 
251 Asp 0.21 
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Further processing of the Phyre2 IFI44 GIMAP2 model in 3D ligand predicts a binding 
site with GTP and magnesium (Figure 8-21A). The predicted binding site includes 
residues 199K and 200S, which form part of the Walker A motif. Furthermore, the 
Walker A motif is predicted to be preceded by a beta sheet and followed by an alpha 
helix, a structural feature that is conserved among nucleotide binding proteins (Figure 
8-21B), supporting the hypothesis that IFI44 may contain a functional GTP binding 
site. 
 
Cell proliferation assays coupled with targeted mutagenesis of the Walker A motif 
would aid in the exploration of this hypothesis. Furthermore, utilisation of IF and 
recombinant viruses, such as rBUNGc-eGFP which expresses GFP-tagged Gc, or 
rBUNL4V5 and rBUNLVL5 which express a V5-tagged L protein, would allow 
possible interactions between IFI44 and viral proteins to be studied (Shi et al., 2009; 
Shi et al., 2010; Power et al., 2015). 
 
 
8.4.2 Anti-Orthobunyavirus Activity of the IFITM Proteins  
 
Mudhasani et al., (2013) reported that the IFN-induced IFITM proteins have anti-
bunyavirus activity, antagonising viruses from the phlebovirus, hantavirus and 
orthobunyavirus genera. However, the spectrum of activity varied; the phlebovirus 
RVFV was inhibited by only IFITM2 and IFIMT3, whilst the orthobunyavirus LACV 
was inhibited by IFITM1, IFITM2 and IFITM3 (Mudhasani et al., 2013). To further 
investigate the spectrum of anti-bunyavirus activity and to determine if the antagonism 
of LACV, an orthobunyavirus in the California serogroup, was representative of pan-
orthobunyavirus activity A549 cell lines constitutively over-expressing IFITM1, 
IFITM2 and IFITM3 were made. Over-expression of IFITM2 and IFITM3, but not 
IFITM1 was confirmed by western blot analysis (Figure 8-11C). Intensity of TagRFP 
expression was reduced in A549-IFITM1 cells in comparison to IFITM2, IFITM3 and 
empty vector cell lines (Figure 8-11B). However, lentivirus transduction of A549-
IFITM1 cells was confirmed by image based cytometry with > 98% of cells positive for 
TagRFP (Figure 8-11A). 
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In this study 5 wild type orthobunyaviruses (BUNV, ANAV, TCMV, BORV and 
BMAV), and 1 recombinant orthobunyavirus (rBUNdelNSs2) were screened for 
antagonism by IFITM1, IFITM2 and IFITM3 proteins. In contrast to LACV, BUNV 
and rBUNdelNSs2 were restricted by over-expression of only IFITM1 and IFIMT3. 
This was evident by image based cytometry, fluorescent microscopy and virus release 
assays (Figure 8-12, Figure 8-13, Figure 8-14, Figure 8-15). There was also a reduction 
in BUNV N protein, detected by western blot analysis on cells over-expressing IFITM1 
and IFITM3 (Figure 8-14). In further diversity the Anopheles A and Anopheles B 
serogroup viruses, ANAV and BORV, had significantly lower titres at 8 h p.i. in cells 
over-expressing IFITM1, IFITM2, and IFITM3 (Figure 8-16). However, at later time 
points antagonism only by IFITM2 and IFITM3 was maintained. BMAV, a member of 
the Tete serogroup, was also antagonised by over-expression of IFITM2 and IFITM3 
but not IFITM1 (Figure 8-16). The Anopheles A serogroup virus TCMV was only 
inhibited by IFITM3 over-expression (Figure 8-16). This demonstrates that not only 
does the spectrum of activity vary between bunyavirus genera, it also varies within 
genera, and within orthobunyavirus serogroups, as Anopheles A serogroup viruses, 
ANAV and TCMV, display differing restriction profiles.  
 
Orthobunyaviruses enter cells by clathrin-mediated endocytosis, and require endosomal 
acidification for entry into the host cell cytoplasm (Santos et al., 2008; Hollidge et al., 
2012). Entry of LACV has also been shown to be Rab5-dependent, Rab7-independent, 
with acidification of early endosomes resulting in membrane fusion and virion release 
into the cytoplasm; residual virions are then released from late endosomes by a virus 
mediated mechanism (Hollidge et al., 2012). Cells over-expressing IFITM1, IFITM2 or 
IFITM3 display changes in cholesterol homeostasis, with the formation of cholesterol 
laden endosomal compartments (Amini-Bavil-Olyaee et al., 2013; Desai et al., 2014). 
This has been attributed to the direct interaction of the IFITM proteins with VAPA and 
disruption of VAPA-OSBP interaction, which deregulates cholesterol homeostasis 
(Amini-Bavil-Olyaee et al., 2013). High levels of cholesterol in endosomal 
compartments has previously been linked with virus antagonism, inhibiting entry of 
IAV (Musiol et al., 2013; Sun and Whittaker, 2003). However, a general blockade on 
membrane fusion due to cholesterol deregulation does not explain the differing 
spectrum of anti-orthobunyavirus antagonism exerted by over-expression of IFITM1, 
IFITM2 or IFITM3, as observed in this study. Moreover, recent publications have 
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shown that IFITM3 antagonism of IAV and MERS-CoV is independent of cholesterol, 
although cholesterol deregulation does occur (Desai et al., 2014; Wrensch et al., 2014). 
 
It is hypothesised that discrete differences in cellular localisation of IFITM proteins, 
coupled with the point at which viruses exit the endosomal pathway, may play a role in 
the level of antagonism. IFITM1 predominately localises at the plasma membrane 
whilst IFITM2 and IFITM3 localise to intracellular compartments (Weston et al., 
2014). IFITM3 co-localises with endosomal markers, including Rab7, LAMP1 and 
CD63; however, the exact localisation of IFITM2 has yet to be established (Feeley et 
al., 2011; Amini-Bavil-Olyaee et al., 2013; Weston et al., 2014). Indeed there is a 
growing body of evidence that only viruses which fuse in late endosomes are 
susceptible to antagonism by IFITM3, whilst virions that exit the endosomal pathway 
at or before the development of late endosomes may circumvent the full force of 
IFITM3 (Weidner et al., 2010; Feeley et al., 2011; Huang et al., 2011; Anafu et al., 
2013; Mudhasani et al., 2013). Exiting from both early and late endosomes, may 
therefore leave LACV susceptible to antagonism by both IFITM2 and IFITM3, 
whereas, orthobunyaviruses showing resistance to IFITM1 and IFITM2 antagonism, 
such as TCMV, may exit the endosomal pathway only at the late endosome (Figure 8-
16). To date IFITM3 is the only IFITM protein to antagonise all orthobunyaviruses 
tested, inhibiting viruses from the Anopheles A, Anopheles B, Bunyamwera, California 
and Tete serogroups, and therefore may have pan-orthobunyavirus activity (Figure 8-
15, Figure 8-15, Figure 8-16) (Mudhasani et al., 2013).  
 
In addition to by-passing IFITM antiviral activity by exiting the endosomal pathway at 
certain points orthobunyaviruses may directly antagonise the IFITM proteins. The 
primary virulence factor of orthobunyaviruses, the NSs protein, has been linked with 
host protein degradation and, during high MOI experiments, IFITM2 and IFITM3 
proteins were not detected by western blot analysis (Figure 8-17). However, as 
expression of IFITM2 and IFITM3 was lost in both BUNV and rBUNdelNSs2 
infections this phenomenon cannot be attributed to the NSs protein (Figure 8-17). 
Moreover, the NSs protein is not encapsidated in mature virus particles and would 
therefore not be present during initial virus entry, the point at which IFITM proteins act 
(Novoa et al., 2005). Furthermore, TCMV, a naturally occurring non-NSs 
orthobunyavirus, was resistant to over-expression of IFITM1 and IFITM2, supporting 
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the hypothesis that resistance to IFITM antagonism cannot be attributed to the NSs 
protein (Figure 8-16). Unfortunately, due to low virus titre high MOI experiments, and 
possible loss of IFITM 2 and IFITM3 expression, during TCMV infection could not be 
investigated. Receptor binding and membrane fusion of orthobunyaviruses is thought to 
be mediated by the Gc protein and a conserved fusion peptide domain located in the Gc 
protein, respectively (Sundin et al., 1987; Pekosz et al., 1995; Pekosz and González-
Scarano, 1996; Hacker and Hardy, 1997; Shi et al., 2007; Shi et al., 2009). However, as 
virus replication is not upregulated in cells over-expressing IFITM proteins it is 
unlikely that the Gc proteins of resistant viruses are utilising IFITM proteins as virus 
entry co-factors, like HCoV-OC43 (Zhao et al., 2014). It has been shown that IFITM1 
binds HCV coreceptors CD81 and occludin, thus inhibiting virus entry, and it may be 
that subtle differences in entry co-factors account for the differing spectrum of IFITM 
antagonism seen in the orthobunyavirus genus (Narayana et al., 2015; Wilkins et al., 
2013).  
 
 
8.4.3 Anti-Orthobunyavirus Activity of BST2 Proteins 
 
Orthobunyavirus assembly occurs at the Golgi where glycoproteins Gn and Gc 
accumulate and associate with viral RNPs. Virions with Golgi-derived envelopes are 
then transported via the exocytic pathway to the cell surface where membrane fusion 
between the plasma membrane and virion containing vacuole occurs, releasing virions 
into the extra-cellular environment (Novoa et al., 2005; Fontana et al., 2008). It is at 
this stage of the virus life cycle that the membrane bound ISG, BST2, is proposed to 
antagonise. BST2 proteins are found in the plasma membrane, trans-Golgi network and 
endocytic compartments, and their expression antagonises a wide range of enveloped 
viruses, ‘tethering’ virus particles to cellular membranes (Kupzig et al., 2003; Neil et 
al., 2008; Van Damme et al., 2008; Jouvenet et al., 2009; Sakuma et al., 2009; 
Radoshitzky et al., 2010; Weidner et al., 2010).  
 
It has been hypothesised that BST2 proteins may act as a host restriction factor for 
orthobunyaviruses as replication of SBV, a pathogen of ruminants, was antagonised by 
over-expression of hBST2, but not oBST2A or oBST2B (Personal communication, Dr 
Mariana Varela, The University of Glasgow). In agreement with this finding the virus 
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titre of BUNV, which is known to infect humans and domestic animals, was not 
inhibited by over-expression of hBST2, oBST2A or oBST2B (Figure 8-17). Moreover, 
the recombinant rBUNdelNSs2 virus, which lacks the primary virulence factor NSs, 
displayed 24-fold lower titres in cells over-expressing hBST2 at 24 h p.i., which was 
followed by reduced detection of N protein by western blot analysis at 36 h p.i. (Figure 
8-18). In further support of the proposed host restriction role for BST2 proteins, the 
Anopheles A and Anopheles B serogroup viruses, TCMV and BORV, which are 
associated with human infection, were not antagonised by over-expression of hBST2 
(Figure 8-18). Furthermore, there was a 28-fold reduction in the virus titre of BMAV, a 
member of the Tete serogroup not linked with human infection, at 24 h p.i. in cells 
over-expressing hBST2 (Figure 8-18). In contrast, there was minimal antagonism of 
ANAV, an Anopheles A serogroup not associated with human or ovine infection (da 
Rosa et al., 1992). ANAV induces high levels of IFN during virus infection, and was 
sensitive to IFN pre-treatment in vitro (Figure 6-5, Figure 6-9). The 293T-tetherin cell 
lines are IFN-competent and as ANAV titres were low, ≤ 3 x 104 p.f.u ml-1 at 48 h p.i., 
sensitivity to a robust type I IFN response may be masking full antagonism of BST2 
over-expression (Figure 8-18).  
 
In testament to the anti-viral role BST2 proteins play, a number of BST2 antagonists 
have been identified, including HIV-1 Vpu, HIV-2 Env, Kaposi’s sarcoma-associated 
herpesvirus (KSHV) K5 and the glycoproteins of Ebola virus and Sendai virus (Bampi 
et al., 2013; Douglas et al., 2009; Goffinet et al., 2009; Le Tortorec and Neil 2009; 
Mansouri et al., 2009; Iwabu et al., 2009; Kaletsky et al., 2009; Habermann et al., 
2010; Hauser et al., 2010; Lopez et al., 2010; Kühl et al., 2011; McNatt et al., 2013;). 
KSHV K5 ubiquinates hBST2, targeting the protein for degradation, whilst HIV-1 Vpu 
removes and displaces hBST2 from the plasma membrane and sites of virus assembly 
(Douglas et al., 2009; Goffinet et al., 2009; Iwabu et al., 2009; Mansouri et al., 2009; 
Habermann et al., 2010; McNatt et al., 2013). The exact mechanism of antagonism by 
the Ebola virus glycoprotein has yet to be elucidated although it has been shown to 
directly interact with BST2, which remains in the plasma membrane (Kaletsky et al., 
2009; Lopez et al., 2010; Kühl et al., 2011). Results presented in this chapter suggest 
that the NSs protein of BUNV may antagonise BST2, as the recombinant 
rBUNdelNSs2 virus which lacks a functional NSs protein displayed increased 
sensitivity to hBST2 in a virus release assay (Figure 8-19). BUNV NSs is a potent 
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antagonist of the type I IFN system; however, in this study hBST2 was constitutively 
over-expressed and not under control of the type I IFN signalling pathway. Moreover, 
NSs mediated inhibition of RNAPII would be expected to effect expression of hBST2, 
oBST2A and oBST2B to similar levels, but rBUNdelNSS2 only showed increased 
sensitivity to hBST2 suggesting targeted or species specific antagonism of hBST2. 
Furthermore, additional mechanisms of orthobunyavirus evasion or antagonism of 
BST2 proteins must exist as naturally occurring non-NSs viruses, TCMV and BORV, 
were also resistant to over-expression of hBST2 and oBST2A (Figure 8-20).  
 
 
8.4.4 Concluding Remarks 
 
The results presented in this chapter suggest that in addition to NSs mediated inhibition 
of the type I IFN response orthobunyaviruses possess uncharacterised mechanisms of 
ISG evasion and antagonism. BUNV and rBUNdelNSs2 viruses consistently down 
regulated the expression of ISGs (IFI44, IFITM3 and MxA) during high MOI 
experiments (Figure 8-2A, Figure 8-8, Figure 8-9, Figure 8-10, Figure 8-17). To lose 
detection of constitutively over-expressed proteins suggests ISG degradation, rather 
than general protein shut-off due to cap snatching by virus L protein as this would also 
occur in BMAV and BORV infections. Furthermore, the utilisation of divergent 
orthobunyaviruses questions the utility of extrapolating results from ‘type’ species, as 
the activity of ISGs varied not only within the orthobunyavirus genus but within virus 
serogroups. The availability of divergent viruses, including naturally occurring non-
NSs viruses, may help elucidate ISG mechanisms of action and virus evasion strategies, 
as uncharacterised, non-NSs mechanisms of over coming the host immune response 
exist. 
 
  
 
 
 
 
 
 
 
 
Chapter 9: Final Reflections 
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9.1 Fulfilment of Aims 
 
The original, primary aim of my PhD was to investigate the anti-bunyavirus activity of 
IFI44. In brief, IFI44 was shown to antagonise BUNV and rBUNdelNSs2 virus 
replication during low MOI experiments, with a significant decrease in viral titre and N 
protein levels early in infection (Figure 8-4. Figure 8-5, Figure 8-7). However, the anti-
viral activity of IFI44 was limited to early time points only (< 24 h p.i.) and there was 
no evidence of anti-viral activity at MOI ≥ 0.1 (Figure 8-4, Figure 8-5, Figure 8-7). The 
decision was therefore made to change the direction of my work to focus on 
orthobunyaviruses that were identified by Mohamed et al., (2009) as lacking a 
functional NSs ORF. 
 
The change in project direction coincided with reports of anti-bunyavirus activity of the 
membrane bound ISGs, IFITM and BST2 (Mudhasani et al., 2013; Personal 
communication, Dr Mariana Varela, University of Glasgow). To test for anti-
orthobunyavirus activity cell lines over-expressing IFITM and BST2 proteins were 
utilised (Figure 8-11). Anti-orthobunyavirus activity was initially confirmed for BUNV 
and rBUNdelNSs2, with reduced viral titres during low MOI experiments (Figure 8-14, 
Figure 8-15, Figure 8-18, Figure 8-19). Anti-orthobunyavirus activity was further 
investigated by screening cell lines with viruses from the Anopheles A (ANAV and 
TCMV), Anopheles B (BORV) and Tete (BMAV) serogroups (Figure 8-16, Figure 8-
20). The results provide evidence of non-NSs mediated mechanisms of ISG evasion 
and antagonism as detection of IFI44, IFITM3 and MxA were repeatedly reduced 
during high MOI experiments with rBUNdelNSs2 (Figure 8-8, Figure 8-9, Figure 8-10, 
Figure 8-17). Furthermore, TCMV, a naturally occurring non-NSs virus, was resistant 
to over-expression of IFITM and BST2 proteins (Figure 8-16, Figure 8-20). The results 
also support the hypothesis that BST2 proteins may play a role in host restriction 
(Figure 8-18, Figure 8-19, Figure 8-20). 
 
To study the prevalence of non-NSs viruses within the orthobunyavirus genus a panel 
of 50 virus isolates belonging to 14 serogroups was obtained from The World 
Reference Center for Emerging Viruses and Arboviruses, University of Texas Medical 
Branch, USA. This ultimately resulted in a panel of 26 viruses that replicated in Vero 
E6 cells. In collaboration with Dr Thomas Briese, CII, New York, HTS was carried out 
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on 21/26 viruses during a 5 week placement at the CII. HTS data supplemented with 
RACE-PCR, RNA ligation and over-lapping PCR reactions resulted in complete 
genome sequences for 19 of these viruses (Table 5-2). For the remaining 2 viruses, 
PLSV and WELV, complete coding sequence and cRNA 5’UTRs and complete S 
segment sequences were obtained (Table 5-2). The sequencing data identified viruses 
in the Anopheles A, Anopheles B, Capim, Guama, Minatitlan, and Tete serogroups as 
non-NSs viruses. It has been postulated that loss of NSs occurs through truncations at 
the C terminus. Interestingly, WELV, a Tete serogroup virus that branches basally to 
the rest of the Tete serogroup was predicted to possess a full length NSs ORF, whilst 
other members of the serogroup contain truncated ORFs that would encode putative 
proteins of only 20 - 36 aa (Figure 5-6, Figure 5-9, Table 5-2). The sequencing data 
also gives further evidence of virus reassortment and challenges current classification 
methods (Figure 5-6, Figure 5-7, Figure 5-8, Figure 5-9, Table 5-4). 
 
To supplement genome sequencing data, basic biological characterisation was carried 
out on all viruses with evidence of replication in Vero E6 cells. This revealed several 
interesting and novel findings. Firstly, the presence of a putative NSs ORF does not 
correlate with in vitro IFN antagonism as Gamboa serogroup viruses struggled to 
replicate at low MOI in IFN-competent A549 cells and induced high levels of IFN 
during virus infection (Figure 4-7, Figure 6-1, Figure 6-2). Secondly, MPOV, which is 
predicted to encode an NSs protein that truncates prior to the C terminal Med8 
interaction domain, is associated with decreased IFN antagonism in vitro in comparison 
to BUNV, BWAV, NDV, or EREV (Figure 6-1, Figure 6-2). Thirdly, antagonism of 
the type I IFN system in vitro is not exhibited by all viruses associated with human 
infection as neutralising antibodies to BORV, a non-NSs virus that induced high levels 
of IFN in vitro, have been isolated from villagers in Brazil (Figure 6-5). However, IFN 
antagonism in vitro did still correlate with viruses associated with clinical illness in 
man. Lastly, metabolic labelling gave evidence of host cell shut-off in viruses lacking 
an NSs ORF (Figure 4-10, Figure 4-11, Figure 4-13). 
 
Determining the complete genome sequence, and not just complete coding sequence, 
facilitated the development of a reverse genetics system for BMAV, a member of the 
Tete serogroup. This allowed mutagenesis of the BMAV N protein, and the role of the 
N protein in low IFN activation to be investigated. Recombinant viruses with mutations 
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proximal to the amino terminus, a region involved in RNA binding and N-N 
interactions in other virus N proteins, induced higher levels of IFN in vitro. It is 
postulated that the highly disordered amino terminal of BMAV N protein may bind 
RNA in an, as yet, uncharacterised conformation with RNP structure contributing to the 
low level of IFN activation observed in vitro. 
 
 
9.2 The Bigger Picture 
 
The work presented in this thesis contributes to 4 major lines of study: IFN induction 
and RNA encapsidation, pathogenesis and the NSs protein, ISG screening, and virus 
evolution and classification. 
 
In 2013 a series of publications reported crystal structures for orthobunyavirus N 
proteins, shedding light on N-N interactions, RNA binding and RNP topology (Figure 
1-4) (Ariza et al., 2013; Reguera et al., 2013; Niu et al., 2013; Dong et al., 2013b). The 
N protein structures were highly conserved, despite low sequence homology, with 
RNA binding occurring in a central cleft and N protomers interacting in a head-to-tail 
fashion to form ordered tetramers in the presence of RNA. However, the work 
presented in this thesis gives evidence of variation within the Tete serogroup N protein 
amino terminus, a key region in N-N interactions and RNA binding. Interestingly, Tete 
serogroup viruses were shown to only induce low levels of IFN in vitro despite lacking 
an NSs protein (Figure 6-6, Figure 6-7). Furthermore, recombinant viruses with 
mutations in the N terminus of the virus N protein induced higher levels of biological 
IFN and IFN-β promoter activity than wt virus (Figure 7-13). Determining the crystal 
structure of Tete serogroup N proteins will greatly aid in future investigations of RNA 
binding and RNP formation, and structural studies are ongoing. The amino termini of 
Tete serogroup N proteins are predicted to be highly disordered (Figure 7-2). This may 
complicate structural analysis by x-ray crystallography as electron density is not 
observed for disordered regions of protein sequence. In lieu of structural data 
measuring IFN induction by purified RNPs and assaying for resistance to RNase may 
help elucidate the role of the N protein in IFN induction and RNA binding.  
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A central dogma in bunyavirology is that the NSs protein, the primary virulence factor, 
antagonises the type I IFN system at the transcriptional level through inhibition of 
RNAPII. The work presented in this thesis challenges this conserved mechanism. 
Firstly, NSs encoding NDV antagonised IFN induction in vitro but did not cause host 
cell shut-off (Figure 6-1, Figure 6-2, Figure 6-4, Figure 4-12). Secondly, Gamboa 
serogroup viruses, which are predicted to encode an NSs protein of 130 aa, struggled to 
replicate in IFN-competent A549 cells at low MOI and induced high levels of IFN 
during virus infection. Thirdly, non-NSs viruses in the Anopheles A, Capim and Tete 
serogroups showed evidence of host-cell shut-off in metabolic labelling experiments 
(Figure 4-.10, Figure 4-11, Figure 4-13) Lastly, non-NSs viruses TCMV, GJAV, 
GMAV, BMAV, TETEV and TSUV induced lower levels of IFN in vitro than 
rBUNdelNSs2 (Figure 6-5). Together these data demonstrate that there is still much to 
learn about the underlying mechanisms of orthobunyavirus pathogenesis and 
broadening research to include non-type species will expedite this endeavour.  
 
Testing ISG cell lines with divergent, non-type, virus species showed that the level of 
anti-virus activity varied within the orthobunyavirus genus, something that had already 
been demonstrated for MxA (Bridgen et al., 2004). However, the work presented in 
this thesis shows not only that activity can vary within the genus, but also within a 
serogroup and within a virus species (Figure 8-16, Figure 8-20). This questions the 
utility of using type species in ISG screens as findings cannot be extrapolated to other 
viruses of interest. Furthermore, as IFITM proteins antagonise virus entry, trapping 
incoming virions within endocytosed vacuoles, studying the pattern of virus restriction 
may help elucidate mechanisms involved in virus entry.  
 
At the start of my studies complete genome sequences were available only for viruses 
in the Bunyamwera, California and Simbu serogroups; now, with the work presented in 
this thesis and recently published reports, complete coding sequences are available for 
viruses in 15 out of 18 ICTV-recognised serogroups and the newly proposed Mapputta 
serogroup. Genome sequencing has revealed that non-NSs viruses are far more 
prevalent than first thought, and that non-NSs viruses from multiple serogroups are 
associated with human infection. This challenges our understanding of orthobunyavirus 
pathogenesis as the NSs protein was thought to be an essential virulence factor in virus 
zoonoses (Hart et al., 2009). Understanding the mechanisms behind non-NSs virus 
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pathogenesis is vital as deletion of the NSs ORF is a key principal in recombinant 
vaccine design. Moreover, it has been documented that recombinant viruses genetically 
modified to lack an NSs ORF can recover virulence over virus passage (Personal 
communication, Dr Mariana Valera, The University of Glasgow).  
 
Genome sequencing has also contributed to the debate surrounding orthobunyavirus 
classification. Orthobunyaviruses are traditionally classified by antigen cross-reactions 
in NTs and CFTs (Plyusnin et al., 2012). This system struggles to classify reassortant 
viruses as NTs, which detect antibodies against the virus glycoproteins, may give 
conflicting results from CFTs, which detect anti-N antibodies. Genome sequencing, 
coupled with phylogenetic analysis, gives a detailed map of virus evolution and it has 
been hailed as a possible solution for virus classification. However, phylogenetic 
analysis is only as good as the sequence data it is based on, and a strategy for the 
classification of reassortant viruses would still need to be developed. Moreover, there 
are documented discrepancies between virus sequences published by different 
laboratories and new serogroups have been proposed on the basis of partial sequencing 
data, even when there were clear gaps in phylogenetic coverage (Nunes et al., 2005; 
Bakonyi et al., 2013; Forshey et al., 2014; Groseth et al., 2014; Hang et al., 2014; 
Hontz et al., 2015). Therefore, any classification system based on phylogenetic analysis 
will require stringent controls. This could involve a minimum requirement for the 
inclusion of specified reference sequences, although this will need continued 
monitoring and updating to reflect current knowledge. 
 
Lastly, the advantages of carrying out basic biological characterisation along side HTS 
must be emphasised; otherwise it is impossible to unravel the link between genome 
characteristics and biological phenotype. Moreover, the importance of determining 
complete genome sequences, as opposed to complete coding sequence, should also be 
noted. Reverse genetics is a powerful tool that allows manipulation of the virus genome 
and the correlation between genotype and phenotype to be studied and robust reverse 
genetics systems have been developed for viruses in the Bunyamwera, Simbu, 
California and now Tete serogroups. They would not have been possible without 
complete genome sequencing.  
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The emergence and rapid spread of SBV in Europe in 2011 highlighted the continued 
threat that orthobunyaviruses pose and emphasised the ongoing threat of virus 
emergence and spread. There are no licensed treatments for orthobunyavirus infections 
with therapeutic options limited to broad spectrum antivirals, that have questionable 
benefit, and general supportive measures. There has been limited success in developing 
vaccines for livestock pathogens such as AKAV, however, most disease control 
programmes rely on vector control and vector avoidance as the primary intervention. 
Understanding the molecular basis of virus replication and pathogenesis will facilitate 
the development of effective therapies, whilst understanding virus evolution will 
facilitate public health planning.  
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Appendix 1: Primer Sequences 
 
A) Primers for RACE-PCR and UTR Sequencing 
 
Primer Name Sequence (5’- 3’)  Description Designed 
Oligo d(T) AP GACCACGCGTATCGATGTCGAC Anchor primer used in all RACE reactions. Roche 
Oligo d(T) Seq Rv GTCGACATCGATACGCG 
Reverse sequencing primer targeting 
the anchor sequence of oligo d(T) 
primer. 
This study 
ANAV S 5'UTR AATGGCATGATGATCTTTAGC 
RACE-PCR and UTR sequencing 
primers for Anopheles A virus S, M 
and L cRNA as indicated. 
This study 
ANAV S 5'UTRseq AATGTTAGGTCACTTGATG 
ANAV S 3'UTR GCTAGAGTTAAGAAAGGAC 
ANAV S 3'UTRseq GAGACAGAGATATGGAGG 
ANAV M 3'UTR ATAGCCAAGACAACCAAG 
ANAV L 5'UTR CGATTTGTGGCAATCCAT 
ANAV L 5'UTRseq CTGATGCTGGATTTCATTG 
ANAV L 3'UTR TTCAACTGCAGAAATGCTTG 
ANAV L 3'UTRseq GCCGTGTGCATTCTTGT 
5 ColAn S 5'UTR CTAACGGCATAACCAGAACTG 
RACE-PCR and UTR sequencing 
primers for ColAn 57389 virus S, M 
and L cRNA as indicated. 
This study 
5 ColAn S 5'UTRseq GGACCTCTCTGTTCATGG 
5 ColAn S 3'UTR ATCTTGGATTTGCACCTGG 
5 ColAn S 3'UTRseq TGGTAAAGAGTGCCGTTG 
5 ColAn M 5'UTR CGGATTTTCACATGCTCAC 
5 ColAn M 5'UTRseq TCCTCCAGTCTTCCACAG 
5 ColAn M 3'UTR ACCAATGCTGGAAATCAAC 
5 ColAn M 3'UTRseq GCAGGGTTGGAGAAGAG 
5 ColAn L 5'UTR CAATCGGGTTAGGTATGTGC 
5 ColAn L 5'UTRseq AGGATGTCAACAAGAGGG 
5 ColAn L 3'UTR GACCCTATTTACCACACATTTG 
5 ColAn L 3'UTRseq TCTACTGTGCTTGCCAG 
6 LMV S 5'UTR AGCTAGCGGCATAATCAGAAC 
RACE-PCR and UTR sequencing 
primers for Las Maloyas virus S, M 
and L cRNA as indicated. 
This study 
6 LMV S 5'UTRseq CCTGGCATCAACTGAAC 
6 LMV S 3'UTR GGGGTAGTTAGAGTTAAAAAGGG 
6 LMV 3'UTRseq GAATTGCTCCAGCCGAC 
6 LMV M 5'UTR AAGTTATTGTTGTGCCGCTG 
6 LMV M 5'UTRseq CCTCCCAGCATCTTCTC 
6 LMV M 3'UTR TGAAAATTGAAGCTGGGCAC 
6 LMV M 3'UTRseq GCATGCTCCTGTATTGGT 
6 LMV L 3'UTR CCATCAAGCAAGCACTTCAC 
6 LMV L 3'UTRseq ACCACACATTTGATATGCC 
6 LMV L 5'UTR GTTCTTGGGTTGATTTGGAG 
6 LMV L 5'UTRseq TTCATTCACAGCCCGAG 
9 TRMV S 5'UTR TAACACCAGCCTTTTCAGCC 
RACE-PCR and UTR sequencing 
primers for Trombetas virus S, M 
and L cRNA as indicated. 
This study 
9 TRMV S 5'UTRseq CCTGGCATTAACTGAACC 
9 TRMV S 3'UTR AGGAGTGGTCAGAGTTAAGAAAG 
9 TRMV S 3'UTRseq ATGGTTAAGAGTGCAGTTG 
9 TRMV M 5'UTR AGAGAGACGCTAGTTGAAGT 
9 TRMV M5'UTRseq TAAAGGACCTCCGACCA 
9 TRMV M 3'UTR CAACACCGATGCCCAAATACC 
9 TRMV M 3'UTRseq ATTCCTGCACTACCTGG 
9 TRMV L 5'UTR TCTTGTTCTCGGGTTGATCT 
9 TRMV L 5'UTRseq CGGGTTAGGTATATGCAC 
9 TRMV L 3'UTR AAACAAGCACTCCACAATGAG 
9 TRMV L 3'UTRseq CGATGTGGTCGGAAATG 
24 TCMV S 5'UTR CGAGCCAGCATTGTATATATCC 
RACE-PCR and UTR sequencing 
primers for Tacaiuma virus BeAn73 
S, M and L cRNA as indicated. 
This study 
24 TCMV S 5'UTRseq AAATGCCCTGTTATGCG 
24 TCMV S 3'UTR AATATGACACCTGGAGAATGGA 
24 TCMV S 3'UTRseq ATTCCCGTCCTCATGTTG 
24 TCMV M 5UTR CACCAACTTGCTTTTCTGGAC 
24 TCMV M 5'UTRseq GCTTGTGGAGATTTGGAC 
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24 TCMV M 3'UTR GGAGAGAGATGACAAATGCAG 
24 TCMV M 3'UTRseq CGGGTTCTTGTTCAGTC 
24 TCMV M 4267fw TAAGAAAGCAGCAGGCAG 
24 TCMV L 5UTR TTTGATAGTCATGTGGACGG 
24 TCMV L 5'UTRseq CAGGGGTAATGTTTGGC 
24 TCMV L 3'UTR GAATGCCTAACACCCCAAGA 
24 TCMV L 3'UTRseq GTGCTTTTGACTTTTCTGG 
24 TCMV L 3'UTRseq 2 ACAGATTCACTTGTGCT 
31 ANBV S 5'UTR CCTCCCGGTAAAGTTCAAGA 
RACE-PCR and UTR sequencing 
primers for Anopheles B virus S, M 
and L cRNA as indicated. 
This study 
31 ANBV S 5'UTRseq ACGTTTTCATCTGCTGC 
31 ANBV S 3'UTR TGTAAAGAAAGGGCAAATGCAG 
31 ANBV S 3'UTRseq CGTCTAGGCCTCACATTG 
31 ANBV M 5'UTR CTGAGTGTATGATTCCTGTGTC 
31 ANBV M 5'UTRseq CTGCAGAGCTTCCAATC 
31 ANBV L 5'UTR CTTAACTTCTCTGAAACATCCC 
31 ANBC L 5'UTRseq ACGTCGTTCCTGTACTC 
31 ANBV L 3'UTR GTAAAATATGAGGTGAACTGGC 
31 ANBV L 3'UTRseq CTTGATTGAACTGGCTCC 
25 BORV S 5'UTR AGAGGCATCACAAATTGGT 
RACE-PCR and UTR sequencing 
primers for Boraceia virus S, M and 
L cRNA as indicated. 
This study 
25 BORV S 5'UTRseq TAAGGTCAGTAGGCTGC 
25 BORV S 3'UTR GATGCAACCCGAATTCTCAG 
25 BORV S 3'UTRseq AGCTGAATGGATGACCAC 
25 BORV L 5'UTR GTTTCACGGGCAACTTTCAT 
25 BORV L 5'UTRseq TGGGTCAAAATCATCAATACAG 
25 BORV L 3'UTR GGCATTTTATCTGTCCTGGTGA 
25 BORV L 3'UTRseq GCTTCCAAAGGTGTTCTTCA 
25 BORV Mm 3'UTR GGCACACCAGGAAGAACTCC 
25 BORV Mgh 3'UTR GCTACCAGACGTCCAGTTTCA 
25 BORV Mgh 5'UTRsq CTGGCAGCTCAAATGATTCT 
25 BORV Mm 5'UTR TCATAATCGGGCCACCAATC 
25 BORV Mgh 3'UTRsq CCCAAATTTCATTTCCATTG 
25 BORV Mgh 5'UTR ATTGAGGCGTTCCATGTCCT 
25 BORV Mm 5'UTRsq ACCTGTTGGTGGGTTTTTCT 
25 BORV Mm 5'UTRsq TTTTTCTGGACGACATTTCC 
29 NDV S 5'UTR AACATTTCTGTGCCTGGG 
RACE-PCR and UTR sequencing 
primers for Nyando virus S, M and 
L cRNA as indicated. 
This study 
29 NDV S 5'UTRseq TATTGACCACTTCCACCT 
29 NDV S 3'UTR TCCCAGGCACAGAAATG 
29 NDV S 3'UTRseq AATTCCTGGGCCGATTC 
29 NDV M 5'UTR GTGTGTTTGAAGAACCTGA 
29 NDV M 5'UTRseq AATGTGAGGTCTTCGTG 
29 NDV M 3'UTR TGGTTAGGTGAAGCAGGT 
29 NDV M 3'UTRseq ACTAGACACATTCAAGAGC 
29 NDV L 5'UTR TGATTGACACCTCCTGAG 
29 NDV L 5'UTRseq ACTGGTAGTTGTCTGGAG 
29 NDV L 3'UTR GCTAGCAAATGACTTCGAC 
29 NDV L 3'UTRseq TCTGGTGGATGAGAAAGTG 
29 NDV S 3'UTRseq2 TGACACCAAAAGACCTTC 
34 M 4304 Fw GGCCTACTGATTTCAATTCT 
RACE-PCR and UTR sequencing 
primers for Eretmapodites virus M 
and L cRNA as indicated. 
This study 
34 M 219 Rv ATATCCCGCTAGTGTTGC 
34 L 112 Rv GCCTTGCAATGAGTATGTC 
34 L 6799 Fw ATGGGTAGGAGCATGTTTGA 
34 L 370Rv AGTAGTGGGCATATAGTTGA 
28 TET S 5'UTR GCCCCTTTCTTTCCAGGT 
RACE-PCR and UTR sequencing 
primers for Tete virus S, M and L 
cRNA as indicated. 
This study 
28 TET S 5'UTRseq CTCAACAGCCAGGTGACG 
28 TET S 3'UTR TGGCTCATGCTATTTTGCTG 
28 TET S 3'UTRseq GTTCTTCCCGCTTGCAGT 
28 TET M 5'UTR TCAGATCGGCATGAAAATGA 
28 TET M 5'UTRseq GATTGCATTTGTGCCAGTTT 
28 TET M 3'UTR GTCTGCGGGCATAACATACC 
28 TET M 3'UTRseq TGCAAAGTGAAAGAGGAAGG 
28 TET L 5'UTR CCACTCATGGGGTTTGCAC 
28 TET L 5'UTRseq AAACATCTTGTCGCCAACTC 
28 TET L 3'UTR ATAGGGCTGGGCTAGACGAC 
28 TET L 3'UTRseq GATGAAAACAAACCGGACAG 
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27 BMV S 5'UTR GCATGGGCTTCTTCAGGTATTC 
RACE-PCR and UTR sequencing 
primers for Batama virus S, M and L 
cRNA as indicated. 
This study 
27 BMV S 5'UTRseq GCATCCTTGCTTTTAGGC 
27 BMV S 3'UTR TACCTGGAAGGAGGGAGCAA 
27 BMV S 3'UTRseq CTCAAGTCTGGCTCGGTG 
27 BMV M 5'UTR CGGCATGAAAACGATTTAGGT 
27 BMV M 5'UTRseq CTTGCTCTCATTGCGTGTT 
27 BMV M 3'UTR TGTCCCCAAGATCAAACAA 
27 BMV M 3'UTRseq GCACCAATTGATCAGACACAC 
27 BMV L 5'UTR CATTTTGTTCCCGACCTTGAC 
27 BMV L 5'UTRseq CAAAGCAGAACTCCCTAGCA 
27 BMV L 3'UTR TGTATGCACAGAGCCGGATT 
27 BMV L 3'UTRseq TTGGGGTGAAATCTTTGCT 
20 MTRV S 5'UTRseq CTTTTGCCTCCTTAGCC 
RACE-PCR and UTR sequencing 
primers for Matruh virus S, M and L 
cRNA as indicated. 
This study 
20 MTRV S 5'UTR GATTTGCTGGGTGAAGGGTG 
20 MTRV S 3'UTRseq GCAGCGCATACAAGGTC 
20 MTRV S 3'UTR ATAAGGAGAAAATGGACACGG 
20 S 865Fw ATTTTTATACCAACCCCGAC 
20 MTRV M 5'UTRseq TCTCGACTGGATTGCAC 
20 MTRV M 5'UTR GTTCCTTCTTCCTTGTCAACT 
20 MTRV M 3'UTRseq GACCTACGATGCACAAC 
20 MTRV M 3'UTR GTTGCTAAAAATGAAGTCCTGG 
20 M 4287 Fw AGACCACCTAAAACTACAGC 
20 MTRV L 5'UTRseq CGCCAATGTAAAAGTCAG 
20 MTRV L 5'UTR TGCCCTTACTATTACTACCTCA 
20 MTRV L 3'UTRseq ACATTGTTGAGCAAGCAG 
20 MTRV L 3'UTR ATGTACAGAGAAGGAATGGATG 
21 TSUV S 5'UTR TATGACGGTTTGCAGGATGATG 
RACE-PCR and UTR sequencing 
primers for Tsuruse-like virus S, M 
and L cRNA as indicated. 
This study 
21 TSUV S 5'UTRseq CATCATCTCCTTTGCCTC 
21 TSUV S 3'UTR GGCTGTTGGATTGGCTAGATG 
21 TSUV S 3'UTRseq GATGCTGACAACTGGTG 
21 TSUV M 5'UTR GTTCCTTCCTCTTTGTCTATCG 
21 TSUV M 5'UTRseq CCCTCCAGTTGTTTCTAC 
21 TSUV M 3'UTR GGAAATGCACAGAAGAAAGTTG 
21 TSUV M 3'UTRseq GTGAAGGAGGAAGGATTG 
21 TSUV L 5'UTR GTCAGCAAAAGCATTCATGT 
21 TSUV L 5'UTRseq GCTCGTGTCATCTGTTG 
21 TSUV L 3'UTR GTGGAACAAGCAGAGTATGAG 
21 TSUV L 3'UTRseq CACACTTCAAACGTAAAGC 
22 WELV S 5'UTR TCTTTCTATCTCTTCCTTGTGC 
RACE-PCR and UTR sequencing 
primers for Weldona virus S and L 
cRNA as indicated. 
This study 
22 WELV S 5'UTRseq GTGACCTCCCAAGAACC 
22 WELV S 3'UTR AGCACAAGGAAGAGATAGAAAG 
22 WELV S 3'UTRseq AAGTTCTACCCACTGGC 
22 S 120Rv ATCCTCTAAACCTGCACCTG 
22 S 796Fw AACATCAATTGATTTAGCTGTCCTTTC 
22 WELV L 5'UTR ATGGTCATTCAATTCAGGAG 
22 WELV L 5'UTRseq TTCGCAAGTCAAAGAACC 
22 WELV L 3'UTRseq CCCCTGCTTTCGCTAAC 
22 WELV L 3'UTR GGCCATCATACCAAAGG 
33 S 206Rv AAGCCCTCAAGAAAAAGAC 
RACE-PCR and UTR sequencing 
primers for Guama virus S, M and L 
cRNA as indicated. 
This study 
33 S 718 Fw CTGGACAAGAGCTGGATTG 
33 S 967Fw AATTAGCCTTGATTGGCAC 
33 M 5'UTR AGCAAATGTGTGTGGTATC 
33 M 4442 Fw TTGTCTGTGAGGCGTTGA 
33 M 5'UTRseq TCTGCAATCCCATGATCC 
33 L 226 Rv CACAATATCCAGAGCAGG 
33 L 6731Fw AAATGGAAGGTACATCATGG 
36 S 188 Rv TTTGCTGGAGTAAGCTGG 
RACE-PCR and UTR sequencing 
primers for Gamboa virus S, M and 
L cRNA as indicated. 
This study 
36 S 761 Fw GTTCTTCACTGCTCTTGG 
36 M 241 Rv TCACAGTCCATTTCCTCCA 
36 M 4825Fw ATAGAACACACGAGGCAAG 
36 L 205 Rv ACCAGCTTCACATCATTCC 
36 L 3'UTR GGCGATGATTTTGATTCAC 
36 L 3'UTRseq ATTAGCACGAGAAGACCT 
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41 Pal S 5'UTR CTGAAGATTGCAATGGCC 
RACE-PCR and UTR sequencing 
primers for Palestina virus S, M and 
L cRNA as indicated. 
This study 
41 Pal S 5'UTRseq CCAATTGTCCATTCCAG 
41 S 864fw AGTTAATGGTAGGTGCGCAC 
41 Pal S 3'UTR CAGAGTCCAACAGAAGC 
41 Pal S 3'UTRseq TTCTAAAGAAACACCTGCG 
41 Pal S 3'UTRseq2 AGTTAATGGTAGGTGCG 
41 M 144 Rv CCCCATCTGTGAAGCATC 
41 Pal M 5'UTR CAGGCATGTAGCTTTTGTTC 
41 Pal M 5'UTRseq GCCTAATGAGTTCGATCC 
41 Pal M 3'UTR AAAGACATTCGATGTGGG 
41 Pal M 3'UTRseq CAGTGCTTGGTGTGTTAG 
41 Pal L 5'UTR GCTAAAGTCCAGATCCAG 
41 Pal L 5'UTRseq TGGTTGTGGGGTCCATC 
41 Pal L 3'UTR TGGACTAACCGAAATGGAG 
41 Pal L 3'UTRseq ATTGGGGACAAATGGTAG 
26 CAPV S 5'UTR TCTTAGATGCAGTCTCGTCC 
RACE-PCR and UTR sequencing 
primers for Capim virus S, M and L 
cRNA as indicated. Additional 
primers (M2, L2) were required to 
reach termini after initial sequencing 
with primers based on HTS data. 
This study 
26 CAPV S 5'UTRseq GCTTCAACCTCAATATTGG 
26 CAPV S 3'UTR TCTCTCATTCTTCCCTGGC 
26 CAPV S 3'UTRseq CAGTGGATGTCAGAAAGG 
26 CAPV M 5'UTR GACGTTGTCCCTTGAAACCA 
26 CAPV M 5'UTRseq GAGACAAGCATTTTCCGTTG 
26 CAPV M 3'UTR TGCACCAAAGGATTGGATTG 
26 CAPV M 3'UTRseq GGACGTGGCTGTGTAAAGTC 
26 CAPV L 5'UTR CGTCATGAAATGCTATTGTGGAG 
26 CAPV L 5'UTRseq CTGAAAGTATTATGGCGGTTG 
26 CAPV L 3'UTR AACGAATGGTCCACAGTAATGC 
26 CAPV L 3'UTRseq ACTGGGTCAAGGCTAAGGAG 
26 CAPV M2 3'UTR GTGTAAAGTCAGTGAGCAAGG 
26 CAPV M2 3'UTRseq ACGAGAGAGAGATGTATGGG 
26 CAPV L2 5'UTR TGGGGAAAAGTTGAAGGAAGTTG 
26 CAPV L2 5'UTRseq TAGACTCATCGCTCACCG 
18 MORV S 5'UTR CGATGGCAAGAGGTAAAAGC 
RACE-PCR and UTR sequencing 
primers for Moriche virus S, M and 
L cRNA as indicated. 
This study 
18 MORV S 5'UTRseq AGTTCTCAGCATCGCTCC 
18 MORV S 3'UTR GGATGACAACAAGGAAGGAGGA 
18 MORV S 3'UTRseq AAGGCTGGACTATCGGCA 
18 MORV M 5'UTR GCATGGAAACTTAGGGATGTAG 
18 MORV M 5'UTRseq ATTTGCTGTTGTTGTTCCC 
18 MORV M 3'UTR TCGCCCTTCCTGAATCTATTTG 
18 MORV M 3'UTRseq GTTGTGTTGGGAACTGTAG 
18 M 4591Fw GGGAGTAAAGTTAAGCTAGATAGG 
18 M 4673Fw ATCAGCGAGATCAACAGG 
18 MORV L 5'UTR GTCAGAAGATATGTGTAGATGC 
18 MORV L 5'UTRseq ATCCTGGCCTAATAGCTTG 
18 MORV L 3'UTR ATAGGGGAAAAGGTAGACTGG 
18 MORV L 3'UTRseq ATGGAAGGTGCAAGTTGG 
17 JD S 5'UTR GTCTTCTGGCTCCACTTCTATG 
RACE-PCR and UTR sequencing 
primers for Juan Diaz virus S, M and 
L cRNA as indicated. 
This study 
17 JD S 5'UTRseq TCTCTAGCAGGGGTTGTC 
17 JD S 3'UTR ATACAGAGTCCAACAAAAGCAG 
17 JD S 3'UTRseq AGAGGATGTGAGGAATGC 
17 JD M 5'UTR TCTGTTTGCTGTGGTTGTTCC 
17 JD M 5'UTRseq ATACCGTGATCCATCTGC 
17 JD M 3'UTR CTGTAAGGAAGAAGTGAATGCC 
17 JD M 3'UTRseq TGTTTCTCCCTATGTGCG 
17 JD L 5'UTR CTGATGAGATATGCAAGTGC 
17 JD L 5'UTRseq AGATTAGTCGCCTCGCAG 
17 JD L 3'UTR AGACGAATCAAATCACTGGGG 
17 JD L 3'UTRseq TAGAAGGGGCTAGTTGGG 
48 S 185Rv TCGTATTCCTCTCCTGGG 
RACE-PCR and UTR sequencing 
primers for M’Poko virus S, M and 
L cRNA as indicated. 
This study 
48 S 774 Fw ACTCTCACTGGACTTGCT 
48 M 151 rv ATTTTCGATCCACCTGTGA 
48 M 4394Fw AAAGCCCAAGGCAAAATG 
48 L 175rv ATAATCGTGTCTCCTGCTC 
48 L 6825 Fw AGAGTACAAACTTCGCGG 
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B) Primers for Sequence Confirmation (PCR products, pGEM-T easy) 
 
Primer Name Sequence (5’- 3’)  Description Designed 
M13-FP TGTAAAACGACGGCCAGT Primers for sequencing pGEM-T easy 
constructs. GATC M13-RP CAGGAAACAGCTATGACC 
BUNCAL2 CCCCTACCACCCACCC 
Primer targeting conserved region in 
California serogroup orthobunyavirus S 
segments. 
Bowen et 
al.,2001 
S25F GTCACAGTAGTGTACTCCACWDNAA Primers targeting conserved terminal 
sequences in orthobunyavirus S segments. 
Mohamed et 
al., 2009 S13+ GTCACAGTAGTGTACYCC 
S13- CTGACAGTAGTGTGCYCC 
BUN S- AGTAGTGTGCTCCAC Primers targeting conserved terminal 
sequences in orthobunyavirus S segments. 
Dunn et al., 
1994 BUN S+ AGTAGTGTACTCCAC 
23 M 51rv GCAGCATTTTAGTTAACATGG 
Primers used for sequence confirmation of 
Anopheles A virus N segment cRNA.  This study 
23 M 155Rv TGGGGGAGGCCATAATC 
23 M 1693fw TGAGAACCATTACAAGCAAG 
23 M 2595rv GCATCTTCATTTCCATAGG 
23 M 3097fw TTGTAATGATGCTGTCGAG 
23 M 4541fw AAACCAAGAGGGTGATTGA 
23 L 570fw GCTGAAGATTGCACATGG 
Primers used for sequence confirmation of 
Anopheles A virus L segment cRNA.  This study 
23 L 1460rv ATGTGGCTACTCTAAAAGTG 
23 L 2172fw AAATAGAGATTGAGCAGCG 
23 L 2824rv CCATTGCAATTAACCAGAAG 
23 L 4827fw GCTCATGATTTTTGCAGTG 
23 L 5734fw GCAAGCTGTTATGAGGAGAG 
23 L 5797rv ATTGATGTCAGGACCATGGA 
23 L 6294Rv CAAGAATGCACACGGCA 
6 LMV M 915 Fw+ TTCTGGGTTATGCTCTGG 
Primers used for sequence confirmation of 
Las Maloyas virus M segment cRNA. This study 
6 LMV M 1782 Fw GATGGAATTGAACTCATGTG 
6 LMV 1864 FwSeq TTGAGCATGAGGACAGC 
6 LMV M 2823 Fw+ GCCAGCAATTAAACCCAC 
6 LMV M 2498Rv TTTTTCAACCATTCTGCAGC 
9 L 2394 fw GAACCTGAACCTCAAACAG Primers used for sequence confirmation of 
Trombetas virus L segment cRNA.  This study 9 L 2953 Rv CAGCGTTCTTTGGCTAATC 
31 M 122 Rv ACTTGCAACTTCACCTCC 
Primers used for sequence confirmation of 
Anopheles B virus M segment cRNA.  This study 
31M 3239 Fw TAATACGACTCACTATAGGGTTGCTTATTTGGTCAATG 
31 M 3485Fw GGGAAAGGAGAGCCAAAG 
31 M 3740Fw GCTGGGTGCTTAGATTG 
31 M 3852RV ATTTAGCTCACAGTCCATCC 
31 M 4066Rv TCTGGTCACTATTTCCGAC 
31 M 4050 fw CGGAAATAGTGACCAGAC 
31M 4156Rv GTTCACTTTTCCATTAGGCAAG 
31 M 4184fw TGGAGACTTGCTTCTTGAG 
31M 4307Rv AGGCCTTCCTCTGAGAC 
31 M 4322rv AAGAAGCCCGTTATAGGAG 
31 M 4340Rv AAGAAGCCCGTTATAGGAG 
31 M 4348Rv CTTTGGTAAAGAAGCCCG 
31 L 2936 fw AATGGGAGACAAAATGCTG 
Primers used for sequence confirmation of 
Anopheles B virus L segment cRNA.  This study 
31 L 3471 Rv TCTTTGAAAACAGCCATTGC 
31 L 3451 Fw TGTGCAATGGCTGTTTTC 
31 L 4277 Rv CTTTTCATCGAACCACTTG 
36 M 862fw GACACTACTGAAAGAATGAG 
Primers used for sequence confirmation of 
Gamboa virus M segment cRNA.  This study 
36 M 1373rv GTTCCGCATGTACATTTCC 
36 M 2863fw GGTGTCTTCTGCTTTGGA 
36 M 3837fw AGAAATAGAAGCAACGGTG 
36 M 3854rv ACCGTTGCTTCTATTTCTG 
36 M 4805rv AAATGCCTATGTTCTGGAC 
41 S 3'term rv AGTAGTGTGCCCCACTGCC Primers used for sequence confirmations of This study 
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41 S 3 term rv seq AGTAGTGTGCCCCACTG Palestina S segment cRNA. 
41M 344fw GCCGAATGATGAGTTGATG 
Primers used for sequence confirmation of 
Palestina virus M segment cRNA.  This study 
41 M 1209 fw AAAGGGAAACTCGAATCG 
41 M 1430 Fw ACCAGGGAAATATCAAGCC 
41M 1448rv GGCTTGATATTTCCCTGGT 
41 M 1880 rv TGCCGCTTTCACTTGAAC 
41 M 1982fw GCGACAGTACCAACAAAG 
41 M 2231 Rv CTGTGCAACTGAGCTTATATC 
41 M 2470 Fw TTGCTGACCCCTTCTGTG 
41 M 2500 fw TATTGCTTTGGGAGGGAC 
41 M 2511 rv CCCAAAGCAATAAGTCCC 
41 M 2983 fw GGCTATCGTTCAGCAAAG 
41 M 3069 Rv ACAAAAACAAGCAACCCTC 
41 M 3225Rv CGCGCCTGCTGATATTAG 
41 M 3563fw TTTGGGTGAGATAAGGGTG 
41 M 3885 rv GAGGGCAAACGGTGTCA 
41 M 4276 rv ATATCCTTTAGCCGCCC 
41 M 4311 Fw GGGCGGCTAAAGGATATTC 
41 M 4435_Fw AGAGGGCTATTTGCTAGTG 
41 M 4486 Fw ATTGCATATTCAAATAAAGGTCC 
41M 4310 Fw PmX TGGGCGGCTAAAGGATATTC Primers for primer extension experiments 
on Palestina virus S and M segments. This study 41S 784 Fw PmX ATTCGGCATCAGGGTTTAAG 
41 L 346fw AAAGTATCGGTTAGTGACG 
Primers used for sequence confirmation of 
Palestina virus L segment cRNA. This study 
41 L 11261rv TGAATTGTTGCTCCCAAG 
41 L 1417 fw AGACACAGTCGTATAATGGT 
41 L 1879Rv TCACTAGCCTTTGACACC 
41 L 2093 fw ACCAAGACGCTTTTTTCAG 
41 L 2263rv ACCCTGGGAACCATATAG 
41 L 2851 rv TATTGCGGGTTTGTCGT 
41 L 3205 fw GAGTGCTCAGGATGTTTTC 
41 L 3778 rv ATCTACTCGCCATATCTTC 
41 L 3793 fw ACGGCAATAAAGCATGG 
41 L 4699rv CCAATTCTTTGCTCGTG 
26 M 2977 fw AAAACAGGGGTGTCTACAG Primers used for sequence confirmation of 
Capim virus M segment cRNA.  This study 26 M 3611 Rv TACATCCTTCCTTCTTGCAG 
 
 
C) Primers for Sequence Confirmation (pTvT7 clones) 
 
Primer Name Sequence (5’- 3’)  Description Designed 
pTvT7 Lin+ GGGTCGGCATGGCATCTC Primers for linearising 
pTvT7 plasmids. This study pTvT7 Lin- CTATAGTGAGTCGTATTAATTTCGCG 
34 pTvT7 S+ TAATACGACTCACTATAGAGTAGTGTACTCCACAATTGAATTC 
Primers for restriction 
free cloning of 
Eretmapodites virus S, 
M and L cRNA into 
pTvT7 backbone. 
This study 
34 pTvT7 S- ATGCCATGCCGACCCAGTAGTGTGCTCCACAATG 
34 pTvT7 M+ TAATACGACTCACTATAGAGTAGTGTACTACCAAGTGAC 
34 pTvT7 M- ATGCCATGCCGACCCAGTAGTGTGCTACCAAGGA 
34 pTvT7 L- ATGCCATGCCGACCCAGTAGTGTGCTCCTACATTAG 
34 pTvT7 L+ TAATACGACTCACTATAGAGTAGTGTACTCCTACATTAAAAATC 
6 pTvT7 S+ TAATACGACTCACTATAGAGTAGTGAACTCCATATAAAGTCAAAAG 
Primers for restriction 
free cloning of Las 
Maloyas virus S, M and 
L cRNA into pTvT7 
backbone. 
This study 
6 pTvT7 S- GATGCCATGCCGACCCAGTAGTGTGCTCCATATCAAGTAC 
6 pTvT7 M+ TAATACGACTCACTATAGAGTAGTGAACTACTCAAAAGAGAAATC 
6 pTvT7 M- GATGCCATGCCGACCCAGTAGTGTGCTACTCAAAGAGAA 
6 pTvT7 L+ TAATACGACTCACTATAGAGTAGTGTACTCCTATAATAAAAACCAGTAG 
6 pTvT7 L- GATGCCATGCCGACCCAGTAGTGTGCTCCTATAATAAAGATACTAA 
5 pTvT7 S+ TAATACGACTCACTATAGaGTAGTGAACTCCATATAAAGTCAAAAG Primers for restriction This study 
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5 pTvT7 S- GATGCCATGCCGACCCAGTAGTGTGCTCCATATAAAGTACATAA 
free cloning of ColAn 
57389 virus S, M and L 
cRNA into pTvT7 
backbone. 
5 pTvT7 M+ TAATACGACTCACTATAGAGTAGTGAACTACTTGCAAAAAAAC 
5 pTvT7 M- GATGCCATGCCGACCCAGTAGTGTGCTACTTGCAAAAAC 
5 pTvT7 L+ TAATACGACTCACTATAGAGTAGTGTACTCCTATAATAAAAATCAATAAAATGG 
5 pTvT7 L- GATGCCATGCCGACCCAGTAGTGTGCTCCTATAATAAAAATACT 
23 pTvT7 S+ TAATACGACTCACTATAGAGTAGTGTACTCCATATAAAGTCAAAC 
Primers for restriction 
free cloning of 
Anopheles A virus S 
segment cRNA into 
pTvT7 backbone. 
This study 
23 pTvT7 S- GATGCCATGCCGACCCAGTAGTGTGCTCCATATAAAGTAC 
24 pTvT7 S+ TAATACGACTCACTATAGAGTAGTGTACCCCACTAGAAG 
Primers for restriction 
free cloning of 
Tacaiuma virus S, M 
and L cRNA into 
pTvT7 backbone. 
This study 
24 pTvT7 S- ATGCCATGCCGACCCAGTAGTGTGCTCCGCTAG 
24 M pTvT7+ TAATACGACTCACTATAGAGTAGTGTACTACTCAGTGGAATAAC 
24 M pTvT7 - GATGCCATGCCGACCCAGTAGTGTGCTACTCAGTAGAAC 
24 pTvT7 L- ATGCCATGCCGACCCAGTAGTGTGCTCCTATCAAG 
24 pTvT7 L+ TAATACGACTCACTATAGAGTAGTGTACTCCCTATCAAAAG 
26 S pTvT7 Fw AGTAGTGAACTTCGTAGGAAGTTAAAATC Primers for restriction 
free cloning of Capim 
virus S segment cRNA 
into pTvT7 backbone. 
This study 26 S pTvT7 Rv GATGCCATGCCGACCCAGTAGTGCTCTTCGTAGAAAGTATTTAAAAC 
pTvT717 JD S+ TTAATACGACTCACTATAGAGTAGTGAACTTCGTAGAAAAGTTC 
Primers for restriction 
free cloning of Juan 
Diaz virus S, M and L 
cRNA into pTvT7 
backbone. 
This study 
pTvT717 JD S- GATGCCATGCCGACCCAGTAGTGTTCTTCGTAGAAAGTATTTAC 
pTvT717 JD M+ TTAATACGACTCACTATAGAGTAGTGTACCGCTGTTAGTAAAAATACC 
pTvT7 17 JD M- GATGCCATGCCGACCCAGTAGTGTTCCGCTGTTTGTAAAATAC 
pTvT7 17 JD L+ TAATACGACTCACTATAGAGTAGTGTACCCTTGACATAATATTTAAAAC 
pTvT7 17 JD L- GATGCCATGCCGACCCaGTAGTGTGCCCTTGACATAG 
20 pTvT7 S Fw+ TAATACGACTCACTATAGAGTAGTGTACTCCACAAAATACAAAATCG 
Primers for restriction 
free cloning of Matruh 
virus S, M and L cRNA 
into pTvT7 backbone. 
This study 
20 pTvT7 S Rv- ATGCCATGCCGACCCAGTAGTGTGCTCCACAAATAC 
20 pTvT7 M Fw+ TAATACGACTCACTATAGAGTAGTGTACTACCATTTAAGAAAACG 
20 pTvT7 M Rv- ATGCCATGCCGACCCAGTAGTGTGCTACCATCTAAGAATTATC 
20 pTvT7 L Fw+ TAATACGACTCACTATAGAGTAGTGTACCCCTGGG 
20 pTvT7 L Rv- ATGCCATGCCGACCCAGTAGTGTGCCCCTGG 
21 pTvT7 S- ATGCCATGCCGACCCAGTAGTGTGCTCCACAAATAC 
Primers for restriction 
free cloning of 
Tsuruse-like virus S, M 
and L cRNA into 
pTvT7 backbone. 
This study 
21 pTvT7 S+ TAATACGACTCACTATAGAGTAGTGTACCCCACAAAATAC 
21 pTvT7 M+ TAATACGACTCACTATAGAGTAGTGTACTACCATTTAAGAAAAC 
21 pTvT7 M- ATGCCATGCCGACCCAGTAGTGTGCTACCATATAAGAATTATC 
21 pTvT7 L+ TAATACGACTCACTATAGAGTAGTGTACCCCTGGGTTTC 
21 pTvT7 L- ATGCCATGCCGACCCAGTAGTGTGCCCCTGGA 
22 pTvT7 S Fw+ TAATACGACTCACTATAGAGTAGTGTATTCCGTAAAAAACAAAAC 
Primers for restriction 
free cloning of 
Weldona virus S 
segment cRNA into 
pTvT7 backbone 
This study 
22 pTvT7 S Rv- ATGCCATGCCGACCCAGTAGTGTGCTCCGTAATAC 
31 M pTvT7 Fw GATGCCATGCCGACCCAGTAGTGTACTACTTGGTAAAGAAAATTC Primers for restriction 
free cloning of 
Anopheles B virus S, 
M and L cRNA into 
pTvT7 backbone. 
This study 31M pTvT7 Rv 
GATGCCATGCCGACCCAGTAGTGTGCTACTTGGTATAGAAA
ATTAC 
31 M pTvT7 Rv55 GATGCCATGCCGACCCAGTAGTGTGCTACTTGGTATAG 
31 M pTvT7 Fw 54 TAATACGACTCACTATAGAGTAGTGTACTACTTGGTAAAGA 
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D) Primers for BMAV Reverse Genetics and Structural Studies 
 
Primer Name Sequence (5’- 3’)  Description Designed 
pTvT7 Lin+ GGGTCGGCATGGCATCTC Primers for linearising pTvT7 
backbone. This study pTvT7 Lin- CTATAGTGAGTCGTATTAATTTCGCG 
pUC118-F AGCGCCCAATACGCAAAC Forward and reverse primers 
for sequencing pTvT7 inserts. 
Designed by 
Dr Xiaohong 
Shi, UoG pUC-R TGCCTGCAGGTCGACTCTAG 
pTvT7 BM S+ TAATACGACTCACTATAGAGTAGTGTACCCCACAAAATAC 
Primers for restriction free 
cloning of wt Batama virus 
(BMAV) into pTvT7 
linearised vector. 
This study 
pTvT7 BM S- ATGCCATGCCGACCCAGTAGTGTGCTCCAC 
pTvT7 BM M- ATGCCATGCCGACCCAGTAGTGTGCTACCA 
pTvT7 BM M+ TACGACTCACTATAGAGTAGTGTACCACCATTTAAGAAAACG 
pTvT7 BM L+ AATACGACTCACTATAGAGTAGTGTACCCCTGGGTTTCG 
pTvT7 BM L- ATGCCATGCCGACCCAGTAGTGTGCCCCTGGA 
BMAV Sdel+ ATGATTGAGATTGATTACCATTTCTCAG Primers for removing N 
terminal 25 aa from pTvT7 
BMAV S construct, and 
adding the first 2 N protein aa 
from Bunyamwera virus. 
This study 
BMAV Sdel- TTTGTATGGTTTGCTATATGCAATC 
BM Sdel QkC+ GCATATAGCAAACCATACAAAATGATTGAGATTGATTACC 
BM Sdel QkC- GGTAATCAATCTCAATCATTTTGTATGGTTTGCTATATGC 
BMAV Sdel29+ AACATGTAAATAATTCTCTTTTAAGAGATAGGGGTTG 
Primers to replace BMAV N 
protein termini (N and C) 
with those of Bunyamwera 
virus 
This study 
BMAV Sdel29- GATTCCGAATTCTTTAAGGAACTCCC 
27 delWN Bu ins Fw GCAAACCATACAAAATGTCAAAGGCAAAGTCACC Primers for adding Weldona virus N protein termini to 
pTvT7 BMAV S construct. 
This study 
27 delWN Bu ins Rv CTTAAAAGAGAATTATTCAATTGATGTTGAATTCTTTAAGGAACTC 
27 delwNWu ins Fw GCAGGTTTAGAGGATGATGAGATTGATTACCATTTCTCAGC Primers for adding Weldona 
virus N protein termini and 
UTRs to pTvT7 BMAV S 
construct. 
This study 27 delwNwU ins Rv 
CTAAATCAATTGATGTTGAATTCTTTAAGGAA
CTCC 
wNwU Cr- TAAGGAACTCCCTAGCAGCCTCAGAGAAAC 
wNwU Cr+ GGAGTTCCTTAAAGAATTCAACATCAATTGATTTAGCTG 
BM_N D24A Fw CCGCATTTGCTGAAGCTGAGATTGATTACC 
Quickchange primers for 
single alanine substitutions in 
pTvT7 BMAV S construct, aa 
residues numbered as for 
wtBMAV. 
This study 
BM_N D24A Rv GGTAATCAATCTCAGCTTCAGCAAATGCGG 
BM_N S18A Fw CAATCAGCGTTGCAGCTGCTGCCGCATTTGCTGAAG 
BM_N S18A Rv CTTCAGCAAATGCGGCAGCAGCTGCAACGCTGATTG 
BM_N S12A Fw GGTGAGTCAGAACCAGCTATCAGCGTTGCAGC 
BM_N S12A Rv GCTGCAACGCTGATAGCTGGTTCTGACTCACC 
BM_N R6A Fw GTCCAAAGTAAAAGCTGGTGAGTCAGAACC 
BM_N R6A Rv GGTTCTGACTCACCAGCTTTTACTTTGGAC 
BM_N I13del Fw GAGTCAGAACCATCAAGCGTTGCAGCTAG 
Quickchange primers for 
single point deletions in 
pTvT7 BMAV S construct, aa 
residues numbered as for 
wtBMAV. 
This study 
BM_N I13del Rv CTAGCTGCAACGCTTGATGGTTCTGACTC 
BM_N P11del Fw GAGGTGAGTCAGAATCAATCAGCGTTGCAG 
BM_N P11del Rv CTGCAACGCTGATTGATTCTGACTCACCTC 
BM_N A19del Fw GCGTTGCAGCTAGTGCATTTGCTGAAGATG 
BM_N A19del Rv CATCTTCAGCAAATGCACTAGCTGCAACGC 
BM_N D24del Fw CCGCATTTGCTGAAGAGATTGATTACCATTTC 
BM_N D24del Rv GAAATGGTAATCAATCTCTTCAGCAAATGCGG 
BM_N R6S12A Fw CAAAATGTCCAAAGTAAAAAGAGGTGAGTCAGAACCATCAATCAGCGTTGCAGCTAG Additional quickchange 
primers for multiple point 
deletions or alanine 
substitutions, as indicated,  in 
pTvT7 BMAV S constructs, 
aa residues numbered as for 
wtBMAV. 
This study 
BM_N R6S12A Rv CTAGCTGCAACGCTGATTGATGGTTCTGACTCACCTCTTTTTACTTTGGACATTTTG 
BM_N P11I13del- GCACTAGCTGCAACGCTTGATTCTGACTCACCTCTTTTTAC 
BM_N P11I13del+ GTAAAAAGAGGTGAGTCAGAATCAAGCGTTGCAGCTAGTGC 
BM_N A19D24 del+ CAAGCGTTGCAGCTAGTGCATTTGCTGAAGAG 
BM_N A19D24 del- CTCTTCAGCAAATGCACTAGCTGCAACGCTTG 
pTM1 BM S+ GAAAAACACGATAATACCATGTCCAAAGTAAAAAGAG Primers for restriction free 
cloning of wt Batama virus 
(BMAV) into pTM1 
This study pTM1 BM S- AATTAGGCCTCTCGAGTTAGTTTCTGTCCTG 
pTM1 BM M+ AAAACACGATAATACCATGAGAATTTTTATAT
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TCTTCTCAAC linearised vector 
pTM1 BM M- TAATTAGGCCTCTCGAGTTATCTGTCTTTATATATTTGGTG 
pTM1 BM L+ AAACACGATAATACCATGGATCAAGAAATGATTAAACG 
pTM1 BM L- ATTAGGCCTCTCGAGCTATGCCTTGAAGTG 
pTM-R CAACTCAGCTTCCTTTCGGGC Primers for sequencing pTM1 
clones.  
Designed by 
Dr Xiaohong 
Shi, UoG pTM-F 
GGTGCACATGCTTTACATGTG 
pHT Lin Fw AATTCGAGCTCCGTCGAC Primers for linerasing 
pEHISTEV. This study pHT Lin Rv GCCCTGAAAATACAGGTTTTCG 
pHT BMAV N Fw+ CCTGTATTTTCAGGGCATGTCCAAAGTAAAAAGAGGTGAG 
Primers for cloning BMAV N 
protein ORF into pEHISTEV. This study 
pHT BMAV N Rv- GTGGTGGTGGTGTTATTAGTTTCTGTCCTGGTCTAATCC 
pHT BM inRv CGACGGAGCTCGAATTTTATTAGTTTCTGTCCTGGTCTAATCC 
pHT BM inFw CCTGTATTTTCAGGGCTCCAAAGTAAAAAGAGGTGAG 
pHT RvSeq AGGGGTTATGCTAGTTATTGC Reverse primers for 
sequencing pEHISTEV 
clones. 
This study pHT RevSeq2 ACTCAGCTTCCTTTCGGG 
 
UoG; University of Glasgow. 
 
E) Primers for Cloning Virus ORFs into pCMV-empty 
 
Primer Name Sequence (5’- 3’)  Description Designed 
CMV-F CGCAAATGGGCGGTAGGCGTG 
Primer for 
sequencing 
pCMV 
GATC 
BUNV N pCMV+Fw CTATAGGCTAGCCACCATGATTGAGTTGGAATTTCACG 
Primers for 
cloning BUNV 
ORFs into 
pCMV 
backbone. 
This study 
BUNV N pCMV-Rv GCGGCCGCTCTAGAATTACATGTTGATTCCGAATTTAGC 
BUNV NSs pCMV- GCGGCCGCTCTAGAATCAGCATCTTCTCAAGTAGG 
BUNV NSs pCMV+ CTATAGGCTAGCCACCATGATGTCGCTGCTAACACC 
BUNV M pCMV+Fw CTATAGGCTAGCCACCATGAGAATTCTAATACTGCTTTTAGC 
BUNV M pCMV-Rv GCGGCCGCTCTAGAATCACTTTTGCTTAATTTCTTGC 
BUNV L pCMV+Fw CTATAGGCTAGCCACCATGGAGGACCAAGCTTATG 
BUNV L pCMV-Rv GCGGCCGCTCTAGAATCAGAAAAAGGTAAATAGAGACTTTCC 
BMAV N pCMV-Rv GCGGCCGCTCTAGAATTAGTTTCTGTCCTGGTCTAATCC 
Primers for 
cloning BMAV 
ORFs into 
pCMV 
backbone. 
This study 
BMAV N pCMV+Fw CTATAGGCTAGCCACCATGTCCAAAGTAAAAAGAGGTGAGT 
BMAV M pCMV+Fw CTATAGGCTAGCCACCATGAGAATTTTTATATTCTTCTCAACAATC 
BMAV M pCMV-Rv GCGGCCGCTCTAGAATTATCTGTCTTTATATATTTGGTGGTC 
BMAV L pCMV+Fw CTATAGGCTAGCCACCATGGATCAAGAAATGATTAAACG 
BMAV L pCMV-Rv GCGGCCGCTCTAGAACTATGCCTTGAAGTGGTAC 
GAMV NSs pCMV+Fw CTATAGGCTAGCCACCATGATTCGACGGCAAGC 
Primers for 
cloning 
specified virus 
ORFs into 
pCMV 
backbone. 
This study 
 
GAMV pCMV-Rv GCGGCCGCTCTAGAATCATTGCTCCATGCTGCC 
WELV N pCMV-Rv GCGGCCGCTCTAGAATCAATTGATGTTGAATTCTTTCAAG 
WELV N pCMV+Fw CTATAGGCTAGCCACCATGTCAAAGGCAAAGTCAC 
WELV NSs pCMV+Fw CTATAGGCTAGCCACCATGATTTGGTCTTTTCTAGTTCAAC 
WELV NSs pCMV-Rv GCGGCCGCTCTAGAACTATCTCTTCCTTGTGCTTAGG 
MTRV NSs pCMV+Fw CTATAGGCTAGCCACCATGAGAAGCAGAAGGCTAAG 
MTRV NSs pCMV-Rv GCGGCCGCTCTAGAATCAGATATTCCGTGTCCATTTTC 
NDV NSs pCMV+Fw CTATAGGCTAGCCACCATGATGTCGAGCCAACTG 
NDV NSs pCMV-Rv GCGGCCGCTCTAGAACTATATATCCTGAGAGTCTATGCATTG 
EREV NSs pCMV-Rv GCGGCCGCTCTAGAACTATATATCCTGACAGTCTGTGG 
EREV NSs pCMV+Fw CTATAGGCTAGCCACCATGATGTCCAGTCTACTGCC 
MPOV NSs pCMV+Fw CTATAGGCTAGCCACCATGTCAGTCGAAGTACTTATAACC 
MPOV NSs pCMV-Rv GCGGCCGCTCTAGAATTAAGTCAGAGTCCGCAAC 
 
GATC; GATC Biotech, DNA Sequencing and Bioinformatics service. 
 
 Appendix 2: Virus Database Excerpt 
For publication purposes only, information on published sequences included in phylogenetic trees is shown. Information has also been condensed, with vector 
information given at the genus level, and geographical location and host range summarised. It should also be noted that only locations with positive virus 
isolations are included, areas positive for neutralising antibodies have been omitted. (N/A) Not available, (NR) Not reported (negative serology), (NTAb) 
Neutralising antibodies. The information included in this appendix was sourced from the International Catalog of Arboviruses (Berge, 1975) and the 
publications referenced in Chapter 1 and Chapter 5 of this thesis. 
 
Virus name Serogroup Accession Numbers Geographic Location  Vector  Natural Host Range 
Human 
Infection S M L 
Abbey lake virus Bunyamwera KJ710424 KJ710423 KJ710425 China Culex N/A NR 
Aino virus Simbu NC018460 NC018459 NC018465 Japan, Australia Culex, Culicoides Cattle, horses NR 
Akabane viru Simbu NC009896 NC009895 NC009894 Japan, Australia, Kenya Culex, Culicoides, Aedes Cattle NR 
Alajuela virus Gamboa KM272188 KM272187 KM272186 Argentina N/A N/A NR 
Anhembi virus Bunyamwera JN572064 JN572063 JN572062 Brazil Wyeomyia Rodents NTAb 
Batai virus Bunyamwera JX846604 JX846605 JX846606 India, SE Asia, Russia, E Europe Culex, Anopheles, Aedes Birds, rodents, ruminants NTAb 
Brazoran virus Unclassified NC022037 NC022038 NC022039 North America Culex. N/A NR 
Bruconha virus  Group C KM280937 KM280924 KM280929 N/A N/A N/A N/A 
Buffalo Creek virus Mapputta KJ481927 KJ481928 KJ481929 N/A N/A N/A N/A 
Bunyamwera virus Bunyamwera NC001927 NC001926 NC001925 Africa  Aedes, Mansonia, Culex. Non-human primates, rodents, domestic animals, birds Clinical cases 
Buttonwillow virus Simbu KF697162 KF697161 KF697160 North America, Africa N/A Non-human primates, guinea pigs Clinical cases 
Bwamba virus Bwamba EU564827 KJ867183 KJ867184 Africa Anopheles N/A Clinical cases 
Cache Valley virus Bunyamwera GU018037 KC436107 KC436106 North America Anopheles, Culisetini Rodents, deer, fox, raccoon, horses, monkeys NTAb 
Cachoeira Porteira 
virus Bunyamwera JN968592 JN968591 JN968590 Brazil N/A N/A N/A 
Calchaqui virus Gamboa KM272185 KM272184 KM272183 Argentina Aedes Horses NR 
Calovo virus Bunyamwera KJ542624 KJ542625 KJ542626 Russia, E Europe, Sri Lanka Aedes, Anopheles N/A NR 
Caraparu virus Group C KF254778 KF254777 KF254776 N/A Culex, Wyeomyia Rodents Clinical cases 
Cat Que virus  NC024075 NC024074 NC024076 N/A N/A N/A N/A 
 Chatanga virus California KF719221 KF719222 KF719223 N/A N/A N/A N/A 
Douglas virus Simbu HE795092 AB698478 HE795090 Australia Culicoides Cattle, sheep, horses, goats, deer, buffalo NR 
Facey's Paddock 
virus Simbu KF697136 KF697137 KF697138 N/A N/A N/A N/A 
Gamboa virus Gamboa KM272176 KM272175 KM272174 South America Aedeomyia N/A N/A 
Gamboa virus Gamboa KM272182 KM272181 KM272180 N/A N/A N/A N/A 
Gamboa virus Gamboa KM27217* KM272178 KM272177 N/A N/A N/A N/A 
Guaroa virus California KM245522 KM245523 KM245524 Colombia, Brazil, Panama Anopheles N/A Clinical cases 
I612045 virus Unclassified HM627180 HM627181 HM627179 N/A N/A N/A N/A 
Iaco virus Bunyamwera JN572067 JN572066 JN572065 N/A Wyeomyia N/A N/A 
Ilesha virus Bunyamwera KF234073 KF234074 KF234075 Africa Anopheles N/A Clinical cases 
Ingwavuma virus Simbu KF697141 KF697140 KF697139 Africa, India, Thailand, Cyprus Aedes, Culex 
Pigs, dogs, ducks, chickens, 
buffalo, cattle, birds NTAb 
Inkoo virus California U47137 U88059 EU789573 Finland Mosquitoes unspeciated Cattle, reindeer, snow hare, red fox, moose, hazel grouse NTAb 
Iquitos virus Simbu KF697144 KF697143 KF697142  N/A N/A  
Jamestown Canyon California HM007350 HM007351 HM007352 North America Aedes, Hybomitra, Chrysops White-tailed deer, moose, elk NTAb 
Jatobal virus Simbu JQ675601 JQ675602 JQ675603 N/A N/A N/A N/A 
Kaeng Khoi virus Unclassified KJ867203 KJ867204 KJ867205 N/A N/A N/A N/A 
Khurdun virus Unclassified KF981635 KF981634 KF981633 N/A N/A Birds N/A 
La Crosse virus Gamboa NC004110 NC004109 NC004108 North America Aedes, Culex Chipmunk, sentinel grey squirrels, sentinel rabbits Clinical cases 
Leanyer virus Simbu HM627177 HM627176 HM627178 N/A N/A N/A N/A 
M'Poko virus Turlock AM711133 N/A N/A Central African Republic Culex  NTAb 
Macaua virus Bunyamwera JN572070 JN572069 JN572068 Brazil Wyeomyia Birds NTAb 
Madre de Dios virus Simbu KF697146 KF697145 KF697147 N/A N/A N/A N/A 
Madrid virus Group C KF254781 KF254780 KF254779 Republic of Panama Culex Sentinel rodents Clinical case 
Manzanilla virus Simbu KF697148 KF697149 KF697150 Trinidad N/A Monkey. NTAb 
Mapputta virus Mapputta KJ481921 KJ481922 KJ481923 Australia Anopheles Cattle, horses, pigs, marsupials, rodents NTAb 
Maprik virus Mapputta NC026282 NC026283 NC026281 New Guinea Aedes, Anopheles, Culicidae N/A NR 
 Marituba virus Group C KF254772 KF254771 KF254770 N/A N/A N/A N/A 
Mermet virus Simbu KF697152 KF697151 KF697153 North America Culex Birds NR 
Mojui dos Campos 
virus Unclassified KH867200 KH867201 KH867202 N/A N/A N/A N/A 
Murrumbidgee virus Mapputta NC022597 NC022596 NC022595 N/A N/A N/A N/A 
Ngari virus Bunyamwera KC608154 KC608153 KC608152 Africa Aedes, Anopheles N/A NR 
Nyando ERET147 Nyando KJ867194 KJ867195 KJ867196 Africa Anopheles N/A N/A 
Nyando UgAr1712 Nyando KH867191 KJ867192 KJ867193 Africa Anopheles N/A Clinical cases 
Nyando virus 
MP401 Nyando KJ867188 KJ837189 KJ867190 
Africa N/A N/A  
Nyando virus 
ArB16055 Nyando AM709781 N/A N/A 
Africa N/A N/A  
Nyando YM176-66 Nyando KJ867197 KJ867198 KJ867199 Africa N/A N/A  
Oriboca virus Group C KF254775 KF254774 KF254773 South America Aedes, Culex Sentinel mice, sentinel monkey, rodents Clinical cases 
Oropouche virus Simbu KP052852 KP052851 KP052850 Brazil, Trinidad Aedes, Culex, Culicoide. Monkeys, sloth, birds Clinical cases 
Orthobunyavirus 
FSL2923 Simbu KF254792 KF254791 KF254790 N/A N/A N/A N/A 
Oyo virus Unclassified HM639778 HM639779 HM639780 N/A N/A N/A N/A 
Peaton virus Simbu HE795095 HE795094 HE795093  Australia Culicoides Cattle NR 
Pongola virus Bwamba EU564828 KJ867177 KJ867178 Africa Aedes, Anopheles Goat, donkey Clinical cases 
Sango virus Simbu HE795101 HE795100 HE795099 Africa Culicoides Cattle (5/2,199) N/A 
Sathuperi virus  Simbu NC018462 NC018466 NC018461 India, Nigeria Culex, Culicoides Cattle NR 
Schmallenberg virus Simbu JX853181 JX853180 JX853179 N/A N/A N/A N/A 
Shamonda virus Simbu NC018464 NC018467 NC018463 Nigeria  Culicoides Cattle NR 
Simbu virus Simbu NC018477 NC018478 NC018476 South Africa Aedes, Coquillettidia N/A NTAb 
Snowshoe hare virus California EU294510 EU262553 EU203678 North America, China 
Aedes, Culiseta, 
Lethocerus 
Lemming, sentinel rabbit, horses, 
deer, moose Clinical cases 
Sororoca virus Bunyamwera JN572073 JN572072 JN572071 Brazil  Sabethini (Tribe)  N/A 
Tahyna virus California GU390673 GQ386823 KF361881 Europe, Africa, Asia, USSR Aedes, Culiseta. 
Rabbit, hare, boar, cattle, horse, 
birds, deer, canis Clinical cases 
Taiassui virus Wyeomyia JN572076 JN572075 JN572074 N/A N/A N/A N/A 
Tensaw virus Bunyamwera FJ943505 FJ943508 FJ943510 North America Aedes, Anopheles, Culex, Mansonia, Psorophora. 
Dogs, raccoon, cattle, cotton rat, 
marsh rabbit, birds Clinical cases 
Tucunduba virus Bunyamwera JN572079 JN572078 JN572077 Brazil Wyeomyia N/A N/A 
Utinga virus Simbu KF697156 KF697155 KF697154 Brazil N/A Primates, sloths, birds, pigs, bat (1/947), marsupial (1/834), rodent N/A 
 (1/1692) 
Utive virus Simbu KF697158 KF697159 KF697157 N/A N/A N/A N/A 
Wyeomyia virus Bunyamwera JN572082 JN572081 JN572080 South America 
Aedes, Anopheles, Culex, 
Coquillettidia, Hemagogus, 
Trichoprosopon, 
Psorophora, Wyeomia 
N/A Clinical cases 
Zungarococha virus Unclassified KF254783 KF254782 JN157805 N/A N/A N/A N/A 
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Appendix 3: Transmembrane Topology Predictions 
 
TMHMM v2.0 predictions for Gamboa virus and Bunyamwera virus M polyproteins. 
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Appendix 4: Non-Compressed Maximum-likelihood 
Phylogenetic Trees 
 
A) N ORF 
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 Oriboca KF254775
 Marituba KF254772
 Zungarococha KF254783
Group C
 Buffalo Creek KJ481927
 Murrumbidgee NC 022597
 Mapputta KJ481821
 Maprik NC 026282
Mapputta
 Tapirape KM225262
 Pauci KM225256
 Rio Preto da Eva KM225259
 Khurdun KF981635
25
94
90
99
100
100
100
98
78
100
99
94
99
54
92
98
98
100
81
99
100
70
100
76
99
76
100
55
49
71
66
87
57
100
87
99
44
99
100
96
97
100
99
99
17
48
39
74
99
18
85
81
90
61
30
62
25
99
68
48
99
100
99
99
97
31
40
65
99
56
90
81
86
97
63
99
92
90
63
99
98
98
98
93
87
93
94
48
77
31
40
55
11
0
19
20
9
0.5
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 Manzanilla KF697149
 Mermet KF697151
 Ingwavuma KF697140
 Cat Que NC 024074
 Buttonwillow KF697161
 Oropouche KP052851
 Iquitos KF697143
 Madre de Dios KF697145
 Jatobal JQ675602
 Perdoes KP691625
 Utinga KF697155
 Utive KF697159
 Faceys Paddock KF697137
 Peaton HE795094
 Sango HE795100
 Shamonda NC 018467
 Akabane NC 009895
 Simbu NC 018478
 Aino NC 018459
 Shuni KF153117
 Schmallenberg JX853180
 Douglas AB698478
 Sathuperi NC 018466
 Leanyer HM627176
Simbu
 Oyo HM639779
 Tete 
 Batama
 I612045 HM627181
 Matruh
 Tsuruse-like
Tete
 Pauci KM225255
 Rio Preto da Eva KM225258
 Tapirape KM225261
 Maprik NC 026283
 Mapputta KJ481922
 Buffalo creek KJ481928
 Murrumbidgee NC 022596
Mapputta
 Brazoran NC 022038
Guama Guama
 Juan Diaz
 Capim
 Moriche
Capim
Minatitlan Palestina
 Oriboca KF254774
 Marituba KF254771
 Zungarococha KF254782
 Bruconha KM280924
 Caraparu KF254777
 Madrid KF254780
 FSL2923 KF254791
Group C
 Alajuela KM272187
 Gamboa
 Gamboa KM272181
 Calchaqui KM272184
 Gamboa KM272178
 Gamboa virus KM272175
Gamboa
Turlock MPoko
 Eretmapodites
 Nyando KJ867195
 Nyando KJ867198
 Nyando KJ867192
 Nyando
 Nyando KJ867189
Nyando
 Kaeng Khoi KJ867204
 Mojui dos Campos KJ867201
 Chatanga KF719222
 Snowshoe hare EU262553
 La Crosse NC 004109
 Tahyna GQ386823
 Keystone KT630289
 Inkoo U88059
 Jamestown Canyon HM007351
California
 Bwamba KJ867183
 Pongola KJ867177
Bwamba
 Guaroa AY380581
 Cache Valley KC436107
 Tensaw FJ943508
 Calovo KJ542625
 Ngari KC608153
 Ilesha KF234074
 Batai JX846605
 Bunyamwera NC 001926
 Abbey lake KJ710423
 Cachoeira Porteira JN968591
 Sororoca JN572072
 Iaco N572066
 Anhembi JN572063
 Tucunduba JN572078
 Macaua N572069
 Taiassui JN572075
 Wyeomyia JN572081
Wyeomyia
Bunyamwera
 Anopheles B
 Boraceia
Anopheles B
 Tacaiuma
 Trombetas 
 ColAn57389
 Anopheles A
 Las Maloyas
Anopheles A
 Tataguine KM972723
 Khurdun KF981634
100
100
97
97
100
100
100
100
100
100
100
100
100
100
100
97
100
59
99
100
100
100
97
93
100
100
100
48
100
42
100
39
100
100
100
99
95
60
100
88
99
99
99
100
100
88
100
100
100
52
98
45
99
100
99
45
100
100
100
100
69
100
100
47
99
100
100
50
83
98
99
64
47
51
100
100
78
82
81
99
99
98
99
8998
56
76
82
50
92
38
56
44
70
67
41
20
0.5
 
B) M ORF 
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 Chatanga KF719223
 Snowshoe hare EU203678
 La Crosse NC 004108
 Tahyna KF361881
 Keystone KT630288
 Inkoo EU789573
 Jamestown Canyon HM007352
Califronia
 Bwamba KJ867184
 Pongola KJ867178 Bwamba
 MPoko virus
 Calchaqui KM272183
 Gamboa
 Gamboa KM272174
 Gamboa KM272180
 Alajuela KM272186
 Gamboa KM272177
Gamboa
 Mojui dos Campos KJ867202
 Nyando
 Nyando KJ867190
 Nyando KJ867193
 Kaeng Khoi KJ867205
 Nyando KJ867199
 Eretmapodites
 Nyando KJ867196
Nyando
 Buffalo Creek KJ481929
 Murrumbidgee NC 022595
 Mapputta KJ481923
 Maprik NC 026281
Mapputta
 Guaroa JN801039
 Bunyamwera NC 001925
 Ngari KC608152
 Ilesha KF234075
 Calovo KJ542626
 Cache Valley KC436106
 Tensaw FJ943510
 Batai JX846606
 Abbey lake KJ710425
 Anhembi JN572062
 Iaco JN572065
 Cachoeira Porteira JN968590
 Sororoca JN572071
 Macaua JN572068
 Tucunduba JN572077
 Taiassui JN572074
 Wyeomyia JN572080
Wyeomyia
Bunyamwera
 Tataguine KM972722
 Tacaiuma
 Anopheles B
 Boraceia Anopheles B
 Anopheles A
 Las Maloyas
 ColAn57689
 Trombetas
Anopheles A
 Brazoran NC 022039
 Juan Diaz
 Moriche
 Capim
Capim
Guama Guama
Minatitlan Palestina
 Marituba KF254770
 Zungarococha JN157805
 Oriboca KF254773
 Bruconha KM280929
 Madrid KF254779
 Caraparu KF254776
 FSL2923 KF254790
Group C
 Douglas HE795090
 Sathuperi NC 018461
 Schmallenberg JX853179
 Shamonda NC 018463
 Akabane NC 009894
 Simbu NC 018476
 Aino NC 018465
 Shuni KF153118
 Peaton HE795093
 Sango HE795099
 Leanyer HM627178
 Cat Que NC 024076
 Ingwavuma KF697139
 Manzanilla KF697150
 Mermet KF697153
 Buttonwillow KF697160
 Faceys Paddock KF697138
 Utinga KF697154
 Utive KF697157
 Jatobal JQ675603
 Madre de Dios KF697147
 Oropouche KP052850
 Iquitos KF697142
 Perdoes KP691624
Simbu
 Oyo HM639780
 Matruh
 Tsuruse-like
 I612045 HM627179
 Batama
 Tete
Tete
 Tapirape KM225260
 Rio Preto da Eva KM225257
 Pauci KM225254
 Khurdun KF981633
100
100
100
43
99
100
100
100
98
100
100
100
100
97
83
100
100
100
100
100
100
100
100
100
100
100
100
100
58
100
93
53
58
100
100
100
100
100
82
100
100
100
100
100
100
100
99
99
100
100
66
100
100
100
100
100
99
86
45
63
100
100
100
100
100
100
75
66
100
77
100
88
63
100
100
100
100
100
100
69
100
100
100
77
100
77
99
51
97
10
24
43
38
24
85
0.5
C) L ORF 
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Appendix 5: rBMAV cRNA Sequences 
A) wt rBMAV S segment cRNA 
 
  
A G T A G T G T A C c C C A C A A A A T A C A A A A T C G T T A A T A C T G A G A A T T T A T A G A T T G C A T A T A G C A A A C C A T A C A A A
A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G A T G
A G A T T G A T T A C C A T T T C T C A G C A G G G G A T G A T G G A G G T G C T C C A T T C A A C C C T A T G G C T G C A T A C A A A G A G T T
C A T G G A A A C T C A T G G C A A G G A T T T A A C T G T C A C C A A C A T A A G A G T C T T T T T C T T G A A G G C T C G C C A G G C T A A A
G A A A T T A T G A G G T C T A A A G C C A A A T C T G A A A T G A C T T T C A C T T T T G G C A G C C T A A C C C T G A C C T T C A A G A A C A
C T C A T C A C C C A T C T A A T C G G C A T T T G A C C G T T G A C C A G G A T G A T T T G A C T A T C A A T A G G G C C A C T G G G T T T A T
G G C C T A C G C A A T C C T C C T G A C T C A T A G G G A G C C T A A A A G C A A G G A T G C A G T T G A A A A G A C C A T C A T C A A T C C T
A T T G C A G A A T C A A A G G G T G T T A C C T G G A A G G A G G G A G C A A A T A T C T A T C T G A G C T T C T T C C C T G G G A C T G A A A
T G T T C A T G C T T G A A T T C A G G T T C T T T C C A C T A G C T G T T G G T C T G G C T A G A T G C C A C A A A G A A A A G A T G G A C A C
T G A A T A C C T G A A G A A G C C C A T G C G T C A A A T G T T G A C T G A T G G A A C A A A G G C T C A A G T C T G G C T C G G T G C C A A G
A T T G A A G A G A T C A G G A A G G C A T A T A A G G T T T G T A T G A A C C T T A A A T T T G T T A A A G C T G G T T T C T C T G A G G C T G
C T A G G G A G T T C C T T A A A G A A T T C G G A T T A G A C C A G G A C A G A A A C T A A A T A A T T C T C T T T T A A G A G A T A G G G G T
T G G T A T A T T T A C C A A C C C C G A C A T G T A A A C A G C T A A A T T A A G C T G C A A T A T G T G G T G G G T G G T T G G G G C A A G A
T T C A G A T C A A C T C A T T A C A A T C T T T T T C C T C A T C A T T A G T T C T A T T C T T A T G T A T t t G T G G A G C A C A C T A C T
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B) rBMAV S segment cRNA – Switch  
Alignment of nucleotide sequences is shown, wt N protein ORF is highlighted in yellow, 
mutated regions in pink. 
 
........ 
........ 
........ 
........ 
........ 
 
  
A G T A G T G T A C c C C A C A A A A T A C A A A A T C G T T A A T A C T G A G A A T T T A T A G A T T G C A T A T A G C A A A C
A G T A G T G T A C c C C A C A A A A T A C A A A A T C G T T A A T A C T G A G A A T T T A T A G A T T G C A T A T A G C A A A C
A G T A G T G T A C c C C A C A A A A T A C A A A A T C G T T A A T A C T G A G A A T T T A T A G A T T G C A T A T A G C A A A C
A G T A G T G T A C c C C A C A A A A T A C A A A A T C G T T A A T A C T G A G A A T T T A T A G A T T G C A T A T A G C A A A C
A G T A G T G T A T T C C G T A A A A A A C A A A A C A A T T T A A T T C A A A G T T A T A T A A A A A G C - - - - - - - - - - -
C A T A C A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T A G T G C C
C A T A C A A A A T G A T - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
C A T A C A A A A T G A T - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
C A T A C A A A A T G T C A A A G G C A A A - - - - - - - - - G T C A C C A A A G A T C G T T T C C C T C A C T G C A G G T G C A
- - T C T C A A A T G T C A A A G G C A A A - - - - - - - - - G T C A C C A A A G A T C G T T T C C C T C A C T G C A G G T G C A
G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A G C A G G G G A T G A T G G A G G T G C T C C A T T C A A
- - - - - - - - - - - - - - T G A G A T T G A T T A C C A T T T C T C A G C A G G G G A T G A T G G A G G T G C T C C A T T C A A
- - - - - - - - - - - - - - T G A G A T T G A T T A C C A T T T C T C A G C A G G G G A T G A T G G A G G T G C T C C A T T C A A
G G T T T A G A G G A T G A T G A G A T T G A T T A C C A T T T C T C A G C A G G G G A T G A T G G A G G T G C T C C A T T C A A
G G T T T A G A G G A T G A T G A G A T T G A T T A C C A T T T C T C A G C A G G G G A T G A T G G A G G T G C T C C A T T C A A
C C C T A T G G C T G C A T A C A A A G A G T T C A T G G A A A C T C A T G G C A A G G A T T T A A C T G T C A C C A A C A T A A
C C C T A T G G C T G C A T A C A A A G A G T T C A T G G A A A C T C A T G G C A A G G A T T T A A C T G T C A C C A A C A T A A
C C C T A T G G C T G C A T A C A A A G A G T T C A T G G A A A C T C A T G G C A A G G A T T T A A C T G T C A C C A A C A T A A
C C C T A T G G C T G C A T A C A A A G A G T T C A T G G A A A C T C A T G G C A A G G A T T T A A C T G T C A C C A A C A T A A
C C C T A T G G C T G C A T A C A A A G A G T T C A T G G A A A C T C A T G G C A A G G A T T T A A C T G T C A C C A A C A T A A
G A G T C T T T T T C T T G A A G G C T C G C C A G G C T A A A G A A A T T A T G A G G T C T A A A G C C A A A T C T G A A A T G
G A G T C T T T T T C T T G A A G G C T C G C C A G G C T A A A G A A A T T A T G A G G T C T A A A G C C A A A T C T G A A A T G
G A G T C T T T T T C T T G A A G G C T C G C C A G G C T A A A G A A A T T A T G A G G T C T A A A G C C A A A T C T G A A A T G
G A G T C T T T T T C T T G A A G G C T C G C C A G G C T A A A G A A A T T A T G A G G T C T A A A G C C A A A T C T G A A A T G
G A G T C T T T T T C T T G A A G G C T C G C C A G G C T A A A G A A A T T A T G A G G T C T A A A G C C A A A T C T G A A A T G
A C T T T C A C T T T T G G C A G C C T A A C C C T G A C C T T C A A G A A C A C T C A T C A C C C A T C T A A T C G G C A T T T
A C T T T C A C T T T T G G C A G C C T A A C C C T G A C C T T C A A G A A C A C T C A T C A C C C A T C T A A T C G G C A T T T
A C T T T C A C T T T T G G C A G C C T A A C C C T G A C C T T C A A G A A C A C T C A T C A C C C A T C T A A T C G G C A T T T
A C T T T C A C T T T T G G C A G C C T A A C C C T G A C C T T C A A G A A C A C T C A T C A C C C A T C T A A T C G G C A T T T
A C T T T C A C T T T T G G C A G C C T A A C C C T G A C C T T C A A G A A C A C T C A T C A C C C A T C T A A T C G G C A T T T
G A C C G T T G A C C A G G A T G A T T T G A C T A T C A A T A G G G C C A C T G G G T T T A T G G C C T A C G C A A T C C T C C
G A C C G T T G A C C A G G A T G A T T T G A C T A T C A A T A G G G C C A C T G G G T T T A T G G C C T A C G C A A T C C T C C
G A C C G T T G A C C A G G A T G A T T T G A C T A T C A A T A G G G C C A C T G G G T T T A T G G C C T A C G C A A T C C T C C
G A C C G T T G A C C A G G A T G A T T T G A C T A T C A A T A G G G C C A C T G G G T T T A T G G C C T A C G C A A T C C T C C
G A C C G T T G A C C A G G A T G A T T T G A C T A T C A A T A G G G C C A C T G G G T T T A T G G C C T A C G C A A T C C T C C
T G A C T C A T A G G G A G C C T A A A A G C A A G G A T G C A G T T G A A A A G A C C A T C A T C A A T C C T A T T G C A G A A
T G A C T C A T A G G G A G C C T A A A A G C A A G G A T G C A G T T G A A A A G A C C A T C A T C A A T C C T A T T G C A G A A
T G A C T C A T A G G G A G C C T A A A A G C A A G G A T G C A G T T G A A A A G A C C A T C A T C A A T C C T A T T G C A G A A
T G A C T C A T A G G G A G C C T A A A A G C A A G G A T G C A G T T G A A A A G A C C A T C A T C A A T C C T A T T G C A G A A
G T T C A T G C T T G A A T T C A G G T T C T T T C C A C T A G C T G T T G G T C T G G C T A G A T G C C A C A A A G A A A A G A
G T T C A T G C T T G A A T T C A G G T T C T T T C C A C T A G C T G T T G G T C T G G C T A G A T G C C A C A A A G A A A A G A
G T T C A T G C T T G A A T T C A G G T T C T T T C C A C T A G C T G T T G G T C T G G C T A G A T G C C A C A A A G A A A A G A
G T T C A T G C T T G A A T T C A G G T T C T T T C C A C T A G C T G T T G G T C T G G C T A G A T G C C A C A A A G A A A A G A
G T T C A T G C T T G A A T T C A G G T T C T T T C C A C T A G C T G T T G G T C T G G C T A G A T G C C A C A A A G A A A A G A
T G G A C A C T G A A T A C C T G A A G A A G C C C A T G C G T C A A A T G T T G A C T G A T G G A A C A A A G G C T C A A G T C
T G G A C A C T G A A T A C C T G A A G A A G C C C A T G C G T C A A A T G T T G A C T G A T G G A A C A A A G G C T C A A G T C
T G G A C A C T G A A T A C C T G A A G A A G C C C A T G C G T C A A A T G T T G A C T G A T G G A A C A A A G G C T C A A G T C
T G G A C A C T G A A T A C C T G A A G A A G C C C A T G C G T C A A A T G T T G A C T G A T G G A A C A A A G G C T C A A G T C
T G G A C A C T G A A T A C C T G A A G A A G C C C A T G C G T C A A A T G T T G A C T G A T G G A A C A A A G G C T C A A G T C
T G G C T C G G T G C C A A G A T T G A A G A G A T C A G G A A G G C A T A T A A G G T T T G T A T G A A C C T T A A A T T T G T
T G G C T C G G T G C C A A G A T T G A A G A G A T C A G G A A G G C A T A T A A G G T T T G T A T G A A C C T T A A A T T T G T
T G G C T C G G T G C C A A G A T T G A A G A G A T C A G G A A G G C A T A T A A G G T T T G T A T G A A C C T T A A A T T T G T
T G G C T C G G T G C C A A G A T T G A A G A G A T C A G G A A G G C A T A T A A G G T T T G T A T G A A C C T T A A A T T T G T
T G G C T C G G T G C C A A G A T T G A A G A G A T C A G G A A G G C A T A T A A G G T T T G A T G A A C C T T A A T T T G T
T A A G C T G G T T T C T C T G A G G C T G C T A G G G A G T T C C T T A A G A T T C G G T T A G A C C G G A C G A
T A A G C T G G T T T C T C T G A G G C T G C T A G G G A G T T C C T T A A G A T T C G G T T A G A C C G G A C G A
T A A G C T G G T T T C T C T G A G G C T G C T A G G G A G T T C C T T A A G A T T C G G T - - - - - - - - - C C A
T A A G C T G G T T T C T C T G A G G C T G C T A G G G A G T T C C T T A A G A T T C A - - - - - - - - - - - - A C T C A
T A A G C T G G T T T C T C T G A G G C T G C T A G G G A G T T C C T T A A G A T T C A - - - - - - - - - - - - A C T C A
A A A T A A - - - - T T C T C T T T T A A G A G A T A G G G G T - - - - - - - - - - - - T G G T A T T A C A A C C C
A A A T A A - - - - T T C T C T T T T A A G A G A T A G G G G T - - - - - - - - - - - - T G G T A T T A C A A C C C
T G A A A T A A - - - - T T C T C T T T T A A G A G A T A G G G G T - - - - - - - - - - - - T G G T A T T A C A A C C C
T G A A T A A - - - - T T C T C T T T T A A G A G A T A G G G G T - - - - - - - - - - - - T G G T A T T A C A A C C C
T G A T T T A G C T G T C C T T T C C C T C G T G A T T G G G G T A A C C T G T A T T A G G G C A T A T C A A G C
C - - - - - - - - - - - - - - G A C A T G T A A A C A G C T A A A T T A A G C T G C A A A G T G G G T G T T G G G G
C - - - - - - - - - - - - - - G A C A T G T A A A C A G C T A A A T T A A G C T G C A A T A T G T G G T G G G T G G T T G G G G C
C - - - - - - - - - - - - - - G A C A T G T A A A C A G C T A A A T T A A G C T G C A A T A T G T G G T G G G T G G T T G G G G C
C - - - - - - - - - - - - - - G A C A T G T A A A C A G C T A A A T T A A G C T G C A A T A T G T G G T G G G T G G T T G G G G C
C C T A T T T A A T T A T A G G A G T C A A A G A C A G C A G T A T A A A T G T C C A A T - - G T G G T G G G T G G T T G G G G C
A A G A T T C A G A T C A A C T C A T T A C A A T C T T T T T C C T C A T C A T T A G T T C T A T T C T T A T G T A T t t G T G G
A A G A T T C A G A T C A A C T C A T T A C A A T C T T T T T C C T C A T C A T T A G T T C T A T T C T T A T G T A T t t G T G G
A A G A T T C A G A T C A A C T C A T T A C A A T C T T T T T C C T C A T C A T T A G T T C T A T T C T T A T G T A T t t G T G G
A A G A T T C A G A T C A A C T C A T T A C A A T C T T T T T C C T C A T C A T T A G T T C T A T T C T T A T G T A T t t G T G G
A - - - - - T T T A T G A G C T C A G A A T A A A T G T - - - - - - C A G A A A T G T T T T G T G T T T T G T A T - - - T A C G G
A G C A C A C T A C T
A G C A C A C T A C T
A G C A C A C T A C T
A G C A C A C T A C T
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C) rBMAV S segment cRNA – Point Mutations 
Alignment of mutated region of S segment cRNAs is shown, wt N protein ORF is highlighted 
in yellow, mutated regions in pink.  
 
 
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A G C T G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A G C T A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T G C T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G C T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A G C T G G T G A G T C A G A A C C A G C T A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A G C T G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T G C T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A G C T G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G C T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A G C T A T C A G C G T T G C A G C T G C T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A G C T A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G C T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T G C T G C C G C A T T T G C T G A A G C T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A G C T G G T G A G T C A G A A C C A G C T A T C A G C G T T G C A G C T G C T G C C G C A T T T G C T G A A G C T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A G C T G G T G A G T C A G A A C C A G C T A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G C T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A G C T G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T G C T G C C G C A T T T G C T G A A G C T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A G C T A T C A G C G T T G C A G C T G C T G C C G C A T T T G C T G A A G C T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A G C T G G T G A G T C A G A A C C A G C T A T C A G C G T T G C A G C T G C T G C C G C A T T T G C T G A A G C T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A - - - A T C A A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A - - - A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T A G T - - - G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A - - - G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A - - - A T C A - - - A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A - - - A T C A A T C A G C G T T G C A G C T A G T - - - G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A A T C A G C G T T G C A G C T A G T - - - G C A T T T G C T G A A - - - G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A - - - A G C G T T G C A G C T A G T - - - G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A A C C A T C A - - - A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A - - - G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A - - - A T C A A T C A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A - - - G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A - - - A T C A - - - A G C G T T G C A G C T A G T - - - G C A T T T G C T G A A G A T G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A - - - A T C A - - - A G C G T T G C A G C T A G T G C C G C A T T T G C T G A A - - - G A G A T T G A T T A C C A T T T C T C A
A A A A T G T C C A A A G T A A A A A G A G G T G A G T C A G A - - - A T C A A T C A G C G T T G C A G C T A G T - - - G C A T T T G C T G A A - - - G A G A T T G A T T A C C A T T T C T C A
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